1	The	DT	O	the	det	2	SENT_1	[p1l93t1356r142b1380],
2	authors	NNS	O	author	nsubj	3	SENT_1	[p1l154t1356r260b1380],
3	’	VBP	O	’	_	0	SENT_1	[p1l154t1356r260b1380],
4	affiliations	NNS	O	affiliation	nsubjpass	6	SENT_1	[p1l273t1356r411b1380],
5	are	VBP	O	be	auxpass	6	SENT_1	[p1l423t1364r462b1380],
6	listed	VBN	O	list	ccomp	3	SENT_1	[p1l475t1356r542b1380],
7	in	IN	O	in	_	0	SENT_1	[p1l556t1358r577b1379],
8	the	DT	O	the	det	9	SENT_1	[p1l589t1356r630b1380],
9	Appendix	NNP	O	Appendix	prep_in	6	SENT_1	[p1l93t1394r222b1425],
10	.	.	O	.	_	0	SENT_1	[p1l93t1394r222b1425],

1	Address	NN	O	address	nsubj	2	SENT_2	[p1l231t1394r335b1417],
2	reprint	VB	O	reprint	_	0	SENT_2	[p1l346t1396r431b1425],
3	requests	NNS	O	request	dobj	2	SENT_2	[p1l441t1398r549b1425],
4	to	TO	O	to	_	0	SENT_2	[p1l558t1398r583b1417],
5	Dr.	NNP	O	Dr.	nn	6	SENT_2	[p1l595t1396r629b1417],
6	lnoue	NN	O	lnoue	prep_to	2	SENT_2	[p1l96t1433r168b1455],
7	at	IN	O	at	_	0	SENT_2	[p1l182t1436r205b1455],
8	the	DT	O	the	det	9	SENT_2	[p1l217t1431r258b1455],
9	Department	NNP	ORGANIZATION	Department	prep_at	6	SENT_2	[p1l273t1434r431b1462],
10	of	IN	ORGANIZATION	of	_	0	SENT_2	[p1l444t1431r472b1455],
11	Respiratory	NNP	ORGANIZATION	Respiratory	nn	12	SENT_2	[p1l483t1434r630b1462],
12	Medicine	NNP	ORGANIZATION	Medicine	prep_of	9	SENT_2	[p1l96t1469r219b1497],
13	,	,	O	,	_	0	SENT_2	[p1l96t1469r219b1497],
14	Tohoku	NNP	ORGANIZATION	Tohoku	nn	16	SENT_2	[p1l228t1469r322b1493],
15	University	NNP	ORGANIZATION	University	nn	16	SENT_2	[p1l333t1471r461b1500],
16	Hospital	NNP	ORGANIZATION	Hospital	conj_or	12	SENT_2	[p1l470t1469r576b1500],
17	1-1	CD	NUMBER	1-1	num	16	SENT_2	[p1l588t1471r628b1497],
18	,	,	O	,	_	0	SENT_2	[p1l588t1471r628b1497],
19	Seiryomachi	NNP	PERSON	Seiryomachi	conj_or	12	SENT_2	[p1l95t1506r262b1537],
20	,	,	O	,	_	0	SENT_2	[p1l95t1506r262b1537],
21	Aobaku	NNP	O	Aobaku	prep_of	9	SENT_2	[p1l275t1506r381b1534],
22	,	,	O	,	_	0	SENT_2	[p1l275t1506r381b1534],
23	Sendai	NN	LOCATION	sendaus	conj_or	12	SENT_2	[p1l395t1506r489b1534],
24	,	,	O	,	_	0	SENT_2	[p1l395t1506r489b1534],
25	980-8574	CD	NUMBER	980-8574	conj_or	12	SENT_2	[p1l503t1508r628b1534],
26	,	,	O	,	_	0	SENT_2	[p1l503t1508r628b1534],
27	Japan	NNP	LOCATION	Japan	conj_or	12	SENT_2	[p1l90t1546r173b1575],
28	,	,	O	,	_	0	SENT_2	[p1l90t1546r173b1575],
29	or	CC	O	or	_	0	SENT_2	[p1l184t1552r210b1568],
30	at	IN	O	at	advmod	12	SENT_2	[p1l219t1548r242b1568],
31	akinoue@idac.tohoku.ac.jp	NN	O	akinoue@idac.tohoku.ac.jp	prep_of	9	SENT_2	[p1l251t1544r618b1575],
32	.	.	O	.	_	0	SENT_2	[p1l251t1544r618b1575],

1	*	NN	O	*	nsubj	4	SENT_3	[p1l94t1615r270b1646],
2	Contributing	VBG	O	contribute	partmod	1	SENT_3	[p1l94t1615r270b1646],
3	members	NNS	O	member	dobj	2	SENT_3	[p1l280t1615r399b1639],
4	ofthe	VBP	O	ofthe	_	0	SENT_3	[p1l409t1615r481b1639],
5	North	NNP	O	North	dobj	4	SENT_3	[p1l493t1615r630b1639],
6	.	.	O	.	_	0	SENT_3	[p1l493t1615r630b1639],

1	—	NN	O	—	_	0	SENT_4	[p1l493t1615r630b1639],
2	.	.	O	.	_	0	SENT_4	[p1l493t1615r630b1639],

1	East	NNP	ORGANIZATION	East	nn	4	SENT_5	[p1l493t1615r630b1639],
2	Japan	NNP	ORGANIZATION	Japan	nn	4	SENT_5	[p1l107t1655r181b1684],
3	Study	NNP	ORGANIZATION	Study	nn	4	SENT_5	[p1l194t1653r267b1684],
4	Group	NNP	ORGANIZATION	Group	nsubjpass	6	SENT_5	[p1l277t1655r359b1684],
5	are	VBP	O	be	auxpass	6	SENT_5	[p1l371t1661r409b1676],
6	listed	VBN	O	list	_	0	SENT_5	[p1l421t1653r488b1676],
7	in	IN	O	in	_	0	SENT_5	[p1l502t1655r522b1676],
8	the	DT	O	the	det	9	SENT_5	[p1l534t1653r575b1676],
9	Appendix	NNP	O	Appendix	prep_in	6	SENT_5	[p1l585t1654r630b1684, p1l112t1690r204b1721],
10	.	.	O	.	_	0	SENT_5	[p1l585t1654r630b1684, p1l112t1690r204b1721],

1	N	NN	MISC	n	nn	3	SENT_6	[p1l96t1767r114b1789],
2	Englj	NNP	MISC	Englj	nn	3	SENT_6	[p1l127t1765r195b1796],
3	Med	NNP	O	Med	_	0	SENT_6	[p1l209t1765r264b1789],
4	2010	CD	DATE	2010	num	3	SENT_6	[p1l274t1767r496b1793],
5	;	:	O	;	_	0	SENT_6	[p1l274t1767r496b1793],
6	362:2380	CD	NUMBER	362:2380	number	7	SENT_6	[p1l274t1767r496b1793],
7	-8	CD	NUMBER	-8	dep	3	SENT_6	[p1l274t1767r496b1793],
8	.	.	O	.	_	0	SENT_6	[p1l274t1767r496b1793],

1	Copyright	NN	O	copyright	_	0	SENT_7	[p1l95t1807r188b1832],
2	©	CD	NUMBER	©	num	6	SENT_7	[p1l197t1809r218b1830],
3	2010	CD	DATE	2010	num	6	SENT_7	[p1l228t1808r278b1826],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_7	[p1l286t1807r426b1826],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_7	[p1l435t1807r512b1826],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_7	[p1l520t1808r592b1832],
7	.	.	O	.	_	0	SENT_7	[p1l520t1808r592b1832],

1	The	DT	O	the	det	4	SENT_8	[p1l961t81r1007b102],
2	NEW	NNP	O	NEW	nn	4	SENT_8	[p1l1025t83r1110b102],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_8	[p1l1130t83r1318b102],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_8	[p1l1337t83r1516b109],
5	of	IN	O	of	_	0	SENT_8	[p1l1536t81r1564b108],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_8	[p1l1576t83r1775b102],

1	l	NN	O	l	_	0	SENT_9	[p1l668t184r671b303],
2	ORIGINAL	NNP	O	ORIGINAL	nn	3	SENT_9	[p1l1158t234r1381b260],
3	ARTICLE	NN	O	article	dep	1	SENT_9	[p1l1393t234r1579b260],
4	l	NN	O	l	tmod	3	SENT_9	[p1l2066t184r2069b303],

1	Geﬁtinib	NN	O	geﬁtinib	_	0	SENT_10	[p1l699t378r967b434],
2	or	CC	O	or	_	0	SENT_10	[p1l998t397r1061b434],
3	Chemotherapy	NN	O	chemotherapy	conj_or	1	SENT_10	[p1l1088t379r1534b449],
4	for	IN	O	for	_	0	SENT_10	[p1l1560t378r1647b434],
5	N	NN	O	n	prep_for	1	SENT_10	[p1l1673t384r1725b434],
6	on	IN	O	on	prep	1	SENT_10	[p1l1729t379r2037b434],
7	.	.	O	.	_	0	SENT_10	[p1l1729t379r2037b434],

1	—	NN	O	—	_	0	SENT_11	[p1l1729t379r2037b434],
2	.	.	O	.	_	0	SENT_11	[p1l1729t379r2037b434],

1	Small	JJ	O	small	_	0	SENT_12	[p1l1729t379r2037b434],

1	Cell	NN	O	cell	_	0	SENT_13	[p1l782t462r897b517],
2	Lung	NN	O	lung	nn	3	SENT_13	[p1l925t467r1080b532],
3	Cancer	NN	O	cancer	dep	1	SENT_13	[p1l1107t466r1317b517],
4	with	IN	O	with	_	0	SENT_13	[p1l1341t462r1475b517],
5	Mutated	JJ	O	mutated	amod	6	SENT_13	[p1l1502t462r1752b517],
6	EGFR	NN	O	egfr	prep_with	3	SENT_13	[p1l1780t466r1963b520],

1	Makoto	NNP	PERSON	Makoto	nn	8	SENT_14	[p1l864t585r990b617],
2	Maemondo	NNP	PERSON	Maemondo	nn	8	SENT_14	[p1l1006t585r1210b622],
3	,	,	O	,	_	0	SENT_14	[p1l1006t585r1210b622],
4	M.D.	NNP	O	M.D.	appos	8	SENT_14	[p1l1227t588r1317b622],
5	,	,	O	,	_	0	SENT_14	[p1l1227t588r1317b622],
6	Ph.D.	NNP	O	Ph.D.	appos	8	SENT_14	[p1l1334t585r1434b622],
7	,	,	O	,	_	0	SENT_14	[p1l1334t585r1434b622],
8	Akira	NNP	PERSON	Akira	_	0	SENT_14	[p1l1447t585r1532b616],
9	lnoue	NN	O	lnoue	dep	8	SENT_14	[p1l1548t588r1651b622],
10	,	,	O	,	_	0	SENT_14	[p1l1548t588r1651b622],
11	M.D.	NNP	O	M.D.	nn	13	SENT_14	[p1l1668t588r1758b622],
12	,	,	O	,	_	0	SENT_14	[p1l1668t588r1758b622],
13	Ph.D.	NNP	O	Ph.D.	appos	9	SENT_14	[p1l1775t585r1874b622],
14	,	,	O	,	_	0	SENT_14	[p1l1775t585r1874b622],

1	Kunihiko	NNP	PERSON	Kunihiko	nn	2	SENT_15	[p1l800t635r947b666],
2	Kobayashi	NNP	PERSON	Kobayashi	_	0	SENT_15	[p1l963t635r1142b676],
3	,	,	O	,	_	0	SENT_15	[p1l963t635r1142b676],
4	M.D.	NNP	O	M.D.	nn	13	SENT_15	[p1l1159t638r1249b672],
5	,	,	O	,	_	0	SENT_15	[p1l1159t638r1249b672],
6	Ph.D.	NNP	O	Ph.D.	appos	13	SENT_15	[p1l1266t635r1366b672],
7	,	,	O	,	_	0	SENT_15	[p1l1266t635r1366b672],
8	Shunichi	NNP	PERSON	Shunichi	appos	13	SENT_15	[p1l1381t635r1527b666],
9	Sugawara	NNP	PERSON	Sugawara	nn	13	SENT_15	[p1l1542t637r1714b676],
10	,	,	O	,	_	0	SENT_15	[p1l1542t637r1714b676],
11	M.D.	NNP	O	M.D.	appos	13	SENT_15	[p1l1731t638r1821b672],
12	,	,	O	,	_	0	SENT_15	[p1l1731t638r1821b672],
13	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_15	[p1l1839t635r1938b672],
14	,	,	O	,	_	0	SENT_15	[p1l1839t635r1938b672],

1	Satoshi	NNP	PERSON	Satoshi	nn	2	SENT_16	[p1l881t684r1004b716],
2	Oizumi	NNP	PERSON	Oizumi	_	0	SENT_16	[p1l1019t686r1153b721],
3	,	,	O	,	_	0	SENT_16	[p1l1019t686r1153b721],
4	M.D.	NNP	O	M.D.	appos	2	SENT_16	[p1l1171t687r1261b721],
5	,	,	O	,	_	0	SENT_16	[p1l1171t687r1261b721],
6	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_16	[p1l1278t684r1377b721],
7	,	,	O	,	_	0	SENT_16	[p1l1278t684r1377b721],
8	Hiroshi	NNP	PERSON	Hiroshi	nn	9	SENT_16	[p1l1394t684r1517b716],
9	lsobe	NN	O	lsobe	appos	2	SENT_16	[p1l1534t684r1632b721],
10	,	,	O	,	_	0	SENT_16	[p1l1534t684r1632b721],
11	M.D.	NNP	O	M.D.	appos	2	SENT_16	[p1l1649t687r1739b721],
12	,	,	O	,	_	0	SENT_16	[p1l1649t687r1739b721],
13	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_16	[p1l1756t684r1855b721],
14	,	,	O	,	_	0	SENT_16	[p1l1756t684r1855b721],
15	Akihiko	NNP	PERSON	Akihiko	nn	16	SENT_16	[p1l864t734r990b766],
16	Gemma	NNP	PERSON	Gemma	appos	2	SENT_16	[p1l1003t736r1148b771],
17	,	,	O	,	_	0	SENT_16	[p1l1003t736r1148b771],
18	M.D.	NNP	O	M.D.	appos	2	SENT_16	[p1l1165t737r1255b771],
19	,	,	O	,	_	0	SENT_16	[p1l1165t737r1255b771],
20	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_16	[p1l1272t734r1372b771],
21	,	,	O	,	_	0	SENT_16	[p1l1272t734r1372b771],
22	Masao	NNP	PERSON	Masao	nn	23	SENT_16	[p1l1389t737r1500b766],
23	Harada	NNP	PERSON	Harada	appos	2	SENT_16	[p1l1515t734r1647b771],
24	,	,	O	,	_	0	SENT_16	[p1l1515t734r1647b771],
25	M.D.	NNP	O	M.D.	appos	2	SENT_16	[p1l1664t737r1754b771],
26	,	,	O	,	_	0	SENT_16	[p1l1664t737r1754b771],
27	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_16	[p1l1771t734r1870b771],
28	,	,	O	,	_	0	SENT_16	[p1l1771t734r1870b771],
29	Hirohisa	NNP	PERSON	Hirohisa	nn	30	SENT_16	[p1l826t784r970b816],
30	Yoshizawa	NNP	PERSON	Yoshizawa	appos	2	SENT_16	[p1l982t784r1172b821],
31	,	,	O	,	_	0	SENT_16	[p1l982t784r1172b821],
32	M.D.	NNP	O	M.D.	appos	2	SENT_16	[p1l1189t787r1279b821],
33	,	,	O	,	_	0	SENT_16	[p1l1189t787r1279b821],
34	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_16	[p1l1296t784r1396b821],
35	,	,	O	,	_	0	SENT_16	[p1l1296t784r1396b821],
36	lchiro	NNP	O	lchiro	nn	37	SENT_16	[p1l1413t784r1506b816],
37	Kinoshita	NNP	PERSON	Kinoshita	appos	2	SENT_16	[p1l1522t784r1688b821],
38	,	,	O	,	_	0	SENT_16	[p1l1522t784r1688b821],
39	M.D.	NNP	O	M.D.	nn	41	SENT_16	[p1l1705t787r1796b821],
40	,	,	O	,	_	0	SENT_16	[p1l1705t787r1796b821],
41	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_16	[p1l1813t784r1912b821],
42	,	,	O	,	_	0	SENT_16	[p1l1813t784r1912b821],

1	Yuka	NNP	PERSON	Yuka	nn	2	SENT_17	[p1l680t834r760b865],
2	Fujita	NNP	PERSON	Fujita	_	0	SENT_17	[p1l776t837r874b875],
3	,	,	O	,	_	0	SENT_17	[p1l776t837r874b875],
4	M.D.	NNP	O	M.D.	nn	20	SENT_17	[p1l890t837r979b871],
5	,	,	O	,	_	0	SENT_17	[p1l890t837r979b871],
6	Ph.D.	NNP	O	Ph.D.	appos	20	SENT_17	[p1l995t834r1092b871],
7	,	,	O	,	_	0	SENT_17	[p1l995t834r1092b871],
8	Shoji	NNP	PERSON	Shoji	appos	20	SENT_17	[p1l1106t834r1186b875],
9	Okinaga	NNP	PERSON	Okinaga	nn	20	SENT_17	[p1l1200t834r1347b875],
10	,	,	O	,	_	0	SENT_17	[p1l1200t834r1347b875],
11	M.D.	NNP	O	M.D.	appos	20	SENT_17	[p1l1364t837r1452b871],
12	,	,	O	,	_	0	SENT_17	[p1l1364t837r1452b871],
13	Ph.D.	NNP	O	Ph.D.	appos	20	SENT_17	[p1l1469t834r1565b871],
14	,	,	O	,	_	0	SENT_17	[p1l1469t834r1565b871],
15	Haruto	NNP	PERSON	Haruto	appos	20	SENT_17	[p1l1582t837r1697b865],
16	Hirano	NNP	PERSON	Hirano	nn	20	SENT_17	[p1l1712t837r1834b871],
17	,	,	O	,	_	0	SENT_17	[p1l1712t837r1834b871],
18	M.D.	NNP	O	M.D.	appos	20	SENT_17	[p1l1850t837r1939b871],
19	,	,	O	,	_	0	SENT_17	[p1l1850t837r1939b871],
20	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_17	[p1l1955t834r2054b871],
21	,	,	O	,	_	0	SENT_17	[p1l1955t834r2054b871],

1	Kozo	NNP	PERSON	Kozo	nn	2	SENT_18	[p1l845t886r926b914],
2	Yoshimori	NNP	PERSON	Yoshimori	_	0	SENT_18	[p1l938t883r1123b920],
3	,	,	O	,	_	0	SENT_18	[p1l938t883r1123b920],
4	M.D.	NNP	O	M.D.	nn	13	SENT_18	[p1l1141t886r1231b920],
5	,	,	O	,	_	0	SENT_18	[p1l1141t886r1231b920],
6	Ph.D.	NNP	O	Ph.D.	appos	13	SENT_18	[p1l1248t883r1347b920],
7	,	,	O	,	_	0	SENT_18	[p1l1248t883r1347b920],
8	Toshiyuki	NNP	PERSON	Toshiyuki	appos	13	SENT_18	[p1l1360t883r1521b924],
9	Harada	NNP	PERSON	Harada	nn	13	SENT_18	[p1l1538t883r1670b920],
10	,	,	O	,	_	0	SENT_18	[p1l1538t883r1670b920],
11	M.D.	NNP	O	M.D.	appos	13	SENT_18	[p1l1687t886r1777b920],
12	,	,	O	,	_	0	SENT_18	[p1l1687t886r1777b920],
13	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_18	[p1l1794t883r1893b920],
14	,	,	O	,	_	0	SENT_18	[p1l1794t883r1893b920],

1	Takashi	NNP	PERSON	Takashi	nn	2	SENT_19	[p1l715t932r844b963],
2	Ogura	NNP	PERSON	Ogura	_	0	SENT_19	[p1l859t934r973b973],
3	,	,	O	,	_	0	SENT_19	[p1l859t934r973b973],
4	M.D.	NNP	O	M.D.	appos	2	SENT_19	[p1l991t935r1081b969],
5	,	,	O	,	_	0	SENT_19	[p1l991t935r1081b969],
6	Masahiro	NNP	PERSON	Masahiro	nn	7	SENT_19	[p1l1098t932r1256b963],
7	Ando	NNP	PERSON	Ando	appos	2	SENT_19	[p1l1268t932r1367b969],
8	,	,	O	,	_	0	SENT_19	[p1l1268t932r1367b969],
9	M.D.	NNP	O	M.D.	appos	2	SENT_19	[p1l1384t935r1474b969],
10	,	,	O	,	_	0	SENT_19	[p1l1384t935r1474b969],
11	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_19	[p1l1491t932r1590b969],
12	,	,	O	,	_	0	SENT_19	[p1l1491t932r1590b969],
13	Hitoshi	NNP	PERSON	Hitoshi	nn	14	SENT_19	[p1l1607t932r1729b963],
14	Miyazawa	NNP	PERSON	Miyazawa	appos	2	SENT_19	[p1l1746t935r1919b973],
15	,	,	O	,	_	0	SENT_19	[p1l1746t935r1919b973],
16	M.S.	NNP	LOCATION	M.S.	appos	2	SENT_19	[p1l1936t934r2019b969],
17	,	,	O	,	_	0	SENT_19	[p1l1936t934r2019b969],
18	Tomoaki	NNP	PERSON	Tomoaki	nn	19	SENT_19	[p1l678t981r826b1012],
19	Tanaka	NNP	PERSON	Tanaka	appos	2	SENT_19	[p1l839t981r970b1018],
20	,	,	O	,	_	0	SENT_19	[p1l839t981r970b1018],
21	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_19	[p1l987t981r1086b1018],
22	,	,	O	,	_	0	SENT_19	[p1l987t981r1086b1018],
23	Yasuo	NNP	PERSON	Yasuo	nn	24	SENT_19	[p1l1099t984r1203b1012],
24	Saijo	NNP	PERSON	Saijo	appos	2	SENT_19	[p1l1217t983r1307b1022],
25	,	,	O	,	_	0	SENT_19	[p1l1217t983r1307b1022],
26	M.D.	NNP	O	M.D.	appos	2	SENT_19	[p1l1324t984r1414b1018],
27	,	,	O	,	_	0	SENT_19	[p1l1324t984r1414b1018],
28	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_19	[p1l1431t981r1530b1018],
29	,	,	O	,	_	0	SENT_19	[p1l1431t981r1530b1018],
30	Koichi	NNP	PERSON	Koichi	nn	31	SENT_19	[p1l1547t981r1647b1012],
31	Hagiwara	NNP	PERSON	Hagiwara	appos	2	SENT_19	[p1l1665t984r1833b1022],
32	,	,	O	,	_	0	SENT_19	[p1l1665t984r1833b1022],
33	M.D.	NNP	O	M.D.	nn	35	SENT_19	[p1l1850t984r1940b1018],
34	,	,	O	,	_	0	SENT_19	[p1l1850t984r1940b1018],
35	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_19	[p1l1957t981r2056b1018],
36	,	,	O	,	_	0	SENT_19	[p1l1957t981r2056b1018],

1	Satoshi	NNP	PERSON	Satoshi	nn	4	SENT_20	[p1l868t1030r992b1062],
2	Morita	NNP	PERSON	Morita	nn	4	SENT_20	[p1l1009t1033r1127b1067],
3	,	,	O	,	_	0	SENT_20	[p1l1009t1033r1127b1067],
4	Ph.D.	NNP	O	Ph.D.	_	0	SENT_20	[p1l1145t1030r1244b1067],
5	,	,	O	,	_	0	SENT_20	[p1l1145t1030r1244b1067],
6	and	CC	O	and	_	0	SENT_20	[p1l1259t1030r1318b1062],
7	Toshihiro	NNP	PERSON	Toshihiro	nn	8	SENT_20	[p1l1331t1030r1494b1062],
8	Nukiwa	NNP	PERSON	Nukiwa	conj_and	4	SENT_20	[p1l1510t1030r1644b1067],
9	,	,	O	,	_	0	SENT_20	[p1l1510t1030r1644b1067],
10	M.D.	NNP	O	M.D.	nn	12	SENT_20	[p1l1661t1033r1752b1067],
11	,	,	O	,	_	0	SENT_20	[p1l1661t1033r1752b1067],
12	Ph.D.	NNP	O	Ph.D.	appos	4	SENT_20	[p1l1769t1030r1868b1067],
13	,	,	O	,	_	0	SENT_20	[p1l1769t1030r1868b1067],

1	for	IN	O	for	_	0	SENT_21	[p1l1036t1079r1083b1111],
2	the	DT	O	the	det	3	SENT_21	[p1l1094t1080r1147b1111],
3	North	NNP	O	North	pobj	1	SENT_21	[p1l1162t1079r1450b1121],
4	.	.	O	.	_	0	SENT_21	[p1l1162t1079r1450b1121],

1	—	NN	O	—	_	0	SENT_22	[p1l1162t1079r1450b1121],
2	.	.	O	.	_	0	SENT_22	[p1l1162t1079r1450b1121],

1	Eastjapan	NNP	O	Eastjapan	_	0	SENT_23	[p1l1162t1079r1450b1121],
2	Study	NNP	O	Study	nn	3	SENT_23	[p1l1465t1080r1560b1121],
3	Group	NNP	O	Group	dep	1	SENT_23	[p1l1572t1082r1700b1121],
4	?	.	O	?	_	0	SENT_23	[p1l1572t1082r1700b1121],
5	"	''	O	"	punct	3	SENT_23	[p1l1572t1082r1700b1121],

1	ABSTRACT	NN	O	abstract	_	0	SENT_24	[p1l1257t1201r1480b1224],

1	BACKGROUND	NN	O	background	nn	2	SENT_25	[p1l671t1311r886b1330],
2	Non	NN	O	non	nsubjpass	36	SENT_25	[p1l669t1354r920b1385],
3	—	CD	NUMBER	—	num	8	SENT_25	[p1l669t1354r920b1385],
4	small	JJ	O	small	amod	8	SENT_25	[p1l669t1354r920b1385],
5	—	JJ	O	—	amod	8	SENT_25	[p1l669t1354r920b1385],
6	cell	NN	O	cell	nn	8	SENT_25	[p1l669t1354r920b1385],
7	lung	NN	O	lung	nn	8	SENT_25	[p1l932t1354r1006b1394],
8	cancer	NN	O	cancer	nsubj	23	SENT_25	[p1l1018t1364r1125b1385],
9	with	IN	O	with	_	0	SENT_25	[p1l1135t1354r1210b1385],
10	sensitive	JJ	O	sensitive	amod	11	SENT_25	[p1l1224t1355r1361b1385],
11	mutations	NNS	O	mutation	prep_with	8	SENT_25	[p1l1375t1355r1540b1385],
12	of	IN	O	of	_	0	SENT_25	[p1l1554t1354r1592b1385],
13	the	DT	O	the	det	16	SENT_25	[p1l1599t1354r1649b1385],
14	epidermal	JJ	O	epidermal	amod	16	SENT_25	[p1l1663t1354r1827b1393],
15	growth	NN	O	growth	nn	16	SENT_25	[p1l1840t1354r1960b1394],
16	factor	NN	O	factor	prep_of	11	SENT_25	[p1l1973t1354r2069b1385],
17	receptor	NN	O	receptor	nn	20	SENT_25	[p1l669t1411r805b1443],
18	(	CD	NUMBER	(	num	20	SENT_25	[p1l819t1407r936b1440],
19	EGFR	NN	ORGANIZATION	egfr	nn	20	SENT_25	[p1l819t1407r936b1440],
20	)	NN	O	)	dep	16	SENT_25	[p1l819t1407r936b1440],
21	is	VBZ	O	be	cop	23	SENT_25	[p1l951t1405r976b1435],
22	highly	RB	O	highly	advmod	23	SENT_25	[p1l991t1404r1094b1444],
23	responsive	JJ	O	responsive	rcmod	2	SENT_25	[p1l1106t1405r1277b1443],
24	to	TO	O	to	_	0	SENT_25	[p1l1291t1411r1322b1435],
25	EGFR	NN	ORGANIZATION	egfr	nn	28	SENT_25	[p1l1336t1407r1434b1437],
26	tyrosine	NN	O	tyrosine	nn	28	SENT_25	[p1l1444t1405r1575b1443],
27	kinase	NN	O	kinase	nn	28	SENT_25	[p1l1588t1404r1694b1435],
28	inhibitors	NNS	O	inhibitor	prep_to	23	SENT_25	[p1l1708t1404r1868b1435],
29	such	JJ	O	such	_	0	SENT_25	[p1l1883t1404r1957b1435],
30	as	IN	O	as	_	0	SENT_25	[p1l1970t1415r2003b1435],
31	geﬁtinib	NN	O	geﬁtinib	prep_such_as	28	SENT_25	[p1l2017t1415r2067b1444, p1l670t1454r783b1492],
32	,	,	O	,	_	0	SENT_25	[p1l2017t1415r2067b1444, p1l670t1454r783b1492],
33	but	CC	O	but	_	0	SENT_25	[p1l799t1455r853b1485],
34	little	JJ	O	little	conj_but	23	SENT_25	[p1l865t1455r941b1485],
35	is	VBZ	O	be	auxpass	36	SENT_25	[p1l955t1455r980b1485],
36	known	VBN	O	know	_	0	SENT_25	[p1l994t1455r1110b1486],
37	about	IN	O	about	_	0	SENT_25	[p1l1123t1455r1218b1485],
38	how	WRB	O	how	advmod	44	SENT_25	[p1l1230t1455r1301b1485],
39	its	PRP$	O	its	poss	40	SENT_25	[p1l1313t1455r1351b1485],
40	efficacy	NN	O	efficacy	nsubj	44	SENT_25	[p1l1366t1454r1497b1494],
41	and	CC	O	and	_	0	SENT_25	[p1l1508t1455r1570b1485],
42	safety	NN	O	safety	nn	43	SENT_25	[p1l1584t1454r1682b1494],
43	profile	NN	O	profile	nsubj	44	SENT_25	[p1l1693t1454r1805b1494],
44	compares	VBZ	O	compare	prepc_about	36	SENT_25	[p1l1819t1465r1979b1494],
45	with	IN	O	with	_	0	SENT_25	[p1l1992t1455r2067b1485],
46	that	DT	O	that	prep_with	44	SENT_25	[p1l670t1504r736b1535],
47	of	IN	O	of	_	0	SENT_25	[p1l748t1504r787b1535],
48	standard	JJ	O	standard	amod	49	SENT_25	[p1l794t1504r941b1535],
49	chemotherapy	NN	O	chemotherapy	prep_of	46	SENT_25	[p1l954t1504r1196b1543],
50	.	.	O	.	_	0	SENT_25	[p1l954t1504r1196b1543],

1	METHODS	NNS	O	method	nsubj	4	SENT_26	[p1l672t1581r824b1600],
2	We	PRP	O	we	nsubj	4	SENT_26	[p1l668t1626r720b1654],
3	randomly	RB	O	randomly	advmod	4	SENT_26	[p1l736t1624r899b1663],
4	assigned	VBD	O	assign	_	0	SENT_26	[p1l913t1624r1061b1663],
5	230	CD	NUMBER	230	num	6	SENT_26	[p1l1076t1626r1136b1654],
6	patients	NNS	O	patient	dobj	4	SENT_26	[p1l1152t1624r1287b1663],
7	with	IN	O	with	_	0	SENT_26	[p1l1301t1624r1378b1655],
8	metastatic	JJ	O	metastatic	amod	14	SENT_26	[p1l1394t1624r1580b1661],
9	,	,	O	,	_	0	SENT_26	[p1l1394t1624r1580b1661],
10	non	JJ	O	non	amod	14	SENT_26	[p1l1598t1624r1852b1654],
11	—	NN	O	—	nn	14	SENT_26	[p1l1598t1624r1852b1654],
12	small-cell	NN	O	small-cell	nn	14	SENT_26	[p1l1598t1624r1852b1654],
13	lung	NN	O	lung	nn	14	SENT_26	[p1l1867t1624r1943b1663],
14	cancer	NN	O	cancer	prep_with	4	SENT_26	[p1l1958t1634r2069b1654],
15	and	CC	O	and	_	0	SENT_26	[p1l669t1674r730b1705],
16	EGFR	NN	ORGANIZATION	egfr	nn	17	SENT_26	[p1l743t1676r841b1706],
17	mutations	NNS	O	mutation	conj_and	14	SENT_26	[p1l851t1674r1016b1705],
18	who	WP	O	who	nsubj	22	SENT_26	[p1l1029t1674r1099b1705],
19	had	VBD	O	have	aux	22	SENT_26	[p1l1114t1674r1174b1705],
20	not	RB	O	not	neg	22	SENT_26	[p1l1188t1680r1242b1705],
21	previously	RB	DATE	previously	advmod	22	SENT_26	[p1l1254t1674r1421b1713],
22	received	VBN	O	receive	rcmod	14	SENT_26	[p1l1433t1674r1564b1705],
23	chemotherapy	NN	O	chemotherapy	dobj	22	SENT_26	[p1l1578t1674r1811b1713],
24	to	TO	O	to	aux	25	SENT_26	[p1l1823t1680r1854b1705],
25	receive	VB	O	receive	xcomp	22	SENT_26	[p1l1869t1674r1978b1705],
26	gef1	NN	O	gef1	nn	28	SENT_26	[p1l1992t1674r2067b1713],
27	—	NN	O	—	nn	28	SENT_26	[p1l1992t1674r2067b1713],
28	tinib	NN	O	tinib	dobj	25	SENT_26	[p1l670t1724r746b1755],
29	or	CC	O	or	_	0	SENT_26	[p1l759t1734r793b1755],
30	carboplatin	NN	O	carboplatin	nn	32	SENT_26	[p1l804t1724r1176b1763],
31	—	CD	NUMBER	—	num	32	SENT_26	[p1l804t1724r1176b1763],
32	paclitaxel	NN	O	paclitaxel	conj_or	28	SENT_26	[p1l804t1724r1176b1763],
33	.	.	O	.	_	0	SENT_26	[p1l804t1724r1176b1763],

1	The	DT	O	the	det	4	SENT_27	[p1l1189t1724r1250b1755],
2	primary	JJ	O	primary	amod	4	SENT_27	[p1l1262t1725r1395b1763],
3	end	NN	O	end	nn	4	SENT_27	[p1l1405t1724r1464b1755],
4	point	NN	O	point	nsubj	9	SENT_27	[p1l1475t1725r1563b1763],
5	was	VBD	O	be	cop	9	SENT_27	[p1l1571t1734r1633b1755],
6	progression	NN	O	progression	npadvmod	8	SENT_27	[p1l1645t1724r1914b1763],
7	—	CD	NUMBER	—	num	6	SENT_27	[p1l1645t1724r1914b1763],
8	free	JJ	O	free	amod	9	SENT_27	[p1l1645t1724r1914b1763],
9	survival	NN	O	survival	_	0	SENT_27	[p1l1926t1724r2066b1761],
10	;	:	O	;	_	0	SENT_27	[p1l1926t1724r2066b1761],
11	secondary	JJ	O	secondary	amod	13	SENT_27	[p1l670t1774r843b1812],
12	end	NN	O	end	nn	13	SENT_27	[p1l856t1774r916b1804],
13	points	NNS	O	point	nsubj	14	SENT_27	[p1l930t1774r1036b1813],
14	included	VBD	O	include	parataxis	9	SENT_27	[p1l1051t1774r1196b1804],
15	overall	JJ	O	overall	amod	16	SENT_27	[p1l1211t1774r1324b1804],
16	survival	NN	O	survival	dobj	14	SENT_27	[p1l1339t1774r1479b1811],
17	,	,	O	,	_	0	SENT_27	[p1l1339t1774r1479b1811],
18	response	NN	O	response	nn	19	SENT_27	[p1l1496t1784r1646b1813],
19	rate	NN	O	rate	conj_and	16	SENT_27	[p1l1661t1780r1733b1811],
20	,	,	O	,	_	0	SENT_27	[p1l1661t1780r1733b1811],
21	and	CC	O	and	_	0	SENT_27	[p1l1749t1774r1812b1804],
22	toxic	JJ	O	toxic	amod	23	SENT_27	[p1l1826t1774r1907b1804],
23	effects	NNS	O	effect	dobj	14	SENT_27	[p1l1922t1773r2040b1804],
24	.	.	O	.	_	0	SENT_27	[p1l1922t1773r2040b1804],

1	RESULTS	NNS	O	result	npadvmod	19	SENT_28	[p1l671t1842r799b1861],
2	In	IN	O	in	_	0	SENT_28	[p1l669t1887r704b1914],
3	the	DT	O	the	det	6	SENT_28	[p1l718t1884r770b1914],
4	planned	VBN	O	plan	amod	6	SENT_28	[p1l784t1884r919b1923],
5	interim	NN	O	interim	nn	6	SENT_28	[p1l933t1884r1057b1914],
6	analysis	NN	O	analysis	prep_in	19	SENT_28	[p1l1071t1884r1203b1923],
7	of	IN	O	of	_	0	SENT_28	[p1l1218t1884r1257b1915],
8	data	NNS	O	datum	prep_of	6	SENT_28	[p1l1265t1884r1336b1915],
9	for	IN	O	for	_	0	SENT_28	[p1l1349t1884r1397b1915],
10	the	DT	O	the	det	13	SENT_28	[p1l1411t1884r1462b1914],
11	first	JJ	ORDINAL	first	amod	13	SENT_28	[p1l1477t1884r1548b1914],
12	200	CD	NUMBER	200	num	13	SENT_28	[p1l1561t1886r1621b1915],
13	patients	NNS	O	patient	prep_for	8	SENT_28	[p1l1635t1885r1777b1923],
14	,	,	O	,	_	0	SENT_28	[p1l1635t1885r1777b1923],
15	progression	NN	O	progression	nsubj	19	SENT_28	[p1l1793t1884r2068b1923],
16	—	CD	NUMBER	—	num	18	SENT_28	[p1l1793t1884r2068b1923],
17	free	JJ	O	free	amod	18	SENT_28	[p1l1793t1884r2068b1923],
18	survival	NN	O	survival	dep	15	SENT_28	[p1l670t1933r796b1964],
19	was	VBD	O	be	_	0	SENT_28	[p1l807t1943r869b1964],
20	significantly	RB	O	significantly	advmod	21	SENT_28	[p1l884t1933r1089b1972],
21	longer	RBR	O	longer	advmod	19	SENT_28	[p1l1100t1933r1205b1972],
22	in	IN	O	in	_	0	SENT_28	[p1l1217t1933r1249b1963],
23	the	DT	O	the	det	25	SENT_28	[p1l1262t1933r1313b1963],
24	geﬂtinib	JJ	O	geﬂtinib	amod	25	SENT_28	[p1l1326t1933r1466b1972],
25	group	NN	O	group	prep_in	21	SENT_28	[p1l1480t1943r1576b1972],
26	than	IN	O	than	dep	19	SENT_28	[p1l1590t1933r1665b1963],
27	in	IN	O	in	_	0	SENT_28	[p1l1678t1933r1710b1963],
28	the	DT	O	the	det	37	SENT_28	[p1l1723t1933r1774b1963],
29	standard	JJ	O	standard	amod	37	SENT_28	[p1l1787t1933r2067b1964],
30	—	NN	O	—	nn	37	SENT_28	[p1l1787t1933r2067b1964],
31	chemo	NN	O	chemo	nn	37	SENT_28	[p1l1787t1933r2067b1964],
32	—	NN	O	—	nn	37	SENT_28	[p1l1787t1933r2067b1964],
33	therapy	NN	O	therapy	nn	37	SENT_28	[p1l670t1982r795b2021],
34	group	NN	O	group	nn	37	SENT_28	[p1l808t1992r906b2021],
35	(	CD	NUMBER	(	num	37	SENT_28	[p1l924t1982r1050b2017],
36	hazard	NN	O	hazard	nn	37	SENT_28	[p1l924t1982r1050b2017],
37	ratio	NN	O	ratio	prep_in	19	SENT_28	[p1l1066t1982r1142b2013],
38	for	IN	O	for	_	0	SENT_28	[p1l1159t1982r1206b2013],
39	death	NN	O	death	nn	42	SENT_28	[p1l1221t1982r1313b2013],
40	or	CC	O	or	_	0	SENT_28	[p1l1329t1992r1363b2013],
41	disease	NN	O	disease	conj_or	39	SENT_28	[p1l1378t1982r1499b2013],
42	progression	NN	O	progression	prep_for	37	SENT_28	[p1l1514t1982r1712b2021],
43	with	IN	O	with	_	0	SENT_28	[p1l1726t1982r1802b2013],
44	geﬁtinib	NN	O	geﬁtinib	nsubj	53	SENT_28	[p1l1817t1982r1970b2021],
45	,	,	O	,	_	0	SENT_28	[p1l1817t1982r1970b2021],
46	0.36	CD	NUMBER	0.36	appos	44	SENT_28	[p1l1988t1984r2066b2019],
47	;	:	O	;	_	0	SENT_28	[p1l1988t1984r2066b2019],
48	P	NN	O	p	dep	49	SENT_28	[p1l669t2033r820b2068],
49	<	JJR	O	<	dep	46	SENT_28	[p1l669t2033r820b2068],
50	0.001	CD	NUMBER	0.001	num	51	SENT_28	[p1l669t2033r820b2068],
51	)	NN	O	)	dep	49	SENT_28	[p1l669t2033r820b2068],
52	,	,	O	,	_	0	SENT_28	[p1l669t2033r820b2068],
53	resulting	VBG	O	result	prepc_with	19	SENT_28	[p1l841t2031r991b2070],
54	in	IN	O	in	_	0	SENT_28	[p1l1008t2031r1040b2061],
55	early	JJ	O	early	amod	56	SENT_28	[p1l1059t2031r1139b2070],
56	termination	NN	O	termination	prep_in	53	SENT_28	[p1l1156t2031r1356b2062],
57	of	IN	O	of	_	0	SENT_28	[p1l1375t2031r1413b2062],
58	the	DT	O	the	det	59	SENT_28	[p1l1425t2031r1477b2061],
59	study	NN	O	study	prep_of	56	SENT_28	[p1l1496t2031r1590b2070],
60	.	.	O	.	_	0	SENT_28	[p1l1496t2031r1590b2070],

1	The	DT	O	the	det	3	SENT_29	[p1l1610t2031r1672b2061],
2	gefitinib	JJ	O	gefitinib	amod	3	SENT_29	[p1l1691t2031r1835b2070],
3	group	NN	O	group	nsubj	4	SENT_29	[p1l1854t2041r1952b2070],
4	had	VBD	O	have	_	0	SENT_29	[p1l1972t2031r2032b2062],
5	a	DT	O	a	det	12	SENT_29	[p1l2051t2041r2068b2061],
6	significantly	RB	O	significantly	advmod	12	SENT_29	[p1l670t2080r881b2119],
7	longer	RBR	O	longer	advmod	12	SENT_29	[p1l891t2080r998b2119],
8	median	JJ	O	median	amod	9	SENT_29	[p1l1010t2080r1135b2111],
9	progression	NN	O	progression	pobj	7	SENT_29	[p1l1148t2080r1423b2119],
10	—	CD	NUMBER	—	num	12	SENT_29	[p1l1148t2080r1423b2119],
11	free	JJ	O	free	amod	12	SENT_29	[p1l1148t2080r1423b2119],
12	survival	NN	O	survival	dobj	4	SENT_29	[p1l1436t2080r1565b2111],
13	(	CD	NUMBER	(	number	14	SENT_29	[p1l1579t2082r1658b2115],
14	10.8	CD	DURATION	10.8	num	15	SENT_29	[p1l1579t2082r1658b2115],
15	months	NNS	NUMBER	month	tmod	12	SENT_29	[p1l1671t2080r1808b2117],
16	,	,	O	,	_	0	SENT_29	[p1l1671t2080r1808b2117],
17	vs.	FW	O	vs.	dep	12	SENT_29	[p1l1821t2090r1864b2111],
18	5.4	CD	DURATION	5.4	num	19	SENT_29	[p1l1880t2082r1927b2111],
19	months	NNS	NUMBER	month	dep	12	SENT_29	[p1l1940t2080r2067b2111],
20	in	IN	O	in	_	0	SENT_29	[p1l669t2129r702b2159],
21	the	DT	O	the	det	23	SENT_29	[p1l719t2129r771b2159],
22	chemotherapy	NN	O	chemotherapy	nn	23	SENT_29	[p1l789t2129r1026b2168],
23	group	NN	O	group	prep_in	19	SENT_29	[p1l1041t2139r1149b2168],
24	;	:	O	;	_	0	SENT_29	[p1l1041t2139r1149b2168],
25	hazard	NN	O	hazard	nn	26	SENT_29	[p1l1168t2129r1283b2160],
26	ratio	NN	O	ratio	dep	12	SENT_29	[p1l1300t2129r1386b2166],
27	,	,	O	,	_	0	SENT_29	[p1l1300t2129r1386b2166],
28	0.30	CD	NUMBER	0.30	appos	26	SENT_29	[p1l1405t2131r1484b2166],
29	;	:	O	;	_	0	SENT_29	[p1l1405t2131r1484b2166],
30	95	CD	NUMBER	95	number	31	SENT_29	[p1l1503t2131r1575b2160],
31	°	CD	NUMBER	°	amod	57	SENT_29	[p1l1503t2131r1575b2160],
32	/	:	O	/	punct	55	SENT_29	[p1l1503t2131r1575b2160],
33	o	NN	O	o	nn	35	SENT_29	[p1l1503t2131r1575b2160],
34	confidence	NN	O	confidence	nn	35	SENT_29	[p1l1592t2129r1775b2160],
35	interval	NN	O	interval	dep	55	SENT_29	[p1l1793t2129r1928b2166],
36	,	,	O	,	_	0	SENT_29	[p1l1793t2129r1928b2166],
37	0.22	CD	NUMBER	0.22	number	39	SENT_29	[p1l1948t2131r2018b2160],
38	to	TO	O	to	dep	39	SENT_29	[p1l2036t2135r2067b2160],
39	0.41	CD	NUMBER	0.41	appos	35	SENT_29	[p1l670t2180r746b2215],
40	;	:	O	;	_	0	SENT_29	[p1l670t2180r746b2215],
41	P	NN	O	p	dep	42	SENT_29	[p1l763t2180r914b2215],
42	<	JJR	O	<	dep	39	SENT_29	[p1l763t2180r914b2215],
43	0.001	CD	NUMBER	0.001	num	44	SENT_29	[p1l763t2180r914b2215],
44	)	NN	O	)	dep	42	SENT_29	[p1l763t2180r914b2215],
45	,	,	O	,	_	0	SENT_29	[p1l763t2180r914b2215],
46	as	RB	O	as	_	0	SENT_29	[p1l932t2188r966b2208],
47	well	RB	O	well	_	0	SENT_29	[p1l981t2178r1050b2209],
48	as	IN	O	as	_	0	SENT_29	[p1l1066t2188r1099b2208],
49	a	DT	O	a	det	52	SENT_29	[p1l1116t2188r1134b2208],
50	higher	JJR	O	higher	amod	52	SENT_29	[p1l1149t2178r1258b2217],
51	response	NN	O	response	nn	52	SENT_29	[p1l1274t2188r1421b2217],
52	rate	NN	O	rate	dep	39	SENT_29	[p1l1438t2185r1500b2208],
53	(	CD	NUMBER	(	number	54	SENT_29	[p1l1519t2180r1632b2213],
54	73.7	CD	NUMBER	73.7	dep	52	SENT_29	[p1l1519t2180r1632b2213],
55	°	NN	O	°	dep	31	SENT_29	[p1l1519t2180r1632b2213],
56	/	:	O	/	punct	55	SENT_29	[p1l1519t2180r1632b2213],
57	o	NN	O	o	dep	12	SENT_29	[p1l1519t2180r1632b2213],
58	vs.	CC	O	vs.	prep	57	SENT_29	[p1l1646t2188r1689b2209],
59	30.7	CD	PERCENT	30.7	num	60	SENT_29	[p1l1708t2180r1819b2215],
60	%	NN	PERCENT	%	dep	58	SENT_29	[p1l1708t2180r1819b2215],
61	,	,	O	,	_	0	SENT_29	[p1l1708t2180r1819b2215],
62	P	NN	O	p	dep	63	SENT_29	[p1l1837t2180r1988b2213],
63	<	JJR	O	<	appos	12	SENT_29	[p1l1837t2180r1988b2213],
64	0.001	CD	NUMBER	0.001	num	65	SENT_29	[p1l1837t2180r1988b2213],
65	)	NN	O	)	dep	63	SENT_29	[p1l1837t2180r1988b2213],
66	.	.	O	.	_	0	SENT_29	[p1l1837t2180r1988b2213],

1	The	DT	O	the	det	4	SENT_30	[p1l2005t2178r2067b2208],
2	median	JJ	O	median	amod	4	SENT_30	[p1l669t2227r795b2258],
3	overall	JJ	O	overall	amod	4	SENT_30	[p1l807t2227r918b2258],
4	survival	NN	O	survival	nsubj	7	SENT_30	[p1l930t2227r1059b2258],
5	was	VBD	O	be	cop	7	SENT_30	[p1l1069t2237r1132b2258],
6	30.5	CD	DURATION	30.5	num	7	SENT_30	[p1l1145t2229r1213b2258],
7	months	NNS	NUMBER	month	_	0	SENT_30	[p1l1226t2227r1353b2258],
8	in	IN	O	in	_	0	SENT_30	[p1l1366t2227r1398b2257],
9	the	DT	O	the	det	11	SENT_30	[p1l1410t2227r1462b2257],
10	geﬁtinib	JJ	O	geﬁtinib	amod	11	SENT_30	[p1l1474t2227r1618b2266],
11	group	NN	O	group	prep_in	7	SENT_30	[p1l1631t2237r1728b2266],
12	and	CC	O	and	_	0	SENT_30	[p1l1741t2227r1802b2258],
13	23.6	CD	DURATION	23.6	num	14	SENT_30	[p1l1814t2229r1884b2258],
14	months	NNS	NUMBER	month	npadvmod	7	SENT_30	[p1l1896t2227r2023b2258],
15	in	IN	O	in	_	0	SENT_30	[p1l2035t2227r2068b2257],
16	the	DT	O	the	det	18	SENT_30	[p1l670t2276r720b2306],
17	chemotherapy	NN	O	chemotherapy	nn	18	SENT_30	[p1l733t2276r965b2315],
18	group	NN	O	group	prep_in	7	SENT_30	[p1l976t2286r1072b2315],
19	(	CD	NUMBER	(	num	22	SENT_30	[p1l1087t2278r1235b2311],
20	P	NN	O	p	nn	22	SENT_30	[p1l1087t2278r1235b2311],
21	=	JJ	O	=	amod	22	SENT_30	[p1l1087t2278r1235b2311],
22	O.	NNP	O	O.	dep	18	SENT_30	[p1l1087t2278r1235b2311],
23	31	CD	NUMBER	31	num	24	SENT_30	[p1l1087t2278r1235b2311],
24	)	CD	NUMBER	)	dep	7	SENT_30	[p1l1087t2278r1235b2311],
25	.	.	O	.	_	0	SENT_30	[p1l1087t2278r1235b2311],

1	The	DT	O	the	det	5	SENT_31	[p1l1248t2276r1310b2306],
2	most	RBS	O	most	advmod	3	SENT_31	[p1l1322t2282r1405b2307],
3	common	JJ	O	common	amod	5	SENT_31	[p1l1415t2286r1561b2307],
4	adverse	JJ	O	adverse	amod	5	SENT_31	[p1l1573t2276r1693b2307],
5	events	NNS	O	event	nsubj	11	SENT_31	[p1l1705t2282r1806b2307],
6	in	IN	O	in	_	0	SENT_31	[p1l1818t2276r1850b2306],
7	the	DT	O	the	det	9	SENT_31	[p1l1863t2276r1913b2306],
8	gefitinib	JJ	O	gefitinib	amod	9	SENT_31	[p1l1926t2276r2067b2315],
9	group	NN	O	group	prep_in	5	SENT_31	[p1l669t2335r767b2364],
10	were	VBD	O	be	cop	11	SENT_31	[p1l782t2335r860b2356],
11	rash	JJ	O	rash	_	0	SENT_31	[p1l876t2325r946b2355],
12	(	NN	O	(	tmod	11	SENT_31	[p1l964t2327r1084b2360],
13	71.1	CD	PERCENT	71.1	num	14	SENT_31	[p1l964t2327r1084b2360],
14	%	NN	PERCENT	%	dep	12	SENT_31	[p1l964t2327r1084b2360],
15	)	CD	NUMBER	)	nn	19	SENT_31	[p1l964t2327r1084b2360],
16	and	CC	O	and	_	0	SENT_31	[p1l1101t2325r1162b2356],
17	elevated	JJ	O	elevated	nn	19	SENT_31	[p1l1178t2325r1311b2356],
18	aminotransferase	NN	O	aminotransferase	nn	19	SENT_31	[p1l1326t2325r1620b2356],
19	levels	NNS	O	level	nsubj	20	SENT_31	[p1l1635t2325r1725b2356],
20	(	VBP	O	(	rcmod	14	SENT_31	[p1l1743t2327r1873b2362],
21	55.3	CD	PERCENT	55.3	num	22	SENT_31	[p1l1743t2327r1873b2362],
22	%	NN	PERCENT	%	dobj	20	SENT_31	[p1l1743t2327r1873b2362],
23	)	CD	NUMBER	)	dep	22	SENT_31	[p1l1743t2327r1873b2362],
24	,	,	O	,	_	0	SENT_31	[p1l1743t2327r1873b2362],
25	and	CC	O	and	_	0	SENT_31	[p1l1890t2325r1952b2356],
26	in	IN	O	in	dobj	20	SENT_31	[p1l1967t2325r1999b2355],
27	the	DT	O	the	det	29	SENT_31	[p1l2015t2325r2067b2355],
28	chemotherapy	NN	O	chemotherapy	nn	29	SENT_31	[p1l670t2374r911b2413],
29	group	NN	O	group	pobj	26	SENT_31	[p1l923t2384r1031b2413],
30	,	,	O	,	_	0	SENT_31	[p1l923t2384r1031b2413],
31	neutropenia	NN	O	neutropenia	appos	29	SENT_31	[p1l1047t2374r1253b2413],
32	(	CD	PERCENT	(	number	33	SENT_31	[p1l1267t2376r1400b2411],
33	77.0	CD	PERCENT	77.0	num	34	SENT_31	[p1l1267t2376r1400b2411],
34	%	NN	PERCENT	%	dep	31	SENT_31	[p1l1267t2376r1400b2411],
35	)	CD	NUMBER	)	dep	22	SENT_31	[p1l1267t2376r1400b2411],
36	,	,	O	,	_	0	SENT_31	[p1l1267t2376r1400b2411],
37	anemia	NN	O	anemia	appos	35	SENT_31	[p1l1415t2375r1540b2404],
38	(	CD	PERCENT	(	number	39	SENT_31	[p1l1555t2376r1689b2411],
39	64.6	CD	PERCENT	64.6	num	40	SENT_31	[p1l1555t2376r1689b2411],
40	%	NN	PERCENT	%	dep	37	SENT_31	[p1l1555t2376r1689b2411],
41	)	CD	NUMBER	)	tmod	20	SENT_31	[p1l1555t2376r1689b2411],
42	,	,	O	,	_	0	SENT_31	[p1l1555t2376r1689b2411],
43	appetite	NN	O	appetite	nn	44	SENT_31	[p1l1704t2374r1840b2413],
44	loss	NN	O	loss	appos	41	SENT_31	[p1l1853t2374r1918b2405],
45	(	CD	PERCENT	(	number	46	SENT_31	[p1l1934t2376r2065b2411],
46	56.6	CD	PERCENT	56.6	num	47	SENT_31	[p1l1934t2376r2065b2411],
47	%	NN	PERCENT	%	dep	44	SENT_31	[p1l1934t2376r2065b2411],
48	)	CD	NUMBER	)	dep	44	SENT_31	[p1l1934t2376r2065b2411],
49	,	,	O	,	_	0	SENT_31	[p1l1934t2376r2065b2411],
50	and	CC	O	and	_	0	SENT_31	[p1l669t2423r731b2454],
51	sensory	JJ	O	sensory	amod	52	SENT_31	[p1l743t2433r871b2462],
52	neuropathy	NN	O	neuropathy	dep	12	SENT_31	[p1l882t2423r1072b2462],
53	(	CD	PERCENT	(	num	52	SENT_31	[p1l1085t2425r1218b2458],
54	54.9	CD	PERCENT	54.9	number	55	SENT_31	[p1l1085t2425r1218b2458],
55	%	NN	PERCENT	%	amod	52	SENT_31	[p1l1085t2425r1218b2458],
56	)	CD	NUMBER	)	dep	12	SENT_31	[p1l1085t2425r1218b2458],
57	.	.	O	.	_	0	SENT_31	[p1l1085t2425r1218b2458],

1	One	CD	NUMBER	one	num	2	SENT_32	[p1l1232t2425r1299b2454],
2	patient	NN	O	patient	nsubj	5	SENT_32	[p1l1311t2423r1428b2462],
3	receiving	VBG	O	receive	partmod	2	SENT_32	[p1l1439t2423r1590b2462],
4	geﬂtinib	NN	O	geﬂtinib	dobj	3	SENT_32	[p1l1601t2423r1746b2462],
5	died	VBD	O	die	_	0	SENT_32	[p1l1759t2423r1830b2454],
6	from	IN	O	from	_	0	SENT_32	[p1l1842t2423r1924b2454],
7	interstitial	JJ	O	interstitial	amod	9	SENT_32	[p1l1936t2423r2067b2453, p1l670t2472r724b2502],
8	lung	NN	O	lung	nn	9	SENT_32	[p1l736t2472r811b2511],
9	disease	NN	O	disease	prep_from	5	SENT_32	[p1l824t2472r953b2503],
10	.	.	O	.	_	0	SENT_32	[p1l824t2472r953b2503],

1	CONCLUSIONS	NNS	O	conclusion	nsubj	24	SENT_33	[p1l670t2552r896b2571],
2	First	JJ	ORDINAL	first	advmod	1	SENT_33	[p1l669t2591r817b2621],
3	—	CD	NUMBER	—	num	5	SENT_33	[p1l669t2591r817b2621],
4	line	NN	O	line	nn	5	SENT_33	[p1l669t2591r817b2621],
5	geﬁtinib	NN	O	geﬁtinib	dep	2	SENT_33	[p1l829t2591r973b2630],
6	for	IN	O	for	_	0	SENT_33	[p1l986t2591r1034b2622],
7	patients	NNS	O	patient	prep_for	1	SENT_33	[p1l1044t2591r1177b2630],
8	with	IN	O	with	_	0	SENT_33	[p1l1188t2591r1264b2622],
9	advanced	JJ	O	advanced	amod	14	SENT_33	[p1l1276t2591r1430b2622],
10	non	JJ	O	non	amod	14	SENT_33	[p1l1442t2591r1691b2622],
11	—	NN	O	—	nn	14	SENT_33	[p1l1442t2591r1691b2622],
12	small-cell	NN	O	small-cell	nn	14	SENT_33	[p1l1442t2591r1691b2622],
13	lung	NN	O	lung	nn	14	SENT_33	[p1l1702t2591r1778b2630],
14	cancer	NN	O	cancer	prep_with	7	SENT_33	[p1l1789t2601r1898b2621],
15	who	WP	O	who	nsubjpass	17	SENT_33	[p1l1907t2591r1978b2622],
16	were	VBD	O	be	auxpass	17	SENT_33	[p1l1989t2601r2067b2622],
17	selected	VBN	O	select	rcmod	1	SENT_33	[p1l670t2642r802b2673],
18	on	IN	O	on	_	0	SENT_33	[p1l817t2652r858b2673],
19	the	DT	O	the	det	20	SENT_33	[p1l873t2642r925b2672],
20	basis	NN	O	basis	prep_on	17	SENT_33	[p1l940t2642r1022b2673],
21	of	IN	O	of	_	0	SENT_33	[p1l1038t2642r1077b2673],
22	EGFR	NN	ORGANIZATION	egfr	nn	23	SENT_33	[p1l1084t2644r1183b2674],
23	mutations	NNS	O	mutation	prep_of	20	SENT_33	[p1l1194t2643r1363b2673],
24	improved	VBD	O	improve	_	0	SENT_33	[p1l1378t2642r1535b2681],
25	progression	NN	O	progression	npadvmod	27	SENT_33	[p1l1549t2642r1824b2681],
26	—	CD	NUMBER	—	num	25	SENT_33	[p1l1549t2642r1824b2681],
27	free	JJ	O	free	amod	28	SENT_33	[p1l1549t2642r1824b2681],
28	survival	NN	O	survival	dobj	24	SENT_33	[p1l1839t2642r1977b2679],
29	,	,	O	,	_	0	SENT_33	[p1l1839t2642r1977b2679],
30	with	IN	O	with	_	0	SENT_33	[p1l1992t2642r2068b2673],
31	acceptable	JJ	O	acceptable	amod	32	SENT_33	[p1l669t2693r839b2732],
32	toxicity	NN	O	toxicity	prep_with	24	SENT_33	[p1l853t2693r978b2732],
33	,	,	O	,	_	0	SENT_33	[p1l853t2693r978b2732],
34	as	IN	O	as	_	0	SENT_33	[p1l993t2703r1026b2723],
35	compared	VBN	O	compare	prepc_as	24	SENT_33	[p1l1041t2693r1203b2732],
36	with	IN	O	with	pcomp	35	SENT_33	[p1l1215t2693r1290b2724],
37	standard	JJ	O	standard	amod	38	SENT_33	[p1l1304t2693r1448b2724],
38	chemotherapy	NN	O	chemotherapy	pobj	36	SENT_33	[p1l1462t2693r1699b2732],
39	.	.	O	.	_	0	SENT_33	[p1l1462t2693r1699b2732],

1	(	NNP	O	(	nn	2	SENT_34	[p1l1717t2695r1921b2728],
2	UMIN	NNP	O	UMIN	_	0	SENT_34	[p1l1717t2695r1921b2728],
3	.	.	O	.	_	0	SENT_34	[p1l1717t2695r1921b2728],

1	—	NN	O	—	_	0	SENT_35	[p1l1717t2695r1921b2728],
2	.	.	O	.	_	0	SENT_35	[p1l1717t2695r1921b2728],

1	CTR	NN	O	ctr	nn	2	SENT_36	[p1l1717t2695r1921b2728],
2	number	NN	O	number	_	0	SENT_36	[p1l1930t2693r2066b2730],
3	,	,	O	,	_	0	SENT_36	[p1l1930t2693r2066b2730],
4	C000000376	NN	O	c000000376	appos	2	SENT_36	[p1l669t2746r897b2779],
5	.	.	O	.	_	0	SENT_36	[p1l669t2746r897b2779],
6	)	SYM	O	)	dep	2	SENT_36	[p1l669t2746r897b2779],

1	NENGLJMED362	NN	O	nengljmed362	_	0	SENT_37	[p1l909t2839r1171b2867],
2	;	:	O	;	_	0	SENT_37	[p1l909t2839r1171b2867],
3	25	CD	NUMBER	25	num	5	SENT_37	[p1l909t2839r1171b2867],
4	NEJM.ORG	NN	O	nejm.org	nn	5	SENT_37	[p1l1206t2845r1330b2867],
5	JUNE24	NN	O	june24	dep	1	SENT_37	[p1l1361t2845r1543b2867],
6	,20	CD	NUMBER	,20	nn	9	SENT_37	[p1l1361t2845r1543b2867],
7	'	''	O	'	_	0	SENT_37	[p1l1361t2845r1543b2867],
8	|	CD	NUMBER	|	dep	6	SENT_37	[p1l1361t2845r1543b2867],
9	O	NN	O	o	dep	5	SENT_37	[p1l1361t2845r1543b2867],

1	The	DT	O	the	det	4	SENT_38	[p1l882t2902r933b2926],
2	New	NNP	O	New	nn	4	SENT_38	[p1l942t2903r1004b2926],
3	England	NNP	O	England	nn	4	SENT_38	[p1l1013t2902r1124b2933],
4	Journal	NNP	O	Journal	_	0	SENT_38	[p1l1133t2902r1230b2926],
5	of	IN	O	of	_	0	SENT_38	[p1l1240t2902r1269b2926],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_38	[p1l1275t2902r1400b2926],

1	Copyright	NN	O	copyright	_	0	SENT_39	[p1l674t2984r809b3015],
2	©	CD	NUMBER	©	num	6	SENT_39	[p1l818t2984r841b3008],
3	2010	CD	DATE	2010	num	6	SENT_39	[p1l852t2984r917b3008],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_39	[p1l926t2984r1117b3008],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_39	[p1l1127t2984r1235b3008],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_39	[p1l1246t2984r1351b3015],
7	.	.	O	.	_	0	SENT_39	[p1l1246t2984r1351b3015],

1	All	DT	O	all	det	2	SENT_40	[p1l1362t2984r1403b3008],
2	rights	NNS	O	rights	nsubj	3	SENT_40	[p1l1412t2984r1487b3015],
3	reserved	VBN	O	reserve	_	0	SENT_40	[p1l1496t2984r1615b3008],
4	.	.	O	.	_	0	SENT_40	[p1l1496t2984r1615b3008],

1	GEFITINIB	NNP	O	GEFITINIB	nn	3	SENT_41	[p1l495t3090r671b3109],
2	OR	NN	O	or	nn	3	SENT_41	[p1l685t3090r730b3109],
3	CHEMOTHERAPY	NNP	O	CHEMOTHERAPY	_	0	SENT_41	[p1l742t3090r1019b3109],
4	FOR	IN	O	for	_	0	SENT_41	[p1l1032t3090r1096b3109],
5	NON	NNP	O	NON	prep_for	3	SENT_41	[p1l1109t3090r1412b3109],
6	.	.	O	.	_	0	SENT_41	[p1l1109t3090r1412b3109],

1	—	NN	O	—	_	0	SENT_42	[p1l1109t3090r1412b3109],
2	.	.	O	.	_	0	SENT_42	[p1l1109t3090r1412b3109],

1	SMALL-CELL	NN	O	small-cell	nn	2	SENT_43	[p1l1109t3090r1412b3109],
2	LUNG	NN	O	lung	_	0	SENT_43	[p1l1426t3090r1517b3109],
3	CANCER	NNP	O	CANCER	dep	2	SENT_43	[p1l1531t3090r1665b3109],

1	ON	NNP	O	ON	_	0	SENT_44	[p1l372t3317r1125b3374],
2	.	.	O	.	_	0	SENT_44	[p1l372t3317r1125b3374],

1	—	NN	O	—	_	0	SENT_45	[p1l372t3317r1125b3374],
2	.	.	O	.	_	0	SENT_45	[p1l372t3317r1125b3374],

1	SMALL-CELL	NN	O	small-cell	nn	3	SENT_46	[p1l372t3317r1125b3374],
2	LUNG	NN	O	lung	nn	3	SENT_46	[p1l1189t3317r1446b3374],
3	CANCER	NNP	O	CANCER	nsubj	5	SENT_46	[p1l1508t3317r1880b3374],
4	IS	VBZ	O	be	cop	5	SENT_46	[p1l1940t3317r2017b3374],
5	A	DT	O	a	_	0	SENT_46	[p1l2077t3318r2137b3373],

1	major	JJ	O	major	amod	2	SENT_47	[p1l372t3426r621b3525],
2	cause	NN	O	cause	_	0	SENT_47	[p1l667t3451r900b3503],
3	of	IN	O	of	_	0	SENT_47	[p1l950t3424r1049b3503],
4	death	NN	O	death	prep_of	2	SENT_47	[p1l1080t3424r1316b3503],
5	from	IN	O	from	_	0	SENT_47	[p1l1365t3424r1575b3503],
6	cancer	NN	O	cancer	prep_from	2	SENT_47	[p1l1624t3450r1923b3503],
7	.	.	O	.	_	0	SENT_47	[p1l1624t3450r1923b3503],

1	The	DT	O	the	det	2	SENT_48	[p1l1973t3424r2133b3503],
2	use	NN	O	use	nsubjpass	7	SENT_48	[p1l372t3580r512b3632],
3	of	IN	O	of	_	0	SENT_48	[p1l550t3553r650b3632],
4	cytotoxic	JJ	O	cytotoxic	amod	5	SENT_48	[p1l669t3555r1057b3654],
5	chemotherapy	NN	O	chemotherapy	prep_of	2	SENT_48	[p1l1094t3553r1705b3654],
6	is	VBZ	O	be	auxpass	7	SENT_48	[p1l1736t3555r1802b3632],
7	associated	VBN	O	associate	_	0	SENT_48	[p1l1841t3555r2132b3632, p1l11t3682r185b3761],
8	with	IN	O	with	_	0	SENT_48	[p1l216t3682r408b3762],
9	a	DT	O	a	det	11	SENT_48	[p1l443t3709r487b3761],
10	response	NN	O	response	nn	11	SENT_48	[p1l520t3708r893b3783],
11	rate	NN	O	rate	prep_with	7	SENT_48	[p1l929t3699r1085b3761],
12	of	IN	O	of	_	0	SENT_48	[p1l1121t3682r1220b3761],
13	20	CD	NUMBER	20	number	15	SENT_48	[p1l1236t3688r1335b3761],
14	to	TO	O	to	dep	15	SENT_48	[p1l1371t3699r1452b3761],
15	35	CD	PERCENT	35	num	16	SENT_48	[p1l1489t3687r1668b3761],
16	%	NN	PERCENT	%	prep_of	11	SENT_48	[p1l1489t3687r1668b3761],
17	and	CC	O	and	_	0	SENT_48	[p1l1702t3682r1858b3761],
18	a	DT	O	a	det	19	SENT_48	[p1l1892t3709r1936b3761],
19	median	NN	O	median	prep_of	11	SENT_48	[p1l1970t3708r2132b3761, p2l12t20r205b99],

1	survival	NN	O	survival	nn	2	SENT_49	[p2l254t20r595b99],
2	time	NN	O	time	nsubj	29	SENT_49	[p2l643t21r839b99],
3	of	IN	O	of	_	0	SENT_49	[p2l888t20r989b99],
4	10	CD	DURATION	10	number	6	SENT_49	[p2l1022t26r1116b99],
5	to	TO	DURATION	to	dep	6	SENT_49	[p2l1166t37r1248b99],
6	12	CD	DURATION	12	num	7	SENT_49	[p2l1302t26r1400b98],
7	months	NNS	NUMBER	month	prep_of	2	SENT_49	[p2l1449t20r1782b99],
8	among	IN	O	among	_	0	SENT_49	[p2l1832t46r2137b121],
9	patients	NNS	O	patient	prep_among	7	SENT_49	[p2l10t149r351b249],
10	with	IN	O	with	_	0	SENT_49	[p2l385t148r580b228],
11	advanced	JJ	O	advanced	amod	13	SENT_49	[p2l616t148r1012b227],
12	non	JJ	O	non	amod	13	SENT_49	[p2l1048t148r1690b227],
13	—	NN	O	—	prep_with	9	SENT_49	[p2l1048t148r1690b227],
14	small	JJ	O	small	amod	16	SENT_49	[p2l1048t148r1690b227],
15	—	NN	O	—	nn	16	SENT_49	[p2l1048t148r1690b227],
16	cell	NN	O	cell	dep	21	SENT_49	[p2l1048t148r1690b227],
17	lung	NN	O	lung	nn	18	SENT_49	[p2l1725t148r1918b249],
18	cancer	NN	O	cancer	dep	16	SENT_49	[p2l1952t174r2132b227, p2l12t281r256b355],
19	.1	CD	NUMBER	.1	num	20	SENT_49	[p2l1952t174r2132b227, p2l12t281r256b355],
20	»	NN	O	»	dep	21	SENT_49	[p2l1952t174r2132b227, p2l12t281r256b355],
21	2	CD	NUMBER	2	dep	9	SENT_49	[p2l1952t174r2132b227, p2l12t281r256b355],
22	Gefitinib	NNP	O	Gefitinib	dep	21	SENT_49	[p2l283t276r676b355],
23	is	VBZ	O	be	cop	29	SENT_49	[p2l703t277r768b355],
24	an	DT	O	a	det	29	SENT_49	[p2l796t302r899b355],
25	orally	RB	O	orally	advmod	26	SENT_49	[p2l926t276r1169b377],
26	administered	VBN	O	administer	amod	29	SENT_49	[p2l1191t276r1760b355],
27	tyrosine	NN	O	tyrosine	nn	29	SENT_49	[p2l1787t277r2133b377],
28	kinase	NN	O	kinase	nn	29	SENT_49	[p2l11t404r290b484],
29	inhibitor	NN	O	inhibitor	_	0	SENT_49	[p2l332t404r714b483],
30	of	IN	O	of	_	0	SENT_49	[p2l754t404r854b483],
31	the	DT	O	the	det	34	SENT_49	[p2l879t404r1012b483],
32	epidermal	JJ	O	epidermal	amod	34	SENT_49	[p2l1055t404r1487b505],
33	growth	NN	O	growth	nn	34	SENT_49	[p2l1529t404r1844b505],
34	factor	NN	O	factor	prep_of	29	SENT_49	[p2l1886t404r2137b483],
35	receptor	NN	O	receptor	nn	38	SENT_49	[p2l11t549r352b633],
36	(	CD	NUMBER	(	num	38	SENT_49	[p2l381t538r700b624],
37	EGFR	NN	ORGANIZATION	egfr	nn	38	SENT_49	[p2l381t538r700b624],
38	)	NN	O	)	dep	34	SENT_49	[p2l381t538r700b624],
39	.	.	O	.	_	0	SENT_49	[p2l381t538r700b624],

1	In	IN	O	in	_	0	SENT_50	[p2l732t540r818b610],
2	two	CD	NUMBER	two	num	5	SENT_50	[p2l846t549r999b611],
3	phase	NN	O	phase	nn	5	SENT_50	[p2l1027t532r1267b633],
4	2	CD	NUMBER	2	num	5	SENT_50	[p2l1294t538r1342b610],
5	studies	NNS	O	study	prep_in	26	SENT_50	[p2l1372t532r1658b611],
6	of	IN	O	of	_	0	SENT_50	[p2l1689t532r1787b611],
7	patients	NNS	O	patient	prep_of	5	SENT_50	[p2l1794t533r2131b633],
8	with	IN	O	with	prep	7	SENT_50	[p2l7t660r202b740],
9	previously	RB	DATE	previously	pcomp	8	SENT_50	[p2l238t660r677b761],
10	treated	VBN	O	treat	partmod	5	SENT_50	[p2l710t660r1008b739],
11	non	JJ	O	non	amod	12	SENT_50	[p2l1045t660r1688b739],
12	—	JJ	O	—	amod	17	SENT_50	[p2l1045t660r1688b739],
13	small	JJ	O	small	amod	17	SENT_50	[p2l1045t660r1688b739],
14	—	NN	O	—	nn	17	SENT_50	[p2l1045t660r1688b739],
15	cell	NN	O	cell	nn	17	SENT_50	[p2l1045t660r1688b739],
16	lung	NN	O	lung	nn	17	SENT_50	[p2l1724t660r1917b761],
17	cancer	NN	O	cancer	dep	10	SENT_50	[p2l1952t686r2132b739, p2l12t814r156b884],
18	,	,	O	,	_	0	SENT_50	[p2l1952t686r2132b739, p2l12t814r156b884],
19	the	DT	O	the	det	21	SENT_50	[p2l199t788r332b867],
20	response	NN	O	response	nn	21	SENT_50	[p2l369t814r750b889],
21	rate	NN	O	rate	nsubj	26	SENT_50	[p2l787t805r947b867],
22	was	VBD	O	be	cop	26	SENT_50	[p2l980t815r1142b867],
23	9	CD	NUMBER	9	number	26	SENT_50	[p2l1182t794r1229b867],
24	to	TO	O	to	dep	26	SENT_50	[p2l1267t805r1349b867],
25	19	CD	NUMBER	19	number	26	SENT_50	[p2l1390t793r1698b867],
26	°	CD	NUMBER	°	_	0	SENT_50	[p2l1390t793r1698b867],
27	/	:	O	/	punct	36	SENT_50	[p2l1390t793r1698b867],
28	o.	NN	O	o.	nn	30	SENT_50	[p2l1390t793r1698b867],
29	3	CD	NUMBER	3	num	30	SENT_50	[p2l1390t793r1698b867],
30	’	NN	O	’	dep	32	SENT_50	[p2l1390t793r1698b867],
31	4	CD	NUMBER	4	num	30	SENT_50	[p2l1390t793r1698b867],
32	In	IN	O	in	dep	36	SENT_50	[p2l1734t796r1823b866],
33	subsequent	JJ	O	subsequent	amod	34	SENT_50	[p2l1862t788r2132b867, p2l12t933r255b1017],
34	phase	NN	O	phase	pobj	32	SENT_50	[p2l294t916r542b1017],
35	3	CD	NUMBER	3	num	36	SENT_50	[p2l590t922r634b995],
36	trials	NNS	O	trial	dep	26	SENT_50	[p2l684t916r927b1012],
37	,	,	O	,	_	0	SENT_50	[p2l684t916r927b1012],
38	the	DT	O	the	det	39	SENT_50	[p2l979t916r1112b995],
39	noninferiority	NN	O	noninferiority	appos	36	SENT_50	[p2l1158t916r1765b1017],
40	of	IN	O	of	_	0	SENT_50	[p2l1808t916r1907b995],
41	gef1	NN	O	gef1	nn	43	SENT_50	[p2l1935t916r2132b1017],
42	—	CD	NUMBER	—	num	43	SENT_50	[p2l1935t916r2132b1017],
43	tinib	NN	O	tinib	prep_of	26	SENT_50	[p2l12t1044r213b1123],
44	as	IN	O	as	mark	54	SENT_50	[p2l247t1071r332b1123],
45	compared	VBN	O	compare	csubjpass	54	SENT_50	[p2l368t1044r794b1145],
46	with	IN	O	with	_	0	SENT_50	[p2l823t1044r1018b1123],
47	docetaxel	NN	O	docetaxel	prep_with	45	SENT_50	[p2l1052t1044r1457b1123],
48	with	IN	O	with	_	0	SENT_50	[p2l1485t1044r1681b1123],
49	respect	NN	O	respect	prep_with	45	SENT_50	[p2l1714t1061r2022b1145],
50	to	TO	O	to	_	0	SENT_50	[p2l2050t1061r2132b1123],
51	overall	JJ	O	overall	amod	52	SENT_50	[p2l12t1172r297b1251],
52	survival	NN	O	survival	prep_to	45	SENT_50	[p2l337t1172r669b1252],
53	was	VBD	O	be	auxpass	54	SENT_50	[p2l702t1199r864b1251],
54	shown	VBN	O	show	advcl	26	SENT_50	[p2l906t1172r1188b1251],
55	in	IN	O	in	_	0	SENT_50	[p2l1226t1173r1309b1250],
56	one	CD	NUMBER	one	num	57	SENT_50	[p2l1348t1198r1499b1251],
57	study	NN	O	study	prep_in	54	SENT_50	[p2l1539t1172r1769b1273],
58	(	NN	O	(	nn	60	SENT_50	[p2l1808t1172r2133b1264],
59	hazard	NN	O	hazard	nn	60	SENT_50	[p2l1808t1172r2133b1264],
60	ratio	NN	O	ratio	tmod	54	SENT_50	[p2l11t1300r230b1394],
61	,	,	O	,	_	0	SENT_50	[p2l11t1300r230b1394],
62	1	CD	NUMBER	1	appos	60	SENT_50	[p2l271t1305r508b1390],
63	.	.	O	.	_	0	SENT_50	[p2l271t1305r508b1390],

1	O2	CD	NUMBER	o2	number	2	SENT_51	[p2l271t1305r508b1390],
2	)	CD	NUMBER	)	nsubjpass	34	SENT_51	[p2l271t1305r508b1390],
3	5	CD	NUMBER	5	dep	2	SENT_51	[p2l271t1305r508b1390],
4	but	CC	O	but	_	0	SENT_51	[p2l544t1299r684b1378],
5	not	RB	O	not	_	0	SENT_51	[p2l710t1316r853b1377],
6	another	DT	O	another	det	9	SENT_51	[p2l879t1299r1214b1377],
7	(	NN	O	(	nn	9	SENT_51	[p2l1248t1299r1573b1390],
8	hazard	NN	O	hazard	nn	9	SENT_51	[p2l1248t1299r1573b1390],
9	ratio	NN	O	ratio	conj_negcc	2	SENT_51	[p2l1605t1300r1824b1394],
10	,	,	O	,	_	0	SENT_51	[p2l1605t1300r1824b1394],
11	1.12	CD	NUMBER	1.12	number	12	SENT_51	[p2l1864t1303r2133b1390],
12	)	CD	NUMBER	)	num	13	SENT_51	[p2l1864t1303r2133b1390],
13	.6	CD	NUMBER	.6	appos	9	SENT_51	[p2l1864t1303r2133b1390],
14	Meanwhile	RB	O	meanwhile	advmod	13	SENT_51	[p2l8t1427r497b1523],
15	,	,	O	,	_	0	SENT_51	[p2l8t1427r497b1523],
16	demographic	JJ	O	demographic	amod	19	SENT_51	[p2l530t1427r1087b1528],
17	and	CC	O	and	_	0	SENT_51	[p2l1112t1427r1267b1506],
18	clinical	JJ	O	clinical	amod	19	SENT_51	[p2l1294t1427r1600b1506],
19	factors	NNS	O	factor	appos	9	SENT_51	[p2l1626t1427r1910b1506],
20	such	JJ	O	such	_	0	SENT_51	[p2l1940t1427r2133b1506],
21	as	IN	O	as	_	0	SENT_51	[p2l11t1582r95b1634],
22	Asian	JJ	MISC	asian	amod	23	SENT_51	[p2l121t1556r361b1634],
23	race	NN	O	race	prep_such_as	2	SENT_51	[p2l389t1581r580b1651],
24	,	,	O	,	_	0	SENT_51	[p2l389t1581r580b1651],
25	female	JJ	O	female	amod	26	SENT_51	[p2l613t1555r895b1634],
26	sex	NN	O	sex	prep_such_as	2	SENT_51	[p2l924t1582r1077b1651],
27	,	,	O	,	_	0	SENT_51	[p2l924t1582r1077b1651],
28	nonsmoking	JJ	O	nonsmoking	amod	29	SENT_51	[p2l1110t1555r1648b1656],
29	status	NN	O	status	prep_such_as	2	SENT_51	[p2l1673t1572r1943b1651],
30	,	,	O	,	_	0	SENT_51	[p2l1673t1572r1943b1651],
31	and	CC	O	and	_	0	SENT_51	[p2l1975t1555r2134b1634],
32	adenocarcinoma	NN	O	adenocarcinoma	conj_and	23	SENT_51	[p2l11t1683r726b1762],
33	were	VBD	O	be	auxpass	34	SENT_51	[p2l760t1709r962b1762],
34	shown	VBN	O	show	_	0	SENT_51	[p2l1005t1683r1287b1762],
35	to	TO	O	to	aux	37	SENT_51	[p2l1329t1700r1410b1762],
36	be	VB	O	be	cop	37	SENT_51	[p2l1454t1683r1550b1762],
37	predictive	JJ	O	predictive	xcomp	34	SENT_51	[p2l1590t1683r2009b1784],
38	of	IN	O	of	_	0	SENT_51	[p2l2052t1683r2152b1762],
39	the	DT	O	the	det	40	SENT_51	[p2l12t1811r144b1890],
40	efficacy	NN	O	efficacy	prep_of	37	SENT_51	[p2l177t1811r514b1912],
41	of	IN	O	of	_	0	SENT_51	[p2l542t1811r642b1890],
42	gefitinib	NN	O	gefitinib	prep_of	40	SENT_51	[p2l656t1811r1049b1912],
43	,	,	O	,	_	0	SENT_51	[p2l656t1811r1049b1912],
44	warranting	VBG	O	warrant	partmod	37	SENT_51	[p2l1083t1812r1569b1912],
45	a	DT	O	a	det	48	SENT_51	[p2l1598t1838r1643b1890],
46	large	JJ	O	large	amod	48	SENT_51	[p2l1672t1811r1885b1912],
47	comparative	JJ	O	comparative	amod	48	SENT_51	[p2l1919t1837r2132b1890, p2l10t1940r358b2040],
48	trial	NN	O	trial	dobj	44	SENT_51	[p2l401t1939r583b2018],
49	(	CD	NUMBER	(	nn	55	SENT_51	[p2l630t1940r860b2031],
50	First	NNP	ORDINAL	First	nn	55	SENT_51	[p2l630t1940r860b2031],
51	Line	NNP	O	Line	nn	55	SENT_51	[p2l896t1940r1083b2018],
52	Iressa	NNP	O	Iressa	nn	55	SENT_51	[p2l1125t1947r1383b2018],
53	vs.	IN	O	vs.	amod	55	SENT_51	[p2l1420t1966r1531b2018],
54	Carboplatinl	NNP	ORGANIZATION	Carboplatinl	nn	55	SENT_51	[p2l1579t1939r2131b2040],
55	Paclitaxel	NN	ORGANIZATION	paclitaxel	dep	48	SENT_51	[p2l9t2067r409b2146],
56	in	IN	O	in	_	0	SENT_51	[p2l439t2068r522b2145],
57	Asia	NNP	LOCATION	Asia	prep_in	48	SENT_51	[p2l550t2068r732b2146],
58	[	CD	NUMBER	[	num	57	SENT_51	[p2l771t2073r1098b2163],
59	IPASS	NNP	O	IPASS	dep	44	SENT_51	[p2l771t2073r1098b2163],
60	]	CD	NUMBER	]	num	59	SENT_51	[p2l771t2073r1098b2163],
61	;	:	O	;	_	0	SENT_51	[p2l771t2073r1098b2163],
62	ClinicalTrials	NNS	O	clinicaltrial	dep	59	SENT_51	[p2l1133t2067r1876b2168],
63	.	.	O	.	_	0	SENT_51	[p2l1133t2067r1876b2168],

1	gov	NN	O	gov	nn	2	SENT_52	[p2l1133t2067r1876b2168],
2	number	NN	O	number	_	0	SENT_52	[p2l1904t2093r2132b2146, p2l12t2195r163b2291],
3	,	,	O	,	_	0	SENT_52	[p2l1904t2093r2132b2146, p2l12t2195r163b2291],
4	NCTOO322452	NN	O	nctoo322452	nn	5	SENT_52	[p2l202t2201r824b2287],
5	)	NN	O	)	appos	2	SENT_52	[p2l202t2201r824b2287],
6	in	IN	O	in	_	0	SENT_52	[p2l863t2196r946b2273],
7	which	WDT	O	which	rel	10	SENT_52	[p2l976t2195r1234b2274],
8	patients	NNS	O	patient	nsubjpass	10	SENT_52	[p2l1268t2196r1602b2296],
9	were	VBD	O	be	auxpass	10	SENT_52	[p2l1635t2221r1833b2275],
10	selected	VBN	O	select	rcmod	5	SENT_52	[p2l1870t2195r2132b2274, p2l12t2324r109b2403],
11	in	IN	O	in	_	0	SENT_52	[p2l142t2325r225b2402],
12	accordance	NN	O	accordance	prep_in	10	SENT_52	[p2l260t2324r740b2403],
13	with	IN	O	with	_	0	SENT_52	[p2l771t2324r966b2403],
14	these	DT	O	these	det	16	SENT_52	[p2l1001t2324r1225b2403],
15	factors	NNS	O	factor	nn	16	SENT_52	[p2l1259t2324r1613b2403],
16	.7	NN	NUMBER	.7	prep_with	10	SENT_52	[p2l1259t2324r1613b2403],

1	In	IN	O	in	_	0	SENT_53	[p2l138t2460r228b2530],
2	May	NNP	DATE	May	prep_in	8	SENT_53	[p2l261t2460r442b2553],
3	2004	CD	DATE	2004	num	2	SENT_53	[p2l473t2458r704b2548],
4	,	,	O	,	_	0	SENT_53	[p2l473t2458r704b2548],
5	two	CD	NUMBER	two	num	7	SENT_53	[p2l746t2469r904b2531],
6	pivotal	JJ	O	pivotal	amod	7	SENT_53	[p2l939t2452r1230b2553],
7	studies	NNS	O	study	nsubj	8	SENT_53	[p2l1267t2452r1567b2531],
8	showed	VBD	O	show	_	0	SENT_53	[p2l1607t2452r1929b2532],
9	that	IN	O	that	complm	22	SENT_53	[p2l1966t2452r2138b2531],
10	the	DT	O	the	det	11	SENT_53	[p2l12t2580r144b2659],
11	presence	NN	O	presence	nsubj	22	SENT_53	[p2l181t2606r556b2681],
12	of	IN	O	of	_	0	SENT_53	[p2l595t2580r695b2659],
13	somatic	JJ	O	somatic	amod	14	SENT_53	[p2l716t2581r1052b2659],
14	mutations	NNS	O	mutation	prep_of	11	SENT_53	[p2l1089t2581r1523b2659],
15	in	IN	O	in	_	0	SENT_53	[p2l1562t2581r1646b2658],
16	the	DT	O	the	det	18	SENT_53	[p2l1684t2580r1817b2659],
17	kinase	NN	O	kinase	nn	18	SENT_53	[p2l1854t2580r2133b2660],
18	domain	NN	O	domain	prep_in	14	SENT_53	[p2l12t2708r331b2787],
19	of	IN	O	of	_	0	SENT_53	[p2l359t2708r456b2787],
20	EGFR	NN	ORGANIZATION	egfr	prep_of	18	SENT_53	[p2l464t2714r714b2792],
21	strongly	RB	O	strongly	advmod	22	SENT_53	[p2l732t2708r1069b2809],
22	correlates	VBZ	O	correlate	ccomp	8	SENT_53	[p2l1092t2708r1489b2787],
23	with	IN	O	with	_	0	SENT_53	[p2l1515t2708r1703b2788],
24	increased	VBN	O	increase	amod	25	SENT_53	[p2l1730t2708r2134b2787],
25	responsiveness	NN	O	responsiveness	prep_with	22	SENT_53	[p2l11t2837r623b2937],
26	to	TO	O	to	_	0	SENT_53	[p2l662t2853r741b2915],
27	EGFR	NN	ORGANIZATION	egfr	nn	30	SENT_53	[p2l777t2842r1026b2920],
28	tyrosine	NN	O	tyrosine	nn	30	SENT_53	[p2l1052t2837r1383b2937],
29	kinase	NN	O	kinase	nn	30	SENT_53	[p2l1419t2836r1687b2916],
30	inhibitors	NNS	O	inhibitor	prep_to	25	SENT_53	[p2l1722t2836r2131b2915],
31	in	IN	O	in	_	0	SENT_53	[p2l11t2965r94b3042],
32	patients	NNS	O	patient	prep_in	25	SENT_53	[p2l129t2965r470b3065],
33	with	IN	O	with	_	0	SENT_53	[p2l505t2964r700b3044],
34	non	JJ	O	non	amod	39	SENT_53	[p2l736t2964r1378b3043],
35	—	JJ	O	—	amod	36	SENT_53	[p2l736t2964r1378b3043],
36	small	JJ	O	small	amod	39	SENT_53	[p2l736t2964r1378b3043],
37	—	NN	O	—	nn	39	SENT_53	[p2l736t2964r1378b3043],
38	cell	NN	O	cell	nn	39	SENT_53	[p2l736t2964r1378b3043],
39	lung	NN	O	lung	prep_with	32	SENT_53	[p2l1413t2964r1607b3065],
40	cancer	NN	O	cancer	dep	39	SENT_53	[p2l1640t2970r2037b3043],
41	.89	CD	NUMBER	.89	num	40	SENT_53	[p2l1640t2970r2037b3043],
42	It	PRP	O	it	nsubjpass	45	SENT_53	[p2l2073t2972r2138b3043],
43	was	VBD	O	be	auxpass	45	SENT_53	[p2l7t3119r169b3172],
44	later	RB	O	later	advmod	45	SENT_53	[p2l212t3092r404b3171],
45	found	VBN	O	find	rcmod	40	SENT_53	[p2l443t3092r695b3171],
46	that	IN	O	that	complm	63	SENT_53	[p2l736t3092r909b3171],
47	subgroups	NNS	O	subgroup	nsubj	63	SENT_53	[p2l946t3092r1392b3193],
48	of	IN	O	of	_	0	SENT_53	[p2l1436t3092r1537b3171],
49	patients	NNS	O	patient	prep_of	47	SENT_53	[p2l1558t3093r1899b3193],
50	with	IN	O	with	_	0	SENT_53	[p2l1938t3092r2133b3171],
51	non	JJ	O	non	amod	57	SENT_53	[p2l11t3220r653b3299],
52	—	JJ	O	—	amod	57	SENT_53	[p2l11t3220r653b3299],
53	small	JJ	O	small	amod	57	SENT_53	[p2l11t3220r653b3299],
54	—	NN	O	—	nn	57	SENT_53	[p2l11t3220r653b3299],
55	cell	NN	O	cell	nn	57	SENT_53	[p2l11t3220r653b3299],
56	lung	NN	O	lung	nn	57	SENT_53	[p2l701t3220r895b3321],
57	cancer	NN	O	cancer	prep_with	49	SENT_53	[p2l942t3246r1222b3299],
58	who	WP	O	who	nsubj	59	SENT_53	[p2l1264t3220r1447b3299],
59	had	VBD	O	have	rcmod	49	SENT_53	[p2l1498t3220r1654b3299],
60	sensitivity	NN	O	sensitivity	dobj	59	SENT_53	[p2l1705t3221r2138b3321],
61	to	TO	O	to	_	0	SENT_53	[p2l12t3365r93b3427],
62	geﬁtinib	NN	O	geﬁtinib	prep_to	60	SENT_53	[p2l131t3348r502b3449],
63	had	VBD	O	have	ccomp	45	SENT_53	[p2l540t3348r696b3427],
64	a	DT	O	a	det	66	SENT_53	[p2l732t3375r777b3427],
65	high	JJ	O	high	amod	66	SENT_53	[p2l812t3348r1007b3449],
66	incidence	NN	O	incidence	dobj	63	SENT_53	[p2l1042t3348r1447b3427],
67	of	IN	O	of	_	0	SENT_53	[p2l1485t3348r1585b3427],
68	EGFR	NN	ORGANIZATION	egfr	nn	69	SENT_53	[p2l1601t3354r1857b3432],
69	mutations	NNS	O	mutation	prep_of	66	SENT_53	[p2l1883t3365r2132b3427, p2l12t3477r252b3555],
70	.	.	O	.	_	0	SENT_53	[p2l1883t3365r2132b3427, p2l12t3477r252b3555],

1	In	IN	O	in	_	0	SENT_54	[p2l306t3484r396b3554],
2	Japan	NNP	LOCATION	Japan	prep_in	11	SENT_54	[p2l435t3484r707b3577],
3	,	,	O	,	_	0	SENT_54	[p2l435t3484r707b3577],
4	30	CD	PERCENT	30	number	5	SENT_54	[p2l763t3482r952b3555],
5	%	NN	PERCENT	%	nsubj	11	SENT_54	[p2l763t3482r952b3555],
6	or	CC	O	or	_	0	SENT_54	[p2l1001t3502r1091b3555],
7	more	JJR	O	more	conj_or	5	SENT_54	[p2l1137t3502r1359b3555],
8	of	IN	O	of	_	0	SENT_54	[p2l1409t3476r1510b3555],
9	patients	NNS	O	patient	prep_of	5	SENT_54	[p2l1539t3477r1888b3577],
10	with	IN	O	with	prep	9	SENT_54	[p2l1935t3476r2133b3555],
11	mutated	VBN	O	mutate	_	0	SENT_54	[p2l11t3604r666b3688],
12	.	.	O	.	_	0	SENT_54	[p2l11t3604r666b3688],

1	—	NN	O	—	_	0	SENT_55	[p2l11t3604r666b3688],
2	.	.	O	.	_	0	SENT_55	[p2l11t3604r666b3688],

1	EGFR	NN	ORGANIZATION	egfr	nsubj	10	SENT_56	[p2l11t3604r666b3688],
2	non	JJ	O	non	amod	1	SENT_56	[p2l710t3604r1365b3683],
3	—	CD	NUMBER	—	num	8	SENT_56	[p2l710t3604r1365b3683],
4	small	JJ	O	small	amod	8	SENT_56	[p2l710t3604r1365b3683],
5	—	JJ	O	—	amod	8	SENT_56	[p2l710t3604r1365b3683],
6	cell	NN	O	cell	nn	8	SENT_56	[p2l710t3604r1365b3683],
7	lung	NN	O	lung	nn	8	SENT_56	[p2l1418t3604r1614b3705],
8	cancer	NN	O	cancer	dep	1	SENT_56	[p2l1666t3630r1952b3683],
9	are	VBP	O	be	cop	10	SENT_56	[p2l2002t3630r2133b3683],
10	male	JJ	O	male	ccomp	25	SENT_56	[p3l11t20r215b99],
11	or	CC	O	or	_	0	SENT_56	[p3l249t46r337b99],
12	have	VBP	O	have	conj_or	10	SENT_56	[p3l368t20r554b99],
13	a	DT	O	a	det	14	SENT_56	[p3l588t47r633b99],
14	history	NN	O	history	dobj	12	SENT_56	[p3l665t20r963b121],
15	of	IN	O	of	_	0	SENT_56	[p3l992t20r1092b99],
16	smol	NN	O	smol	prep_of	14	SENT_56	[p3l1108t20r1662b121],
17	<	JJR	O	<	dep	16	SENT_56	[p3l1108t20r1662b121],
18	ing	CD	NUMBER	ing	num	19	SENT_56	[p3l1108t20r1662b121],
19	.1	NN	NUMBER	.1	dep	17	SENT_56	[p3l1108t20r1662b121],
20	°	CD	NUMBER	°	num	21	SENT_56	[p3l1108t20r1662b121],
21	’11	CD	NUMBER	’11	dobj	10	SENT_56	[p3l1108t20r1662b121],
22	Therefore	RB	O	therefore	advmod	10	SENT_56	[p3l1693t20r2128b116],
23	,	,	O	,	_	0	SENT_56	[p3l1693t20r2128b116],
24	we	PRP	O	we	nsubj	25	SENT_56	[p3l7t175r124b228],
25	hypothesized	VBD	O	hypothesize	_	0	SENT_56	[p3l176t148r749b249],
26	that	IN	O	that	complm	40	SENT_56	[p3l800t148r972b227],
27	selecting	NN	O	selecting	nn	28	SENT_56	[p3l1020t148r1403b249],
28	patients	NNS	O	patient	nsubj	40	SENT_56	[p3l1449t149r1790b249],
29	on	IN	O	on	_	0	SENT_56	[p3l1844t174r1950b227],
30	the	DT	O	the	det	31	SENT_56	[p3l2001t148r2133b227],
31	basis	NN	O	basis	prep_on	28	SENT_56	[p3l12t276r223b355],
32	of	IN	O	of	_	0	SENT_56	[p3l258t276r358b355],
33	EGFR	NN	ORGANIZATION	egfr	nn	34	SENT_56	[p3l369t282r626b360],
34	mutations	NNS	O	mutation	prep_of	31	SENT_56	[p3l647t277r1082b355],
35	rather	RB	O	rather	_	0	SENT_56	[p3l1116t276r1375b355],
36	than	IN	O	than	_	0	SENT_56	[p3l1405t276r1601b355],
37	clinical	JJ	O	clinical	amod	38	SENT_56	[p3l1633t276r1947b355],
38	factors	NNS	O	factor	prep_on	28	SENT_56	[p3l1978t276r2132b355, p3l12t421r174b483],
39	would	MD	O	would	aux	40	SENT_56	[p3l212t404r478b483],
40	result	VB	O	result	ccomp	25	SENT_56	[p3l519t404r763b483],
41	in	IN	O	in	_	0	SENT_56	[p3l798t405r882b482],
42	a	DT	O	a	det	43	SENT_56	[p3l922t431r966b483],
43	population	NN	O	population	prep_in	40	SENT_56	[p3l1004t404r1475b505],
44	with	IN	O	with	_	0	SENT_56	[p3l1512t404r1707b483],
45	a	DT	O	a	det	47	SENT_56	[p3l1748t431r1792b483],
46	greater	JJR	O	greater	amod	47	SENT_56	[p3l1831t421r2136b505],
47	sensitivity	NN	O	sensitivity	prep_with	43	SENT_56	[p3l13t533r446b633],
48	to	TO	O	to	_	0	SENT_56	[p3l481t549r562b611],
49	gefitinib	NN	O	gefitinib	prep_to	40	SENT_56	[p3l603t532r997b633],
50	.	.	O	.	_	0	SENT_56	[p3l603t532r997b633],

1	Our	PRP$	O	we	poss	5	SENT_57	[p3l140t666r309b739],
2	previous	JJ	O	previous	amod	5	SENT_57	[p3l344t661r714b761],
3	prospective	JJ	O	prospective	amod	5	SENT_57	[p3l754t661r1278b761],
4	,	,	O	,	_	0	SENT_57	[p3l754t661r1278b761],
5	phase	NN	O	phase	dep	25	SENT_57	[p3l1321t660r1574b761],
6	2	CD	NUMBER	2	num	7	SENT_57	[p3l1614t666r1661b738],
7	studies	NNS	O	study	dobj	5	SENT_57	[p3l1703t660r2009b739],
8	of	IN	O	of	_	0	SENT_57	[p3l2051t660r2152b739],
9	gefitinib	NN	O	gefitinib	nn	10	SENT_57	[p3l11t788r382b889],
10	therapy	NN	O	therapy	prep_of	7	SENT_57	[p3l418t788r740b889],
11	in	IN	O	in	_	0	SENT_57	[p3l769t789r852b866],
12	patients	NNS	O	patient	prep_in	5	SENT_57	[p3l885t789r1227b889],
13	with	IN	O	with	_	0	SENT_57	[p3l1259t788r1454b867],
14	advanced	JJ	O	advanced	amod	19	SENT_57	[p3l1488t788r1884b867],
15	nonsmall	JJ	O	nonsmall	amod	19	SENT_57	[p3l1917t814r2137b867, p3l13t916r430b995],
16	—	NN	O	—	nn	19	SENT_57	[p3l1917t814r2137b867, p3l13t916r430b995],
17	cell	NN	O	cell	nn	19	SENT_57	[p3l1917t814r2137b867, p3l13t916r430b995],
18	lung	NN	O	lung	nn	19	SENT_57	[p3l475t916r669b1017],
19	cancer	NN	O	cancer	prep_with	12	SENT_57	[p3l711t942r993b995],
20	and	CC	O	and	_	0	SENT_57	[p3l1035t916r1192b995],
21	EGFR	NN	ORGANIZATION	egfr	nn	22	SENT_57	[p3l1236t922r1493b1000],
22	mutations12	NN	O	mutations12	conj_and	19	SENT_57	[p3l1528t917r2134b995],
23	‘	CD	NUMBER	‘	num	24	SENT_57	[p3l1528t917r2134b995],
24	14	CD	NUMBER	14	nsubj	25	SENT_57	[p3l1528t917r2134b995],
25	revealed	VBD	O	reveal	_	0	SENT_57	[p3l11t1044r362b1123],
26	a	DT	O	a	det	28	SENT_57	[p3l405t1071r449b1123],
27	response	NN	O	response	nn	28	SENT_57	[p3l491t1070r871b1145],
28	rate	NN	O	rate	dobj	25	SENT_57	[p3l915t1061r1075b1123],
29	of	IN	O	of	_	0	SENT_57	[p3l1120t1044r1220b1123],
30	more	JJR	O	more	mwe	31	SENT_57	[p3l1245t1070r1464b1123],
31	than	IN	O	than	quantmod	32	SENT_57	[p3l1508t1044r1705b1123],
32	70	CD	PERCENT	70	num	33	SENT_57	[p3l1749t1049r1933b1123],
33	%	NN	PERCENT	%	prep_of	28	SENT_57	[p3l1749t1049r1933b1123],
34	and	CC	O	and	_	0	SENT_57	[p3l1975t1044r2133b1123],
35	progression	NN	O	progression	npadvmod	37	SENT_57	[p3l10t1172r734b1273],
36	—	CD	NUMBER	—	num	35	SENT_57	[p3l10t1172r734b1273],
37	free	JJ	O	free	amod	38	SENT_57	[p3l10t1172r734b1273],
38	survival	NN	O	survival	prep_of	28	SENT_57	[p3l772t1172r1111b1251],
39	of	IN	O	of	_	0	SENT_57	[p3l1147t1172r1248b1251],
40	9	CD	DURATION	9	number	42	SENT_57	[p3l1266t1178r1312b1251],
41	to	TO	DURATION	to	dep	42	SENT_57	[p3l1350t1189r1432b1251],
42	10	CD	DURATION	10	num	43	SENT_57	[p3l1473t1178r1567b1251],
43	months	NNS	NUMBER	month	prep_of	28	SENT_57	[p3l1604t1172r1961b1251],
44	.	.	O	.	_	0	SENT_57	[p3l1604t1172r1961b1251],

1	We	PRP	O	we	nsubj	3	SENT_58	[p3l2000t1180r2133b1251],
2	also	RB	O	also	advmod	3	SENT_58	[p3l11t1300r182b1379],
3	developed	VBD	O	develop	_	0	SENT_58	[p3l225t1300r652b1401],
4	a	DT	O	a	det	8	SENT_58	[p3l692t1327r736b1379],
5	rapid	JJ	O	rapid	amod	8	SENT_58	[p3l775t1300r1016b1401],
6	,	,	O	,	_	0	SENT_58	[p3l775t1300r1016b1401],
7	sensitive	JJ	O	sensitive	amod	8	SENT_58	[p3l1064t1301r1427b1379],
8	method	NN	O	method	dobj	3	SENT_58	[p3l1468t1300r1800b1379],
9	for	IN	O	for	_	0	SENT_58	[p3l1841t1300r1964b1379],
10	detecting	VBG	O	detect	prepc_for	3	SENT_58	[p3l2002t1300r2132b1379, p3l12t1429r318b1529],
11	sensitive	JJ	O	sensitive	amod	13	SENT_58	[p3l369t1429r741b1507],
12	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_58	[p3l794t1434r1052b1512],
13	mutations	NNS	O	mutation	dobj	10	SENT_58	[p3l1095t1429r1564b1507],
14	:	:	O	:	_	0	SENT_58	[p3l1095t1429r1564b1507],
15	the	DT	O	the	det	16	SENT_58	[p3l1621t1428r1756b1507],
16	peptide	NN	O	peptide	dep	21	SENT_58	[p3l1808t1428r2133b1529],
17	nucleic	JJ	O	nucleic	amod	18	SENT_58	[p3l11t1556r309b1635],
18	acid	NN	O	acid	dep	16	SENT_58	[p3l341t1556r848b1636],
19	—	NN	O	—	nn	20	SENT_58	[p3l341t1556r848b1636],
20	locl	NN	O	locl	dep	21	SENT_58	[p3l341t1556r848b1636],
21	<	JJR	O	<	dep	26	SENT_58	[p3l341t1556r848b1636],
22	ed	CD	NUMBER	ed	num	24	SENT_58	[p3l341t1556r848b1636],
23	nucleic	JJ	O	nucleic	amod	24	SENT_58	[p3l881t1556r1179b1635],
24	acid	NN	O	acid	dep	21	SENT_58	[p3l1211t1556r1382b1635],
25	(	CD	NUMBER	(	num	26	SENT_58	[p3l1419t1563r1885b1648],
26	PNA	NN	O	pna	dep	3	SENT_58	[p3l1419t1563r1885b1648],
27	.	.	O	.	_	0	SENT_58	[p3l1419t1563r1885b1648],

1	—	NN	O	—	_	0	SENT_59	[p3l1419t1563r1885b1648],
2	.	.	O	.	_	0	SENT_59	[p3l1419t1563r1885b1648],

1	LNA	NN	ORGANIZATION	lna	nn	4	SENT_60	[p3l1419t1563r1885b1648],
2	)	CD	NUMBER	)	num	4	SENT_60	[p3l1419t1563r1885b1648],
3	poly	NN	O	poly	nn	4	SENT_60	[p3l1922t1556r2132b1657],
4	—	NN	O	—	dep	11	SENT_60	[p3l1922t1556r2132b1657],
5	merase	NN	O	merase	nn	7	SENT_60	[p3l11t1684r935b1763],
6	—	NN	O	—	nn	7	SENT_60	[p3l11t1684r935b1763],
7	chain	NN	O	chain	dep	4	SENT_60	[p3l11t1684r935b1763],
8	—	CD	NUMBER	—	num	9	SENT_60	[p3l11t1684r935b1763],
9	reaction	NN	O	reaction	dep	11	SENT_60	[p3l11t1684r935b1763],
10	(	CD	NUMBER	(	num	11	SENT_60	[p3l978t1690r1212b1776],
11	PCR	NN	O	pcr	dep	15	SENT_60	[p3l978t1690r1212b1776],
12	)	JJ	O	)	amod	14	SENT_60	[p3l978t1690r1212b1776],
13	clamp	NN	O	clamp	nn	14	SENT_60	[p3l1257t1684r1509b1785],
14	method	NN	O	method	dep	11	SENT_60	[p3l1548t1684r1961b1763],
15	.15	CD	NUMBER	.15	_	0	SENT_60	[p3l1548t1684r1961b1763],
16	We	PRP	O	we	nsubj	18	SENT_60	[p3l2001t1692r2133b1763],
17	then	RB	O	then	advmod	18	SENT_60	[p3l12t1812r202b1891],
18	undertook	VBD	O	undertake	rcmod	15	SENT_60	[p3l238t1812r690b1892],
19	a	DT	O	a	det	22	SENT_60	[p3l721t1839r766b1891],
20	phase	NN	O	phase	nn	22	SENT_60	[p3l799t1812r1048b1913],
21	3	CD	NUMBER	3	num	22	SENT_60	[p3l1085t1818r1129b1891],
22	study	NN	O	study	dobj	18	SENT_60	[p3l1170t1812r1400b1913],
23	comparing	VBG	O	compare	partmod	22	SENT_60	[p3l1433t1813r1902b1913],
24	geritinib	NN	O	geritinib	dobj	23	SENT_60	[p3l1935t1812r2132b1913, p3l12t1940r208b2019],
25	and	CC	O	and	_	0	SENT_60	[p3l244t1940r400b2019],
26	standard	JJ	O	standard	amod	30	SENT_60	[p3l437t1940r808b2019],
27	carboplatin	NN	O	carboplatin	nn	30	SENT_60	[p3l844t1940r1782b2041],
28	—	NN	O	—	nn	30	SENT_60	[p3l844t1940r1782b2041],
29	paclitaxel	NN	O	paclitaxel	nn	30	SENT_60	[p3l844t1940r1782b2041],
30	chemotherapy	NN	O	chemotherapy	dobj	23	SENT_60	[p3l1817t1940r2132b2019, p3l12t2068r327b2169],
31	in	IN	O	in	_	0	SENT_60	[p3l353t2069r435b2146],
32	patients	NNS	O	patient	prep_in	15	SENT_60	[p3l466t2069r799b2169],
33	who	WP	O	who	nsubj	35	SENT_60	[p3l829t2068r1009b2147],
34	had	VBD	O	have	aux	35	SENT_60	[p3l1043t2068r1196b2147],
35	advanced	VBN	O	advance	rcmod	32	SENT_60	[p3l1227t2068r1616b2147],
36	non	JJ	O	non	amod	42	SENT_60	[p3l1647t2068r2132b2147],
37	—	JJ	O	—	amod	38	SENT_60	[p3l1647t2068r2132b2147],
38	small	JJ	O	small	amod	42	SENT_60	[p3l1647t2068r2132b2147],
39	—	NN	O	—	nn	42	SENT_60	[p3l1647t2068r2132b2147],
40	cell	NN	O	cell	nn	42	SENT_60	[p3l12t2196r151b2275],
41	lung	NN	O	lung	nn	42	SENT_60	[p3l177t2196r363b2297],
42	cancer	NN	O	cancer	dobj	35	SENT_60	[p3l389t2222r658b2275],
43	with	IN	O	with	_	0	SENT_60	[p3l679t2196r867b2276],
44	sensitive	JJ	O	sensitive	amod	46	SENT_60	[p3l896t2197r1243b2275],
45	EGFR	NN	ORGANIZATION	egfr	nn	46	SENT_60	[p3l1268t2202r1518b2280],
46	mutations	NNS	O	mutation	prep_with	42	SENT_60	[p3l1535t2197r1952b2275],
47	and	CC	O	and	_	0	SENT_60	[p3l1982t2196r2134b2275],
48	who	WP	O	who	nsubj	52	SENT_60	[p3l7t2324r189b2404],
49	had	VBD	O	have	aux	52	SENT_60	[p3l230t2324r386b2403],
50	not	RB	O	not	neg	52	SENT_60	[p3l426t2341r568b2403],
51	previously	RB	DATE	previously	advmod	52	SENT_60	[p3l602t2324r1041b2425],
52	received	VBN	O	receive	rcmod	32	SENT_60	[p3l1076t2324r1421b2404],
53	chemotherapy	NN	O	chemotherapy	dobj	52	SENT_60	[p3l1462t2324r2085b2425],
54	.	.	O	.	_	0	SENT_60	[p3l1462t2324r2085b2425],

1	METHODS	NNS	O	method	_	0	SENT_61	[p3l805t2571r1352b2631],

1	PATIENT	NN	O	patient	nn	2	SENT_62	[p3l17t2819r339b2868],
2	popuumon	NNS	O	popuumon	nsubjpass	12	SENT_62	[p3l376t2818r888b2869],
3	This	DT	O	this	det	4	SENT_62	[p3l7t2920r196b2998],
4	multicenter	NN	O	multicenter	dep	2	SENT_62	[p3l238t2920r755b3016],
5	,	,	O	,	_	0	SENT_62	[p3l238t2920r755b3016],
6	randomized	VBN	O	randomize	partmod	12	SENT_62	[p3l800t2920r1347b3016],
7	,	,	O	,	_	0	SENT_62	[p3l800t2920r1347b3016],
8	phase	NN	O	phase	nsubjpass	12	SENT_62	[p3l1391t2920r1641b3020],
9	3	CD	NUMBER	3	num	10	SENT_62	[p3l1681t2925r1725b2999],
10	trial	NN	O	trial	dep	8	SENT_62	[p3l1769t2920r1947b2998],
11	was	VBD	O	be	auxpass	12	SENT_62	[p3l1981t2946r2145b2999],
12	approved	VBN	O	approve	_	0	SENT_62	[p3l11t3048r395b3148],
13	by	IN	O	by	_	0	SENT_62	[p3l426t3048r522b3148],
14	the	DT	O	the	det	17	SENT_62	[p3l548t3048r680b3126],
15	institutional	JJ	O	institutional	amod	17	SENT_62	[p3l709t3048r1234b3127],
16	review	NN	O	review	nn	17	SENT_62	[p3l1263t3049r1539b3127],
17	board	NN	O	board	agent	12	SENT_62	[p3l1566t3048r1812b3126],
18	of	IN	O	of	_	0	SENT_62	[p3l1842t3047r1942b3126],
19	each	DT	O	each	det	21	SENT_62	[p3l1954t3048r2147b3126],
20	participating	VBG	O	participate	amod	21	SENT_62	[p3l9t3176r548b3277],
21	center	NN	O	center	prep_of	17	SENT_62	[p3l577t3192r846b3254],
22	.	.	O	.	_	0	SENT_62	[p3l577t3192r846b3254],

1	Eligibility	NN	O	eligibility	nn	2	SENT_63	[p3l881t3176r1283b3277],
2	criteria	NNS	O	criterion	nsubj	3	SENT_63	[p3l1309t3177r1600b3254],
3	included	VBD	O	include	_	0	SENT_63	[p3l1628t3176r1982b3255],
4	the	DT	O	the	det	5	SENT_63	[p3l2013t3176r2147b3254],
5	presence	NN	O	presence	nsubj	14	SENT_63	[p3l9t3330r387b3405],
6	of	IN	O	of	_	0	SENT_63	[p3l421t3303r521b3383],
7	advanced	JJ	O	advanced	amod	9	SENT_63	[p3l535t3304r933b3384],
8	non	JJ	O	non	amod	9	SENT_63	[p3l965t3304r1612b3383],
9	—	NN	O	—	prep_of	5	SENT_63	[p3l965t3304r1612b3383],
10	small	JJ	O	small	amod	14	SENT_63	[p3l965t3304r1612b3383],
11	—	NN	O	—	nn	14	SENT_63	[p3l965t3304r1612b3383],
12	cell	NN	O	cell	nn	14	SENT_63	[p3l965t3304r1612b3383],
13	lung	NN	O	lung	nn	14	SENT_63	[p3l1643t3304r1838b3406],
14	cancer	NN	O	cancer	xcomp	3	SENT_63	[p3l1867t3330r2150b3383],
15	harboring	VBG	O	harbor	partmod	14	SENT_63	[p3l11t3433r449b3534],
16	sensitive	JJ	O	sensitive	amod	18	SENT_63	[p3l477t3433r842b3512],
17	EGFR	NN	ORGANIZATION	egfr	nn	18	SENT_63	[p3l870t3438r1129b3516],
18	mutations	NNS	O	mutation	dobj	15	SENT_63	[p3l1147t3434r1609b3528],
19	,	,	O	,	_	0	SENT_63	[p3l1147t3434r1609b3528],
20	the	DT	O	the	det	21	SENT_63	[p3l1645t3433r1778b3511],
21	absence	NN	O	absence	appos	18	SENT_63	[p3l1807t3433r2147b3511],
22	of	IN	O	of	_	0	SENT_63	[p3l12t3561r112b3640],
23	the	DT	O	the	det	28	SENT_63	[p3l127t3562r260b3640],
24	resistant	JJ	O	resistant	amod	28	SENT_63	[p3l294t3563r668b3640],
25	EGFR	NN	ORGANIZATION	egfr	nn	28	SENT_63	[p3l695t3567r953b3645],
26	mutation	NN	O	mutation	nn	28	SENT_63	[p3l975t3563r1370b3641],
27	T79OM	NN	O	t79om	nn	28	SENT_63	[p3l1400t3567r1704b3640],
28	(	NN	O	(	prep_of	21	SENT_63	[p3l1743t3563r1855b3653],
29	in	IN	O	in	_	0	SENT_63	[p3l1743t3563r1855b3653],
30	which	WDT	O	which	rel	37	SENT_63	[p3l1883t3562r2148b3641],
31	threonine	NN	O	threonine	nsubjpass	37	SENT_63	[p3l12t3691r434b3769],
32	at	IN	O	at	_	0	SENT_63	[p3l463t3707r542b3769],
33	amino	NN	O	amino	nn	34	SENT_63	[p3l565t3692r842b3769],
34	acid	NN	O	acid	prep_at	31	SENT_63	[p3l870t3691r1042b3769],
35	790	CD	NUMBER	790	num	34	SENT_63	[p3l1071t3696r1224b3769],
36	is	VBZ	O	be	auxpass	37	SENT_63	[p3l1253t3691r1319b3769],
37	substituted	VBN	O	substitute	rcmod	21	SENT_63	[p3l1351t3691r1832b3770],
38	by	IN	O	by	_	0	SENT_63	[p3l1861t3691r1958b3791],
39	methionine	NN	O	methionine	nn	40	SENT_63	[p3l1983t3717r2145b3769, p4l12t21r417b117],
40	)	NN	O	)	agent	37	SENT_63	[p3l1983t3717r2145b3769, p4l12t21r417b117],
41	,	,	O	,	_	0	SENT_63	[p3l1983t3717r2145b3769, p4l12t21r417b117],

1	no	DT	O	no	det	2	SENT_64	[p4l454t46r559b100],
2	history	NN	O	history	nsubjpass	33	SENT_64	[p4l591t21r891b122],
3	of	IN	O	of	_	0	SENT_64	[p4l919t20r1018b100],
4	chemotherapy	NN	O	chemotherapy	prep_of	2	SENT_64	[p4l1032t21r1647b122],
5	,	,	O	,	_	0	SENT_64	[p4l1032t21r1647b122],
6	and	CC	O	and	_	0	SENT_64	[p4l1683t21r1839b100],
7	an	DT	O	a	det	8	SENT_64	[p4l1870t47r1973b100],
8	age	NN	O	age	conj_and	2	SENT_64	[p4l2003t47r2147b123],
9	of	IN	O	of	_	0	SENT_64	[p4l12t149r111b229],
10	75	CD	DURATION	75	num	11	SENT_64	[p4l124t157r217b229],
11	years	NNS	NUMBER	year	prep_of	8	SENT_64	[p4l247t176r463b251],
12	or	CC	O	or	_	0	SENT_64	[p4l496t176r584b229],
13	younger	JJR	O	younger	amod	14	SENT_64	[p4l607t176r952b252],
14	(	NN	O	(	nsubjpass	33	SENT_64	[p4l984t150r1346b242],
15	because	IN	O	because	mark	22	SENT_64	[p4l984t150r1346b242],
16	a	DT	O	a	det	17	SENT_64	[p4l1375t176r1420b229],
17	beneﬁt	NN	O	beneﬁt	nsubj	22	SENT_64	[p4l1449t149r1749b229],
18	of	IN	O	of	_	0	SENT_64	[p4l1774t149r1874b229],
19	a	DT	O	a	det	21	SENT_64	[p4l1884t176r1929b229],
20	platinum	NN	O	platinum	nn	21	SENT_64	[p4l1957t150r2145b251, p4l11t279r521b359],
21	—	NN	O	—	prep_of	17	SENT_64	[p4l1957t150r2145b251, p4l11t279r521b359],
22	based	VBN	O	base	dep	14	SENT_64	[p4l1957t150r2145b251, p4l11t279r521b359],
23	regimen	NNS	O	regimen	dobj	22	SENT_64	[p4l556t280r914b381],
24	in	IN	O	in	_	0	SENT_64	[p4l948t280r1032b356],
25	patients	NNS	O	patient	prep_in	23	SENT_64	[p4l1065t280r1409b380],
26	>	JJR	O	>	amod	25	SENT_64	[p4l1452t286r1593b358],
27	75	CD	DURATION	75	num	28	SENT_64	[p4l1452t286r1593b358],
28	years	NNS	NUMBER	year	tmod	26	SENT_64	[p4l1627t305r1848b380],
29	of	IN	O	of	_	0	SENT_64	[p4l1886t278r1987b358],
30	age	NN	O	age	prep_of	25	SENT_64	[p4l2002t305r2147b381],
31	is	VBZ	O	be	auxpass	33	SENT_64	[p4l11t410r76b487],
32	not	RB	O	not	neg	33	SENT_64	[p4l112t425r255b487],
33	established	VBN	O	establish	_	0	SENT_64	[p4l285t409r825b500],
34	)	NN	O	)	dobj	33	SENT_64	[p4l285t409r825b500],
35	.	.	O	.	_	0	SENT_64	[p4l285t409r825b500],

1	Table	NNP	O	Table	nsubj	20	SENT_65	[p4l860t409r1096b487],
2	1	CD	NUMBER	1	num	1	SENT_65	[p4l1135t414r1180b486],
3	in	IN	O	in	_	0	SENT_65	[p4l1214t410r1298b486],
4	the	DT	O	the	det	7	SENT_65	[p4l1331t409r1465b487],
5	Supplementary	NNP	O	Supplementary	nn	7	SENT_65	[p4l1501t409r2152b509],
6	Appendix	NNP	O	Appendix	nn	7	SENT_65	[p4l7t537r427b637],
7	(	NN	O	(	nn	19	SENT_65	[p4l469t537r868b628],
8	available	JJ	O	available	amod	19	SENT_65	[p4l469t537r868b628],
9	with	IN	O	with	_	0	SENT_65	[p4l904t537r1101b616],
10	the	DT	O	the	det	12	SENT_65	[p4l1142t537r1276b615],
11	full	JJ	O	full	amod	12	SENT_65	[p4l1317t536r1466b616],
12	text	NN	O	text	prep_with	8	SENT_65	[p4l1506t553r1668b615],
13	of	IN	O	of	_	0	SENT_65	[p4l1705t536r1805b615],
14	this	DT	O	this	det	15	SENT_65	[p4l1828t537r1988b615],
15	article	NN	O	article	prep_of	12	SENT_65	[p4l2031t563r2145b615, p4l12t665r189b743],
16	at	IN	O	at	_	0	SENT_65	[p4l218t681r297b743],
17	N	NN	O	n	prep_at	15	SENT_65	[p4l320t672r395b744],
18	EJM.org	NN	O	ejm.org	nn	19	SENT_65	[p4l398t671r773b766],
19	)	NN	O	)	prep_in	1	SENT_65	[p4l398t671r773b766],
20	lists	VBZ	O	list	_	0	SENT_65	[p4l808t665r982b743],
21	the	DT	O	the	det	23	SENT_65	[p4l1014t665r1148b743],
22	detailed	JJ	O	detailed	amod	23	SENT_65	[p4l1178t665r1522b743],
23	eligibility	NN	O	eligibility	dobj	20	SENT_65	[p4l1552t665r1964b766],
24	and	CC	O	and	_	0	SENT_65	[p4l1988t665r2147b743],
25	exclusion	NN	O	exclusion	nn	26	SENT_65	[p4l12t793r412b872],
26	criteria	NNS	O	criterion	dobj	20	SENT_65	[p4l447t794r774b871],
27	.	.	O	.	_	0	SENT_65	[p4l447t794r774b871],

1	The	DT	O	the	det	2	SENT_66	[p4l811t793r972b871],
2	authors	NNS	O	author	nsubj	3	SENT_66	[p4l1006t793r1330b872],
3	attest	VBP	O	attest	_	0	SENT_66	[p4l1366t809r1605b871],
4	to	TO	O	to	_	0	SENT_66	[p4l1634t810r1716b871],
5	the	DT	O	the	det	6	SENT_66	[p4l1752t793r1886b871],
6	fidelity	NN	O	fidelity	prep_to	3	SENT_66	[p4l1919t792r2145b871, p4l11t922r119b1021],
7	of	IN	O	of	_	0	SENT_66	[p4l152t920r253b999],
8	the	DT	O	the	det	9	SENT_66	[p4l272t921r405b999],
9	article	NN	O	article	prep_of	6	SENT_66	[p4l442t921r711b999],
10	to	TO	O	to	_	0	SENT_66	[p4l749t938r831b999],
11	the	DT	O	the	det	13	SENT_66	[p4l870t921r1004b999],
12	full	JJ	O	full	amod	13	SENT_66	[p4l1041t920r1191b1000],
13	protocol	NN	O	protocol	prep_to	3	SENT_66	[p4l1226t921r1589b1021],
14	and	CC	O	and	_	0	SENT_66	[p4l1626t921r1784b999],
15	statistical	JJ	O	statistical	amod	18	SENT_66	[p4l1823t922r2145b999, p4l12t1050r511b1150],
16	—	NN	O	—	nn	18	SENT_66	[p4l1823t922r2145b999, p4l12t1050r511b1150],
17	analysis	NN	O	analysis	nn	18	SENT_66	[p4l1823t922r2145b999, p4l12t1050r511b1150],
18	plan	NN	O	plan	conj_and	13	SENT_66	[p4l547t1050r759b1150],
19	.	.	O	.	_	0	SENT_66	[p4l547t1050r759b1150],

1	DETECTION	NN	O	detection	nn	4	SENT_67	[p4l16t1326r466b1377],
2	or	CC	O	or	_	0	SENT_67	[p4l507t1326r610b1377],
3	EGFR	NN	MISC	egfr	nn	4	SENT_67	[p4l645t1326r842b1377],
4	MUTATIONS	NNS	MISC	mutation	nsubjpass	10	SENT_67	[p4l883t1326r1351b1377],
5	Cytologic	JJ	MISC	cytologic	amod	8	SENT_67	[p4l11t1427r411b1528],
6	or	CC	O	or	_	0	SENT_67	[p4l446t1452r534b1505],
7	histologic	JJ	O	histologic	conj_or	5	SENT_67	[p4l565t1427r984b1528],
8	specimens	NNS	O	specimen	dep	4	SENT_67	[p4l1020t1428r1461b1527],
9	Were	VBD	O	be	auxpass	10	SENT_67	[p4l1493t1453r1694b1506],
10	examined	VBN	O	examine	_	0	SENT_67	[p4l1729t1427r2147b1505],
11	for	IN	O	for	_	0	SENT_67	[p4l11t1554r137b1633],
12	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_67	[p4l181t1562r398b1634],
13	mutations	NNS	O	mutation	prep_for	10	SENT_67	[p4l439t1556r885b1634],
14	by	IN	O	by	_	0	SENT_67	[p4l936t1555r1035b1655],
15	means	NNS	O	means	_	0	SENT_67	[p4l1078t1581r1364b1633],
16	of	IN	O	of	_	0	SENT_67	[p4l1415t1554r1516b1633],
17	the	DT	O	the	det	18	SENT_67	[p4l1547t1555r1682b1633],
18	PNA	NNP	ORGANIZATION	PNA	prep_by_means_of	10	SENT_67	[p4l1729t1562r2151b1634],
19	.	.	O	.	_	0	SENT_67	[p4l1729t1562r2151b1634],

1	—	NN	O	—	_	0	SENT_68	[p4l1729t1562r2151b1634],
2	.	.	O	.	_	0	SENT_68	[p4l1729t1562r2151b1634],

1	LNA	NNP	O	LNA	_	0	SENT_69	[p4l1729t1562r2151b1634],
2	PCR	NN	O	pcr	nn	4	SENT_69	[p4l9t1688r203b1767],
3	clamp	NN	O	clamp	nn	4	SENT_69	[p4l233t1683r494b1784],
4	method	NN	O	method	dep	1	SENT_69	[p4l535t1683r892b1762],
5	.	.	O	.	_	0	SENT_69	[p4l535t1683r892b1762],

1	Briefly	RB	O	briefly	advmod	15	SENT_70	[p4l936t1682r1239b1784],
2	,	,	O	,	_	0	SENT_70	[p4l936t1682r1239b1784],
3	genomic	JJ	O	genomic	amod	5	SENT_70	[p4l1284t1684r1656b1785],
4	DNA	NN	O	dna	nn	5	SENT_70	[p4l1694t1690r1904b1763],
5	fragments	NNS	O	fragment	nsubjpass	15	SENT_70	[p4l1940t1682r2146b1785, p4l11t1829r273b1891],
6	containing	VBG	O	contain	partmod	5	SENT_70	[p4l307t1813r780b1914],
7	mutation	NN	O	mutation	nn	9	SENT_70	[p4l808t1813r1203b1892],
8	hot	JJ	O	hot	amod	9	SENT_70	[p4l1234t1812r1378b1891],
9	spots	NNS	O	spot	dobj	6	SENT_70	[p4l1405t1828r1630b1913],
10	of	IN	O	of	_	0	SENT_70	[p4l1664t1811r1764b1891],
11	the	DT	O	the	det	13	SENT_70	[p4l1778t1812r1911b1891],
12	EGFR	NN	ORGANIZATION	egfr	nn	13	SENT_70	[p4l1940t1819r2153b1892],
13	gene	NN	O	gene	prep_of	9	SENT_70	[p4l11t1967r211b2043],
14	were	VBD	O	be	auxpass	15	SENT_70	[p4l243t1967r446b2021],
15	amplified	VBN	O	amplify	_	0	SENT_70	[p4l481t1940r901b2042],
16	with	IN	O	with	_	0	SENT_70	[p4l932t1941r1129b2021],
17	the	DT	O	the	det	18	SENT_70	[p4l1165t1941r1298b2020],
18	use	NN	O	use	prep_with	15	SENT_70	[p4l1334t1967r1475b2021],
19	of	IN	O	of	_	0	SENT_70	[p4l1512t1940r1612b2020],
20	a	DT	O	a	det	22	SENT_70	[p4l1629t1967r1674b2020],
21	PCR	NN	O	pcr	nn	22	SENT_70	[p4l1706t1946r1899b2025],
22	assay	NN	O	assay	prep_of	18	SENT_70	[p4l1923t1967r2152b2042],
23	in	IN	O	in	_	0	SENT_70	[p4l11t2071r95b2147],
24	the	DT	O	the	det	25	SENT_70	[p4l137t2070r273b2148],
25	presence	NN	O	presence	prep_in	22	SENT_70	[p4l313t2096r698b2170],
26	of	IN	O	of	_	0	SENT_70	[p4l741t2069r842b2148],
27	a	DT	O	a	det	28	SENT_70	[p4l865t2096r909b2148],
28	peptide	NN	O	peptide	prep_of	25	SENT_70	[p4l948t2070r1276b2170],
29	nucleic	JJ	O	nucleic	amod	32	SENT_70	[p4l1317t2070r1624b2149],
30	acid	NN	O	acid	nn	32	SENT_70	[p4l1663t2070r1839b2148],
31	clamp	NN	O	clamp	nn	32	SENT_70	[p4l1880t2070r2147b2170],
32	primer	NN	O	primer	dobj	15	SENT_70	[p4l10t2199r296b2298],
33	synthesized	VBN	O	synthesize	partmod	32	SENT_70	[p4l318t2198r804b2298],
34	from	IN	O	from	_	0	SENT_70	[p4l829t2197r1034b2276],
35	a	DT	O	a	det	38	SENT_70	[p4l1057t2224r1102b2276],
36	peptide	NN	O	peptide	nn	38	SENT_70	[p4l1123t2198r1431b2298],
37	nucleic	JJ	O	nucleic	amod	38	SENT_70	[p4l1456t2198r1743b2277],
38	acid	NN	O	acid	prep_from	33	SENT_70	[p4l1766t2198r1931b2276],
39	with	IN	O	with	_	0	SENT_70	[p4l1951t2198r2148b2277],
40	a	DT	O	a	det	44	SENT_70	[p4l11t2352r55b2404],
41	Wild	NNP	O	Wild	nn	44	SENT_70	[p4l79t2326r480b2426],
42	—	CD	NUMBER	—	num	44	SENT_70	[p4l79t2326r480b2426],
43	type	NN	O	type	nn	44	SENT_70	[p4l79t2326r480b2426],
44	sequence	NN	O	sequence	prep_with	38	SENT_70	[p4l511t2352r916b2426],
45	.	.	O	.	_	0	SENT_70	[p4l511t2352r916b2426],

1	This	DT	O	this	det	2	SENT_71	[p4l949t2326r1134b2404],
2	method	NN	O	method	nsubj	3	SENT_71	[p4l1166t2326r1495b2404],
3	results	VBZ	O	result	_	0	SENT_71	[p4l1524t2326r1803b2405],
4	in	IN	O	in	_	0	SENT_71	[p4l1835t2327r1917b2403],
5	preferential	JJ	O	preferential	amod	6	SENT_71	[p4l1946t2325r2146b2426, p4l12t2454r346b2532],
6	amplification	NN	O	amplification	prep_in	3	SENT_71	[p4l393t2453r994b2554],
7	of	IN	O	of	_	0	SENT_71	[p4l1041t2453r1143b2532],
8	the	DT	O	the	det	10	SENT_71	[p4l1172t2454r1308b2532],
9	mutant	JJ	O	mutant	amod	10	SENT_71	[p4l1355t2470r1676b2533],
10	sequence	NN	O	sequence	prep_of	6	SENT_71	[p4l1719t2480r2142b2554],
11	,	,	O	,	_	0	SENT_71	[p4l1719t2480r2142b2554],
12	which	WDT	O	which	nsubjpass	15	SENT_71	[p4l7t2582r276b2661],
13	is	VBZ	O	be	auxpass	15	SENT_71	[p4l319t2583r386b2660],
14	then	RB	O	then	advmod	15	SENT_71	[p4l433t2582r628b2660],
15	detected	VBN	O	detect	rcmod	10	SENT_71	[p4l673t2582r1041b2660],
16	by	IN	O	by	_	0	SENT_71	[p4l1086t2582r1184b2682],
17	a	DT	O	a	det	19	SENT_71	[p4l1223t2608r1268b2660],
18	fluorescent	JJ	O	fluorescent	amod	19	SENT_71	[p4l1310t2581r1811b2661],
19	primer	NN	O	primer	agent	15	SENT_71	[p4l1849t2583r2151b2682],
20	that	WDT	O	that	nsubj	21	SENT_71	[p4l12t2711r185b2789],
21	incorporates	VBZ	O	incorporate	rcmod	19	SENT_71	[p4l211t2712r755b2811],
22	locked	VBN	O	lock	dep	21	SENT_71	[p4l788t2711r1069b2790],
23	nucleic	JJ	O	nucleic	amod	24	SENT_71	[p4l1100t2711r1400b2790],
24	acids	NNS	O	acid	dobj	22	SENT_71	[p4l1431t2711r1644b2789],
25	to	TO	O	to	aux	26	SENT_71	[p4l1679t2727r1761b2789],
26	increase	VB	O	increase	xcomp	22	SENT_71	[p4l1793t2712r2147b2789],
27	the	DT	O	the	det	28	SENT_71	[p4l12t2839r141b2917],
28	specificity	NN	O	specificity	dobj	26	SENT_71	[p4l172t2838r605b2939],
29	.	.	O	.	_	0	SENT_71	[p4l172t2838r605b2939],

1	As	IN	O	as	_	0	SENT_72	[p4l636t2846r741b2917],
2	a	DT	O	a	det	3	SENT_72	[p4l771t2865r816b2917],
3	result	NN	O	result	prep_as	10	SENT_72	[p4l843t2839r1096b2934],
4	,	,	O	,	_	0	SENT_72	[p4l843t2839r1096b2934],
5	a	DT	O	a	det	8	SENT_72	[p4l1130t2865r1174b2917],
6	mutant	JJ	O	mutant	amod	8	SENT_72	[p4l1202t2855r1507b2918],
7	EGFR	NN	ORGANIZATION	egfr	nn	8	SENT_72	[p4l1530t2846r1737b2919],
8	sequence	NN	O	sequence	nsubjpass	10	SENT_72	[p4l1761t2865r2147b2939],
9	is	VBZ	O	be	auxpass	10	SENT_72	[p4l11t2969r77b3046],
10	detected	VBN	O	detect	_	0	SENT_72	[p4l108t2968r468b3046],
11	in	IN	O	in	_	0	SENT_72	[p4l496t2969r581b3045],
12	specimens	NNS	O	specimen	prep_in	10	SENT_72	[p4l611t2969r1061b3068],
13	that	WDT	O	that	dep	14	SENT_72	[p4l1092t2968r1266b3046],
14	contain	VBP	O	contain	rcmod	12	SENT_72	[p4l1290t2969r1616b3046],
15	100	CD	NUMBER	100	number	17	SENT_72	[p4l1648t2973r1797b3046],
16	to	TO	O	to	dep	17	SENT_72	[p4l1827t2984r1909b3046],
17	1000	CD	NUMBER	1000	num	19	SENT_72	[p4l1943t2973r2147b3046],
18	excess	JJ	O	excess	amod	19	SENT_72	[p4l12t3122r269b3174],
19	copies	NNS	O	copy	dobj	14	SENT_72	[p4l303t3097r559b3196],
20	of	IN	O	of	_	0	SENT_72	[p4l592t3095r691b3174],
21	Wild	NNP	O	Wild	prep_of	19	SENT_72	[p4l699t3096r1090b3196],
22	—	CD	NUMBER	—	num	25	SENT_72	[p4l699t3096r1090b3196],
23	type	NN	O	type	nn	25	SENT_72	[p4l699t3096r1090b3196],
24	EGFR	NN	ORGANIZATION	egfr	nn	25	SENT_72	[p4l1119t3103r1326b3176],
25	sequence	NN	O	sequence	nsubj	14	SENT_72	[p4l1353t3122r1749b3196],
26	.	.	O	.	_	0	SENT_72	[p4l1353t3122r1749b3196],

1	The	DT	O	the	det	2	SENT_73	[p4l1783t3096r1940b3174],
2	sensitivity	NN	O	sensitivity	_	0	SENT_73	[p4l1972t3122r2146b3174, p4l13t3225r299b3324],
3	and	CC	O	and	_	0	SENT_73	[p4l321t3224r479b3302],
4	specificity	NN	O	specificity	conj_and	2	SENT_73	[p4l507t3223r951b3324],
5	of	IN	O	of	_	0	SENT_73	[p4l973t3223r1073b3302],
6	the	DT	O	the	det	7	SENT_73	[p4l1081t3224r1214b3302],
7	PNA	NNP	ORGANIZATION	PNA	prep_of	2	SENT_73	[p4l1239t3231r1654b3303],
8	.	.	O	.	_	0	SENT_73	[p4l1239t3231r1654b3303],

1	—	NN	O	—	_	0	SENT_74	[p4l1239t3231r1654b3303],
2	.	.	O	.	_	0	SENT_74	[p4l1239t3231r1654b3303],

1	LNA	NNP	O	LNA	nn	4	SENT_75	[p4l1239t3231r1654b3303],
2	PCR	NN	O	pcr	nn	4	SENT_75	[p4l1675t3229r1869b3307],
3	clamp	NN	O	clamp	nn	4	SENT_75	[p4l1885t3224r2147b3324],
4	method	NN	O	method	nsubj	7	SENT_75	[p4l11t3353r345b3431],
5	are	VBP	O	be	cop	7	SENT_75	[p4l379t3379r509b3431],
6	97	CD	PERCENT	97	number	7	SENT_75	[p4l544t3358r729b3432],
7	%	NN	PERCENT	%	_	0	SENT_75	[p4l544t3358r729b3432],
8	and	CC	O	and	_	0	SENT_75	[p4l763t3353r922b3431],
9	100	CD	PERCENT	100	number	10	SENT_75	[p4l960t3358r1221b3449],
10	%	NN	PERCENT	%	conj_and	7	SENT_75	[p4l960t3358r1221b3449],
11	,	,	O	,	_	0	SENT_75	[p4l960t3358r1221b3449],
12	respectiVely	NNP	O	respectiVely	dep	14	SENT_75	[p4l1261t3353r1952b3453],
13	.15	CD	NUMBER	.15	num	12	SENT_75	[p4l1261t3353r1952b3453],
14	>	JJR	O	>	conj_and	7	SENT_75	[p4l1261t3353r1952b3453],
15	15	CD	NUMBER	15	dep	7	SENT_75	[p4l1261t3353r1952b3453],

1	STUDY	NN	O	study	_	0	SENT_76	[p4l11t3629r268b3680],
2	DESIGN	NN	O	design	dep	1	SENT_76	[p4l305t3629r603b3680],
3	AND	CC	O	and	_	0	SENT_76	[p4l642t3630r812b3679],
4	TREATMENT	NN	O	treatment	dep	1	SENT_76	[p4l843t3630r1316b3679],

1	Before	IN	O	before	_	0	SENT_77	[p5l10t31r281b110],
2	randomization	NN	O	randomization	prep_before	6	SENT_77	[p5l315t32r968b128],
3	,	,	O	,	_	0	SENT_77	[p5l315t32r968b128],
4	patients	NNS	O	patient	nsubjpass	6	SENT_77	[p5l1005t33r1342b132],
5	were	VBD	O	be	auxpass	6	SENT_77	[p5l1372t58r1572b111],
6	stratified	VBN	O	stratify	_	0	SENT_77	[p5l1606t31r1993b110],
7	according	VBG	O	accord	_	0	SENT_77	[p5l2025t58r2145b110, p5l12t160r334b262],
8	to	TO	O	to	prepc_according_to	6	SENT_77	[p5l356t177r436b239],
9	sex	NN	O	sex	pobj	6	SENT_77	[p5l464t186r614b257],
10	,	,	O	,	_	0	SENT_77	[p5l464t186r614b257],
11	clinical	JJ	O	clinical	amod	12	SENT_77	[p5l645t160r945b239],
12	stage	NN	O	stage	pobj	6	SENT_77	[p5l971t176r1183b262],
13	of	IN	O	of	_	0	SENT_77	[p5l1209t159r1308b239],
14	non	JJ	O	non	amod	20	SENT_77	[p5l1314t160r1932b239],
15	—	JJ	O	—	amod	20	SENT_77	[p5l1314t160r1932b239],
16	small-cell	NN	O	small-cell	nn	20	SENT_77	[p5l1314t160r1932b239],
17	lung	NN	O	lung	nn	20	SENT_77	[p5l1955t160r2150b262],
18	cancer	NN	O	cancer	nn	20	SENT_77	[p5l12t316r294b368],
19	(	CD	NUMBER	(	num	20	SENT_77	[p5l326t296r544b386],
20	IIIB	NN	O	iiib	prep_of	12	SENT_77	[p5l326t296r544b386],
21	,	,	O	,	_	0	SENT_77	[p5l326t296r544b386],
22	IV	CD	NUMBER	iv	pobj	6	SENT_77	[p5l579t297r686b385],
23	,	,	O	,	_	0	SENT_77	[p5l579t297r686b385],
24	or	CC	O	or	_	0	SENT_77	[p5l723t315r812b368],
25	postoperative	JJ	O	postoperative	amod	27	SENT_77	[p5l839t291r1422b390],
26	relapse	NN	O	relapse	nn	27	SENT_77	[p5l1453t290r1806b390],
27	)	NN	O	)	conj_or	9	SENT_77	[p5l1453t290r1806b390],
28	,	,	O	,	_	0	SENT_77	[p5l1453t290r1806b390],
29	and	CC	O	and	_	0	SENT_77	[p5l1842t290r2001b368],
30	institution	NN	O	institution	pobj	6	SENT_77	[p5l2031t291r2145b367, p5l13t419r392b497],
31	.	.	O	.	_	0	SENT_77	[p5l2031t291r2145b367, p5l13t419r392b497],

1	Eligible	JJ	O	eligible	amod	2	SENT_78	[p5l421t418r737b519],
2	patients	NNS	O	patient	nsubjpass	5	SENT_78	[p5l761t419r1096b518],
3	Were	VBD	O	be	auxpass	5	SENT_78	[p5l1119t444r1319b497],
4	randomly	RB	O	randomly	advmod	5	SENT_78	[p5l1344t418r1753b518],
5	assigned	VBN	O	assign	_	0	SENT_78	[p5l1773t418r2147b519],
6	to	TO	O	to	aux	7	SENT_78	[p5l12t562r93b625],
7	receive	VB	O	receive	xcomp	5	SENT_78	[p5l124t547r415b626],
8	either	CC	O	either	prep	7	SENT_78	[p5l444t546r693b625],
9	gefitinib	JJ	O	gefitinib	amod	10	SENT_78	[p5l718t545r1092b648],
10	(	NN	O	(	dep	8	SENT_78	[p5l1128t553r1231b638],
11	at	IN	O	at	_	0	SENT_78	[p5l1128t553r1231b638],
12	a	DT	O	a	det	13	SENT_78	[p5l1255t572r1299b625],
13	dose	NN	O	dose	prep_at	7	SENT_78	[p5l1327t546r1522b625],
14	of	IN	O	of	_	0	SENT_78	[p5l1553t545r1653b625],
15	250	CD	NUMBER	250	num	16	SENT_78	[p5l1663t551r1816b625],
16	mg	NN	O	mg	prep_of	13	SENT_78	[p5l1846t572r1986b648],
17	per	IN	O	per	_	0	SENT_78	[p5l2010t572r2151b647],
18	day	NN	DURATION	day	prep_per	16	SENT_78	[p5l12t676r161b776],
19	orally	RB	O	orally	amod	18	SENT_78	[p5l192t676r465b776],
20	)	CD	NUMBER	)	tmod	19	SENT_78	[p5l192t676r465b776],
21	or	CC	O	or	_	0	SENT_78	[p5l505t701r596b754],
22	standard	JJ	O	standard	amod	23	SENT_78	[p5l629t676r1017b754],
23	chemotherapy	NN	O	chemotherapy	prep_of	13	SENT_78	[p5l1052t676r1692b776],
24	.	.	O	.	_	0	SENT_78	[p5l1052t676r1692b776],

1	The	DT	O	the	det	3	SENT_79	[p5l1729t676r1893b754],
2	standard	JJ	O	standard	amod	3	SENT_79	[p5l1929t692r2145b754, p5l12t804r207b882],
3	chemotherapy	NN	O	chemotherapy	nsubj	4	SENT_79	[p5l255t804r869b904],
4	consisted	VBD	O	consist	_	0	SENT_79	[p5l913t804r1318b882],
5	of	IN	O	of	_	0	SENT_79	[p5l1366t803r1466b882],
6	paclitaxel	NN	O	paclitaxel	nn	7	SENT_79	[p5l1493t804r1907b904],
7	(	NN	O	(	prep_of	4	SENT_79	[p5l1958t811r2062b895],
8	at	IN	O	at	_	0	SENT_79	[p5l1958t811r2062b895],
9	a	DT	O	a	det	10	SENT_79	[p5l2104t830r2149b882],
10	dose	NN	O	dose	prep_at	4	SENT_79	[p5l12t932r207b1011],
11	of	IN	O	of	_	0	SENT_79	[p5l240t931r341b1011],
12	200	CD	NUMBER	200	num	13	SENT_79	[p5l355t937r510b1011],
13	mg	NN	O	mg	prep_of	10	SENT_79	[p5l543t958r682b1034],
14	per	IN	O	per	_	0	SENT_79	[p5l710t958r851b1033],
15	square	NN	O	square	nn	16	SENT_79	[p5l882t958r1165b1033],
16	meter	NN	O	meter	prep_per	13	SENT_79	[p5l1198t948r1448b1011],
17	of	IN	O	of	_	0	SENT_79	[p5l1478t931r1578b1011],
18	body-surface	JJ	O	body-surface	amod	19	SENT_79	[p5l1593t931r2147b1033],
19	area	NN	O	area	prep_of	16	SENT_79	[p5l11t1087r210b1156],
20	,	,	O	,	_	0	SENT_79	[p5l11t1087r210b1156],
21	given	VBN	O	give	prep	4	SENT_79	[p5l241t1062r465b1162],
22	intravenously	RB	O	intravenously	advmod	23	SENT_79	[p5l490t1061r1059b1161],
23	over	IN	O	over	pcomp	21	SENT_79	[p5l1082t1086r1257b1140],
24	a	DT	O	a	det	27	SENT_79	[p5l1280t1087r1325b1139],
25	3-hour	JJ	DURATION	3-hour	amod	27	SENT_79	[p5l1350t1061r1635b1140],
26	period	NN	O	period	nn	27	SENT_79	[p5l1657t1061r1957b1161],
27	)	NN	O	)	pobj	23	SENT_79	[p5l1657t1061r1957b1161],
28	and	CC	O	and	_	0	SENT_79	[p5l1988t1061r2148b1139],
29	carboplatin	NN	O	carboplatin	nn	30	SENT_79	[p5l12t1190r509b1290],
30	(	NN	O	(	pobj	23	SENT_79	[p5l544t1196r647b1281],
31	at	IN	O	at	_	0	SENT_79	[p5l544t1196r647b1281],
32	a	DT	O	a	det	34	SENT_79	[p5l672t1216r717b1268],
33	dose	NN	O	dose	nn	34	SENT_79	[p5l746t1190r941b1268],
34	equivalent	NN	O	equivalent	prep_at	27	SENT_79	[p5l973t1190r1416b1290],
35	to	TO	O	to	_	0	SENT_79	[p5l1442t1206r1524b1268],
36	an	DT	O	a	det	37	SENT_79	[p5l1554t1216r1659b1268],
37	area	NN	O	area	prep_to	34	SENT_79	[p5l1688t1216r1869b1268],
38	under	IN	O	under	_	0	SENT_79	[p5l1897t1190r2149b1269],
39	the	DT	O	the	det	42	SENT_79	[p5l12t1318r145b1397],
40	concentration	NN	O	concentration	nn	42	SENT_79	[p5l191t1319r1043b1397],
41	—	CD	NUMBER	—	num	42	SENT_79	[p5l191t1319r1043b1397],
42	time	NN	O	time	prep_under	37	SENT_79	[p5l191t1319r1043b1397],
43	curve	NN	O	curve	nn	46	SENT_79	[p5l1089t1344r1318b1398],
44	[	CD	NUMBER	[	num	46	SENT_79	[p5l1373t1324r1616b1409],
45	AUC	NN	O	auc	nn	46	SENT_79	[p5l1373t1324r1616b1409],
46	]	NN	O	]	dep	4	SENT_79	[p5l1373t1324r1616b1409],
47	of	IN	O	of	_	0	SENT_79	[p5l1671t1317r1772b1397],
48	6	CD	NUMBER	6	prep_of	46	SENT_79	[p5l1798t1324r1869b1415],
49	,	,	O	,	_	0	SENT_79	[p5l1798t1324r1869b1415],
50	given	VBN	O	give	ccomp	4	SENT_79	[p5l1919t1319r2148b1420],
51	intravenously	RB	O	intravenously	advmod	50	SENT_79	[p5l11t1448r591b1548],
52	over	IN	O	over	_	0	SENT_79	[p5l623t1473r803b1527],
53	a	DT	O	a	det	56	SENT_79	[p5l834t1474r879b1526],
54	1-hour	JJ	DURATION	1-hour	amod	56	SENT_79	[p5l917t1448r1197b1527],
55	period	NN	O	period	nn	56	SENT_79	[p5l1228t1448r1561b1548],
56	)	NN	O	)	prep_over	50	SENT_79	[p5l1228t1448r1561b1548],
57	,	,	O	,	_	0	SENT_79	[p5l1228t1448r1561b1548],
58	both	CC	O	both	dep	50	SENT_79	[p5l1602t1448r1801b1526],
59	administered	VBN	O	administer	conj	50	SENT_79	[p5l1836t1448r2145b1526, p5l11t1576r299b1654],
60	on	IN	O	on	_	0	SENT_79	[p5l332t1601r438b1654],
61	the	DT	DURATION	the	det	63	SENT_79	[p5l470t1576r604b1654],
62	first	JJ	DURATION	first	amod	63	SENT_79	[p5l636t1575r821b1654],
63	day	NN	DURATION	day	prep_on	59	SENT_79	[p5l849t1576r996b1676],
64	of	IN	O	of	_	0	SENT_79	[p5l1024t1575r1125b1654],
65	every	DT	SET	every	det	67	SENT_79	[p5l1139t1602r1361b1676],
66	3-week	JJ	SET	3-week	amod	67	SENT_79	[p5l1390t1576r1696b1655],
67	cycle	NN	O	cycle	prep_of	63	SENT_79	[p5l1724t1576r1952b1676],
68	.	.	O	.	_	0	SENT_79	[p5l1724t1576r1952b1676],

1	The	DT	O	the	_	0	SENT_80	[p5l1985t1576r2147b1654],

1	N	NN	O	n	nn	3	SENT_81	[p5l570t1761r584b1776],
2	ENGLJ	NN	O	englj	nn	3	SENT_81	[p5l598t1761r676b1783],
3	MED	NN	O	med	_	0	SENT_81	[p5l691t1761r743b1776],
4	362	CD	NUMBER	362	dep	3	SENT_81	[p5l753t1755r832b1783],
5	;	:	O	;	_	0	SENT_81	[p5l753t1755r832b1783],
6	25	CD	NUMBER	25	num	8	SENT_81	[p5l753t1755r832b1783],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_81	[p5l867t1761r991b1783],
8	JUNEZ	NN	O	junez	dep	3	SENT_81	[p5l1022t1761r1110b1783],
9	,2	CD	NUMBER	,2	number	10	SENT_81	[p5l1129t1761r1204b1781],
10	o1o	CD	NUMBER	o1o	num	11	SENT_81	[p5l1129t1761r1204b1781],
11	2331	CD	DATE	2331	dep	8	SENT_81	[p5l1939t1751r2016b1774],

1	The	DT	O	the	det	4	SENT_82	[p5l702t1794r753b1818],
2	New	NNP	LOCATION	New	nn	4	SENT_82	[p5l762t1795r824b1818],
3	England	NNP	LOCATION	England	nn	4	SENT_82	[p5l833t1794r944b1825],
4	J	NNP	O	J	_	0	SENT_82	[p5l952t1795r965b1818],
5	oumal	JJ	O	oumal	amod	7	SENT_82	[p5l966t1794r1050b1818],
6	o	NN	O	o	nn	7	SENT_82	[p5l1059t1802r1075b1818],
7	edicine	NN	O	edicine	dep	4	SENT_82	[p5l1125t1794r1220b1818],

1	Copyright	NN	O	copyright	_	0	SENT_83	[p5l494t1876r629b1907],
2	©	CD	NUMBER	©	num	6	SENT_83	[p5l638t1876r661b1900],
3	2010	CD	DATE	2010	num	6	SENT_83	[p5l671t1876r737b1900],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_83	[p5l746t1876r937b1900],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_83	[p5l947t1876r1055b1900],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_83	[p5l1065t1876r1170b1907],
7	.	.	O	.	_	0	SENT_83	[p5l1065t1876r1170b1907],

1	All	DT	O	all	det	2	SENT_84	[p5l1181t1876r1223b1900],
2	rights	NNS	O	rights	nsubj	3	SENT_84	[p5l1232t1876r1306b1907],
3	reserved	VBN	O	reserve	_	0	SENT_84	[p5l1316t1876r1435b1900],
4	.	.	O	.	_	0	SENT_84	[p5l1316t1876r1435b1900],

1	The	DT	O	the	det	4	SENT_85	[p5l673t1982r719b2003],
2	NEW	NNP	O	NEW	nn	4	SENT_85	[p5l737t1984r822b2003],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_85	[p5l841t1984r1030b2003],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_85	[p5l1049t1984r1228b2010],
5	of	IN	O	of	_	0	SENT_85	[p5l1248t1982r1276b2009],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_85	[p5l1288t1984r1487b2003],

1	carboplatin	NN	O	carboplatin	nn	2	SENT_86	[p5l12t2205r510b2305],
2	dose	NN	O	dose	nsubjpass	6	SENT_86	[p5l541t2205r736b2284],
3	in	IN	O	in	_	0	SENT_86	[p5l766t2206r850b2283],
4	milligrams	NNS	O	milligram	prep_in	2	SENT_86	[p5l881t2205r1360b2306],
5	was	VBD	O	be	auxpass	6	SENT_86	[p5l1389t2231r1552b2284],
6	calculated	VBN	O	calculate	_	0	SENT_86	[p5l1586t2205r2023b2284],
7	by	IN	O	by	_	0	SENT_86	[p5l2054t2205r2152b2305],
8	means	NNS	O	means	nsubj	17	SENT_86	[p5l12t2359r293b2412],
9	of	IN	O	of	_	0	SENT_86	[p5l338t2332r438b2412],
10	the	DT	O	the	det	14	SENT_86	[p5l464t2333r597b2412],
11	Calvert	NNP	LOCATION	Calvert	nn	14	SENT_86	[p5l640t2333r945b2413],
12	formula	NN	O	formulum	nn	14	SENT_86	[p5l983t2332r1329b2413],
13	(	CD	NUMBER	(	num	14	SENT_86	[p5l1375t2339r1660b2424],
14	AUCx	NN	O	aucx	prep_of	8	SENT_86	[p5l1375t2339r1660b2424],
15	[	CD	NUMBER	[	dep	8	SENT_86	[p5l1692t2333r1850b2424],
16	the	DT	O	the	dep	8	SENT_86	[p5l1692t2333r1850b2424],
17	calculated	VBN	O	calculate	agent	6	SENT_86	[p5l1893t2333r2147b2413, p5l11t2462r220b2541],
18	creatinine	NN	O	creatinine	nn	19	SENT_86	[p5l260t2463r694b2541],
19	clearance	NN	O	clearance	tmod	17	SENT_86	[p5l734t2462r1138b2540],
20	in	IN	O	in	_	0	SENT_86	[p5l1177t2463r1260b2540],
21	milliliters	NNS	O	milliliter	prep_in	19	SENT_86	[p5l1300t2462r1725b2540],
22	per	IN	O	per	_	0	SENT_86	[p5l1765t2488r1906b2562],
23	minute	NN	DURATION	minute	nn	25	SENT_86	[p5l1942t2463r2147b2540, p5l12t2596r371b2686],
24	+25	CD	NUMBER	+25	num	25	SENT_86	[p5l1942t2463r2147b2540, p5l12t2596r371b2686],
25	]	NN	O	]	prep_per	21	SENT_86	[p5l1942t2463r2147b2540, p5l12t2596r371b2686],
26	;	:	O	;	_	0	SENT_86	[p5l1942t2463r2147b2540, p5l12t2596r371b2686],
27	WWW.freekinetics.com/auccalcl.htm	NNP	O	WWW.freekinetics.com/auccalcl.htm	dep	19	SENT_86	[p5l396t2589r1958b2681],
28	)	CD	NUMBER	)	num	27	SENT_86	[p5l396t2589r1958b2681],
29	.	.	O	.	_	0	SENT_86	[p5l396t2589r1958b2681],

1	The	DT	O	the	det	4	SENT_87	[p5l1986t2590r2148b2668],
2	glomerular	JJ	O	glomerular	amod	4	SENT_87	[p5l12t2719r498b2821],
3	filtration	NN	O	filtration	nn	4	SENT_87	[p5l535t2718r927b2799],
4	rate	NN	O	rate	nsubjpass	6	SENT_87	[p5l966t2736r1128b2798],
5	was	VBD	O	be	auxpass	6	SENT_87	[p5l1163t2746r1326b2799],
6	estimated	VBN	O	estimate	_	0	SENT_87	[p5l1370t2719r1794b2799],
7	according	VBG	O	accord	_	0	SENT_87	[p5l1832t2719r2147b2799, p5l11t2849r151b2950],
8	to	TO	O	to	prepc_according_to	6	SENT_87	[p5l182t2865r264b2928],
9	the	DT	O	the	det	11	SENT_87	[p5l299t2848r433b2927],
10	Cocl	NN	O	cocl	dep	11	SENT_87	[p5l465t2847r1186b2928],
11	<	JJR	O	<	pobj	6	SENT_87	[p5l465t2847r1186b2928],
12	croft	CD	NUMBER	croft	dep	11	SENT_87	[p5l465t2847r1186b2928],
13	.	.	O	.	_	0	SENT_87	[p5l465t2847r1186b2928],

1	—	NN	O	—	_	0	SENT_88	[p5l465t2847r1186b2928],
2	.	.	O	.	_	0	SENT_88	[p5l465t2847r1186b2928],

1	Gault	NNP	PERSON	Gault	nn	3	SENT_89	[p5l465t2847r1186b2928],
2	method	NN	O	method	nn	3	SENT_89	[p5l1214t2848r1548b2928],
3	(	NN	O	(	nsubj	33	SENT_89	[p5l1586t2854r2031b2950],
4	[	CD	NUMBER	[	npadvmod	5	SENT_89	[p5l1586t2854r2031b2950],
5	140-age	JJ	O	140-age	amod	3	SENT_89	[p5l1586t2854r2031b2950],
6	in	IN	O	in	_	0	SENT_89	[p5l2064t2849r2148b2926],
7	years	NNS	DURATION	year	prep_in	3	SENT_89	[p5l7t2983r248b3077],
8	]	CD	NUMBER	]	num	7	SENT_89	[p5l7t2983r248b3077],
9	x	CC	O	x	_	0	SENT_89	[p5l277t3008r321b3051],
10	[	CD	NUMBER	[	prep_in	3	SENT_89	[p5l351t2977r629b3068],
11	actual	JJ	O	actual	amod	12	SENT_89	[p5l351t2977r629b3068],
12	Weight	NNP	O	Weight	dep	10	SENT_89	[p5l663t2977r953b3078],
13	in	IN	O	in	_	0	SENT_89	[p5l987t2978r1069b3055],
14	kilograms	NNS	O	kilogram	prep_in	12	SENT_89	[p5l1108t2977r1564b3078],
15	]	SYM	O	]	dep	12	SENT_89	[p5l1108t2977r1564b3078],
16	-	:	O	-	_	0	SENT_89	[p5l1589t3002r1644b3056],
17	:	:	O	:	_	0	SENT_89	[p5l1589t3002r1644b3056],
18	[	CD	NUMBER	[	number	19	SENT_89	[p5l1668t2983r1795b3068],
19	72	CD	NUMBER	72	num	23	SENT_89	[p5l1668t2983r1795b3068],
20	x	NN	O	x	nn	23	SENT_89	[p5l1815t3008r1860b3051],
21	serum	NN	O	serum	nn	23	SENT_89	[p5l1883t3003r2148b3056],
22	creatinine	NN	O	creatinine	nn	23	SENT_89	[p5l12t3106r446b3183],
23	level	NN	O	level	dep	10	SENT_89	[p5l475t3104r665b3184],
24	in	IN	O	in	_	0	SENT_89	[p5l695t3106r778b3182],
25	milligrams	NNS	O	milligram	prep_in	23	SENT_89	[p5l808t3104r1288b3206],
26	per	IN	O	per	_	0	SENT_89	[p5l1318t3130r1460b3205],
27	deciliter	NN	O	deciliter	prep_per	25	SENT_89	[p5l1487t3104r1839b3183],
28	{	CD	NUMBER	{	num	27	SENT_89	[p5l1863t3102r1946b3208],
29	x	CC	O	x	_	0	SENT_89	[p5l1863t3102r1946b3208],
30	0.85	CD	NUMBER	0.85	conj_x	23	SENT_89	[p5l1969t3111r2144b3183],
31	in	IN	O	in	_	0	SENT_89	[p5l11t3234r95b3310],
32	women	NNS	O	woman	prep_in	30	SENT_89	[p5l123t3230r561b3336],
33	}	VBP	O	}	_	0	SENT_89	[p5l123t3230r561b3336],
34	]	CD	NUMBER	]	number	35	SENT_89	[p5l123t3230r561b3336],
35	)	CD	NUMBER	)	dobj	33	SENT_89	[p5l123t3230r561b3336],
36	.	.	O	.	_	0	SENT_89	[p5l123t3230r561b3336],

1	Chemotherapy	NN	O	chemotherapy	nsubjpass	3	SENT_90	[p5l599t3232r1234b3333],
2	was	VBD	O	be	auxpass	3	SENT_90	[p5l1257t3259r1421b3312],
3	continued	VBN	O	continue	_	0	SENT_90	[p5l1456t3232r1888b3312],
4	for	IN	O	for	_	0	SENT_90	[p5l1921t3231r2045b3311],
5	at	IN	O	at	quantmod	7	SENT_90	[p5l2074t3249r2153b3311],
6	least	JJS	O	least	mwe	5	SENT_90	[p5l11t3360r207b3438],
7	three	CD	NUMBER	three	num	8	SENT_90	[p5l237t3360r453b3438],
8	cycles	NNS	O	cycle	prep_for	3	SENT_90	[p5l488t3360r754b3460],
9	.	.	O	.	_	0	SENT_90	[p5l488t3360r754b3460],

1	Gefitinib	NNP	O	Gefitinib	nsubjpass	3	SENT_91	[p5l794t3359r1180b3439],
2	was	VBD	O	be	auxpass	3	SENT_91	[p5l1212t3386r1373b3440],
3	administered	VBN	O	administer	_	0	SENT_91	[p5l1409t3360r1970b3439],
4	until	IN	O	until	_	0	SENT_91	[p5l2004t3386r2147b3440, p5l12t3489r102b3568],
5	disease	NN	O	disease	nn	6	SENT_91	[p5l142t3489r454b3569],
6	progression	NN	O	progression	prep_until	3	SENT_91	[p5l492t3490r1030b3591],
7	,	,	O	,	_	0	SENT_91	[p5l492t3490r1030b3591],
8	development	NN	O	development	appos	6	SENT_91	[p5l1076t3489r1629b3590],
9	of	IN	O	of	_	0	SENT_91	[p5l1664t3488r1764b3569],
10	intolerable	JJ	O	intolerable	amod	11	SENT_91	[p5l1784t3489r2147b3569, p5l12t3617r136b3696],
11	toxic	JJ	O	toxic	amod	12	SENT_91	[p5l171t3618r378b3696],
12	effects	NNS	O	effect	prep_of	8	SENT_91	[p5l413t3616r720b3713],
13	,	,	O	,	_	0	SENT_91	[p5l413t3616r720b3713],
14	or	CC	O	or	_	0	SENT_91	[p5l762t3643r851b3696],
15	Withdrawal	NN	O	withdrawal	prep_of	8	SENT_91	[p5l878t3617r1372b3697],
16	of	IN	O	of	_	0	SENT_91	[p5l1407t3616r1508b3696],
17	consent	NN	O	consent	prep_of	15	SENT_91	[p5l1525t3634r1882b3696],
18	.	.	O	.	_	0	SENT_91	[p5l1525t3634r1882b3696],

1	CLINICAL	JJ	O	clinical	amod	3	SENT_92	[p6l12t126r381b177],
2	ASSESSMENTS	NNS	O	assessment	nn	3	SENT_92	[p6l411t126r981b177],
3	Assessments	NNS	O	assessment	nsubjpass	8	SENT_92	[p6l8t234r563b304],
4	made	VBN	O	make	partmod	3	SENT_92	[p6l616t226r849b305],
5	before	IN	O	before	_	0	SENT_92	[p6l901t225r1172b305],
6	enrollment	NN	O	enrollment	prep_before	4	SENT_92	[p6l1224t226r1704b305],
7	are	VBP	O	be	auxpass	8	SENT_92	[p6l1750t252r1879b304],
8	summarized	VBN	O	summarize	_	0	SENT_92	[p6l1933t252r2147b305, p6l12t354r369b433],
9	in	IN	O	in	_	0	SENT_92	[p6l403t355r486b432],
10	Table	NNP	O	Table	prep_in	8	SENT_92	[p6l516t354r752b433],
11	2	CD	NUMBER	2	num	10	SENT_92	[p6l788t360r835b432],
12	in	IN	O	in	_	0	SENT_92	[p6l871t355r955b432],
13	the	DT	O	the	det	15	SENT_92	[p6l989t354r1122b432],
14	Supplementary	NNP	O	Supplementary	nn	15	SENT_92	[p6l1159t354r1809b454],
15	Appendix	NNP	O	Appendix	prep_in	8	SENT_92	[p6l1835t362r2147b454, p6l12t482r168b561],
16	.	.	O	.	_	0	SENT_92	[p6l1835t362r2147b454, p6l12t482r168b561],

1	Assessment	NNP	O	Assessment	nsubjpass	11	SENT_93	[p6l215t490r729b560],
2	of	IN	O	of	_	0	SENT_93	[p6l769t481r869b561],
3	the	DT	O	the	det	4	SENT_93	[p6l896t482r1029b560],
4	tumor	NN	O	tumor	prep_of	1	SENT_93	[p6l1074t499r1344b562],
5	for	IN	O	for	_	0	SENT_93	[p6l1385t481r1509b561],
6	a	DT	O	a	det	7	SENT_93	[p6l1549t508r1594b560],
7	response	NN	O	response	prep_for	4	SENT_93	[p6l1637t508r2020b582],
8	to	TO	O	to	_	0	SENT_93	[p6l2065t499r2147b561],
9	treatment	NN	O	treatment	prep_to	7	SENT_93	[p6l12t627r439b688],
10	was	VBD	O	be	auxpass	11	SENT_93	[p6l464t636r627b690],
11	performed	VBN	O	perform	_	0	SENT_93	[p6l662t609r1122b710],
12	by	IN	O	by	_	0	SENT_93	[p6l1157t610r1255b710],
13	means	NNS	O	means	_	0	SENT_93	[p6l1285t636r1565b688],
14	of	IN	O	of	_	0	SENT_93	[p6l1604t609r1704b689],
15	computed	JJ	O	computed	amod	16	SENT_93	[p6l1720t610r2149b710],
16	tomography	NN	O	tomography	prep_by_means_of	11	SENT_93	[p6l12t739r541b840],
17	(	CD	NUMBER	(	num	19	SENT_93	[p6l575t745r753b830],
18	CT	NN	O	ct	nn	19	SENT_93	[p6l575t745r753b830],
19	)	NN	O	)	dep	16	SENT_93	[p6l575t745r753b830],
20	every	DT	SET	every	det	22	SENT_93	[p6l793t765r1016b839],
21	2	CD	SET	2	num	22	SENT_93	[p6l1045t745r1092b817],
22	months	NNS	NUMBER	month	tmod	11	SENT_93	[p6l1127t739r1481b818],
23	.	.	O	.	_	0	SENT_93	[p6l1127t739r1481b818],

1	Unidirectional	JJ	O	unidirectional	amod	2	SENT_94	[p6l1520t739r2149b818],
2	measurements	NNS	O	measurement	nsubjpass	4	SENT_94	[p6l12t883r643b946],
3	were	VBD	O	be	auxpass	4	SENT_94	[p6l682t892r885b946],
4	adopted	VBN	O	adopt	dep	16	SENT_94	[p6l925t866r1270b966],
5	on	IN	O	on	_	0	SENT_94	[p6l1311t892r1418b945],
6	the	DT	O	the	det	7	SENT_94	[p6l1459t866r1592b944],
7	basis	NN	O	basis	prep_on	4	SENT_94	[p6l1635t866r1847b945],
8	of	IN	O	of	_	0	SENT_94	[p6l1891t865r1991b945],
9	the	DT	O	the	det	12	SENT_94	[p6l2014t866r2148b944],
10	Response	NN	O	response	nn	12	SENT_94	[p6l11t1001r433b1095],
11	Evaluation	NN	O	evaluation	nn	12	SENT_94	[p6l487t995r952b1074],
12	Criteria	NNS	O	criterion	prep_of	7	SENT_94	[p6l1008t996r1342b1074],
13	in	IN	O	in	_	0	SENT_94	[p6l1396t996r1481b1073],
14	Solid	JJ	O	solid	amod	15	SENT_94	[p6l1539t995r1756b1074],
15	Tumors	NNS	O	tumor	prep_in	4	SENT_94	[p6l1808t1001r2145b1074],
16	(	VBP	O	(	_	0	SENT_94	[p6l17t1130r397b1221],
17	RECIST	NNP	O	RECIST	nsubj	16	SENT_94	[p6l17t1130r397b1221],
18	,	,	O	,	_	0	SENT_94	[p6l17t1130r397b1221],
19	Version	NNP	O	Version	appos	17	SENT_94	[p6l432t1125r742b1204],
20	1.0	CD	NUMBER	1.0	number	21	SENT_94	[p6l779t1129r1033b1216],
21	)	CD	NUMBER	)	dep	19	SENT_94	[p6l779t1129r1033b1216],
22	.	.	O	.	_	0	SENT_94	[p6l779t1129r1033b1216],

1	“	NN	O	“	nn	2	SENT_95	[p6l779t1129r1033b1216],
2	Progression	NN	O	progression	nsubj	27	SENT_95	[p6l1066t1123r1779b1226],
3	—	CD	NUMBER	—	num	5	SENT_95	[p6l1066t1123r1779b1226],
4	free	JJ	O	free	amod	5	SENT_95	[p6l1066t1123r1779b1226],
5	survival	NN	O	survival	nsubjpass	7	SENT_95	[p6l1814t1124r2148b1204],
6	was	VBD	O	be	auxpass	7	SENT_95	[p6l7t1278r168b1332],
7	evaluated	VBN	O	evaluate	rcmod	2	SENT_95	[p6l203t1252r599b1332],
8	for	IN	O	for	_	0	SENT_95	[p6l630t1251r752b1331],
9	the	DT	O	the	det	10	SENT_95	[p6l782t1252r913b1330],
10	period	NN	O	period	prep_for	7	SENT_95	[p6l943t1252r1217b1352],
11	from	IN	O	from	_	0	SENT_95	[p6l1248t1251r1456b1331],
12	the	DT	O	the	det	13	SENT_95	[p6l1488t1252r1620b1330],
13	date	NN	O	date	prep_from	10	SENT_95	[p6l1652t1252r1828b1331],
14	of	IN	O	of	_	0	SENT_95	[p6l1861t1251r1960b1331],
15	randomization	NN	O	randomization	prep_of	13	SENT_95	[p6l1973t1278r2147b1330, p6l12t1381r510b1460],
16	to	TO	O	to	_	0	SENT_95	[p6l541t1398r623b1460],
17	the	DT	O	the	det	18	SENT_95	[p6l656t1381r789b1460],
18	date	NN	O	date	prep_to	7	SENT_95	[p6l821t1381r999b1460],
19	when	WRB	O	when	advmod	24	SENT_95	[p6l1026t1381r1260b1460],
20	disease	NN	O	disease	nn	21	SENT_95	[p6l1292t1381r1604b1460],
21	progression	NN	O	progression	nsubjpass	24	SENT_95	[p6l1633t1382r2148b1482],
22	was	VBD	O	be	auxpass	24	SENT_95	[p6l7t1535r171b1588],
23	first	JJ	ORDINAL	first	advmod	24	SENT_95	[p6l212t1508r397b1587],
24	observed	VBN	O	observe	dep	18	SENT_95	[p6l431t1509r814b1588],
25	or	CC	O	or	_	0	SENT_95	[p6l853t1535r942b1588],
26	death	NN	O	death	nsubj	27	SENT_95	[p6l978t1509r1217b1588],
27	occurred	VBD	O	occur	_	0	SENT_95	[p6l1256t1509r1661b1588],
28	.	.	O	.	_	0	SENT_95	[p6l1256t1509r1661b1588],

1	Treatment	NN	O	treatment	nn	2	SENT_96	[p6l1701t1515r2153b1587],
2	response	NN	O	response	nsubjpass	7	SENT_96	[p6l12t1663r395b1738],
3	and	CC	O	and	_	0	SENT_96	[p6l438t1637r597b1717],
4	progression-free	JJ	O	progression-free	amod	5	SENT_96	[p6l639t1636r1352b1739],
5	survival	NN	O	survival	conj_and	2	SENT_96	[p6l1397t1637r1730b1717],
6	were	VBD	O	be	auxpass	7	SENT_96	[p6l1769t1663r1972b1717],
7	determined	VBN	O	determine	_	0	SENT_96	[p6l2016t1637r2147b1717, p6l12t1765r407b1844],
8	by	IN	O	by	_	0	SENT_96	[p6l453t1765r551b1865],
9	external	JJ	O	external	amod	10	SENT_96	[p6l591t1765r942b1843],
10	review	NN	O	review	agent	7	SENT_96	[p6l986t1766r1268b1845],
11	of	IN	O	of	_	0	SENT_96	[p6l1309t1764r1409b1844],
12	the	DT	O	the	det	14	SENT_96	[p6l1436t1765r1570b1843],
13	CT	NN	O	ct	nn	14	SENT_96	[p6l1615t1771r1739b1844],
14	films	NNS	O	film	prep_of	10	SENT_96	[p6l1780t1764r2008b1843],
15	by	IN	O	by	_	0	SENT_96	[p6l2055t1765r2153b1865],
16	experts	NNS	O	expert	agent	7	SENT_96	[p6l12t1910r324b1993],
17	who	WP	O	who	nsubj	20	SENT_96	[p6l359t1893r542b1973],
18	were	VBD	O	be	cop	20	SENT_96	[p6l576t1919r779b1973],
19	not	RB	O	not	neg	20	SENT_96	[p6l816t1910r959b1972],
20	aware	JJ	O	aware	rcmod	16	SENT_96	[p6l990t1919r1242b1973],
21	of	IN	O	of	_	0	SENT_96	[p6l1279t1892r1379b1972],
22	the	DT	O	the	det	24	SENT_96	[p6l1398t1893r1531b1971],
23	treatment	NN	O	treatment	nn	24	SENT_96	[p6l1569t1910r1995b1971],
24	assignments	NNS	O	assignment	prep_of	20	SENT_96	[p6l2026t1919r2147b1971, p6l13t2023r485b2124],
25	.	.	O	.	_	0	SENT_96	[p6l2026t1919r2147b1971, p6l13t2023r485b2124],

1	Overall	JJ	O	overall	amod	2	SENT_97	[p6l523t2022r833b2102],
2	survival	NN	O	survival	nsubjpass	4	SENT_97	[p6l865t2022r1199b2102],
3	was	VBD	O	be	auxpass	4	SENT_97	[p6l1226t2049r1390b2102],
4	evaluated	VBN	O	evaluate	_	0	SENT_97	[p6l1424t2022r1829b2102],
5	for	IN	O	for	_	0	SENT_97	[p6l1861t2021r1984b2102],
6	the	DT	O	the	det	7	SENT_97	[p6l2014t2022r2148b2101],
7	period	NN	O	period	prep_for	4	SENT_97	[p6l11t2150r284b2250],
8	from	IN	O	from	_	0	SENT_97	[p6l314t2149r522b2229],
9	the	DT	O	the	det	10	SENT_97	[p6l553t2150r684b2228],
10	date	NN	O	date	prep_from	4	SENT_97	[p6l716t2150r891b2229],
11	of	IN	O	of	_	0	SENT_97	[p6l922t2149r1021b2229],
12	randomization	NN	O	randomization	prep_of	10	SENT_97	[p6l1032t2150r1664b2229],
13	to	TO	O	to	_	0	SENT_97	[p6l1695t2167r1775b2229],
14	the	DT	O	the	det	15	SENT_97	[p6l1807t2150r1939b2228],
15	date	NN	O	date	prep_to	4	SENT_97	[p6l1970t2150r2148b2229],
16	of	IN	O	of	_	0	SENT_97	[p6l12t2278r113b2359],
17	death	NN	O	death	prep_of	15	SENT_97	[p6l142t2279r403b2359],
18	.	.	O	.	_	0	SENT_97	[p6l142t2279r403b2359],

1	Toxic	JJ	O	toxic	amod	2	SENT_98	[p6l452t2280r683b2359],
2	effects	NNS	O	effect	nsubjpass	4	SENT_98	[p6l729t2278r1012b2358],
3	were	VBD	O	be	auxpass	4	SENT_98	[p6l1056t2305r1260b2359],
4	assessed	VBN	O	assess	_	0	SENT_98	[p6l1305t2279r1676b2359],
5	according	VBG	O	accord	_	0	SENT_98	[p6l1722t2279r2151b2381],
6	to	TO	O	to	prepc_according_to	4	SENT_98	[p6l12t2426r94b2488],
7	the	DT	O	the	det	10	SENT_98	[p6l128t2409r262b2488],
8	National	NNP	ORGANIZATION	National	nn	10	SENT_98	[p6l292t2409r668b2488],
9	Cancer	NNP	ORGANIZATION	Cancer	nn	10	SENT_98	[p6l699t2415r1000b2488],
10	Institute	NNP	ORGANIZATION	Institute	pobj	4	SENT_98	[p6l1027t2410r1394b2488],
11	Common	NNP	ORGANIZATION	Common	nn	15	SENT_98	[p6l1426t2415r1830b2488],
12	Terminology	NNP	ORGANIZATION	Terminology	nn	15	SENT_98	[p6l1858t2410r2147b2488, p6l12t2537r308b2638],
13	Criteria	NNP	ORGANIZATION	Criteria	nn	15	SENT_98	[p6l337t2538r661b2616],
14	(	CD	NUMBER	(	num	15	SENT_98	[p6l697t2543r1144b2633],
15	NCI	NNP	ORGANIZATION	NCI	dep	10	SENT_98	[p6l697t2543r1144b2633],
16	.	.	O	.	_	0	SENT_98	[p6l697t2543r1144b2633],

1	—	NN	O	—	_	0	SENT_99	[p6l697t2543r1144b2633],
2	.	.	O	.	_	0	SENT_99	[p6l697t2543r1144b2633],

1	CTC	NNP	ORGANIZATION	CTC	_	0	SENT_100	[p6l697t2543r1144b2633],
2	,	,	O	,	_	0	SENT_100	[p6l697t2543r1144b2633],
3	version	NN	O	version	appos	1	SENT_100	[p6l1178t2538r1488b2616],
4	3.0	CD	NUMBER	3.0	num	3	SENT_100	[p6l1522t2543r1673b2632],
5	;	:	O	;	_	0	SENT_100	[p6l1522t2543r1673b2632],
6	http://ctep	NN	O	http://ctep	dep	1	SENT_100	[p6l1709t2537r2147b2637],
7	.	.	O	.	_	0	SENT_100	[p6l16t2665r1978b2766],

1	cancer	NN	O	cancer	_	0	SENT_101	[p6l16t2665r1978b2766],
2	.	.	O	.	_	0	SENT_101	[p6l16t2665r1978b2766],

1	gov/protocolDevelopment/electronic	JJ	O	gov/protocoldevelopment/electronic	amod	2	SENT_102	[p6l16t2665r1978b2766],
2	_	NN	O	_	_	0	SENT_102	[p6l16t2665r1978b2766],
3	applications/docs/ctcaev3	NN	O	applications/docs/ctcaev3	dep	2	SENT_102	[p6l11t2791r1343b2892],
4	.	.	O	.	_	0	SENT_102	[p6l11t2791r1343b2892],

1	pdf	NN	O	pdf	_	0	SENT_103	[p6l11t2791r1343b2892],
2	)	NN	O	)	dep	1	SENT_103	[p6l11t2791r1343b2892],
3	.	.	O	.	_	0	SENT_103	[p6l11t2791r1343b2892],

1	STATISTICAL	JJ	O	statistical	amod	2	SENT_104	[p6l12t3068r504b3119],
2	ANALYSIS	NN	O	analysis	nsubj	9	SENT_104	[p6l534t3068r912b3119],
3	The	DT	O	the	det	6	SENT_104	[p6l8t3168r170b3247],
4	primary	JJ	O	primary	amod	6	SENT_104	[p6l204t3169r556b3269],
5	end	NN	O	end	nn	6	SENT_104	[p6l588t3168r742b3248],
6	point	NN	O	point	dep	2	SENT_104	[p6l776t3169r1008b3269],
7	Was	VBD	O	be	cop	9	SENT_104	[p6l1034t3195r1197b3248],
8	progression-free	JJ	O	progression-free	amod	9	SENT_104	[p6l1233t3167r1946b3270],
9	survival	NN	O	survival	_	0	SENT_104	[p6l1983t3194r2147b3248, p6l7t3297r227b3394],
10	,	,	O	,	_	0	SENT_104	[p6l1983t3194r2147b3248, p6l7t3297r227b3394],
11	as	IN	O	as	_	0	SENT_104	[p6l267t3324r353b3376],
12	a	DT	O	a	det	13	SENT_104	[p6l390t3324r434b3376],
13	measure	NN	O	measure	prep_as	9	SENT_104	[p6l468t3323r832b3377],
14	of	IN	O	of	_	0	SENT_104	[p6l868t3296r968b3377],
15	the	DT	O	the	det	16	SENT_104	[p6l986t3297r1119b3376],
16	superiority	NN	O	superiority	prep_of	13	SENT_104	[p6l1156t3298r1625b3398],
17	of	IN	O	of	_	0	SENT_104	[p6l1656t3296r1756b3377],
18	gefitinib	NN	O	gefitinib	prep_of	16	SENT_104	[p6l1773t3296r2147b3399],
19	over	IN	O	over	_	0	SENT_104	[p6l12t3452r196b3506],
20	carboplatin	NN	O	carboplatin	nn	22	SENT_104	[p6l238t3426r1256b3526],
21	—	CD	NUMBER	—	num	22	SENT_104	[p6l238t3426r1256b3526],
22	paclitaxel	NN	O	paclitaxel	prep_over	18	SENT_104	[p6l238t3426r1256b3526],
23	.	.	O	.	_	0	SENT_104	[p6l238t3426r1256b3526],

1	From	IN	O	from	_	0	SENT_105	[p6l1305t3434r1538b3505],
2	our	PRP$	O	we	poss	4	SENT_105	[p6l1583t3452r1732b3505],
3	previous	JJ	O	previous	amod	4	SENT_105	[p6l1772t3427r2146b3526],
4	data	NNS	O	datum	prep_from	7	SENT_105	[p6l12t3555r219b3652],
5	,	,	O	,	_	0	SENT_105	[p6l12t3555r219b3652],
6	We	PRP	O	we	nsubj	7	SENT_105	[p6l264t3582r382b3635],
7	hypothesized	VBD	O	hypothesize	_	0	SENT_105	[p6l426t3555r1003b3656],
8	that	IN	O	that	complm	16	SENT_105	[p6l1047t3555r1221b3634],
9	the	DT	O	the	det	11	SENT_105	[p6l1260t3555r1393b3634],
10	progression-free	JJ	O	progression-free	amod	11	SENT_105	[p6l1435t3554r2148b3657],
11	survival	NN	O	survival	nsubj	16	SENT_105	[p6l13t3684r347b3764],
12	with	IN	O	with	_	0	SENT_105	[p6l378t3684r574b3764],
13	gefitinib	NN	O	gefitinib	prep_with	11	SENT_105	[p6l609t3683r983b3786],
14	was	VBD	O	be	cop	16	SENT_105	[p6l1015t3711r1178b3764],
15	9.7	CD	DURATION	9.7	num	16	SENT_105	[p6l1217t3690r1338b3764],
16	months	NNS	NUMBER	month	ccomp	7	SENT_105	[p6l1374t3684r1728b3780],
17	;	:	O	;	_	0	SENT_105	[p6l1374t3684r1728b3780],
18	from	IN	O	from	_	0	SENT_105	[p6l1767t3683r1979b3764],
19	the	DT	O	the	det	20	SENT_105	[p6l2014t3684r2148b3763],
20	results	NNS	O	result	prep_from	36	SENT_105	[p7l12t21r290b101],
21	of	IN	O	of	_	0	SENT_105	[p7l329t20r428b101],
22	the	DT	O	the	det	29	SENT_105	[p7l445t21r576b100],
23	Iressa	NNP	O	Iressa	nn	29	SENT_105	[p7l610t29r860b100],
24	N	NNP	O	N	nn	29	SENT_105	[p7l891t29r967b101],
25	SCLC	NNP	ORGANIZATION	SCLC	nn	29	SENT_105	[p7l969t27r1191b101],
26	Trial	NNP	O	Trial	nn	29	SENT_105	[p7l1226t21r1425b100],
27	Assessing	NNP	O	Assessing	nn	29	SENT_105	[p7l1457t22r1880b123],
28	Combination	NNP	O	Combination	nn	29	SENT_105	[p7l1912t27r2147b101, p7l12t150r374b229],
29	Treatment	NN	O	treatment	prep_of	20	SENT_105	[p7l399t156r851b228],
30	(	CD	NUMBER	(	num	29	SENT_105	[p7l878t157r1019b241],
31	IN	IN	O	in	_	0	SENT_105	[p7l878t157r1019b241],
32	TACT	NN	O	tact	prep_in	36	SENT_105	[p7l1021t155r1399b246],
33	)	CD	NUMBER	)	number	34	SENT_105	[p7l1021t155r1399b246],
34	,18	CD	NUMBER	,18	num	32	SENT_105	[p7l1021t155r1399b246],
35	we	PRP	O	we	nsubj	36	SENT_105	[p7l1424t176r1542b229],
36	hypothesized	VBD	O	hypothesize	parataxis	7	SENT_105	[p7l1570t150r2148b250],
37	that	IN	O	that	complm	48	SENT_105	[p7l12t279r186b358],
38	the	DT	O	the	det	42	SENT_105	[p7l224t279r357b358],
39	progression	NN	O	progression	nn	42	SENT_105	[p7l399t278r1111b381],
40	—	CD	NUMBER	—	num	42	SENT_105	[p7l399t278r1111b381],
41	free	JJ	O	free	amod	42	SENT_105	[p7l399t278r1111b381],
42	survival	NN	O	survival	nsubj	48	SENT_105	[p7l1156t279r1490b359],
43	with	IN	O	with	_	0	SENT_105	[p7l1527t279r1723b359],
44	standard	JJ	O	standard	amod	45	SENT_105	[p7l1767t279r2148b359],
45	chemotherapy	NN	O	chemotherapy	prep_with	42	SENT_105	[p7l12t408r615b508],
46	was	VBD	O	be	cop	48	SENT_105	[p7l638t434r799b487],
47	6.7	CD	DURATION	6.7	num	48	SENT_105	[p7l833t414r956b487],
48	months	NNS	NUMBER	month	ccomp	36	SENT_105	[p7l988t408r1335b487],
49	.	.	O	.	_	0	SENT_105	[p7l988t408r1335b487],

1	We	PRP	O	we	nsubj	2	SENT_106	[p7l1369t416r1501b486],
2	estimated	VBD	O	estimate	_	0	SENT_106	[p7l1533t408r1948b487],
3	that	IN	O	that	complm	11	SENT_106	[p7l1980t408r2153b486],
4	a	DT	O	a	det	5	SENT_106	[p7l11t562r56b614],
5	total	NN	O	total	nsubjpass	11	SENT_106	[p7l82t536r276b615],
6	of	IN	O	of	_	0	SENT_106	[p7l303t535r402b615],
7	230	CD	NUMBER	230	num	8	SENT_106	[p7l411t542r563b615],
8	events	NNS	O	event	prep_of	5	SENT_106	[p7l591t553r851b616],
9	would	MD	O	would	aux	11	SENT_106	[p7l875t536r1138b616],
10	be	VB	O	be	auxpass	11	SENT_106	[p7l1166t536r1262b615],
11	needed	VBN	O	need	ccomp	2	SENT_106	[p7l1289t536r1589b615],
12	for	IN	O	for	_	0	SENT_106	[p7l1616t535r1738b615],
13	the	DT	O	the	det	14	SENT_106	[p7l1762t536r1893b614],
14	study	NN	O	study	prep_for	11	SENT_106	[p7l1922t536r2153b636],
15	to	TO	O	to	aux	16	SENT_106	[p7l12t681r94b743],
16	have	VB	O	have	xcomp	11	SENT_106	[p7l131t664r323b744],
17	a	DT	O	a	det	18	SENT_106	[p7l358t690r403b742],
18	power	NN	O	power	nsubj	23	SENT_106	[p7l435t690r704b764],
19	of	IN	O	of	_	0	SENT_106	[p7l738t663r838b743],
20	80	CD	PERCENT	80	num	21	SENT_106	[p7l856t670r1045b744],
21	%	NN	PERCENT	%	prep_of	18	SENT_106	[p7l856t670r1045b744],
22	to	TO	O	to	aux	23	SENT_106	[p7l1081t681r1163b743],
23	confirm	VB	O	confirm	ccomp	16	SENT_106	[p7l1200t663r1555b743],
24	the	DT	O	the	det	25	SENT_106	[p7l1591t664r1724b742],
25	superiority	NN	O	superiority	dobj	23	SENT_106	[p7l1762t665r2147b764, p7l11t794r120b894],
26	of	IN	O	of	_	0	SENT_106	[p7l147t792r248b873],
27	gefitinib	NN	O	gefitinib	prep_of	25	SENT_106	[p7l260t792r634b895],
28	over	IN	O	over	_	0	SENT_106	[p7l668t819r847b873],
29	standard	JJ	O	standard	amod	30	SENT_106	[p7l878t793r1259b873],
30	chemotherapy	NN	O	chemotherapy	prep_over	23	SENT_106	[p7l1291t793r1918b894],
31	,	,	O	,	_	0	SENT_106	[p7l1291t793r1918b894],
32	with	IN	O	with	_	0	SENT_106	[p7l1952t793r2148b873],
33	the	DT	O	the	det	34	SENT_106	[p7l12t922r144b1001],
34	use	NN	O	use	prep_with	23	SENT_106	[p7l178t949r317b1002],
35	of	IN	O	of	_	0	SENT_106	[p7l353t921r452b1002],
36	a	DT	O	a	det	38	SENT_106	[p7l467t949r512b1001],
37	log-rank	JJ	O	log-rank	amod	38	SENT_106	[p7l543t922r908b1024],
38	test	NN	O	test	prep_of	34	SENT_106	[p7l938t939r1090b1001],
39	and	CC	O	and	_	0	SENT_106	[p7l1119t922r1276b1002],
40	a	DT	O	a	det	43	SENT_106	[p7l1309t949r1354b1001],
41	two-sided	JJ	O	two-sided	amod	43	SENT_106	[p7l1387t922r1802b1002],
42	significance	NN	O	significance	nn	43	SENT_106	[p7l1838t921r2147b1024, p7l12t1077r254b1130],
43	level	NN	O	level	conj_and	34	SENT_106	[p7l289t1051r479b1131],
44	of	IN	O	of	_	0	SENT_106	[p7l514t1050r615b1131],
45	5	CD	PERCENT	5	num	46	SENT_106	[p7l634t1057r790b1131],
46	%	NN	PERCENT	%	prep_of	43	SENT_106	[p7l634t1057r790b1131],
47	.	.	O	.	_	0	SENT_106	[p7l634t1057r790b1131],

1	Setting	VBG	O	set	partmod	22	SENT_107	[p7l833t1052r1140b1153],
2	the	DT	O	the	det	3	SENT_107	[p7l1173t1051r1306b1130],
3	duration	NN	O	duration	dobj	1	SENT_107	[p7l1342t1051r1710b1131],
4	of	IN	O	of	_	0	SENT_107	[p7l1746t1050r1847b1131],
5	enrollment	NN	O	enrollment	prep_of	3	SENT_107	[p7l1864t1051r2147b1131, p7l12t1196r234b1257],
6	to	TO	O	to	_	0	SENT_107	[p7l265t1196r347b1258],
7	2	CD	DURATION	2	num	8	SENT_107	[p7l384t1185r432b1257],
8	years	NNS	NUMBER	year	prep_to	1	SENT_107	[p7l464t1205r685b1279],
9	with	IN	O	with	_	0	SENT_107	[p7l718t1179r915b1259],
10	a	DT	O	a	det	13	SENT_107	[p7l949t1205r994b1257],
11	minimum	JJ	O	minimum	amod	13	SENT_107	[p7l1028t1180r1465b1259],
12	folloW	JJ	O	follow	amod	13	SENT_107	[p7l1501t1178r1912b1279],
13	—	NN	O	—	prep_with	8	SENT_107	[p7l1501t1178r1912b1279],
14	up	IN	O	up	_	0	SENT_107	[p7l1501t1178r1912b1279],
15	period	NN	O	period	prep_up	1	SENT_107	[p7l1947t1180r2147b1279, p7l12t1307r118b1386],
16	of	IN	O	of	_	0	SENT_107	[p7l147t1306r247b1386],
17	6	CD	DURATION	6	num	18	SENT_107	[p7l257t1313r304b1386],
18	months	NNS	NUMBER	month	prep_of	15	SENT_107	[p7l333t1307r684b1403],
19	,	,	O	,	_	0	SENT_107	[p7l333t1307r684b1403],
20	we	PRP	O	we	nsubj	22	SENT_107	[p7l714t1333r831b1387],
21	initially	RB	O	initially	advmod	22	SENT_107	[p7l859t1307r1194b1407],
22	planned	VBD	O	plan	_	0	SENT_107	[p7l1216t1307r1566b1407],
23	to	TO	O	to	aux	24	SENT_107	[p7l1595t1324r1676b1386],
24	enroll	VB	O	enroll	xcomp	22	SENT_107	[p7l1706t1307r1956b1386],
25	320	CD	NUMBER	320	num	26	SENT_107	[p7l1985t1313r2133b1386],
26	patients	NNS	O	patient	dobj	24	SENT_107	[p7l11t1437r376b1535],
27	.	.	O	.	_	0	SENT_107	[p7l11t1437r376b1535],

1	Kaplan	NNP	PERSON	Kaplan	_	0	SENT_108	[p7l140t1563r743b1663],
2	.	.	O	.	_	0	SENT_108	[p7l140t1563r743b1663],

1	—	NN	O	—	_	0	SENT_109	[p7l140t1563r743b1663],
2	.	.	O	.	_	0	SENT_109	[p7l140t1563r743b1663],

1	Meier	JJR	PERSON	meier	amod	3	SENT_110	[p7l140t1563r743b1663],
2	survival	NN	O	survival	nn	3	SENT_110	[p7l781t1563r1113b1643],
3	curves	NNS	O	curve	nsubjpass	5	SENT_110	[p7l1153t1589r1423b1643],
4	were	VBD	O	be	auxpass	5	SENT_110	[p7l1461t1589r1662b1643],
5	drawn	VBN	O	draw	_	0	SENT_110	[p7l1703t1563r1974b1643],
6	for	IN	O	for	_	0	SENT_110	[p7l2014t1562r2137b1642],
7	progression	NN	O	progression	npadvmod	9	SENT_110	[p7l11t1691r718b1793],
8	—	CD	NUMBER	—	num	7	SENT_110	[p7l11t1691r718b1793],
9	free	JJ	O	free	amod	10	SENT_110	[p7l11t1691r718b1793],
10	survival	NN	O	survival	prep_for	5	SENT_110	[p7l762t1692r1093b1771],
11	and	CC	O	and	_	0	SENT_110	[p7l1134t1692r1292b1771],
12	were	VBD	O	be	auxpass	13	SENT_110	[p7l1329t1718r1530b1771],
13	compared	VBN	O	compare	conj_and	5	SENT_110	[p7l1573t1692r1999b1792],
14	by	IN	O	by	_	0	SENT_110	[p7l2041t1692r2139b1792],
15	means	NNS	O	means	_	0	SENT_110	[p7l12t1846r287b1899],
16	of	IN	O	of	_	0	SENT_110	[p7l324t1819r422b1899],
17	a	DT	O	a	det	20	SENT_110	[p7l438t1846r482b1898],
18	log	NN	O	log	nn	20	SENT_110	[p7l514t1820r876b1921],
19	—	CD	NUMBER	—	num	20	SENT_110	[p7l514t1820r876b1921],
20	ranl	NN	O	ranl	prep_by_means_of	13	SENT_110	[p7l514t1820r876b1921],
21	<	JJR	O	<	amod	22	SENT_110	[p7l514t1820r876b1921],
22	test	NN	O	test	dobj	5	SENT_110	[p7l906t1837r1076b1899],
23	.	.	O	.	_	0	SENT_110	[p7l906t1837r1076b1899],

1	Hazard	NN	O	hazard	nn	2	SENT_111	[p7l1116t1820r1427b1899],
2	ratios	NNS	O	ratio	nsubjpass	11	SENT_111	[p7l1462t1821r1697b1899],
3	(	CD	NUMBER	(	dep	2	SENT_111	[p7l1738t1820r1916b1911],
4	and	CC	O	and	_	0	SENT_111	[p7l1738t1820r1916b1911],
5	95	CD	PERCENT	95	number	6	SENT_111	[p7l1951t1825r2135b1899],
6	%	NN	PERCENT	%	amod	8	SENT_111	[p7l1951t1825r2135b1899],
7	conﬁdence	NN	O	conﬁdence	nn	8	SENT_111	[p7l12t1947r474b2027],
8	intervals	NNS	O	interval	conj_and	2	SENT_111	[p7l506t1948r889b2039],
9	)	CD	NUMBER	)	dep	8	SENT_111	[p7l506t1948r889b2039],
10	were	VBD	O	be	auxpass	11	SENT_111	[p7l923t1974r1122b2028],
11	calculated	VBN	O	calculate	_	0	SENT_111	[p7l1154t1948r1579b2028],
12	with	IN	O	with	_	0	SENT_111	[p7l1606t1948r1799b2028],
13	the	DT	O	the	det	14	SENT_111	[p7l1831t1948r1961b2027],
14	use	NN	O	use	prep_with	11	SENT_111	[p7l1993t1974r2134b2028],
15	of	IN	O	of	_	0	SENT_111	[p7l12t2075r112b2155],
16	a	DT	O	a	det	21	SENT_111	[p7l131t2102r175b2154],
17	Cox	NN	ORGANIZATION	cox	amod	21	SENT_111	[p7l212t2082r374b2155],
18	proportional	JJ	O	proportional	amod	21	SENT_111	[p7l408t2076r1310b2176],
19	—	NN	O	—	nn	21	SENT_111	[p7l408t2076r1310b2176],
20	hazards	NNS	O	hazard	nn	21	SENT_111	[p7l408t2076r1310b2176],
21	analysis	NN	O	analysis	prep_of	14	SENT_111	[p7l1350t2076r1706b2176],
22	.	.	O	.	_	0	SENT_111	[p7l1350t2076r1706b2176],

1	Prespeci	NNP	O	Prespeci	nsubj	3	SENT_112	[p7l1748t2077r2133b2176],
2	—	CD	NUMBER	—	num	1	SENT_112	[p7l1748t2077r2133b2176],
3	fied	VBD	O	fie	_	0	SENT_112	[p7l12t2203r177b2283],
4	adjustment	NN	O	adjustment	nn	5	SENT_112	[p7l213t2204r695b2304],
5	factors	NNS	O	factor	nsubj	6	SENT_112	[p7l726t2203r1016b2283],
6	included	VBD	O	include	ccomp	3	SENT_112	[p7l1054t2204r1421b2283],
7	sex	NN	O	sex	dobj	6	SENT_112	[p7l1459t2230r1593b2282],
8	and	CC	O	and	_	0	SENT_112	[p7l1626t2204r1784b2283],
9	clinical	JJ	O	clinical	amod	10	SENT_112	[p7l1821t2204r2134b2282],
10	stage	NN	O	stage	dobj	6	SENT_112	[p7l13t2326r256b2410],
11	.	.	O	.	_	0	SENT_112	[p7l13t2326r256b2410],

1	Secondary	JJ	O	secondary	amod	3	SENT_113	[p7l143t2437r580b2536],
2	end	NN	O	end	nn	3	SENT_113	[p7l605t2437r756b2515],
3	points	NNS	O	point	nsubj	4	SENT_113	[p7l784t2438r1048b2536],
4	included	VBD	O	include	_	0	SENT_113	[p7l1079t2437r1439b2516],
5	overall	JJ	O	overall	amod	6	SENT_113	[p7l1468t2437r1747b2516],
6	survival	NN	O	survival	dobj	4	SENT_113	[p7l1778t2437r2129b2532],
7	,	,	O	,	_	0	SENT_113	[p7l1778t2437r2129b2532],
8	response	NN	O	response	nn	9	SENT_113	[p7l12t2590r400b2664],
9	rate	NN	O	rate	dobj	4	SENT_113	[p7l443t2581r630b2660],
10	,	,	O	,	_	0	SENT_113	[p7l443t2581r630b2660],
11	time	NN	O	time	dobj	4	SENT_113	[p7l679t2565r875b2642],
12	to	TO	O	to	_	0	SENT_113	[p7l919t2581r1001b2643],
13	the	DT	O	the	det	14	SENT_113	[p7l1045t2564r1181b2642],
14	deterioration	NN	O	deterioration	prep_to	11	SENT_113	[p7l1224t2564r1794b2643],
15	of	IN	O	of	_	0	SENT_113	[p7l1837t2563r1938b2643],
16	performance	NN	O	performance	nn	17	SENT_113	[p7l1961t2590r2133b2664, p7l12t2692r422b2772],
17	status	NN	O	status	prep_of	14	SENT_113	[p7l469t2710r720b2772],
18	(	CD	NUMBER	(	num	28	SENT_113	[p7l772t2700r1124b2784],
19	Eastern	NNP	ORGANIZATION	Eastern	nn	28	SENT_113	[p7l772t2700r1124b2784],
20	Cooperative	NNP	ORGANIZATION	Cooperative	nn	28	SENT_113	[p7l1169t2694r1679b2793],
21	Oncology	NNP	ORGANIZATION	Oncology	nn	28	SENT_113	[p7l1725t2693r2139b2794],
22	Group	NNP	ORGANIZATION	Group	nn	28	SENT_113	[p7l12t2826r281b2920],
23	[	CD	NUMBER	[	num	28	SENT_113	[p7l336t2826r656b2911],
24	ECOG	NNP	O	ECOG	nn	28	SENT_113	[p7l336t2826r656b2911],
25	]	CD	NUMBER	]	num	28	SENT_113	[p7l336t2826r656b2911],
26	performance	NN	O	performance	nn	28	SENT_113	[p7l709t2819r1263b2920],
27	status	NN	O	status	nn	28	SENT_113	[p7l1309t2837r1560b2900],
28	score	NN	TIME	score	rcmod	17	SENT_113	[p7l1609t2846r1830b2899],
29	of	IN	TIME	of	_	0	SENT_113	[p7l1875t2819r1974b2899],
30	23	CD	TIME	23	prep_of	14	SENT_113	[p7l2000t2826r2129b2916],
31	,	,	O	,	_	0	SENT_113	[p7l2000t2826r2129b2916],
32	capability	NN	O	capability	prep_to	11	SENT_113	[p7l12t2948r412b3048],
33	of	IN	O	of	_	0	SENT_113	[p7l440t2947r538b3027],
34	only	RB	O	only	advmod	36	SENT_113	[p7l552t2948r730b3048],
35	limited	JJ	O	limited	amod	36	SENT_113	[p7l755t2948r1051b3027],
36	self	NN	O	self	prep_of	32	SENT_113	[p7l1084t2947r1447b3044],
37	—	NN	O	—	nn	38	SENT_113	[p7l1084t2947r1447b3044],
38	care	NN	O	care	dep	32	SENT_113	[p7l1084t2947r1447b3044],
39	,	,	O	,	_	0	SENT_113	[p7l1084t2947r1447b3044],
40	or	CC	O	or	_	0	SENT_113	[p7l1485t2974r1572b3027],
41	confinement	NN	O	confinement	prep_to	11	SENT_113	[p7l1601t2947r2139b3027],
42	to	TO	O	to	_	0	SENT_113	[p7l12t3094r95b3156],
43	a	DT	O	a	det	44	SENT_113	[p7l138t3103r183b3155],
44	bed	NN	O	bed	prep_to	41	SENT_113	[p7l225t3077r380b3156],
45	or	CC	O	or	_	0	SENT_113	[p7l423t3103r513b3156],
46	chair	NN	O	chair	prep_to	41	SENT_113	[p7l554t3077r777b3155],
47	for	IN	O	for	_	0	SENT_113	[p7l817t3076r942b3156],
48	>	JJR	O	>	amod	49	SENT_113	[p7l988t3082r1225b3156],
49	500/o	NN	O	500/o	prep_for	44	SENT_113	[p7l988t3082r1225b3156],
50	of	IN	O	of	_	0	SENT_113	[p7l1267t3076r1368b3156],
51	waking	VBG	O	wake	amod	53	SENT_113	[p7l1388t3077r1716b3178],
52	hours19	NN	O	hours19	nn	53	SENT_113	[p7l1756t3077r2129b3173],
53	)	NN	O	)	prep_of	49	SENT_113	[p7l1756t3077r2129b3173],
54	,	,	O	,	_	0	SENT_113	[p7l1756t3077r2129b3173],
55	and	CC	O	and	_	0	SENT_113	[p7l11t3205r167b3284],
56	toxic	JJ	O	toxic	amod	57	SENT_113	[p7l202t3206r403b3284],
57	effects	NNS	O	effect	dobj	4	SENT_113	[p7l438t3204r736b3284],
58	.	.	O	.	_	0	SENT_113	[p7l438t3204r736b3284],

1	Overall	JJ	O	overall	amod	2	SENT_114	[p7l776t3205r1077b3284],
2	survival	NN	O	survival	_	0	SENT_114	[p7l1112t3205r1437b3284],
3	and	CC	O	and	_	0	SENT_114	[p7l1471t3205r1626b3284],
4	the	DT	O	the	det	5	SENT_114	[p7l1660t3205r1791b3283],
5	time	NN	O	time	conj_and	2	SENT_114	[p7l1827t3206r2016b3284],
6	to	TO	O	to	prep	2	SENT_114	[p7l2051t3222r2133b3284],

1	ECOG	NN	ORGANIZATION	ecog	nn	4	SENT_115	[p7l11t3338r270b3411],
2	performance	NN	O	performance	nn	4	SENT_115	[p7l301t3331r835b3432],
3	status	NN	O	status	nn	4	SENT_115	[p7l867t3349r1108b3411],
4	score	NN	TIME	score	nsubjpass	10	SENT_115	[p7l1143t3358r1355b3411],
5	of	IN	TIME	of	_	0	SENT_115	[p7l1387t3331r1485b3411],
6	3	CD	TIME	3	prep_of	4	SENT_115	[p7l1499t3338r1542b3411],
7	or	CC	O	or	_	0	SENT_115	[p7l1578t3358r1664b3411],
8	more	JJR	O	more	prep_of	4	SENT_115	[p7l1693t3358r1906b3411],
9	were	VBD	O	be	auxpass	10	SENT_115	[p7l1932t3358r2134b3412],
10	analyzed	VBN	O	analyze	_	0	SENT_115	[p7l11t3461r376b3561],
11	in	IN	O	in	_	0	SENT_115	[p7l411t3462r492b3539],
12	the	DT	O	the	det	14	SENT_115	[p7l529t3461r657b3539],
13	same	JJ	O	same	amod	14	SENT_115	[p7l696t3487r909b3540],
14	way	NN	O	way	prep_in	10	SENT_115	[p7l942t3487r1105b3561],
15	as	IN	O	as	_	0	SENT_115	[p7l1136t3487r1220b3539],
16	progression	NN	O	progression	npadvmod	18	SENT_115	[p7l1257t3460r1933b3562],
17	—	CD	NUMBER	—	num	16	SENT_115	[p7l1257t3460r1933b3562],
18	free	JJ	O	free	amod	19	SENT_115	[p7l1257t3460r1933b3562],
19	survival	NN	O	survival	prep_as	14	SENT_115	[p7l1970t3487r2133b3540, p7l7t3588r225b3668],
20	.	.	O	.	_	0	SENT_115	[p7l1970t3487r2133b3540, p7l7t3588r225b3668],

1	The	DT	O	the	det	3	SENT_116	[p7l267t3588r428b3666],
2	response	NN	O	response	nn	3	SENT_116	[p7l467t3614r848b3688],
3	rate	NN	O	rate	nsubjpass	10	SENT_116	[p7l888t3605r1047b3666],
4	and	CC	O	and	_	0	SENT_116	[p7l1086t3588r1244b3667],
5	rate	NN	O	rate	conj_and	3	SENT_116	[p7l1284t3605r1444b3666],
6	of	IN	O	of	_	0	SENT_116	[p7l1484t3587r1584b3667],
7	toxic	JJ	O	toxic	amod	8	SENT_116	[p7l1605t3589r1811b3667],
8	effects	NNS	O	effect	prep_of	3	SENT_116	[p7l1850t3587r2132b3666],
9	were	VBD	O	be	auxpass	10	SENT_116	[p8l7t47r213b100],
10	compared	VBN	O	compare	_	0	SENT_116	[p8l268t21r703b121],
11	between	IN	O	between	_	0	SENT_116	[p8l758t21r1123b100],
12	the	DT	O	the	det	14	SENT_116	[p8l1177t21r1312b99],
13	two	CD	NUMBER	two	num	14	SENT_116	[p8l1367t38r1527b100],
14	groups	NNS	O	group	prep_between	10	SENT_116	[p8l1582t47r1884b122],
15	with	IN	O	with	_	0	SENT_116	[p8l1935t21r2134b100],
16	Fisher	NNP	PERSON	Fisher	poss	19	SENT_116	[p8l11t149r335b227],
17	’s	POS	O	’s	_	0	SENT_116	[p8l11t149r335b227],
18	exact	JJ	O	exact	amod	19	SENT_116	[p8l373t166r594b227],
19	test	NN	O	test	prep_with	10	SENT_116	[p8l625t166r780b227],
20	and	CC	O	and	_	0	SENT_116	[p8l809t149r967b227],
21	the	DT	O	the	det	23	SENT_116	[p8l1003t149r1136b227],
22	Wilcoxon	NNP	PERSON	Wilcoxon	nn	23	SENT_116	[p8l1168t149r1577b227],
23	test	NN	O	test	conj_and	19	SENT_116	[p8l1613t165r1787b244],
24	,	,	O	,	_	0	SENT_116	[p8l1613t165r1787b244],
25	respectively	RB	O	respectively	advmod	23	SENT_116	[p8l1829t175r2133b248, p8l12t276r249b376],
26	.	.	O	.	_	0	SENT_116	[p8l1829t175r2133b248, p8l12t276r249b376],

1	Each	DT	O	each	det	2	SENT_117	[p8l290t276r493b354],
2	analysis	NN	O	analysis	nsubjpass	4	SENT_117	[p8l529t276r869b376],
3	was	VBD	O	be	auxpass	4	SENT_117	[p8l903t302r1066b356],
4	performed	VBN	O	perform	_	0	SENT_117	[p8l1103t275r1560b376],
5	with	IN	O	with	_	0	SENT_117	[p8l1592t276r1787b356],
6	the	DT	O	the	det	7	SENT_117	[p8l1824t276r1957b354],
7	use	NN	O	use	prep_with	4	SENT_117	[p8l1993t302r2134b356],
8	of	IN	O	of	_	0	SENT_117	[p8l12t404r113b484],
9	a	DT	O	a	det	11	SENT_117	[p8l133t431r177b483],
10	two	CD	NUMBER	two	num	11	SENT_117	[p8l217t405r660b501],
11	—	CD	NUMBER	—	prep_of	7	SENT_117	[p8l217t405r660b501],
12	sided	VBD	O	side	partmod	11	SENT_117	[p8l217t405r660b501],
13	,	,	O	,	_	0	SENT_117	[p8l217t405r660b501],
14	5	CD	PERCENT	5	number	15	SENT_117	[p8l708t410r839b484],
15	%	NN	PERCENT	%	amod	17	SENT_117	[p8l708t410r839b484],
16	significance	NN	O	significance	nn	17	SENT_117	[p8l880t404r1403b506],
17	level	NN	O	level	conj_and	7	SENT_117	[p8l1442t405r1631b484],
18	and	CC	O	and	_	0	SENT_117	[p8l1671t405r1828b484],
19	a	DT	O	a	det	23	SENT_117	[p8l1867t431r1912b483],
20	95	CD	PERCENT	95	number	21	SENT_117	[p8l1950t410r2134b484],
21	%	NN	PERCENT	%	amod	23	SENT_117	[p8l1950t410r2134b484],
22	confidence	NN	O	confidence	nn	23	SENT_117	[p8l12t531r474b611],
23	interval	NN	O	interval	conj_and	7	SENT_117	[p8l504t532r822b612],
24	by	IN	O	by	_	0	SENT_117	[p8l853t532r949b632],
25	means	NNS	O	means	_	0	SENT_117	[p8l975t558r1249b610],
26	of	IN	O	of	_	0	SENT_117	[p8l1283t531r1381b611],
27	SAS	NNP	ORGANIZATION	SAS	prep_by_means_of	4	SENT_117	[p8l1396t538r1552b611],
28	for	IN	O	for	_	0	SENT_117	[p8l1585t531r1706b611],
29	Windows	NNP	MISC	Windows	nn	32	SENT_117	[p8l1730t532r2132b612],
30	software	NN	O	software	nn	32	SENT_117	[p8l13t659r385b739],
31	(	NN	O	(	nn	32	SENT_117	[p8l430t660r749b751],
32	release	NN	O	release	prep_for	27	SENT_117	[p8l430t660r749b751],
33	9.1	CD	NUMBER	9.1	dep	32	SENT_117	[p8l788t666r932b756],
34	,	,	O	,	_	0	SENT_117	[p8l788t666r932b756],
35	SAS	NNP	ORGANIZATION	SAS	nn	37	SENT_117	[p8l980t666r1138b739],
36	Institute	NNP	ORGANIZATION	Institute	nn	37	SENT_117	[p8l1179t661r1593b751],
37	)	NN	O	)	appos	32	SENT_117	[p8l1179t661r1593b751],
38	.	.	O	.	_	0	SENT_117	[p8l1179t661r1593b751],

1	One	CD	NUMBER	one	num	3	SENT_118	[p8l141t795r314b867],
2	interim	NN	O	interim	nn	3	SENT_118	[p8l350t790r675b867],
3	analysis	NN	O	analysis	nsubjpass	5	SENT_118	[p8l710t789r1057b888],
4	was	VBD	O	be	auxpass	5	SENT_118	[p8l1091t815r1256b868],
5	planned	VBN	O	plan	_	0	SENT_118	[p8l1293t789r1649b888],
6	to	TO	O	to	aux	7	SENT_118	[p8l1685t806r1768b867],
7	analyze	VB	O	analyze	xcomp	5	SENT_118	[p8l1804t789r2134b888],
8	the	DT	O	the	det	14	SENT_118	[p8l12t917r140b995],
9	primary	JJ	O	primary	amod	14	SENT_118	[p8l167t918r504b1017],
10	end	NN	O	end	nn	14	SENT_118	[p8l527t917r675b996],
11	point	NN	O	point	nn	14	SENT_118	[p8l701t918r922b1017],
12	(	NN	O	(	nn	14	SENT_118	[p8l948t916r1473b1018],
13	signiﬁcance	NN	O	signiﬁcance	nn	14	SENT_118	[p8l948t916r1473b1018],
14	level	NN	O	level	nn	19	SENT_118	[p8l1499t917r1699b1013],
15	,	,	O	,	_	0	SENT_118	[p8l1499t917r1699b1013],
16	P	NN	O	p	appos	14	SENT_118	[p8l1730t923r2129b1008],
17	=	JJ	O	=	amod	19	SENT_118	[p8l1730t923r2129b1008],
18	0.003	CD	NUMBER	0.003	tmod	17	SENT_118	[p8l1730t923r2129b1008],
19	)	NN	O	)	dobj	7	SENT_118	[p8l1730t923r2129b1008],
20	.	.	O	.	_	0	SENT_118	[p8l1730t923r2129b1008],

1	The	DT	O	the	det	2	SENT_119	[p8l8t1044r169b1122],
2	Lan	NN	MISC	lan	_	0	SENT_119	[p8l208t1051r748b1122],
3	.	.	O	.	_	0	SENT_119	[p8l208t1051r748b1122],

1	—	NN	O	—	_	0	SENT_120	[p8l208t1051r748b1122],
2	.	.	O	.	_	0	SENT_120	[p8l208t1051r748b1122],

1	DeMets	NNS	O	demet	nn	2	SENT_121	[p8l208t1051r748b1122],
2	method	NN	O	method	nsubjpass	4	SENT_121	[p8l791t1044r1122b1123],
3	was	VBD	O	be	auxpass	4	SENT_121	[p8l1157t1070r1320b1124],
4	used	VBN	O	use	_	0	SENT_121	[p8l1362t1044r1559b1124],
5	to	TO	O	to	aux	6	SENT_121	[p8l1600t1061r1681b1123],
6	adjust	VB	O	adjust	xcomp	4	SENT_121	[p8l1722t1044r1979b1144],
7	for	IN	O	for	_	0	SENT_121	[p8l2014t1043r2137b1123],
8	multiple	JJ	O	multiple	amod	9	SENT_121	[p8l12t1173r360b1273],
9	comparisons	NNS	O	comparison	prep_for	6	SENT_121	[p8l399t1174r963b1273],
10	.	.	O	.	_	0	SENT_121	[p8l399t1174r963b1273],

1	The	DT	O	the	det	2	SENT_122	[p8l1004t1173r1162b1252],
2	O’Brien	NNP	O	O’Brien	_	0	SENT_122	[p8l1200t1173r1918b1274],
3	.	.	O	.	_	0	SENT_122	[p8l1200t1173r1918b1274],

1	—	NN	O	—	_	0	SENT_123	[p8l1200t1173r1918b1274],
2	.	.	O	.	_	0	SENT_123	[p8l1200t1173r1918b1274],

1	Fleming	NNP	PERSON	Fleming	nsubjpass	9	SENT_124	[p8l1200t1173r1918b1274],
2	type	NN	O	type	dep	3	SENT_124	[p8l1953t1190r2134b1273],
3	alpha	NN	O	alpha	amod	1	SENT_124	[p8l11t1301r681b1402],
4	—	CD	NUMBER	—	num	6	SENT_124	[p8l11t1301r681b1402],
5	spending	NN	O	spending	nn	6	SENT_124	[p8l11t1301r681b1402],
6	function	NN	O	function	nsubjpass	9	SENT_124	[p8l717t1300r1083b1380],
7	was	VBD	O	be	auxpass	9	SENT_124	[p8l1119t1327r1281b1380],
8	also	RB	O	also	advmod	9	SENT_124	[p8l1322t1301r1493b1380],
9	used	VBN	O	use	_	0	SENT_124	[p8l1534t1301r1754b1380],
10	.	.	O	.	_	0	SENT_124	[p8l1534t1301r1754b1380],

1	RESULTS	NNS	O	result	_	0	SENT_125	[p8l836t1598r1311b1656],

1	PATIENT	NN	O	patient	nn	2	SENT_126	[p8l17t1832r338b1880],
2	CHARACTERISTICS	NNS	O	characteristic	nsubjpass	6	SENT_126	[p8l369t1831r1096b1881],
3	The	DT	O	the	det	4	SENT_126	[p8l8t1930r169b2008],
4	study	NN	O	study	dep	2	SENT_126	[p8l219t1930r449b2030],
5	was	VBD	O	be	auxpass	6	SENT_126	[p8l488t1956r651b2009],
6	begun	VBN	O	begin	_	0	SENT_126	[p8l702t1930r971b2031],
7	in	IN	O	in	_	0	SENT_126	[p8l1019t1931r1102b2008],
8	March	NNP	DATE	March	prep_in	6	SENT_126	[p8l1148t1930r1424b2008],
9	2006	CD	DATE	2006	num	8	SENT_126	[p8l1472t1936r1705b2009],
10	.	.	O	.	_	0	SENT_126	[p8l1472t1936r1705b2009],

1	The	DT	O	the	det	3	SENT_127	[p8l1755t1930r1916b2008],
2	pre	JJ	O	pre	amod	3	SENT_127	[p8l1963t1956r2133b2030],
3	—	NN	O	—	nsubj	4	SENT_127	[p8l1963t1956r2133b2030],
4	planned	VBD	O	plan	_	0	SENT_127	[p8l11t2057r354b2157],
5	interim	JJ	O	interim	amod	6	SENT_127	[p8l378t2058r691b2135],
6	analysis	NN	O	analysis	nsubjpass	8	SENT_127	[p8l716t2057r1048b2157],
7	was	VBD	O	be	auxpass	8	SENT_127	[p8l1071t2083r1231b2137],
8	performed	VBN	O	perform	dep	35	SENT_127	[p8l1258t2056r1706b2157],
9	4	CD	DURATION	4	num	10	SENT_127	[p8l1730t2064r1779b2136],
10	months	NNS	NUMBER	month	dep	16	SENT_127	[p8l1805t2057r2132b2136],
11	after	IN	O	after	dep	16	SENT_127	[p8l11t2184r213b2263],
12	the	DT	O	the	det	14	SENT_127	[p8l248t2185r381b2263],
13	200th	JJ	O	200th	amod	14	SENT_127	[p8l419t2185r668b2264],
14	patient	NN	O	patient	nsubjpass	16	SENT_127	[p8l703t2186r1006b2285],
15	was	VBD	O	be	auxpass	16	SENT_127	[p8l1034t2211r1196b2265],
16	enrolled	VBN	O	enrol	ccomp	8	SENT_127	[p8l1237t2185r1588b2264],
17	(	CD	NUMBER	(	num	18	SENT_127	[p8l1631t2192r1836b2285],
18	May	NNP	DATE	May	dobj	16	SENT_127	[p8l1631t2192r1836b2285],
19	2009	CD	DATE	2009	num	18	SENT_127	[p8l1870t2191r2130b2281],
20	)	CD	NUMBER	)	dep	18	SENT_127	[p8l1870t2191r2130b2281],
21	;	:	O	;	_	0	SENT_127	[p8l1870t2191r2130b2281],
22	it	PRP	O	it	nsubj	23	SENT_127	[p8l11t2315r70b2392],
23	showed	VBD	O	show	parataxis	8	SENT_127	[p8l97t2314r420b2393],
24	a	DT	O	a	det	26	SENT_127	[p8l449t2340r493b2392],
25	significant	JJ	O	significant	amod	26	SENT_127	[p8l523t2313r991b2415],
26	difference	NN	O	difference	dobj	23	SENT_127	[p8l1017t2313r1448b2393],
27	in	IN	O	in	_	0	SENT_127	[p8l1478t2315r1561b2392],
28	progressionfree	JJ	O	progressionfree	amod	29	SENT_127	[p8l1590t2315r2132b2415, p8l12t2441r174b2521],
29	survival	NN	O	survival	prep_in	23	SENT_127	[p8l219t2442r550b2521],
30	between	IN	O	between	_	0	SENT_127	[p8l594t2442r952b2521],
31	the	DT	O	the	det	34	SENT_127	[p8l996t2442r1128b2521],
32	two	CD	NUMBER	two	num	34	SENT_127	[p8l1173t2459r1329b2521],
33	treatment	NN	O	treatment	nn	34	SENT_127	[p8l1375t2459r1799b2521],
34	groups	NNS	O	group	prep_between	29	SENT_127	[p8l1837t2468r2132b2543],
35	(	VBP	O	(	dep	4	SENT_127	[p8l17t2575r434b2665],
36	P	NN	O	p	dep	37	SENT_127	[p8l17t2575r434b2665],
37	<	JJR	O	<	dobj	35	SENT_127	[p8l17t2575r434b2665],
38	0.001	CD	NUMBER	0.001	num	39	SENT_127	[p8l17t2575r434b2665],
39	)	NN	O	)	nsubj	35	SENT_127	[p8l17t2575r434b2665],
40	,	,	O	,	_	0	SENT_127	[p8l17t2575r434b2665],
41	and	CC	O	and	_	0	SENT_127	[p8l487t2569r644b2648],
42	the	DT	O	the	det	44	SENT_127	[p8l692t2569r824b2647],
43	independent	JJ	O	independent	amod	44	SENT_127	[p8l871t2569r1409b2669],
44	data	NNS	O	datum	nsubj	49	SENT_127	[p8l1452t2569r1634b2648],
45	and	CC	O	and	_	0	SENT_127	[p8l1679t2569r1837b2648],
46	safety	NN	O	safety	nn	48	SENT_127	[p8l1885t2568r2138b2669],
47	monitoring	NN	O	monitoring	nn	48	SENT_127	[p8l12t2699r496b2799],
48	committee	NN	O	committee	conj_and	44	SENT_127	[p8l519t2699r971b2777],
49	recommended	VBD	O	recommend	conj_and	4	SENT_127	[p8l996t2698r1601b2777],
50	termination	NN	O	termination	dobj	49	SENT_127	[p8l1627t2699r2134b2777],
51	of	IN	O	of	_	0	SENT_127	[p8l12t2824r113b2904],
52	the	DT	O	the	det	53	SENT_127	[p8l130t2825r263b2903],
53	study	NN	O	study	prep_of	50	SENT_127	[p8l300t2825r542b2925],
54	.	.	O	.	_	0	SENT_127	[p8l300t2825r542b2925],

1	Therefore	RB	O	therefore	advmod	6	SENT_128	[p8l579t2824r1019b2921],
2	,	,	O	,	_	0	SENT_128	[p8l579t2824r1019b2921],
3	the	DT	O	the	det	4	SENT_128	[p8l1061t2825r1193b2903],
4	study	NN	O	study	nsubjpass	6	SENT_128	[p8l1231t2825r1460b2925],
5	was	VBD	O	be	auxpass	6	SENT_128	[p8l1486t2851r1649b2905],
6	stopped	VBN	O	stop	_	0	SENT_128	[p8l1688t2825r2026b2925],
7	at	IN	O	at	_	0	SENT_128	[p8l2060t2842r2139b2903],
8	the	DT	DATE	the	det	9	SENT_128	[p8l12t2953r145b3031],
9	end	NN	DATE	end	prep_at	6	SENT_128	[p8l181t2953r334b3032],
10	of	IN	DATE	of	_	0	SENT_128	[p8l369t2952r469b3032],
11	May	NNP	DATE	May	prep_of	9	SENT_128	[p8l482t2961r663b3053],
12	2009.20	CD	DATE	2009.20	num	11	SENT_128	[p8l693t2959r1000b3032],

1	In	IN	O	in	_	0	SENT_129	[p8l140t3089r229b3159],
2	total	NN	O	total	prep_in	7	SENT_129	[p8l272t3081r497b3177],
3	,	,	O	,	_	0	SENT_129	[p8l272t3081r497b3177],
4	230	CD	NUMBER	230	num	5	SENT_129	[p8l545t3087r700b3160],
5	patients	NNS	O	patient	nsubjpass	7	SENT_129	[p8l742t3082r1091b3181],
6	were	VBD	O	be	auxpass	7	SENT_129	[p8l1130t3107r1336b3161],
7	enrolled	VBN	O	enrol	_	0	SENT_129	[p8l1379t3081r1737b3160],
8	from	IN	O	from	_	0	SENT_129	[p8l1779t3080r1992b3160],
9	43	CD	NUMBER	43	num	10	SENT_129	[p8l2033t3087r2130b3160],
10	institutions	NNS	O	institution	prep_from	7	SENT_129	[p8l11t3211r506b3289],
11	in	IN	O	in	_	0	SENT_129	[p8l546t3211r629b3288],
12	Japan	NNP	LOCATION	Japan	nn	14	SENT_129	[p8l658t3218r902b3310],
13	(	NNP	O	(	nn	14	SENT_129	[p8l945t3211r1128b3311],
14	Fig	NNP	O	Fig	prep_in	10	SENT_129	[p8l945t3211r1128b3311],
15	.	.	O	.	_	0	SENT_129	[p8l945t3211r1128b3311],

1	1	CD	NUMBER	1	_	0	SENT_130	[p8l1177t3216r1272b3301],
2	)	NN	O	)	dep	1	SENT_130	[p8l1177t3216r1272b3301],
3	.	.	O	.	_	0	SENT_130	[p8l1177t3216r1272b3301],

1	Half	NN	O	half	nn	4	SENT_131	[p8l1315t3209r1521b3288],
2	(	NN	O	(	nn	4	SENT_131	[p8l1546t3216r1721b3301],
3	115	CD	NUMBER	115	num	4	SENT_131	[p8l1546t3216r1721b3301],
4	patients	NNS	O	patient	nsubjpass	8	SENT_131	[p8l1761t3211r2129b3310],
5	)	CD	NUMBER	)	dep	4	SENT_131	[p8l1761t3211r2129b3310],
6	were	VBD	O	be	auxpass	8	SENT_131	[p8l7t3364r209b3417],
7	randomly	RB	O	randomly	advmod	8	SENT_131	[p8l249t3338r664b3438],
8	assigned	VBN	O	assign	_	0	SENT_131	[p8l699t3338r1073b3439],
9	to	TO	O	to	aux	10	SENT_131	[p8l1113t3355r1194b3417],
10	receive	VB	O	receive	xcomp	8	SENT_131	[p8l1235t3339r1524b3417],
11	gefitinib	NN	O	gefitinib	dobj	10	SENT_131	[p8l1564t3337r1936b3439],
12	and	CC	O	and	_	0	SENT_131	[p8l1977t3338r2134b3417],
13	half	NN	O	half	conj_and	11	SENT_131	[p8l12t3464r192b3543],
14	to	TO	O	to	aux	15	SENT_131	[p8l204t3482r283b3544],
15	receive	VB	O	receive	xcomp	10	SENT_131	[p8l315t3466r591b3545],
16	carboplatin-paclitaxel	NN	O	carboplatin-paclitaxel	dobj	15	SENT_131	[p8l623t3465r1559b3565],
17	.	.	O	.	_	0	SENT_131	[p8l623t3465r1559b3565],

1	Two	CD	NUMBER	two	num	2	SENT_132	[p8l1592t3471r1764b3545],
2	patients	NNS	O	patient	nsubjpass	4	SENT_132	[p8l1795t3466r2132b3565],
3	were	VBD	O	be	auxpass	4	SENT_132	[p8l7t3619r206b3673],
4	excluded	VBN	O	exclude	_	0	SENT_132	[p8l247t3593r612b3672],
5	because	IN	O	because	mark	8	SENT_132	[p8l652t3593r982b3672],
6	they	PRP	O	they	nsubjpass	8	SENT_132	[p8l1023t3593r1202b3693],
7	were	VBD	O	be	auxpass	8	SENT_132	[p8l1233t3619r1432b3673],
8	found	VBN	O	find	advcl	4	SENT_132	[p8l1472t3592r1720b3673],
9	to	TO	O	to	aux	11	SENT_132	[p8l1761t3610r1841b3672],
10	be	VB	O	be	cop	11	SENT_132	[p8l1883t3593r1978b3672],
11	ineligible	JJ	O	ineligible	xcomp	8	SENT_132	[p8l2018t3594r2133b3671, p9l12t21r337b122],
12	.	.	O	.	_	0	SENT_132	[p8l2018t3594r2133b3671, p9l12t21r337b122],

1	In	IN	O	in	_	0	SENT_133	[p9l371t29r459b99],
2	the	DT	O	the	det	4	SENT_133	[p9l488t21r619b100],
3	chemotherapy	NN	O	chemotherapy	nn	4	SENT_133	[p9l650t21r1248b121],
4	group	NN	O	group	prep_in	10	SENT_133	[p9l1273t47r1542b122],
5	,	,	O	,	_	0	SENT_133	[p9l1273t47r1542b122],
6	1	CD	NUMBER	1	num	7	SENT_133	[p9l1581t27r1625b99],
7	patient	NN	O	patient	nsubjpass	10	SENT_133	[p9l1654t22r1950b121],
8	was	VBD	O	be	auxpass	10	SENT_133	[p9l1970t47r2133b100],
9	not	RB	O	not	neg	10	SENT_133	[p9l12t166r150b228],
10	evaluated	VBN	O	evaluate	_	0	SENT_133	[p9l178t149r563b228],
11	for	IN	O	for	_	0	SENT_133	[p9l595t148r714b228],
12	safety	NN	O	safety	prep_for	10	SENT_133	[p9l745t148r998b249],
13	,	,	O	,	_	0	SENT_133	[p9l745t148r998b249],
14	owing	VBG	O	owe	xcomp	10	SENT_133	[p9l1036t150r1297b250],
15	to	TO	O	to	_	0	SENT_133	[p9l1326t166r1405b228],
16	lack	NN	O	lack	prep_to	14	SENT_133	[p9l1438t149r1607b228],
17	of	IN	O	of	_	0	SENT_133	[p9l1636t148r1733b228],
18	receipt	NN	O	receipt	prep_of	16	SENT_133	[p9l1747t150r2025b249],
19	of	IN	O	of	_	0	SENT_133	[p9l2053t148r2152b228],
20	the	DT	O	the	det	22	SENT_133	[p9l12t277r143b356],
21	study	NN	O	study	nn	22	SENT_133	[p9l177t277r403b377],
22	drugs	NNS	O	drug	prep_of	18	SENT_133	[p9l432t277r695b378],
23	,	,	O	,	_	0	SENT_133	[p9l432t277r695b378],
24	and	CC	O	and	_	0	SENT_133	[p9l733t277r888b356],
25	3	CD	NUMBER	3	num	26	SENT_133	[p9l921t283r965b356],
26	others	NNS	O	other	nsubjpass	28	SENT_133	[p9l1003t277r1264b356],
27	were	VBD	O	be	auxpass	28	SENT_133	[p9l1294t303r1493b356],
28	excluded	VBN	O	exclude	conj_and	10	SENT_133	[p9l1527t277r1892b356],
29	from	IN	O	from	_	0	SENT_133	[p9l1924t276r2134b356],
30	the	DT	O	the	det	31	SENT_133	[p9l12t405r145b483],
31	analysis	NN	O	analysis	prep_from	28	SENT_133	[p9l184t405r523b505],
32	of	IN	O	of	_	0	SENT_133	[p9l566t404r666b484],
33	progression	NN	O	progression	npadvmod	35	SENT_133	[p9l686t404r1394b506],
34	—	CD	NUMBER	—	num	33	SENT_133	[p9l686t404r1394b506],
35	free	JJ	O	free	amod	36	SENT_133	[p9l686t404r1394b506],
36	survival	NN	O	survival	prep_of	31	SENT_133	[p9l1435t405r1790b484],
37	.	.	O	.	_	0	SENT_133	[p9l1435t405r1790b484],

1	2382	CD	DATE	2382	num	4	SENT_134	[p9l149t581r226b604],
2	N	NN	O	n	nn	4	SENT_134	[p9l963t591r977b606],
3	ENGLJ	NN	O	englj	nn	4	SENT_134	[p9l991t591r1069b613],
4	MED362	NN	O	med362	_	0	SENT_134	[p9l1084t585r1225b613],
5	;	:	O	;	_	0	SENT_134	[p9l1084t585r1225b613],
6	25	CD	NUMBER	25	num	7	SENT_134	[p9l1084t585r1225b613],
7	NE	NNS	O	ne	dep	4	SENT_134	[p9l1260t591r1290b606],
8	M.ORG	NNP	O	M.ORG	nn	9	SENT_134	[p9l1305t591r1384b607],
9	JUNE	NNP	DATE	JUNE	dep	7	SENT_134	[p9l1415t591r1479b613],
10	24	CD	DATE	24	num	9	SENT_134	[p9l1490t591r1526b613],
11	,	,	DATE	,	_	0	SENT_134	[p9l1490t591r1526b613],
12	2010	CD	DATE	2010	num	9	SENT_134	[p9l1537t591r1597b607],

1	The	DT	O	the	det	3	SENT_135	[p9l936t624r987b648],
2	New	NNP	O	New	nn	3	SENT_135	[p9l996t625r1058b648],
3	England	NNP	O	England	_	0	SENT_135	[p9l1067t624r1178b655],
4	Journ	NNP	O	Journ	nn	5	SENT_135	[p9l1187t625r1260b648],
5	Medicine	NNP	O	Medicine	dep	3	SENT_135	[p9l1330t624r1455b648],

1	Downloaded	VBN	O	download	_	0	SENT_136	[p9l378t665r548b688],
2	from	IN	O	from	_	0	SENT_136	[p9l557t665r622b688],
3	nejm.org	NN	O	nejm.org	prep_from	1	SENT_136	[p9l630t665r749b695],
4	at	IN	O	at	_	0	SENT_136	[p9l759t669r782b688],
5	UW-Madison	NN	O	uw-madison	prep_at	1	SENT_136	[p9l790t665r973b688],
6	on	IN	O	on	_	0	SENT_136	[p9l982t672r1015b688],
7	Janu	NNP	DATE	Janu	prep_on	1	SENT_136	[p9l1023t665r1084b688],
8	5	CD	DATE	5	num	7	SENT_136	[p9l1136t665r1159b692],
9	,	,	DATE	,	_	0	SENT_136	[p9l1136t665r1159b692],
10	2014	CD	DATE	2014	num	7	SENT_136	[p9l1169t665r1242b688],
11	.	.	O	.	_	0	SENT_136	[p9l1169t665r1242b688],

1	For	IN	O	for	_	0	SENT_137	[p9l1252t665r1299b688],
2	personal	JJ	O	personal	amod	4	SENT_137	[p9l1307t665r1419b695],
3	use	NN	O	use	nn	4	SENT_137	[p9l1428t672r1472b688],
4	nl	NN	O	nl	pobj	1	SENT_137	[p9l1498t665r1523b688],
5	.	.	O	.	_	0	SENT_137	[p9l1542t684r1546b688],

1	No	DT	O	no	det	3	SENT_138	[p9l1557t665r1596b688],
2	other	JJ	O	other	amod	3	SENT_138	[p9l1606t665r1674b688],
3	uses	NNS	O	use	_	0	SENT_138	[p9l1683t672r1739b688],
4	without	IN	O	without	_	0	SENT_138	[p9l1749t665r1850b688],
5	permission	NN	O	permission	prep_without	3	SENT_138	[p9l1858t665r2011b695],
6	.	.	O	.	_	0	SENT_138	[p9l1858t665r2011b695],

1	Copyright	NN	O	copyright	nn	5	SENT_139	[p9l729t706r863b737],
2	©	CD	NUMBER	©	num	5	SENT_139	[p9l872t706r896b730],
3	2010	CD	DATE	2010	num	5	SENT_139	[p9l906t706r971b730],
4	Massa	NNP	PERSON	Massa	nn	5	SENT_139	[p9l980t707r1065b730],
5	etts	NNP	O	etts	_	0	SENT_139	[p9l1127t710r1171b730],
6	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_139	[p9l1181t706r1289b730],
7	Society	NNP	ORGANIZATION	Society	dep	5	SENT_139	[p9l1300t706r1405b737],
8	.	.	O	.	_	0	SENT_139	[p9l1300t706r1405b737],

1	All	DT	O	all	det	2	SENT_140	[p9l1416t706r1457b730],
2	r	NN	O	r	_	0	SENT_140	[p9l1466t706r1483b730],
3	'	''	O	'	_	0	SENT_140	[p9l1466t706r1483b730],
4	reserved	VBN	O	reserve	partmod	2	SENT_140	[p9l1551t706r1669b730],
5	.	.	O	.	_	0	SENT_140	[p9l1551t706r1669b730],

1	GEFITINIB	NNP	O	GEFITINIB	nn	3	SENT_141	[p9l496t749r672b768],
2	OR	NN	O	or	nn	3	SENT_141	[p9l686t749r731b768],
3	CHEMOTHERAPY	NNP	O	CHEMOTHERAPY	_	0	SENT_141	[p9l743t749r1020b768],
4	FOR	IN	O	for	_	0	SENT_141	[p9l1033t749r1097b768],
5	NON	NNP	O	NON	prep_for	3	SENT_141	[p9l1110t749r1413b768],
6	.	.	O	.	_	0	SENT_141	[p9l1110t749r1413b768],

1	—	NN	O	—	_	0	SENT_142	[p9l1110t749r1413b768],
2	.	.	O	.	_	0	SENT_142	[p9l1110t749r1413b768],

1	SMALL-CELL	NN	O	small-cell	nn	2	SENT_143	[p9l1110t749r1413b768],
2	LUNG	NN	O	lung	_	0	SENT_143	[p9l1427t749r1518b768],
3	CANCER	NNP	O	CANCER	dep	2	SENT_143	[p9l1532t749r1666b768],

1	114	CD	NUMBER	114	nsubj	3	SENT_144	[p9l1231t1478r1271b1498],
2	Met	NNP	O	Met	dep	3	SENT_144	[p9l1282t1479r1327b1499],
3	criteria	NNS	O	criterion	_	0	SENT_144	[p9l1336t1479r1417b1499],
4	and	CC	O	and	_	0	SENT_144	[p9l1427t1476r1469b1499],
5	were	VBD	O	be	auxpass	6	SENT_144	[p9l1479t1484r1534b1499],
6	included	VBN	O	include	conj_and	3	SENT_144	[p9l1545t1476r1644b1499],
7	in	IN	O	in	_	0	SENT_144	[p9l1252t1512r1271b1532],
8	intention-to-treat	JJ	O	intention-to-treat	amod	9	SENT_144	[p9l1282t1512r1485b1532],
9	population	NN	O	population	prep_in	6	SENT_144	[p9l1495t1510r1623b1539],

1	Figure	NNP	O	Figure	_	0	SENT_145	[p9l266t2344r350b2376],
2	1	CD	NUMBER	1	dep	1	SENT_145	[p9l362t2345r384b2368],
3	.	.	O	.	_	0	SENT_145	[p9l362t2345r384b2368],

1	Randomization	NN	O	randomization	_	0	SENT_146	[p9l397t2343r603b2368],
2	and	CC	O	and	_	0	SENT_146	[p9l615t2343r664b2368],
3	Follow-up	JJ	MISC	follow-up	amod	6	SENT_146	[p9l678t2343r812b2376],
4	ofthe	NN	O	ofthe	nn	6	SENT_146	[p9l823t2343r902b2368],
5	Study	NN	O	study	nn	6	SENT_146	[p9l913t2343r991b2376],
6	Patients	NNS	O	patient	conj_and	1	SENT_146	[p9l1003t2344r1121b2373],
7	,	,	O	,	_	0	SENT_146	[p9l1003t2344r1121b2373],
8	According	VBG	O	accord	_	0	SENT_146	[p9l1132t2343r1272b2376],
9	to	TO	O	to	prepc_according_to	1	SENT_146	[p9l1281t2347r1308b2368],
10	Treatment	NNP	ORGANIZATION	Treatment	nn	11	SENT_146	[p9l1318t2345r1461b2368],
11	Group	NNP	ORGANIZATION	Group	pobj	1	SENT_146	[p9l1471t2345r1566b2376],
12	.	.	O	.	_	0	SENT_146	[p9l1471t2345r1566b2376],

1	At	IN	O	at	_	0	SENT_147	[p9l136t2607r234b2677],
2	the	DT	O	the	det	5	SENT_147	[p9l260t2599r390b2677],
3	data	NNS	O	datum	nn	5	SENT_147	[p9l421t2599r601b2678],
4	cutoff	NN	O	cutoff	nn	5	SENT_147	[p9l630t2598r897b2678],
5	point	NN	O	point	prep_at	20	SENT_147	[p9l907t2600r1133b2699],
6	(	RB	O	(	advmod	5	SENT_147	[p9l1162t2599r1387b2699],
7	early	JJ	DATE	early	amod	8	SENT_147	[p9l1162t2599r1387b2699],
8	December	NNP	DATE	December	tmod	20	SENT_147	[p9l1412t2599r1843b2678],
9	2009	CD	DATE	2009	num	10	SENT_147	[p9l1870t2605r2128b2695],
10	)	CD	NUMBER	)	nsubj	20	SENT_147	[p9l1870t2605r2128b2695],
11	,	,	O	,	_	0	SENT_147	[p9l1870t2605r2128b2695],
12	the	DT	O	the	det	14	SENT_147	[p9l12t2727r144b2805],
13	median	JJ	O	median	amod	14	SENT_147	[p9l189t2727r512b2806],
14	folloW	NN	O	follow	appos	10	SENT_147	[p9l556t2726r964b2827],
15	—	CD	NUMBER	—	num	14	SENT_147	[p9l556t2726r964b2827],
16	up	RP	O	up	prep	14	SENT_147	[p9l556t2726r964b2827],
17	period	NN	O	period	dep	16	SENT_147	[p9l1008t2727r1285b2827],
18	was	VBD	O	be	cop	20	SENT_147	[p9l1325t2753r1488b2807],
19	527	CD	DURATION	527	num	20	SENT_147	[p9l1536t2733r1683b2806],
20	days	NNS	NUMBER	day	_	0	SENT_147	[p9l1728t2727r1912b2827],
21	(	VBP	O	(	rcmod	20	SENT_147	[p9l1964t2733r2132b2818],
22	>	JJR	O	>	dobj	21	SENT_147	[p9l1964t2733r2132b2818],
23	17	CD	DURATION	17	num	24	SENT_147	[p9l1964t2733r2132b2818],
24	months	NNS	NUMBER	month	tmod	22	SENT_147	[p9l11t2856r356b2952],
25	;	:	O	;	_	0	SENT_147	[p9l11t2856r356b2952],
26	range	NN	O	range	dep	22	SENT_147	[p9l395t2882r652b2957],
27	,	,	O	,	_	0	SENT_147	[p9l395t2882r652b2957],
28	30	CD	NUMBER	30	appos	26	SENT_147	[p9l693t2862r791b2935],
29	to	TO	O	to	_	0	SENT_147	[p9l827t2873r907b2935],
30	1261	CD	DATE	1261	number	31	SENT_147	[p9l946t2862r1190b2947],
31	)	CD	NUMBER	)	prep_to	21	SENT_147	[p9l946t2862r1190b2947],
32	.	.	O	.	_	0	SENT_147	[p9l946t2862r1190b2947],

1	The	DT	O	the	det	3	SENT_148	[p9l1226t2856r1384b2934],
2	median	JJ	O	median	amod	3	SENT_148	[p9l1419t2856r1737b2935],
3	duration	NN	O	duration	nsubj	9	SENT_148	[p9l1772t2856r2133b2935],
4	of	IN	O	of	_	0	SENT_148	[p9l12t2983r112b3063],
5	gefitinib	NN	O	gefitinib	nn	6	SENT_148	[p9l127t2983r498b3085],
6	treatment	NN	O	treatment	prep_of	3	SENT_148	[p9l533t3001r957b3062],
7	was	VBD	O	be	cop	9	SENT_148	[p9l981t3010r1144b3063],
8	308	CD	DURATION	308	num	9	SENT_148	[p9l1180t2990r1332b3063],
9	days	NNS	NUMBER	day	dep	26	SENT_148	[p9l1368t2984r1552b3084],
10	(	JJ	O	(	amod	11	SENT_148	[p9l1592t2991r1881b3085],
11	range	NN	O	range	attr	9	SENT_148	[p9l1592t2991r1881b3085],
12	,	,	O	,	_	0	SENT_148	[p9l1592t2991r1881b3085],
13	14	CD	NUMBER	14	number	16	SENT_148	[p9l1924t2990r2016b3063],
14	to	TO	O	to	dep	16	SENT_148	[p9l2050t3001r2132b3063],
15	1219	CD	DATE	1219	number	16	SENT_148	[p9l15t3117r268b3207],
16	)	CD	NUMBER	)	appos	11	SENT_148	[p9l15t3117r268b3207],
17	;	:	O	;	_	0	SENT_148	[p9l15t3117r268b3207],
18	the	DT	O	the	det	20	SENT_148	[p9l324t3111r456b3189],
19	median	JJ	O	median	amod	20	SENT_148	[p9l507t3111r830b3190],
20	number	NN	O	number	dep	16	SENT_148	[p9l881t3111r1219b3190],
21	of	IN	O	of	_	0	SENT_148	[p9l1268t3110r1368b3190],
22	3-week	JJ	DURATION	3-week	amod	23	SENT_148	[p9l1401t3111r1706b3191],
23	cycles	NNS	O	cycle	prep_of	20	SENT_148	[p9l1753t3111r1998b3211],
24	of	IN	O	of	_	0	SENT_148	[p9l2052t3110r2152b3190],
25	chemotherapy	NN	O	chemotherapy	prep_of	23	SENT_148	[p9l12t3240r599b3340],
26	was	VBD	O	be	_	0	SENT_148	[p9l620t3266r778b3319],
27	4	CD	NUMBER	4	num	29	SENT_148	[p9l809t3246r858b3319],
28	(	NN	O	(	nn	29	SENT_148	[p9l893t3246r1169b3341],
29	range	NN	O	range	nsubj	26	SENT_148	[p9l893t3246r1169b3341],
30	,	,	O	,	_	0	SENT_148	[p9l893t3246r1169b3341],
31	1	CD	NUMBER	1	number	33	SENT_148	[p9l1209t3246r1253b3318],
32	to	TO	O	to	dep	33	SENT_148	[p9l1284t3257r1363b3319],
33	7	CD	NUMBER	7	appos	29	SENT_148	[p9l1396t3246r1494b3331],
34	)	CD	NUMBER	)	dep	33	SENT_148	[p9l1396t3246r1494b3331],
35	.	.	O	.	_	0	SENT_148	[p9l1396t3246r1494b3331],

1	Three	CD	NUMBER	three	num	2	SENT_149	[p9l1526t3240r1765b3318],
2	patients	NNS	O	patient	nsubj	14	SENT_149	[p9l1794t3241r2130b3340],
3	in	IN	O	in	_	0	SENT_149	[p9l11t3369r92b3446],
4	the	DT	O	the	det	6	SENT_149	[p9l128t3368r259b3446],
5	geﬁtinib	JJ	O	geﬁtinib	amod	6	SENT_149	[p9l294t3367r657b3469],
6	group	NN	O	group	prep_in	2	SENT_149	[p9l693t3394r941b3469],
7	and	CC	O	and	_	0	SENT_149	[p9l977t3368r1133b3447],
8	11	CD	NUMBER	11	num	9	SENT_149	[p9l1171t3374r1266b3446],
9	patients	NNS	O	patient	prep_in	2	SENT_149	[p9l1301t3369r1634b3468],
10	in	IN	O	in	_	0	SENT_149	[p9l1671t3369r1753b3446],
11	the	DT	O	the	det	13	SENT_149	[p9l1789t3368r1919b3446],
12	chemotherapy	NN	O	chemotherapy	nn	13	SENT_149	[p9l1956t3368r2132b3446, p9l11t3496r474b3596],
13	group	NN	O	group	prep_in	9	SENT_149	[p9l508t3522r760b3597],
14	received	VBD	O	receive	_	0	SENT_149	[p9l800t3496r1146b3575],
15	second	JJ	ORDINAL	second	amod	18	SENT_149	[p9l1186t3496r1676b3575],
16	—	NN	O	—	nn	18	SENT_149	[p9l1186t3496r1676b3575],
17	line	NN	O	line	nn	18	SENT_149	[p9l1186t3496r1676b3575],
18	treatment	NN	O	treatment	dobj	14	SENT_149	[p9l1716t3513r2139b3574],
19	before	IN	O	before	mark	21	SENT_149	[p9l12t3623r280b3703],
20	they	PRP	O	they	nsubj	21	SENT_149	[p9l313t3624r496b3724],
21	had	VBD	O	have	advcl	14	SENT_149	[p9l523t3624r679b3703],
22	RECIST	NNP	O	RECIST	dobj	21	SENT_149	[p9l710t3623r1398b3707],
23	—	CD	NUMBER	—	num	22	SENT_149	[p9l710t3623r1398b3707],
24	deﬁned	VBN	O	deﬁned	partmod	22	SENT_149	[p9l710t3623r1398b3707],
25	disease	NN	O	disease	nn	26	SENT_149	[p9l1430t3624r1740b3703],
26	progression	NN	O	progression	dobj	24	SENT_149	[p9l1771t3650r2132b3725, p10l12t22r215b100],
27	.	.	O	.	_	0	SENT_149	[p9l1771t3650r2132b3725, p10l12t22r215b100],

1	The	DT	O	the	det	2	SENT_150	[p10l263t21r425b99],
2	data	NNS	O	datum	nsubj	27	SENT_150	[p10l472t21r659b100],
3	on	IN	O	on	_	0	SENT_150	[p10l703t47r810b100],
4	progression	NN	O	progression	prep_on	2	SENT_150	[p10l854t20r1578b122],
5	—	CD	NUMBER	—	num	7	SENT_150	[p10l854t20r1578b122],
6	free	JJ	O	free	amod	7	SENT_150	[p10l854t20r1578b122],
7	survival	NN	O	survival	nsubjpass	12	SENT_150	[p10l1627t21r1965b100],
8	for	IN	O	for	_	0	SENT_150	[p10l2011t20r2136b100],
9	these	DT	O	these	det	10	SENT_150	[p10l12t148r235b226],
10	patients	NNS	O	patient	prep_for	7	SENT_150	[p10l279t149r620b248],
11	were	VBD	O	be	auxpass	12	SENT_150	[p10l663t174r865b228],
12	censored	VBN	O	censor	rcmod	2	SENT_150	[p10l911t148r1293b227],
13	at	IN	O	at	_	0	SENT_150	[p10l1337t165r1416b226],
14	the	DT	O	the	det	15	SENT_150	[p10l1457t148r1589b226],
15	time	NN	O	time	prep_at	12	SENT_150	[p10l1635t149r1827b226],
16	of	IN	O	of	_	0	SENT_150	[p10l1873t147r1973b227],
17	the	DT	O	the	det	20	SENT_150	[p10l2001t148r2133b226],
18	last	JJ	O	last	amod	20	SENT_150	[p10l10t277r163b354],
19	CT	NN	O	ct	nn	20	SENT_150	[p10l194t283r318b355],
20	evaluation	NN	O	evaluation	prep_of	15	SENT_150	[p10l351t277r793b356],
21	at	IN	O	at	_	0	SENT_150	[p10l828t294r907b355],
22	which	WDT	O	which	rel	24	SENT_150	[p10l933t277r1196b356],
23	they	PRP	O	they	nsubj	24	SENT_150	[p10l1232t277r1415b376],
24	did	VBD	O	do	rcmod	20	SENT_150	[p10l1448t277r1582b355],
25	not	RB	O	not	neg	24	SENT_150	[p10l1618t294r1761b355],
26	yet	RB	O	yet	advmod	27	SENT_150	[p10l1787t294r1912b376],
27	have	VBP	O	have	_	0	SENT_150	[p10l1943t277r2133b356],
28	evidence	NN	O	evidence	dobj	27	SENT_150	[p10l12t405r362b484],
29	of	IN	O	of	_	0	SENT_150	[p10l395t404r492b484],
30	disease	NN	O	disease	nn	31	SENT_150	[p10l506t405r803b484],
31	progression	NN	O	progression	prep_of	28	SENT_150	[p10l834t406r1344b506],
32	.	.	O	.	_	0	SENT_150	[p10l834t406r1344b506],

1	Demographic	JJ	O	demographic	amod	4	SENT_151	[p10l1380t405r1946b506],
2	and	CC	O	and	_	0	SENT_151	[p10l1976t405r2134b484],
3	disease	NN	O	disease	conj_and	1	SENT_151	[p10l12t534r322b613],
4	characteristics	NNS	O	characteristic	nsubj	9	SENT_151	[p10l361t534r982b612],
5	at	IN	O	at	_	0	SENT_151	[p10l1022t551r1101b612],
6	baseline	NN	O	baseline	prep_at	4	SENT_151	[p10l1134t534r1487b613],
7	were	VBD	O	be	cop	9	SENT_151	[p10l1521t560r1722b613],
8	well	RB	O	well	advmod	9	SENT_151	[p10l1756t534r1934b613],
9	balanced	JJ	O	balanced	_	0	SENT_151	[p10l1972t534r2132b613, p10l11t662r261b741],
10	between	IN	O	between	_	0	SENT_151	[p10l301t662r659b741],
11	the	DT	O	the	det	13	SENT_151	[p10l698t662r831b740],
12	two	CD	NUMBER	two	num	13	SENT_151	[p10l871t679r1029b741],
13	groups	NNS	O	group	prep_between	9	SENT_151	[p10l1070t688r1364b763],
14	(	RB	O	(	dep	15	SENT_151	[p10l1411t662r1673b753],
15	Table	NNP	O	Table	dep	13	SENT_151	[p10l1411t662r1673b753],
16	1	CD	NUMBER	1	number	17	SENT_151	[p10l1718t668r1814b753],
17	)	CD	NUMBER	)	num	15	SENT_151	[p10l1718t668r1814b753],
18	.	.	O	.	_	0	SENT_151	[p10l1718t668r1814b753],

1	EFFICACY	NN	O	efficacy	_	0	SENT_152	[p10l16t937r384b987],

1	The	DT	O	the	det	3	SENT_153	[p10l7t1046r171b1124],
2	interim	JJ	O	interim	amod	3	SENT_153	[p10l229t1047r555b1124],
3	analysis	NN	O	analysis	nsubj	4	SENT_153	[p10l613t1046r961b1146],
4	performed	VBN	O	perform	dep	8	SENT_153	[p10l1020t1045r1487b1146],
5	in	IN	O	in	_	0	SENT_153	[p10l1544t1047r1629b1124],
6	May	NNP	DATE	May	prep_in	4	SENT_153	[p10l1684t1054r1867b1146],
7	2009	CD	DATE	2009	num	6	SENT_153	[p10l1921t1052r2133b1125],
8	showed	VBD	O	show	_	0	SENT_153	[p10l12t1175r330b1254],
9	that	IN	O	that	complm	14	SENT_153	[p10l361t1175r530b1253],
10	progression	NN	O	progression	nsubj	14	SENT_153	[p10l555t1174r1247b1276],
11	—	CD	NUMBER	—	num	13	SENT_153	[p10l555t1174r1247b1276],
12	free	JJ	O	free	amod	13	SENT_153	[p10l555t1174r1247b1276],
13	survival	NN	O	survival	dep	10	SENT_153	[p10l1280t1175r1604b1254],
14	was	VBD	O	be	ccomp	8	SENT_153	[p10l1630t1201r1791b1254],
15	signiﬁcantly	RB	O	signiﬁcantly	advmod	14	SENT_153	[p10l1825t1174r2132b1276, p10l12t1303r277b1403],
16	longer	RBR	O	longer	advmod	14	SENT_153	[p10l310t1303r590b1404],
17	in	IN	O	in	_	0	SENT_153	[p10l625t1304r709b1381],
18	the	DT	O	the	det	20	SENT_153	[p10l748t1303r883b1381],
19	gefitinib	JJ	O	gefitinib	amod	20	SENT_153	[p10l921t1302r1302b1404],
20	group	NN	O	group	prep_in	16	SENT_153	[p10l1341t1329r1598b1404],
21	than	IN	O	than	dep	14	SENT_153	[p10l1638t1303r1838b1381],
22	in	IN	O	in	_	0	SENT_153	[p10l1876t1304r1960b1381],
23	the	DT	O	the	det	27	SENT_153	[p10l1999t1303r2134b1381],
24	chemotherapy	NN	O	chemotherapy	nn	27	SENT_153	[p10l11t1431r626b1531],
25	group	NN	O	group	nn	27	SENT_153	[p10l675t1457r929b1532],
26	(	CD	NUMBER	(	num	27	SENT_153	[p10l990t1431r1365b1527],
27	median	NN	O	median	prep_in	14	SENT_153	[p10l990t1431r1365b1527],
28	,	,	O	,	_	0	SENT_153	[p10l990t1431r1365b1527],
29	10.4	CD	DURATION	10.4	num	30	SENT_153	[p10l1427t1437r1599b1510],
30	months	NNS	NUMBER	month	appos	27	SENT_153	[p10l1653t1431r1983b1510],
31	vs.	CC	O	vs.	prep	30	SENT_153	[p10l2034t1457r2144b1510],
32	5.5	CD	DURATION	5.5	num	33	SENT_153	[p10l12t1566r131b1637],
33	months	NNS	NUMBER	month	dep	31	SENT_153	[p10l165t1558r513b1654],
34	;	:	O	;	_	0	SENT_153	[p10l165t1558r513b1654],
35	hazard	NN	O	hazard	nn	36	SENT_153	[p10l548t1558r841b1637],
36	ratio	NN	O	ratio	dep	30	SENT_153	[p10l872t1559r1066b1637],
37	for	IN	O	for	_	0	SENT_153	[p10l1099t1557r1221b1637],
38	death	NN	O	death	nn	41	SENT_153	[p10l1249t1558r1484b1637],
39	or	CC	O	or	_	0	SENT_153	[p10l1516t1584r1604b1637],
40	disease	NN	O	disease	nn	41	SENT_153	[p10l1633t1558r1938b1637],
41	progression	NN	O	progression	prep_for	36	SENT_153	[p10l1968t1584r2148b1658, p10l10t1688r368b1789],
42	with	IN	O	with	_	0	SENT_153	[p10l401t1687r595b1767],
43	geﬁtinib	NN	O	geﬁtinib	prep_with	41	SENT_153	[p10l634t1686r1021b1789],
44	,	,	O	,	_	0	SENT_153	[p10l634t1686r1021b1789],
45	0.36	CD	NUMBER	0.36	appos	43	SENT_153	[p10l1065t1693r1264b1784],
46	;	:	O	;	_	0	SENT_153	[p10l1065t1693r1264b1784],
47	95	CD	PERCENT	95	number	48	SENT_153	[p10l1307t1693r1490b1767],
48	%	NN	PERCENT	%	num	53	SENT_153	[p10l1307t1693r1490b1767],
49	confidence	NN	O	confidence	nn	53	SENT_153	[p10l1529t1686r1994b1767],
50	interval	NN	O	interval	nn	53	SENT_153	[p10l2032t1688r2148b1765, p10l11t1816r257b1895],
51	[	CD	NUMBER	[	num	53	SENT_153	[p10l306t1822r489b1912],
52	CI	NN	O	ci	nn	53	SENT_153	[p10l306t1822r489b1912],
53	]	NN	O	]	dep	30	SENT_153	[p10l306t1822r489b1912],
54	,	,	O	,	_	0	SENT_153	[p10l306t1822r489b1912],
55	0.25	CD	NUMBER	0.25	num	57	SENT_153	[p10l536t1822r717b1895],
56	to	TO	O	to	dep	57	SENT_153	[p10l762t1833r845b1895],
57	0.51	CD	NUMBER	0.51	appos	53	SENT_153	[p10l888t1822r1093b1911],
58	;	:	O	;	_	0	SENT_153	[p10l888t1822r1093b1911],
59	P	NN	O	p	dep	30	SENT_153	[p10l1137t1822r1513b1907],
60	<	JJR	O	<	dep	59	SENT_153	[p10l1137t1822r1513b1907],
61	0.001	CD	NUMBER	0.001	num	64	SENT_153	[p10l1137t1822r1513b1907],
62	)	NN	O	)	nn	64	SENT_153	[p10l1137t1822r1513b1907],
63	(	CD	NUMBER	(	num	64	SENT_153	[p10l1565t1817r1750b1917],
64	Fig	NN	O	fig	nsubj	8	SENT_153	[p10l1565t1817r1750b1917],
65	.	.	O	.	_	0	SENT_153	[p10l1565t1817r1750b1917],

1	1	CD	NUMBER	1	_	0	SENT_154	[p10l1800t1822r1845b1894],
2	in	IN	O	in	_	0	SENT_154	[p10l1886t1817r1971b1894],
3	the	DT	O	the	det	6	SENT_154	[p10l2012t1816r2149b1894],
4	Supplementary	NNP	O	Supplementary	nn	6	SENT_154	[p10l12t1944r638b2045],
5	Appendix	NNP	O	Appendix	nn	6	SENT_154	[p10l664t1944r1114b2045],
6	)	NN	O	)	prep_in	1	SENT_154	[p10l664t1944r1114b2045],
7	.	.	O	.	_	0	SENT_154	[p10l664t1944r1114b2045],

1	A	DT	O	a	det	3	SENT_155	[p10l1149t1952r1215b2022],
2	significant	JJ	O	significant	amod	3	SENT_155	[p10l1248t1943r1698b2046],
3	difference	NN	O	difference	nsubj	6	SENT_155	[p10l1726t1943r2149b2024],
4	was	VBD	O	be	aux	6	SENT_155	[p10l6t2100r165b2153],
5	again	RB	O	again	advmod	6	SENT_155	[p10l191t2074r420b2175],
6	observed	VBN	O	observe	_	0	SENT_155	[p10l445t2073r814b2153],
7	in	IN	O	in	_	0	SENT_155	[p10l837t2074r919b2151],
8	the	DT	O	the	det	10	SENT_155	[p10l943t2073r1073b2152],
9	final	JJ	O	final	amod	10	SENT_155	[p10l1098t2072r1294b2152],
10	analysis	NN	O	analysis	prep_in	6	SENT_155	[p10l1318t2073r1668b2174],
11	,	,	O	,	_	0	SENT_155	[p10l1318t2073r1668b2174],
12	performed	VBN	O	perform	dep	6	SENT_155	[p10l1696t2072r2149b2174],
13	in	IN	O	in	_	0	SENT_155	[p10l10t2203r93b2280],
14	December	NNP	DATE	December	prep_in	12	SENT_155	[p10l127t2202r568b2282],
15	2009	CD	DATE	2009	num	14	SENT_155	[p10l600t2209r808b2282],
16	(	CD	NUMBER	(	num	18	SENT_155	[p10l849t2202r1201b2294],
17	median	NN	O	median	nn	18	SENT_155	[p10l849t2202r1201b2294],
18	progression	NN	O	progression	tmod	12	SENT_155	[p10l1234t2201r1948b2304],
19	—	CD	NUMBER	—	num	21	SENT_155	[p10l1234t2201r1948b2304],
20	free	JJ	O	free	amod	21	SENT_155	[p10l1234t2201r1948b2304],
21	survival	NN	O	survival	dep	18	SENT_155	[p10l1985t2228r2148b2282, p10l6t2331r225b2428],
22	,	,	O	,	_	0	SENT_155	[p10l1985t2228r2148b2282, p10l6t2331r225b2428],
23	10.8	CD	DURATION	10.8	num	24	SENT_155	[p10l273t2337r446b2411],
24	months	NNS	NUMBER	month	dobj	6	SENT_155	[p10l487t2331r816b2411],
25	with	IN	O	with	_	0	SENT_155	[p10l853t2331r1050b2411],
26	gefitinib	NN	O	gefitinib	prep_with	24	SENT_155	[p10l1088t2330r1463b2433],
27	vs.	CC	O	vs.	_	0	SENT_155	[p10l1499t2358r1608b2411],
28	5.4	CD	DURATION	5.4	num	29	SENT_155	[p10l1655t2338r1778b2411],
29	months	NNS	NUMBER	month	conj_vs.	24	SENT_155	[p10l1817t2331r2147b2411],
30	with	IN	O	with	_	0	SENT_155	[p10l6t2460r202b2539],
31	chemotherapy	NN	O	chemotherapy	prep_with	29	SENT_155	[p10l248t2460r881b2560],
32	;	:	O	;	_	0	SENT_155	[p10l248t2460r881b2560],
33	hazard	NN	O	hazard	nn	34	SENT_155	[p10l930t2460r1229b2539],
34	ratio	NN	O	ratio	dep	29	SENT_155	[p10l1274t2461r1495b2556],
35	,	,	O	,	_	0	SENT_155	[p10l1274t2461r1495b2556],
36	0.30	CD	NUMBER	0.30	appos	34	SENT_155	[p10l1545t2466r1750b2556],
37	;	:	O	;	_	0	SENT_155	[p10l1545t2466r1750b2556],
38	95	CD	PERCENT	95	num	40	SENT_155	[p10l1799t2465r1984b2539],
39	%	NN	PERCENT	%	nn	40	SENT_155	[p10l1799t2465r1984b2539],
40	CI	NN	O	ci	dep	29	SENT_155	[p10l2028t2466r2144b2556],
41	,	,	O	,	_	0	SENT_155	[p10l2028t2466r2144b2556],
42	0.22	CD	NUMBER	0.22	number	44	SENT_155	[p10l10t2595r195b2668],
43	to	TO	O	to	dep	44	SENT_155	[p10l237t2606r321b2668],
44	0.41	CD	NUMBER	0.41	appos	40	SENT_155	[p10l363t2595r565b2684],
45	;	:	O	;	_	0	SENT_155	[p10l363t2595r565b2684],
46	P	NN	O	p	dep	47	SENT_155	[p10l609t2595r984b2680],
47	<	JJR	O	<	dep	29	SENT_155	[p10l609t2595r984b2680],
48	0.001	CD	NUMBER	0.001	num	49	SENT_155	[p10l609t2595r984b2680],
49	)	NN	O	)	dep	47	SENT_155	[p10l609t2595r984b2680],
50	(	CD	NUMBER	(	num	51	SENT_155	[p10l1036t2590r1221b2690],
51	Fig	NN	O	fig	dep	47	SENT_155	[p10l1036t2590r1221b2690],
52	.	.	O	.	_	0	SENT_155	[p10l1036t2590r1221b2690],

1	2A	NN	O	2a	_	0	SENT_156	[p10l1267t2595r1438b2680],
2	)	NN	O	)	dep	1	SENT_156	[p10l1267t2595r1438b2680],
3	.	.	O	.	_	0	SENT_156	[p10l1267t2595r1438b2680],

1	The	DT	O	the	det	7	SENT_157	[p10l1482t2589r1646b2667],
2	1-year	JJ	DURATION	1-year	amod	7	SENT_157	[p10l1691t2595r1950b2689],
3	and	CC	O	and	_	0	SENT_157	[p10l1987t2589r2149b2668],
4	2	CD	NUMBER	2	number	5	SENT_157	[p10l10t2724r258b2818],
5	—	CD	NUMBER	—	dep	6	SENT_157	[p10l10t2724r258b2818],
6	year	NN	NUMBER	year	conj_and	2	SENT_157	[p10l10t2724r258b2818],
7	rates	NNS	O	rate	_	0	SENT_157	[p10l283t2734r478b2796],
8	of	IN	O	of	_	0	SENT_157	[p10l509t2716r608b2797],
9	progression	NN	O	progression	prep_of	7	SENT_157	[p10l615t2716r1296b2819],
10	—	CD	NUMBER	—	num	12	SENT_157	[p10l615t2716r1296b2819],
11	free	JJ	O	free	amod	12	SENT_157	[p10l615t2716r1296b2819],
12	survival	NN	O	survival	nsubj	18	SENT_157	[p10l1326t2717r1645b2797],
13	were	VBD	O	be	cop	18	SENT_157	[p10l1668t2743r1864b2797],
14	42.1	CD	PERCENT	42.1	number	18	SENT_157	[p10l1891t2723r2150b2797],
15	%	NN	PERCENT	%	dep	18	SENT_157	[p10l1891t2723r2150b2797],
16	and	CC	O	and	_	0	SENT_157	[p10l10t2846r169b2926],
17	8.4	CD	PERCENT	8.4	dep	7	SENT_157	[p10l199t2852r434b2943],
18	%	NN	PERCENT	%	dep	7	SENT_157	[p10l199t2852r434b2943],
19	,	,	O	,	_	0	SENT_157	[p10l199t2852r434b2943],
20	respectively	RB	O	respectively	advmod	18	SENT_157	[p10l469t2846r988b2947],
21	,	,	O	,	_	0	SENT_157	[p10l469t2846r988b2947],
22	in	IN	O	in	_	0	SENT_157	[p10l1023t2847r1106b2924],
23	the	DT	O	the	det	25	SENT_157	[p10l1137t2846r1270b2925],
24	gefitinib	JJ	O	gefitinib	amod	25	SENT_157	[p10l1300t2845r1674b2948],
25	group	NN	O	group	prep_in	7	SENT_157	[p10l1705t2872r1960b2948],
26	and	CC	O	and	_	0	SENT_157	[p10l1990t2846r2150b2926],
27	3.2	CD	PERCENT	3.2	num	28	SENT_157	[p10l11t2980r229b3054],
28	%	NN	PERCENT	%	num	31	SENT_157	[p10l11t2980r229b3054],
29	and	CC	O	and	_	0	SENT_157	[p10l263t2975r424b3054],
30	o	NN	PERCENT	o	conj_and	28	SENT_157	[p10l460t2980r621b3071],
31	%	NN	PERCENT	%	conj_and	25	SENT_157	[p10l460t2980r621b3071],
32	,	,	O	,	_	0	SENT_157	[p10l460t2980r621b3071],
33	respectively	RB	O	respectively	advmod	25	SENT_157	[p10l663t2975r1193b3075],
34	,	,	O	,	_	0	SENT_157	[p10l663t2975r1193b3075],
35	in	IN	O	in	_	0	SENT_157	[p10l1233t2976r1319b3053],
36	the	DT	O	the	det	38	SENT_157	[p10l1354t2975r1491b3053],
37	chemotherapy	NN	O	chemotherapy	nn	38	SENT_157	[p10l1527t2975r2154b3075],
38	group	NN	O	group	prep_in	7	SENT_157	[p10l10t3130r293b3205],
39	.	.	O	.	_	0	SENT_157	[p10l10t3130r293b3205],

1	Subgroup	NN	MISC	subgroup	nn	2	SENT_158	[p10l346t3104r769b3205],
2	analyses	NNS	O	analysis	nsubj	3	SENT_158	[p10l816t3104r1187b3204],
3	showed	VBD	O	show	_	0	SENT_158	[p10l1236t3104r1568b3183],
4	that	IN	O	that	complm	6	SENT_158	[p10l1613t3104r1790b3182],
5	women	NNS	O	woman	nsubj	6	SENT_158	[p10l1826t3130r2150b3183],
6	had	VBD	O	have	ccomp	3	SENT_158	[p10l10t3232r167b3312],
7	significantly	RB	O	significantly	advmod	8	SENT_158	[p10l198t3231r746b3334],
8	longer	JJR	O	longer	advmod	11	SENT_158	[p10l769t3232r1046b3334],
9	progression	NN	O	progression	dep	11	SENT_158	[p10l1071t3231r1785b3334],
10	—	CD	NUMBER	—	num	9	SENT_158	[p10l1071t3231r1785b3334],
11	free	JJ	O	free	amod	12	SENT_158	[p10l1071t3231r1785b3334],
12	survival	NN	O	survival	dobj	6	SENT_158	[p10l1816t3232r2150b3312],
13	than	IN	O	than	_	0	SENT_158	[p10l11t3361r205b3439],
14	men	NNS	O	man	prep_than	6	SENT_158	[p10l237t3387r422b3439],
15	(	CD	NUMBER	(	num	16	SENT_158	[p10l460t3361r828b3457],
16	median	NN	O	median	dep	14	SENT_158	[p10l460t3361r828b3457],
17	,	,	O	,	_	0	SENT_158	[p10l460t3361r828b3457],
18	6.5	CD	NUMBER	6.5	appos	14	SENT_158	[p10l866t3367r988b3440],
19	vs.	CC	O	vs.	prep	18	SENT_158	[p10l1020t3387r1127b3440],
20	6.0	CD	DURATION	6.0	num	21	SENT_158	[p10l1166t3367r1291b3440],
21	months	NNS	NUMBER	month	dep	19	SENT_158	[p10l1324t3361r1672b3457],
22	;	:	O	;	_	0	SENT_158	[p10l1324t3361r1672b3457],
23	hazard	NN	O	hazard	nn	24	SENT_158	[p10l1709t3361r2002b3440],
24	ratio	NN	O	ratio	dep	18	SENT_158	[p10l2035t3387r2148b3439, p10l11t3491r120b3570],
25	for	IN	O	for	_	0	SENT_158	[p10l152t3489r274b3570],
26	death	NN	O	death	nn	29	SENT_158	[p10l301t3490r537b3570],
27	or	CC	O	or	_	0	SENT_158	[p10l567t3516r655b3570],
28	disease	NN	O	disease	conj_or	26	SENT_158	[p10l684t3490r990b3570],
29	progression	NN	O	progression	prep_for	24	SENT_158	[p10l1019t3491r1546b3592],
30	,	,	O	,	_	0	SENT_158	[p10l1019t3491r1546b3592],
31	0.68	CD	NUMBER	0.68	appos	29	SENT_158	[p10l1582t3496r1781b3587],
32	;	:	O	;	_	0	SENT_158	[p10l1582t3496r1781b3587],
33	95	CD	PERCENT	95	num	34	SENT_158	[p10l1816t3496r1998b3570],
34	%	NN	PERCENT	%	dep	18	SENT_158	[p10l1816t3496r1998b3570],
35	CI	NN	O	ci	dep	34	SENT_158	[p10l2028t3496r2144b3587],
36	,	,	O	,	_	0	SENT_158	[p10l2028t3496r2144b3587],
37	0.51	CD	NUMBER	0.51	dep	39	SENT_158	[p10l10t3625r187b3698],
38	to	TO	O	to	dep	39	SENT_158	[p10l219t3636r301b3698],
39	0.92	CD	NUMBER	0.92	advmod	34	SENT_158	[p10l335t3625r534b3715],
40	;	:	O	;	_	0	SENT_158	[p10l335t3625r534b3715],
41	P	NN	O	p	dep	18	SENT_158	[p10l568t3625r936b3710],
42	=	JJ	O	=	amod	44	SENT_158	[p10l568t3625r936b3710],
43	0.01	CD	NUMBER	0.01	tmod	42	SENT_158	[p10l568t3625r936b3710],
44	)	NN	O	)	dep	41	SENT_158	[p10l568t3625r936b3710],
45	.	.	O	.	_	0	SENT_158	[p10l568t3625r936b3710],

1	The	DT	O	the	det	4	SENT_159	[p10l970t3619r1132b3697],
2	objective	JJ	O	objective	amod	4	SENT_159	[p10l1165t3619r1540b3719],
3	response	NN	O	response	nn	4	SENT_159	[p10l1572t3645r1956b3719],
4	rate	NN	O	rate	nsubj	7	SENT_159	[p10l1988t3636r2149b3697],
5	was	VBD	O	be	cop	7	SENT_159	[p11l6t49r172b102],
6	significantly	RB	O	significantly	advmod	7	SENT_159	[p11l219t21r782b124],
7	higher	JJR	O	higher	_	0	SENT_159	[p11l821t22r1110b124],
8	in	IN	O	in	_	0	SENT_159	[p11l1150t23r1236b100],
9	the	DT	O	the	det	11	SENT_159	[p11l1279t22r1416b101],
10	gefitinib	JJ	O	gefitinib	amod	11	SENT_159	[p11l1459t21r1844b124],
11	group	NN	O	group	prep_in	7	SENT_159	[p11l1889t48r2148b124],
12	than	IN	O	than	_	0	SENT_159	[p11l11t151r208b229],
13	the	DT	O	the	det	15	SENT_159	[p11l248t151r382b229],
14	chemotherapy	NN	O	chemotherapy	nn	15	SENT_159	[p11l422t151r1037b251],
15	group	NN	O	group	prep_than	7	SENT_159	[p11l1072t177r1326b252],
16	(	CD	PERCENT	(	number	17	SENT_159	[p11l1371t156r1666b242],
17	73.7	CD	PERCENT	73.7	dep	18	SENT_159	[p11l1371t156r1666b242],
18	%	NN	PERCENT	%	dep	15	SENT_159	[p11l1371t156r1666b242],
19	vs.	CC	O	vs.	prep	15	SENT_159	[p11l1700t177r1810b230],
20	30.7	CD	PERCENT	30.7	num	21	SENT_159	[p11l1856t156r2144b247],
21	%	NN	PERCENT	%	dep	19	SENT_159	[p11l1856t156r2144b247],
22	,	,	O	,	_	0	SENT_159	[p11l1856t156r2144b247],

1	N	NN	O	n	nn	3	SENT_160	[p11l570t320r584b335],
2	ENGLJ	NN	O	englj	nn	3	SENT_160	[p11l598t320r676b342],
3	MED	NN	O	med	_	0	SENT_160	[p11l691t320r743b335],
4	362	CD	NUMBER	362	dep	3	SENT_160	[p11l753t314r832b342],
5	;	:	O	;	_	0	SENT_160	[p11l753t314r832b342],
6	25	CD	NUMBER	25	num	8	SENT_160	[p11l753t314r832b342],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_160	[p11l867t320r991b342],
8	JUNE	NN	DATE	june	dep	4	SENT_160	[p11l1022t320r1086b342],
9	24	CD	DATE	24	dep	8	SENT_160	[p11l1097t320r1133b342],
10	,	,	DATE	,	_	0	SENT_160	[p11l1097t320r1133b342],
11	2010	CD	DATE	2010	num	12	SENT_160	[p11l1144t320r1204b336],
12	2333	CD	DATE	2333	appos	9	SENT_160	[p11l1939t310r2015b333],

1	The	DT	O	the	det	4	SENT_161	[p11l702t353r753b377],
2	New	NNP	O	New	nn	4	SENT_161	[p11l762t354r824b377],
3	England	NNP	O	England	nn	4	SENT_161	[p11l833t353r944b384],
4	Journal	NNP	O	Journal	_	0	SENT_161	[p11l952t353r1050b377],
5	of	IN	O	of	_	0	SENT_161	[p11l1059t353r1088b377],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_161	[p11l1095t353r1220b377],

1	Copyright	NN	O	copyright	_	0	SENT_162	[p11l494t435r629b466],
2	©	CD	NUMBER	©	num	6	SENT_162	[p11l638t435r661b459],
3	2010	CD	DATE	2010	num	6	SENT_162	[p11l671t435r737b459],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_162	[p11l746t435r937b459],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_162	[p11l947t435r1055b459],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_162	[p11l1065t435r1170b466],
7	.	.	O	.	_	0	SENT_162	[p11l1065t435r1170b466],

1	All	DT	O	all	det	2	SENT_163	[p11l1181t435r1223b459],
2	rights	NNS	O	rights	nsubj	3	SENT_163	[p11l1232t435r1306b466],
3	reserved	VBN	O	reserve	_	0	SENT_163	[p11l1316t435r1435b459],
4	.	.	O	.	_	0	SENT_163	[p11l1316t435r1435b459],

1	The	DT	O	the	det	4	SENT_164	[p11l673t541r719b562],
2	NEW	NNP	O	NEW	nn	4	SENT_164	[p11l737t543r822b562],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_164	[p11l841t543r1030b562],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_164	[p11l1049t543r1228b569],
5	of	IN	O	of	_	0	SENT_164	[p11l1248t541r1276b568],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_164	[p11l1288t543r1487b562],

1	Table	NNP	O	Table	_	0	SENT_165	[p11l59t765r201b813],
2	1	CD	NUMBER	1	dep	1	SENT_165	[p11l221t770r262b813],
3	.	.	O	.	_	0	SENT_165	[p11l221t770r262b813],

1	Baseline	NN	O	baseline	nn	2	SENT_166	[p11l285t765r502b813],
2	Characteristics	NNS	O	characteristic	_	0	SENT_166	[p11l519t765r910b813],
3	of	IN	O	of	_	0	SENT_166	[p11l929t764r989b813],
4	the	DT	O	the	det	6	SENT_166	[p11l993t765r1078b813],
5	Intention-to-Treat	NNP	ORGANIZATION	Intention-to-Treat	nn	6	SENT_166	[p11l1099t766r1562b813],
6	Population	NNP	ORGANIZATION	Population	prep_of	2	SENT_166	[p11l1582t765r1878b828],
7	,	,	O	,	_	0	SENT_166	[p11l1582t765r1878b828],
8	According	VBG	O	accord	_	0	SENT_166	[p11l59t845r326b908],
9	to	TO	O	to	prepc_according_to	2	SENT_166	[p11l341t853r392b893],
10	Treatment	NNP	ORGANIZATION	Treatment	nn	11	SENT_166	[p11l409t850r684b893],
11	Group	NNP	ORGANIZATION	Group	pobj	2	SENT_166	[p11l700t848r915b908],
12	.	.	O	.	_	0	SENT_166	[p11l700t848r915b908],

1	*	NN	O	*	_	0	SENT_167	[p11l700t848r915b908],

1	Geﬁtinib	NNP	O	Geﬁtinib	nn	4	SENT_168	[p11l1149t988r1376b1037],
2	Carbop	NNP	O	Carbop	nn	4	SENT_168	[p11l1499t988r2086b1051],
3	|	NN	O	|	nn	4	SENT_168	[p11l1499t988r2086b1051],
4	atin	NN	O	atin	_	0	SENT_168	[p11l1499t988r2086b1051],
5	.	.	O	.	_	0	SENT_168	[p11l1499t988r2086b1051],

1	—	NN	O	—	_	0	SENT_169	[p11l1499t988r2086b1051],
2	.	.	O	.	_	0	SENT_169	[p11l1499t988r2086b1051],

1	Pac	NN	O	pac	_	0	SENT_170	[p11l1499t988r2086b1051],
2	|	SYM	O	|	dep	3	SENT_170	[p11l1499t988r2086b1051],
3	itaxe	FW	O	itaxe	rcmod	1	SENT_170	[p11l1499t988r2086b1051],
4	|	FW	O	|	dep	1	SENT_170	[p11l1499t988r2086b1051],

1	Characteristic	JJ	O	characteristic	amod	3	SENT_171	[p11l60t1061r423b1109],
2	(	NN	O	(	nn	3	SENT_171	[p11l1149t1065r1207b1124],
3	N	NN	O	n	dep	16	SENT_171	[p11l1149t1065r1207b1124],
4	=	JJ	O	=	dep	3	SENT_171	[p11l1222t1085r1255b1101],
5	114	CD	NUMBER	114	number	6	SENT_171	[p11l1269t1065r1376b1124],
6	)	CD	NUMBER	)	num	12	SENT_171	[p11l1269t1065r1376b1124],
7	(	NN	O	(	nn	12	SENT_171	[p11l1680t1065r1738b1124],
8	N	NN	O	n	nn	12	SENT_171	[p11l1680t1065r1738b1124],
9	=	JJ	O	=	amod	12	SENT_171	[p11l1753t1085r1786b1101],
10	114	CD	NUMBER	114	number	11	SENT_171	[p11l1799t1065r1907b1124],
11	)	CD	NUMBER	)	dep	9	SENT_171	[p11l1799t1065r1907b1124],
12	Sex	NN	O	sex	dep	4	SENT_171	[p11l62t1175r228b1220],
13	—	CD	NUMBER	—	num	14	SENT_171	[p11l62t1175r228b1220],
14	no.	NN	O	no.	dep	16	SENT_171	[p11l248t1189r324b1220],
15	(	CD	PERCENT	(	num	16	SENT_171	[p11l351t1174r436b1235],
16	%	NN	PERCENT	%	_	0	SENT_171	[p11l351t1174r436b1235],
17	)	CD	NUMBER	)	dep	16	SENT_171	[p11l351t1174r436b1235],

1	Male	JJ	O	male	amod	2	SENT_172	[p11l161t1283r285b1331],
2	42	CD	NUMBER	42	dep	14	SENT_172	[p11l1161t1287r1220b1330],
3	(	CD	NUMBER	(	number	4	SENT_172	[p11l1246t1286r1390b1346],
4	36.8	CD	NUMBER	36.8	num	5	SENT_172	[p11l1246t1286r1390b1346],
5	)	NN	O	)	dep	2	SENT_172	[p11l1246t1286r1390b1346],
6	41	CD	NUMBER	41	number	7	SENT_172	[p11l1698t1287r1756b1330],
7	(	CD	NUMBER	(	num	9	SENT_172	[p11l1784t1286r1928b1346],
8	36.0	CD	NUMBER	36.0	number	9	SENT_172	[p11l1784t1286r1928b1346],
9	)	CD	NUMBER	)	npadvmod	10	SENT_172	[p11l1784t1286r1928b1346],
10	Female	JJ	O	female	amod	5	SENT_172	[p11l161t1394r346b1442],
11	72	CD	NUMBER	72	dep	14	SENT_172	[p11l1165t1398r1220b1442],
12	(	CD	NUMBER	(	num	14	SENT_172	[p11l1246t1398r1390b1457],
13	63.2	CD	NUMBER	63.2	num	14	SENT_172	[p11l1246t1398r1390b1457],
14	)	NN	O	)	_	0	SENT_172	[p11l1246t1398r1390b1457],
15	73	CD	NUMBER	73	number	16	SENT_172	[p11l1702t1398r1755b1442],
16	(	CD	NUMBER	(	dep	14	SENT_172	[p11l1784t1397r1928b1457],
17	64.0	CD	NUMBER	64.0	num	18	SENT_172	[p11l1784t1397r1928b1457],
18	)	NN	O	)	dep	16	SENT_172	[p11l1784t1397r1928b1457],

1	Age	NNP	O	Age	_	0	SENT_173	[p11l59t1508r157b1569],
2	—	CD	NUMBER	—	num	3	SENT_173	[p11l174t1535r238b1539],
3	yr	NN	DURATION	yr	dep	1	SENT_173	[p11l254t1522r301b1568],

1	Mean	NN	O	mean	_	0	SENT_174	[p11l161t1620r302b1664],
2	63.9:7.7	CD	NUMBER	63.9:7.7	number	3	SENT_174	[p11l1152t1620r1374b1664],
3	62.6:8.9	CD	NUMBER	62.6:8.9	dep	1	SENT_174	[p11l1683t1619r1904b1665],
4	Range	NNP	O	Range	dep	3	SENT_174	[p11l161t1731r318b1790],
5	43-75	CD	NUMBER	43-75	num	4	SENT_174	[p11l1184t1731r1337b1775],
6	35-75	CD	NUMBER	35-75	dep	1	SENT_174	[p11l1716t1731r1868b1775],

1	Smoking	NN	O	smoking	nn	2	SENT_175	[p11l62t1838r293b1902],
2	status	NN	O	status	_	0	SENT_175	[p11l312t1847r468b1886],
3	—	CD	NUMBER	—	num	4	SENT_175	[p11l486t1868r550b1872],
4	no.	NN	O	no.	dep	2	SENT_175	[p11l570t1855r646b1886],
5	(	CD	PERCENT	(	num	6	SENT_175	[p11l673t1840r759b1901],
6	%	NN	PERCENT	%	dep	4	SENT_175	[p11l673t1840r759b1901],
7	)	CD	NUMBER	)	dep	2	SENT_175	[p11l673t1840r759b1901],

1	Never	RB	O	never	neg	2	SENT_176	[p11l161t1953r314b1997],
2	smoked	VBN	O	smoke	_	0	SENT_176	[p11l332t1949r535b1997],
3	75	CD	NUMBER	75	number	4	SENT_176	[p11l1165t1953r1218b1997],
4	(	CD	NUMBER	(	dobj	2	SENT_176	[p11l1246t1952r1371b2012],
5	65.8	CD	NUMBER	65.8	num	7	SENT_176	[p11l1246t1952r1371b2012],
6	66	CD	NUMBER	66	num	7	SENT_176	[p11l1700t1953r1759b1997],
7	(	NN	O	(	dep	4	SENT_176	[p11l1784t1953r1928b2012],
8	57.9	CD	NUMBER	57.9	number	9	SENT_176	[p11l1784t1953r1928b2012],
9	)	CD	NUMBER	)	num	10	SENT_176	[p11l1784t1953r1928b2012],
10	Previous	JJ	O	previous	dep	18	SENT_176	[p11l161t2064r381b2108],
11	or	CC	O	or	_	0	SENT_176	[p11l402t2077r455b2108],
12	current	JJ	DATE	current	amod	13	SENT_176	[p11l472t2069r660b2108],
13	smoker	NN	O	smoker	conj_or	10	SENT_176	[p11l680t2060r875b2108],
14	39	CD	NUMBER	39	number	15	SENT_176	[p11l1163t2064r1221b2108],
15	(	CD	NUMBER	(	num	13	SENT_176	[p11l1246t2064r1390b2123],
16	34.2	CD	NUMBER	34.2	num	17	SENT_176	[p11l1246t2064r1390b2123],
17	)	NN	O	)	dep	18	SENT_176	[p11l1246t2064r1390b2123],
18	48	CD	NUMBER	48	dep	4	SENT_176	[p11l1698t2063r1758b2109],
19	(	CD	NUMBER	(	number	20	SENT_176	[p11l1784t2064r1927b2123],
20	42.1	CD	NUMBER	42.1	dep	18	SENT_176	[p11l1784t2064r1927b2123],
21	)	NN	O	)	dep	20	SENT_176	[p11l1784t2064r1927b2123],

1	ECOG	NN	O	ecog	_	0	SENT_177	[p11l65t2175r221b2219],
2	performance	NN	O	performance	nn	5	SENT_177	[p11l246t2170r578b2234],
3	status	NN	O	status	nn	5	SENT_177	[p11l599t2180r754b2219],
4	score	NN	NUMBER	score	nn	5	SENT_177	[p11l776t2188r914b2219],
5	—	NN	O	—	dep	1	SENT_177	[p11l930t2201r995b2205],

1	no.	RB	O	no.	dep	3	SENT_178	[p11l256t2260r332b2292],
2	(	CD	PERCENT	(	num	3	SENT_178	[p11l359t2246r445b2306],
3	%	NN	PERCENT	%	dep	4	SENT_178	[p11l359t2246r445b2306],
4	)	CD	NUMBER	)	_	0	SENT_178	[p11l359t2246r445b2306],

1	Histologic	JJ	O	histologic	amod	2	SENT_179	[p11l65t2687r332b2751],
2	diagnosis	NN	O	diagnosis	_	0	SENT_179	[p11l350t2687r600b2751],
3	—	CD	NUMBER	—	num	4	SENT_179	[p11l618t2717r683b2722],
4	no.	NN	O	no.	dep	2	SENT_179	[p11l703t2704r779b2736],
5	(	CD	PERCENT	(	num	6	SENT_179	[p11l806t2690r892b2751],
6	%	NN	PERCENT	%	dep	4	SENT_179	[p11l806t2690r892b2751],
7	)	CD	NUMBER	)	dep	2	SENT_179	[p11l806t2690r892b2751],

1	Adenocarcinoma	NN	O	adenocarcinoma	dep	11	SENT_180	[p11l155t2798r603b2847],
2	103	CD	NUMBER	103	num	1	SENT_180	[p11l1133t2801r1218b2847],
3	(	CD	NUMBER	(	number	4	SENT_180	[p11l1246t2801r1390b2861],
4	90.4	CD	NUMBER	90.4	dep	1	SENT_180	[p11l1246t2801r1390b2861],
5	)	NN	O	)	dep	4	SENT_180	[p11l1246t2801r1390b2861],
6	110	CD	NUMBER	110	num	5	SENT_180	[p11l1671t2801r1760b2847],
7	(	NN	O	(	dep	11	SENT_180	[p11l1784t2802r1928b2861],
8	96.5	CD	NUMBER	96.5	num	7	SENT_180	[p11l1784t2802r1928b2861],
9	)	CD	NUMBER	)	num	11	SENT_180	[p11l1784t2802r1928b2861],
10	Large-cell	JJ	MISC	large-cell	amod	11	SENT_180	[p11l161t2909r403b2973],
11	carcinoma	NN	O	carcinoma	dep	21	SENT_180	[p11l426t2914r699b2958],
12	1	CD	NUMBER	1	dep	11	SENT_180	[p11l1197t2914r1219b2957],
13	(	CD	NUMBER	(	number	14	SENT_180	[p11l1246t2913r1358b2973],
14	0.9	CD	NUMBER	0.9	num	18	SENT_180	[p11l1246t2913r1358b2973],
15	)	NN	O	)	nn	18	SENT_180	[p11l1246t2913r1358b2973],
16	o	NN	O	o	nn	18	SENT_180	[p11l1730t2913r1759b2958],
17	Adenosquamous	JJ	MISC	adenosquamous	amod	18	SENT_180	[p11l155t3021r603b3083],
18	carcinoma	NN	O	carcinoma	dep	12	SENT_180	[p11l623t3025r897b3069],
19	2	CD	NUMBER	2	number	20	SENT_180	[p11l1194t3025r1220b3068],
20	(	CD	NUMBER	(	num	18	SENT_180	[p11l1246t3024r1358b3084],
21	1.8	CD	NUMBER	1.8	dep	22	SENT_180	[p11l1246t3024r1358b3084],
22	)	NN	O	)	dep	24	SENT_180	[p11l1246t3024r1358b3084],
23	1	CD	NUMBER	1	num	22	SENT_180	[p11l1736t3025r1756b3068],
24	(	NN	O	(	dep	28	SENT_180	[p11l1784t3024r1895b3084],
25	0.9	CD	NUMBER	0.9	num	24	SENT_180	[p11l1784t3024r1895b3084],
26	)	CD	NUMBER	)	num	28	SENT_180	[p11l1784t3024r1895b3084],
27	Squamous-cell	JJ	O	squamous-cell	amod	28	SENT_180	[p11l158t3132r542b3194],
28	carcinoma	NN	O	carcinoma	dep	32	SENT_180	[p11l564t3136r838b3180],
29	3	CD	NUMBER	3	num	30	SENT_180	[p11l1194t3135r1218b3179],
30	(	NN	O	(	dep	28	SENT_180	[p11l1246t3135r1358b3195],
31	2.6	CD	NUMBER	2.6	num	32	SENT_180	[p11l1246t3135r1358b3195],
32	)	NN	O	)	dep	39	SENT_180	[p11l1246t3135r1358b3195],
33	2	CD	NUMBER	2	number	34	SENT_180	[p11l1732t3136r1758b3179],
34	(	CD	NUMBER	(	num	36	SENT_180	[p11l1784t3134r1895b3195],
35	1.8	CD	NUMBER	1.8	number	36	SENT_180	[p11l1784t3134r1895b3195],
36	)	CD	NUMBER	)	dep	32	SENT_180	[p11l1784t3134r1895b3195],
37	Other	JJ	O	other	amod	38	SENT_180	[p11l158t3242r310b3291],
38	5	CD	NUMBER	5	dep	36	SENT_180	[p11l1194t3247r1218b3291],
39	(	NN	O	(	dep	41	SENT_180	[p11l1246t3246r1358b3306],
40	4.4	CD	NUMBER	4.4	num	39	SENT_180	[p11l1246t3246r1358b3306],
41	)	NN	O	)	dep	43	SENT_180	[p11l1246t3246r1358b3306],
42	1	CD	NUMBER	1	num	41	SENT_180	[p11l1735t3247r1756b3290],
43	(	CD	NUMBER	(	dep	45	SENT_180	[p11l1784t3246r1895b3306],
44	0.9	CD	NUMBER	0.9	num	45	SENT_180	[p11l1784t3246r1895b3306],
45	)	NN	O	)	_	0	SENT_180	[p11l1784t3246r1895b3306],

1	Clinical	JJ	O	clinical	amod	2	SENT_181	[p11l61t3353r249b3402],
2	stage	NN	O	stage	_	0	SENT_181	[p11l272t3363r408b3417],
3	—	CD	NUMBER	—	num	4	SENT_181	[p11l425t3383r490b3388],
4	no.	NN	O	no.	dep	2	SENT_181	[p11l510t3370r585b3402],
5	(	CD	PERCENT	(	num	6	SENT_181	[p11l613t3356r698b3417],
6	%	NN	PERCENT	%	dep	4	SENT_181	[p11l613t3356r698b3417],
7	)	CD	NUMBER	)	dep	2	SENT_181	[p11l613t3356r698b3417],

1	IIIB	NN	ORGANIZATION	iiib	nn	3	SENT_182	[p11l161t3469r247b3512],
2	15	CD	NUMBER	15	num	3	SENT_182	[p11l1165t3469r1218b3513],
3	(	NN	O	(	dep	12	SENT_182	[p11l1246t3469r1390b3528],
4	13.2	CD	NUMBER	13.2	number	5	SENT_182	[p11l1246t3469r1390b3528],
5	)	CD	NUMBER	)	dep	3	SENT_182	[p11l1246t3469r1390b3528],
6	21	CD	NUMBER	21	num	7	SENT_182	[p11l1700t3469r1756b3512],
7	(	NN	O	(	dep	5	SENT_182	[p11l1784t3468r1928b3528],
8	13.4	CD	NUMBER	13.4	num	9	SENT_182	[p11l1784t3468r1928b3528],
9	)	NN	O	)	dep	12	SENT_182	[p11l1784t3468r1928b3528],
10	IV	CD	NUMBER	iv	num	12	SENT_182	[p11l161t3580r211b3624],
11	88	CD	NUMBER	88	num	12	SENT_182	[p11l1162t3579r1221b3624],
12	(	NN	O	(	dep	22	SENT_182	[p11l1246t3580r1390b3639],
13	77.2	CD	NUMBER	77.2	number	14	SENT_182	[p11l1246t3580r1390b3639],
14	)	CD	NUMBER	)	dep	12	SENT_182	[p11l1246t3580r1390b3639],
15	84	CD	NUMBER	84	num	16	SENT_182	[p11l1700t3579r1758b3624],
16	(	NN	O	(	dep	14	SENT_182	[p11l1784t3580r1928b3639],
17	73.7	CD	NUMBER	73.7	number	18	SENT_182	[p11l1784t3580r1928b3639],
18	)	CD	NUMBER	)	num	20	SENT_182	[p11l1784t3580r1928b3639],
19	Postoperative	JJ	O	postoperative	amod	20	SENT_182	[p11l161t3691r517b3749],
20	relapse	NN	O	relapse	dep	14	SENT_182	[p11l539t3687r723b3749],
21	11	CD	NUMBER	11	num	22	SENT_182	[p11l1165t3691r1219b3734],
22	(	NN	O	(	dep	28	SENT_182	[p11l1246t3691r1358b3750],
23	9.6	CD	NUMBER	9.6	number	24	SENT_182	[p11l1246t3691r1358b3750],
24	)	CD	NUMBER	)	dep	22	SENT_182	[p11l1246t3691r1358b3750],
25	9	CD	NUMBER	9	num	26	SENT_182	[p11l1732t3691r1758b3735],
26	(	NN	O	(	dep	24	SENT_182	[p11l1784t3691r1895b3750],
27	7.9	CD	NUMBER	7.9	num	28	SENT_182	[p11l1784t3691r1895b3750],
28	)	NN	O	)	_	0	SENT_182	[p11l1784t3691r1895b3750],

1	Tvnn	NNP	O	Tvnn	nn	2	SENT_183	[p11l59t3802r182b3834],
2	n1	NN	O	n1	_	0	SENT_183	[p11l201t3797r413b3834],
3	‘	SYM	O	‘	dep	2	SENT_183	[p11l201t3797r413b3834],
4	-	:	O	-	_	0	SENT_183	[p11l201t3797r413b3834],
5	FCFP	NN	O	fcfp	nn	6	SENT_183	[p11l201t3797r413b3834],
6	rnilfafinn	NN	O	rnilfafinn	dep	2	SENT_183	[p11l437t3802r672b3834],
7	:	:	O	:	_	0	SENT_183	[p11l691t3827r756b3832],
8	nn	NN	O	nn	nn	10	SENT_183	[p11l776t3815r837b3834],
9	(	NN	O	(	nn	10	SENT_183	[p11l879t3800r964b3834],
10	o	NN	O	o	dep	6	SENT_183	[p11l879t3800r964b3834],
11	/	:	O	/	punct	12	SENT_183	[p11l879t3800r964b3834],
12	\	CD	NUMBER	\	dep	10	SENT_183	[p11l879t3800r964b3834],
13	\	IN	O	\	dep	12	SENT_183	[p11l879t3800r964b3834],

1	I	PRP	O	I	_	0	SENT_184	[p12l73t6r181b33],
2	,	,	O	,	_	0	SENT_184	[p12l73t6r181b33],
3	rJ	NNP	O	rJ	nn	4	SENT_184	[p12l73t6r181b33],
4	\	NNP	O	\	appos	1	SENT_184	[p12l73t6r181b33],
5	.	.	O	.	_	0	SENT_184	[p12l73t6r181b33],

1	p	NN	O	p	nn	2	SENT_185	[p12l73t6r181b33],
2	\	NN	O	\	_	0	SENT_185	[p12l202t6r245b18],
3	II	CD	NUMBER	ii	dep	2	SENT_185	[p12l202t6r245b18],
4	I	PRP	O	I	nsubj	5	SENT_185	[p12l273t6r359b18],
5	_	VBP	O	_	rcmod	2	SENT_185	[p12l273t6r359b18],
6	\	CD	NUMBER	\	num	8	SENT_185	[p12l273t6r359b18],
7	JI	NNP	O	JI	nn	8	SENT_185	[p12l273t6r359b18],
8	l	NN	O	l	nsubj	10	SENT_185	[p12l386t6r415b17],
9	\	NN	O	\	nn	10	SENT_185	[p12l386t6r415b17],
10	IIIUII-v	NN	O	iiiuii-v	xcomp	5	SENT_185	[p12l437t6r672b18],
11	|	CD	NUMBER	|	num	12	SENT_185	[p12l437t6r672b18],
12	|	NN	O	|	dep	10	SENT_185	[p12l437t6r672b18],
13	.	.	O	.	_	0	SENT_185	[p12l437t6r672b18],

1	I	PRP	O	I	nsubj	2	SENT_186	[p12l437t6r672b18],
2	\	VBP	O	\	_	0	SENT_186	[p12l437t6r672b18],
3	.	.	O	.	_	0	SENT_186	[p12l437t6r672b18],

1	III	NNP	O	III	nn	3	SENT_187	[p12l437t6r672b18],
2	II	NNP	O	II	nn	3	SENT_187	[p12l776t6r852b18],
3	\	NNP	O	\	_	0	SENT_187	[p12l776t6r852b18],
4	.	.	O	.	_	0	SENT_187	[p12l776t6r852b18],

1	lo	FW	O	lo	nn	2	SENT_188	[p12l776t6r852b18],
2	\	FW	O	\	_	0	SENT_188	[p12l879t6r964b33],
3	/	:	O	/	punct	4	SENT_188	[p12l879t6r964b33],
4	VI	NNP	O	VI	dep	2	SENT_188	[p12l879t6r964b33],

1	Exon	NN	O	exon	dep	16	SENT_189	[p12l161t85r279b129],
2	19	CD	NUMBER	19	num	1	SENT_189	[p12l305t85r361b129],
3	deletion	NN	O	deletion	dep	1	SENT_189	[p12l381t81r588b129],
4	58	CD	NUMBER	58	num	3	SENT_189	[p12l1163t84r1221b129],
5	(	CD	NUMBER	(	number	6	SENT_189	[p12l1246t84r1390b144],
6	50.9	CD	NUMBER	50.9	num	7	SENT_189	[p12l1246t84r1390b144],
7	)	NN	O	)	dep	3	SENT_189	[p12l1246t84r1390b144],
8	59	CD	NUMBER	59	number	9	SENT_189	[p12l1700t85r1758b129],
9	(	CD	NUMBER	(	dep	3	SENT_189	[p12l1784t84r1928b144],
10	51.8	CD	NUMBER	51.8	num	11	SENT_189	[p12l1784t84r1928b144],
11	)	NN	O	)	dep	9	SENT_189	[p12l1784t84r1928b144],
12	L858R	NN	O	l858r	dep	16	SENT_189	[p12l161t195r318b240],
13	49	CD	NUMBER	49	num	12	SENT_189	[p12l1161t196r1221b240],
14	(	CD	NUMBER	(	num	16	SENT_189	[p12l1246t195r1390b255],
15	43.0	CD	NUMBER	43.0	num	16	SENT_189	[p12l1246t195r1390b255],
16	)	NN	O	)	dep	25	SENT_189	[p12l1246t195r1390b255],
17	48	CD	NUMBER	48	number	18	SENT_189	[p12l1698t195r1758b240],
18	(	CD	NUMBER	(	num	20	SENT_189	[p12l1784t196r1928b255],
19	42.1	CD	NUMBER	42.1	number	20	SENT_189	[p12l1784t196r1928b255],
20	)	CD	NUMBER	)	dep	16	SENT_189	[p12l1784t196r1928b255],
21	Other	JJ	O	other	amod	23	SENT_189	[p12l158t303r310b351],
22	7	CD	NUMBER	7	number	23	SENT_189	[p12l1196t307r1221b351],
23	(	CD	NUMBER	(	dep	20	SENT_189	[p12l1246t307r1358b366],
24	6.1	CD	NUMBER	6.1	num	25	SENT_189	[p12l1246t307r1358b366],
25	)	NN	O	)	dep	27	SENT_189	[p12l1246t307r1358b366],
26	7	CD	NUMBER	7	num	27	SENT_189	[p12l1734t307r1759b351],
27	(	NN	O	(	dep	29	SENT_189	[p12l1784t307r1895b366],
28	6.1	CD	NUMBER	6.1	num	29	SENT_189	[p12l1784t307r1895b366],
29	)	NN	O	)	_	0	SENT_189	[p12l1784t307r1895b366],

1	*	NN	O	*	nn	2	SENT_190	[p12l9t471r38b498],
2	P	NN	O	p	nsubj	3	SENT_190	[p12l62t466r367b515],
3	|	VBD	O	|	_	0	SENT_190	[p12l62t466r367b515],
4	us	PRP	O	we	dobj	3	SENT_190	[p12l62t466r367b515],
5	—	RB	O	—	advmod	3	SENT_190	[p12l62t466r367b515],
6	minus	CC	O	minus	prep	3	SENT_190	[p12l62t466r367b515],
7	values	NNS	O	value	dep	6	SENT_190	[p12l389t466r553b515],
8	are	VBP	O	be	cop	9	SENT_190	[p12l577t483r654b515],
9	means	NNS	O	means	rcmod	7	SENT_190	[p12l679t483r849b515],
10	:	:	O	:	_	0	SENT_190	[p12l873t470r998b515],
11	SD	NN	O	sd	dep	9	SENT_190	[p12l873t470r998b515],
12	.	.	O	.	_	0	SENT_190	[p12l873t470r998b515],

1	ECOG	NN	ORGANIZATION	ecog	nsubj	2	SENT_191	[p12l1026t470r1182b515],
2	denotes	VBZ	O	denote	_	0	SENT_191	[p12l1208t466r1414b515],
3	Eastern	NNP	ORGANIZATION	Eastern	nn	6	SENT_191	[p12l1442t471r1631b515],
4	Cooperative	NNP	ORGANIZATION	Cooperative	nn	6	SENT_191	[p12l1657t470r1970b529],
5	Oncology	NNP	ORGANIZATION	Oncology	nn	6	SENT_191	[p12l58t539r310b603],
6	Group	NNP	ORGANIZATION	Group	dobj	2	SENT_191	[p12l331t543r511b602],
7	.	.	O	.	_	0	SENT_191	[p12l331t543r511b602],

1	P	NN	O	p	_	0	SENT_192	[p12l563t744r834b808],
2	<	JJR	O	<	dep	1	SENT_192	[p12l563t744r834b808],
3	0.001	CD	NUMBER	0.001	dep	2	SENT_192	[p12l563t744r834b808],
4	)	NN	O	)	nn	6	SENT_192	[p12l563t744r834b808],
5	(	CD	NUMBER	(	num	6	SENT_192	[p12l871t740r1067b808],
6	Table	NNP	O	Table	dep	1	SENT_192	[p12l871t740r1067b808],
7	2	CD	NUMBER	2	number	8	SENT_192	[p12l1097t744r1172b808],
8	)	CD	NUMBER	)	dep	6	SENT_192	[p12l1097t744r1172b808],
9	.	.	O	.	_	0	SENT_192	[p12l1097t744r1172b808],

1	The	DT	O	the	det	4	SENT_193	[p12l1202t740r1322b798],
2	median	JJ	O	median	amod	4	SENT_193	[p12l1350t740r1592b799],
3	progression-free	JJ	O	progression-free	amod	4	SENT_193	[p12l1619t739r2148b815],
4	survival	NN	O	survival	nsubj	10	SENT_193	[p12l565t835r812b894],
5	and	CC	O	and	_	0	SENT_193	[p12l840t835r958b894],
6	response	NN	O	response	nn	7	SENT_193	[p12l986t854r1271b909],
7	rate	NN	O	rate	nsubj	10	SENT_193	[p12l1299t847r1419b893],
8	did	VBD	O	do	aux	10	SENT_193	[p12l1448t835r1548b894],
9	not	RB	O	not	neg	10	SENT_193	[p12l1577t847r1684b894],
10	differ	VB	O	differ	_	0	SENT_193	[p12l1709t834r1888b894],
11	significantly	RB	O	significantly	advmod	10	SENT_193	[p12l1916t834r2147b910, p12l564t930r758b1004],
12	between	IN	O	between	_	0	SENT_193	[p12l780t930r1047b989],
13	patients	NNS	O	patient	prep_between	10	SENT_193	[p12l1072t931r1327b1004],
14	with	IN	O	with	_	0	SENT_193	[p12l1351t930r1497b989],
15	the	DT	O	the	det	17	SENT_193	[p12l1523t930r1622b988],
16	EGFR	NN	ORGANIZATION	egfr	nn	17	SENT_193	[p12l1647t934r1837b992],
17	mutation	NN	O	mutation	prep_with	13	SENT_193	[p12l1855t931r2148b989],
18	consisting	VBG	O	consist	partmod	17	SENT_193	[p12l564t1026r883b1100],
19	of	IN	O	of	_	0	SENT_193	[p12l901t1024r974b1084],
20	an	DT	O	a	det	23	SENT_193	[p12l981t1044r1056b1083],
21	exon	NN	O	exon	nn	23	SENT_193	[p12l1077t1044r1221b1084],
22	19	CD	NUMBER	19	num	23	SENT_193	[p12l1244t1029r1314b1084],
23	deletion	NN	O	deletion	prep_of	18	SENT_193	[p12l1336t1025r1582b1084],
24	(	CD	NUMBER	(	number	25	SENT_193	[p12l1606t1029r1750b1093],
25	11.5	CD	DURATION	11.5	num	26	SENT_193	[p12l1606t1029r1750b1093],
26	months	NNS	NUMBER	month	tmod	23	SENT_193	[p12l1773t1025r2009b1084],
27	and	CC	O	and	_	0	SENT_193	[p12l2031t1025r2149b1084],
28	82.8	CD	PERCENT	82.8	num	29	SENT_193	[p12l564t1124r780b1188],
29	%	NN	PERCENT	%	prep_of	18	SENT_193	[p12l564t1124r780b1188],
30	)	CD	NUMBER	)	dep	29	SENT_193	[p12l564t1124r780b1188],
31	and	CC	O	and	_	0	SENT_193	[p12l808t1120r926b1179],
32	those	DT	O	those	prep_of	18	SENT_193	[p12l951t1120r1124b1179],
33	with	IN	O	with	_	0	SENT_193	[p12l1144t1120r1290b1179],
34	the	DT	O	the	det	38	SENT_193	[p12l1315t1120r1414b1178],
35	L858R	NN	O	l858r	nn	38	SENT_193	[p12l1438t1124r1647b1182],
36	point	NN	O	point	nn	38	SENT_193	[p12l1662t1121r1834b1194],
37	mutation	NN	O	mutation	nn	38	SENT_193	[p12l1855t1121r2148b1179],
38	(	NN	O	(	prep_with	32	SENT_193	[p12l567t1216r650b1283],
39	in	IN	O	in	_	0	SENT_193	[p12l567t1216r650b1283],
40	which	WDT	O	which	rel	47	SENT_193	[p12l668t1215r864b1274],
41	leucine	NN	O	leucine	nsubjpass	47	SENT_193	[p12l885t1215r1111b1274],
42	at	IN	O	at	_	0	SENT_193	[p12l1132t1227r1191b1273],
43	amino	NN	O	amino	nn	44	SENT_193	[p12l1208t1216r1413b1274],
44	acid	NN	O	acid	prep_at	41	SENT_193	[p12l1436t1215r1563b1274],
45	858	CD	NUMBER	858	num	44	SENT_193	[p12l1585t1219r1695b1274],
46	is	VBZ	O	be	auxpass	47	SENT_193	[p12l1717t1216r1766b1273],
47	replaced	VBN	O	replace	rcmod	32	SENT_193	[p12l1789t1215r2057b1289],
48	by	IN	O	by	_	0	SENT_193	[p12l2079t1215r2152b1289],
49	arginine	NN	O	arginine	agent	47	SENT_193	[p12l563t1311r852b1385],
50	)	CD	NUMBER	)	num	49	SENT_193	[p12l563t1311r852b1385],
51	(	CD	NUMBER	(	number	52	SENT_193	[p12l886t1314r1036b1378],
52	10.8	CD	DURATION	10.8	num	53	SENT_193	[p12l886t1314r1036b1378],
53	months	NNS	NUMBER	month	tmod	49	SENT_193	[p12l1063t1310r1308b1369],
54	and	CC	O	and	_	0	SENT_193	[p12l1335t1310r1453b1369],
55	67.3	CD	PERCENT	67.3	num	56	SENT_193	[p12l1479t1314r1684b1378],
56	%	NN	PERCENT	%	agent	47	SENT_193	[p12l1479t1314r1684b1378],
57	)	CD	NUMBER	)	number	58	SENT_193	[p12l1479t1314r1684b1378],
58	(	CD	NUMBER	(	num	59	SENT_193	[p12l1717t1311r1853b1385],
59	Fig	NN	O	fig	dep	56	SENT_193	[p12l1717t1311r1853b1385],
60	.	.	O	.	_	0	SENT_193	[p12l1717t1311r1853b1385],

1	2B	NN	O	2b	_	0	SENT_194	[p12l1885t1314r2006b1378],
2	)	NN	O	)	dep	1	SENT_194	[p12l1885t1314r2006b1378],
3	.	.	O	.	_	0	SENT_194	[p12l1885t1314r2006b1378],

1	The	DT	O	the	det	3	SENT_195	[p12l657t1405r776b1463],
2	overall	JJ	O	overall	amod	3	SENT_195	[p12l801t1405r1009b1464],
3	survival	NN	O	survival	nsubj	6	SENT_195	[p12l1035t1405r1277b1464],
4	did	VBD	O	do	aux	6	SENT_195	[p12l1302t1405r1401b1464],
5	not	RB	O	not	neg	6	SENT_195	[p12l1426t1417r1531b1464],
6	differ	VB	O	differ	_	0	SENT_195	[p12l1553t1404r1728b1464],
7	significantly	RB	O	significantly	advmod	6	SENT_195	[p12l1751t1404r2152b1480],
8	between	IN	O	between	_	0	SENT_195	[p12l564t1500r831b1559],
9	the	DT	O	the	det	12	SENT_195	[p12l862t1500r961b1558],
10	two	CD	NUMBER	two	num	12	SENT_195	[p12l992t1512r1110b1559],
11	treatment	NN	O	treatment	nn	12	SENT_195	[p12l1142t1512r1459b1558],
12	groups	NNS	O	group	prep_between	6	SENT_195	[p12l1485t1519r1724b1575],
13	.	.	O	.	_	0	SENT_195	[p12l1485t1519r1724b1575],

1	The	DT	O	the	det	4	SENT_196	[p12l1756t1500r1876b1558],
2	median	JJ	O	median	amod	4	SENT_196	[p12l1907t1500r2148b1559],
3	survival	NN	O	survival	nn	4	SENT_196	[p12l565t1595r812b1654],
4	time	NN	O	time	nsubj	12	SENT_196	[p12l851t1596r995b1653],
5	and	CC	O	and	_	0	SENT_196	[p12l1033t1595r1151b1654],
6	the	DT	O	the	det	9	SENT_196	[p12l1190t1595r1289b1653],
7	2-year	JJ	DURATION	2-year	amod	9	SENT_196	[p12l1327t1599r1519b1669],
8	survival	NN	O	survival	nn	9	SENT_196	[p12l1557t1595r1805b1654],
9	rate	NN	O	rate	conj_and	4	SENT_196	[p12l1843t1607r1962b1653],
10	were	VBD	O	be	cop	12	SENT_196	[p12l1998t1614r2148b1654],
11	30.5	CD	DURATION	30.5	num	12	SENT_196	[p12l564t1694r694b1749],
12	months	NNS	NUMBER	month	_	0	SENT_196	[p12l728t1690r972b1749],
13	and	CC	O	and	_	0	SENT_196	[p12l1005t1690r1123b1749],
14	61.4	CD	PERCENT	61.4	num	15	SENT_196	[p12l1154t1694r1346b1749],
15	%	NN	PERCENT	%	conj_and	12	SENT_196	[p12l1154t1694r1346b1749],
16	for	IN	O	for	_	0	SENT_196	[p12l1377t1689r1469b1749],
17	the	DT	O	the	det	19	SENT_196	[p12l1499t1690r1598b1748],
18	gefitinib	JJ	O	gefitinib	amod	19	SENT_196	[p12l1629t1689r1907b1765],
19	group	NN	O	group	prep_for	15	SENT_196	[p12l1939t1709r2144b1765],
20	,	,	O	,	_	0	SENT_196	[p12l1939t1709r2144b1765],
21	as	IN	O	as	_	0	SENT_196	[p12l563t1804r627b1843],
22	compared	VBN	O	compare	prepc_as	12	SENT_196	[p12l666t1785r984b1859],
23	with	IN	O	with	_	0	SENT_196	[p12l1017t1785r1163b1844],
24	23.6	CD	DURATION	23.6	num	25	SENT_196	[p12l1199t1789r1333b1844],
25	months	NNS	NUMBER	month	prep_with	22	SENT_196	[p12l1370t1785r1614b1844],
26	and	CC	O	and	_	0	SENT_196	[p12l1652t1785r1770b1844],
27	46.7	CD	PERCENT	46.7	num	28	SENT_196	[p12l1805t1789r2022b1856],
28	%	NN	PERCENT	%	prep_with	22	SENT_196	[p12l1805t1789r2022b1856],
29	,	,	O	,	_	0	SENT_196	[p12l1805t1789r2022b1856],
30	respectively	RB	O	respectively	advmod	22	SENT_196	[p12l2063t1804r2147b1843, p12l565t1880r884b1954],
31	,	,	O	,	_	0	SENT_196	[p12l2063t1804r2147b1843, p12l565t1880r884b1954],
32	for	IN	O	for	_	0	SENT_196	[p12l929t1879r1021b1939],
33	the	DT	O	the	det	37	SENT_196	[p12l1060t1880r1159b1938],
34	carboplatin	NN	O	carboplatin	nn	37	SENT_196	[p12l1201t1880r1918b1954],
35	—	NN	O	—	nn	37	SENT_196	[p12l1201t1880r1918b1954],
36	paclitaxel	NN	O	paclitaxel	nn	37	SENT_196	[p12l1201t1880r1918b1954],
37	group	NN	O	group	prep_for	12	SENT_196	[p12l1959t1899r2147b1955],

1	(	NN	O	(	nn	2	SENT_197	[p12l17t2154r385b2239],
2	P	NN	O	p	nsubj	3	SENT_197	[p12l17t2154r385b2239],
3	=	JJ	O	=	_	0	SENT_197	[p12l17t2154r385b2239],
4	O.	NNP	O	O.	iobj	3	SENT_197	[p12l17t2154r385b2239],
5	31	CD	NUMBER	31	num	4	SENT_197	[p12l17t2154r385b2239],
6	)	CD	NUMBER	)	num	8	SENT_197	[p12l17t2154r385b2239],
7	(	CD	NUMBER	(	num	8	SENT_197	[p12l430t2149r613b2249],
8	Fig	NN	O	fig	dobj	3	SENT_197	[p12l430t2149r613b2249],
9	.	.	O	.	_	0	SENT_197	[p12l430t2149r613b2249],

1	2C	NN	O	2c	_	0	SENT_198	[p12l656t2154r822b2239],
2	)	NN	O	)	dep	1	SENT_198	[p12l656t2154r822b2239],
3	.	.	O	.	_	0	SENT_198	[p12l656t2154r822b2239],

1	Neither	DT	O	neither	det	2	SENT_199	[p12l861t2148r1185b2227],
2	sex	NN	O	sex	nsubj	6	SENT_199	[p12l1219t2174r1354b2226],
3	nor	CC	O	nor	_	0	SENT_199	[p12l1386t2174r1532b2227],
4	clinical	JJ	O	clinical	amod	5	SENT_199	[p12l1565t2148r1878b2226],
5	stage	NN	O	stage	conj_nor	2	SENT_199	[p12l1914t2165r2134b2249],
6	had	VBD	O	have	_	0	SENT_199	[p12l12t2276r171b2355],
7	a	DT	O	a	det	9	SENT_199	[p12l208t2302r252b2354],
8	significant	JJ	O	significant	amod	9	SENT_199	[p12l291t2275r772b2377],
9	effect	NN	O	effect	dobj	6	SENT_199	[p12l805t2275r1053b2354],
10	on	IN	O	on	_	0	SENT_199	[p12l1088t2302r1195b2355],
11	overall	JJ	O	overall	amod	12	SENT_199	[p12l1233t2276r1527b2355],
12	survival	NN	O	survival	prep_on	9	SENT_199	[p12l1566t2276r1930b2355],
13	.	.	O	.	_	0	SENT_199	[p12l1566t2276r1930b2355],

1	The	DT	O	the	det	2	SENT_200	[p12l1971t2276r2134b2354],
2	time	NN	O	time	nsubj	15	SENT_200	[p12l12t2404r199b2481],
3	to	TO	O	to	_	0	SENT_200	[p12l231t2420r310b2482],
4	an	DT	O	a	det	8	SENT_200	[p12l344t2429r444b2481],
5	ECOG	NN	O	ecog	nn	8	SENT_200	[p12l475t2409r735b2482],
6	performance	NN	O	performance	nn	8	SENT_200	[p12l767t2402r1301b2503],
7	status	NN	O	status	nn	8	SENT_200	[p12l1334t2420r1575b2483],
8	score	NN	TIME	score	prep_to	2	SENT_200	[p12l1611t2429r1823b2482],
9	of	IN	TIME	of	_	0	SENT_200	[p12l1856t2402r1954b2482],
10	3	CD	TIME	3	prep_of	8	SENT_200	[p12l1969t2409r2012b2482],
11	or	CC	O	or	_	0	SENT_200	[p12l2049t2429r2137b2482],
12	more	JJR	O	more	conj_or	10	SENT_200	[p12l12t2558r228b2611],
13	did	VBD	O	do	aux	15	SENT_200	[p12l262t2532r395b2611],
14	not	RB	O	not	neg	15	SENT_200	[p12l429t2549r569b2611],
15	differ	VB	O	differ	_	0	SENT_200	[p12l599t2531r833b2611],
16	significantly	RB	O	significantly	advmod	15	SENT_200	[p12l865t2531r1395b2633],
17	between	IN	O	between	_	0	SENT_200	[p12l1425t2532r1777b2611],
18	the	DT	O	the	det	20	SENT_200	[p12l1810t2532r1941b2610],
19	two	CD	NUMBER	two	num	20	SENT_200	[p12l1975t2549r2133b2611],
20	groups	NNS	O	group	prep_between	15	SENT_200	[p12l12t2659r332b2734],
21	.	.	O	.	_	0	SENT_200	[p12l12t2659r332b2734],

1	SAFETY	NN	O	safety	nsubjpass	16	SENT_201	[p12l12t2908r297b2958],
2	All	DT	O	all	det	3	SENT_201	[p12l8t3006r133b3084],
3	patients	NNS	O	patient	dep	1	SENT_201	[p12l163t3007r504b3106],
4	who	WP	O	who	nsubj	6	SENT_201	[p12l533t3006r716b3086],
5	had	VBD	O	have	aux	6	SENT_201	[p12l749t3006r905b3085],
6	received	VBN	O	receive	rcmod	1	SENT_201	[p12l937t3006r1282b3086],
7	at	IN	O	at	quantmod	9	SENT_201	[p12l1312t3023r1391b3084],
8	least	JJS	O	least	mwe	7	SENT_201	[p12l1417t3006r1616b3084],
9	one	CD	NUMBER	one	num	10	SENT_201	[p12l1643t3032r1794b3085],
10	dose	NN	O	dose	dobj	6	SENT_201	[p12l1827t3006r2021b3085],
11	of	IN	O	of	_	0	SENT_201	[p12l2053t3005r2152b3085],
12	a	DT	O	a	det	14	SENT_201	[p12l11t3161r56b3213],
13	study	NN	O	study	nn	14	SENT_201	[p12l87t3135r317b3235],
14	drug	NN	O	drug	prep_of	10	SENT_201	[p12l345t3135r549b3236],
15	were	VBD	O	be	auxpass	16	SENT_201	[p12l573t3161r774b3214],
16	included	VBN	O	include	_	0	SENT_201	[p12l805t3135r1172b3214],
17	in	IN	O	in	_	0	SENT_201	[p12l1203t3136r1286b3213],
18	the	DT	O	the	det	20	SENT_201	[p12l1319t3135r1451b3213],
19	safety	NN	O	safety	nn	20	SENT_201	[p12l1485t3134r1738b3235],
20	analysis	NN	O	analysis	prep_in	16	SENT_201	[p12l1764t3135r2128b3235],
21	.	.	O	.	_	0	SENT_201	[p12l1764t3135r2128b3235],

1	The	DT	O	the	det	5	SENT_202	[p12l8t3263r169b3341],
2	most	RBS	O	most	advmod	3	SENT_202	[p12l198t3280r414b3342],
3	common	JJ	O	common	amod	5	SENT_202	[p12l439t3289r820b3342],
4	adverse	JJ	O	adverse	amod	5	SENT_202	[p12l849t3263r1163b3342],
5	events	NNS	O	event	nsubj	14	SENT_202	[p12l1193t3280r1457b3342],
6	in	IN	O	in	_	0	SENT_202	[p12l1487t3264r1570b3341],
7	the	DT	O	the	det	9	SENT_202	[p12l1600t3263r1732b3341],
8	gefitinib	JJ	O	gefitinib	amod	9	SENT_202	[p12l1761t3262r2133b3364],
9	group	NN	O	group	prep_in	5	SENT_202	[p12l12t3417r264b3492],
10	were	VBD	O	be	cop	14	SENT_202	[p12l301t3417r502b3470],
11	rash	JJ	O	rash	amod	14	SENT_202	[p12l543t3391r725b3469],
12	and	CC	O	and	_	0	SENT_202	[p12l765t3391r923b3470],
13	elevated	JJ	O	elevated	conj_and	11	SENT_202	[p12l963t3391r1305b3470],
14	levels	NNS	O	level	_	0	SENT_202	[p12l1344t3391r1574b3470],
15	of	IN	O	of	_	0	SENT_202	[p12l1618t3390r1717b3470],
16	aspartate	NN	O	aspartate	nn	17	SENT_202	[p12l1739t3408r2133b3491],
17	aminotransferase	NN	O	aminotransferase	prep_of	14	SENT_202	[p12l11t3517r736b3597],
18	or	CC	O	or	_	0	SENT_202	[p12l763t3544r848b3597],
19	alanine	NN	O	alanine	nn	20	SENT_202	[p12l871t3518r1175b3596],
20	aminotransferase	NN	O	aminotransferase	prep_of	14	SENT_202	[p12l1200t3517r1946b3614],
21	,	,	O	,	_	0	SENT_202	[p12l1200t3517r1946b3614],
22	and	CC	O	and	_	0	SENT_202	[p12l1976t3518r2134b3597],
23	in	IN	O	in	conj_and	14	SENT_202	[p12l11t3648r95b3725],
24	the	DT	O	the	det	26	SENT_202	[p12l123t3647r255b3726],
25	chemotherapy	NN	O	chemotherapy	nn	26	SENT_202	[p12l284t3647r896b3747],
26	group	NN	O	group	pobj	23	SENT_202	[p12l919t3673r1193b3748],
27	,	,	O	,	_	0	SENT_202	[p12l919t3673r1193b3748],
28	appetite	NN	O	appetite	nn	29	SENT_202	[p12l1226t3648r1568b3747],
29	loss	NN	O	loss	appos	26	SENT_202	[p12l1596t3647r1784b3743],
30	,	,	O	,	_	0	SENT_202	[p12l1596t3647r1784b3743],
31	neutropenia	NN	O	neutropenia	appos	29	SENT_202	[p12l1818t3664r2133b3726, p13l11t21r270b119],
32	,	,	O	,	_	0	SENT_202	[p12l1818t3664r2133b3726, p13l11t21r270b119],

1	anemia	NN	O	anemia	nsubj	5	SENT_203	[p13l309t21r647b115],
2	,	,	O	,	_	0	SENT_203	[p13l309t21r647b115],
3	and	CC	O	and	dep	5	SENT_203	[p13l685t20r843b98],
4	sensory	JJ	O	sensory	amod	5	SENT_203	[p13l878t46r1207b119],
5	neuropathy	NN	O	neuropathy	_	0	SENT_203	[p13l1236t20r1726b119],
6	(	CD	NUMBER	(	num	7	SENT_203	[p13l1760t20r2022b110],
7	Table	NNP	O	Table	dep	5	SENT_203	[p13l1760t20r2022b110],
8	3	CD	NUMBER	3	num	7	SENT_203	[p13l2059t26r2129b115],
9	,	,	O	,	_	0	SENT_203	[p13l2059t26r2129b115],
10	and	CC	O	and	_	0	SENT_203	[p13l11t148r169b226],
11	Table	NNP	O	Table	conj_and	5	SENT_203	[p13l199t148r433b226],
12	3	CD	NUMBER	3	num	11	SENT_203	[p13l470t154r514b227],
13	in	IN	O	in	_	0	SENT_203	[p13l551t149r634b225],
14	the	DT	O	the	det	17	SENT_203	[p13l669t148r801b226],
15	Supplementary	NNP	O	Supplementary	nn	17	SENT_203	[p13l837t148r1484b247],
16	Appendix	NNP	O	Appendix	nn	17	SENT_203	[p13l1509t148r1975b247],
17	)	NN	O	)	prep_in	5	SENT_203	[p13l1509t148r1975b247],
18	.	.	O	.	_	0	SENT_203	[p13l1509t148r1975b247],

1	Interstitial	JJ	O	interstitial	amod	3	SENT_204	[p13l2013t155r2133b225, p13l12t276r375b355],
2	lung	NN	O	lung	nn	3	SENT_204	[p13l401t276r594b377],
3	disease	NN	O	disease	nsubjpass	5	SENT_204	[p13l619t276r929b355],
4	was	VBD	O	be	auxpass	5	SENT_204	[p13l952t302r1115b355],
5	reported	VBN	O	report	_	0	SENT_204	[p13l1144t276r1511b376],
6	in	IN	O	in	_	0	SENT_204	[p13l1537t277r1621b354],
7	six	CD	NUMBER	six	num	8	SENT_204	[p13l1649t277r1767b354],
8	patients	NNS	O	patient	prep_in	5	SENT_204	[p13l1790t277r2131b376],
9	(	IN	O	(	_	0	SENT_204	[p13l17t410r283b495],
10	5.3	CD	PERCENT	5.3	number	11	SENT_204	[p13l17t410r283b495],
11	%	NN	PERCENT	%	amod	12	SENT_204	[p13l17t410r283b495],
12	)	CD	NUMBER	)	prep_(	5	SENT_204	[p13l17t410r283b495],
13	in	IN	O	in	_	0	SENT_204	[p13l332t405r416b482],
14	the	DT	O	the	det	16	SENT_204	[p13l460t404r594b482],
15	gefitinib	JJ	O	gefitinib	amod	16	SENT_204	[p13l638t403r1018b505],
16	group	NN	O	group	prep_in	12	SENT_204	[p13l1063t430r1345b505],
17	;	:	O	;	_	0	SENT_204	[p13l1063t430r1345b505],
18	three	CD	NUMBER	three	num	19	SENT_204	[p13l1393t404r1617b482],
19	cases	NNS	O	case	nsubj	21	SENT_204	[p13l1662t430r1888b482],
20	were	VBD	O	be	cop	21	SENT_204	[p13l1929t430r2134b483],
21	severe	JJ	O	severe	parataxis	5	SENT_204	[p13l13t558r281b628],
22	,	,	O	,	_	0	SENT_204	[p13l13t558r281b628],
23	and	CC	O	and	_	0	SENT_204	[p13l318t532r471b611],
24	one	CD	NUMBER	one	nsubj	29	SENT_204	[p13l503t558r651b611],
25	of	IN	O	of	_	0	SENT_204	[p13l683t531r781b611],
26	the	DT	O	the	det	27	SENT_204	[p13l795t532r923b610],
27	three	CD	NUMBER	three	prep_of	24	SENT_204	[p13l955t532r1166b611],
28	was	VBD	O	be	cop	29	SENT_204	[p13l1193t558r1351b611],
29	fatal	JJ	O	fatal	parataxis	5	SENT_204	[p13l1386t531r1588b611],
30	.	.	O	.	_	0	SENT_204	[p13l1386t531r1588b611],

1	One	CD	NUMBER	one	num	2	SENT_205	[p13l1626t538r1793b611],
2	grade	NN	O	grade	nsubjpass	26	SENT_205	[p13l1824t532r2054b633],
3	4	CD	NUMBER	4	num	4	SENT_205	[p13l2085t538r2134b611],
4	seizure	NN	O	seizure	dep	2	SENT_205	[p13l13t661r304b739],
5	in	IN	O	in	_	0	SENT_205	[p13l330t661r411b738],
6	the	DT	O	the	det	8	SENT_205	[p13l438t660r566b738],
7	gefitinib	JJ	O	gefitinib	amod	8	SENT_205	[p13l592t659r946b761],
8	group	NN	O	group	prep_in	4	SENT_205	[p13l974t686r1217b761],
9	and	CC	O	and	_	0	SENT_205	[p13l1245t660r1398b739],
10	one	CD	NUMBER	one	num	11	SENT_205	[p13l1425t686r1572b739],
11	grade	NN	O	grade	nsubjpass	26	SENT_205	[p13l1597t660r1827b761],
12	4	CD	NUMBER	4	num	14	SENT_205	[p13l1852t667r1902b739],
13	cerebral	JJ	O	cerebral	amod	14	SENT_205	[p13l1929t686r2133b738, p13l12t788r176b867],
14	infarction	NN	O	infarction	dep	11	SENT_205	[p13l205t787r623b867],
15	and	CC	O	and	_	0	SENT_205	[p13l653t788r809b867],
16	one	CD	NUMBER	one	num	17	SENT_205	[p13l840t814r989b867],
17	grade	NN	O	grade	conj_and	2	SENT_205	[p13l1019t788r1254b889],
18	4	CD	NUMBER	4	num	20	SENT_205	[p13l1283t795r1333b867],
19	bowel	NN	O	bowel	nn	20	SENT_205	[p13l1364t788r1613b867],
20	obstruction	NN	O	obstruction	dep	17	SENT_205	[p13l1644t788r2134b867],
21	in	IN	O	in	_	0	SENT_205	[p13l11t917r95b994],
22	the	DT	O	the	det	24	SENT_205	[p13l142t916r275b994],
23	chemotherapy	NN	O	chemotherapy	nn	24	SENT_205	[p13l324t916r934b1016],
24	group	NN	O	group	prep_in	20	SENT_205	[p13l977t942r1230b1017],
25	were	VBD	O	be	auxpass	26	SENT_205	[p13l1274t942r1475b995],
26	observed	VBN	O	observe	_	0	SENT_205	[p13l1524t916r1928b995],
27	.	.	O	.	_	0	SENT_205	[p13l1524t916r1928b995],

1	The	DT	O	the	det	2	SENT_206	[p13l1976t916r2134b994],
2	incidence	NN	O	incidence	nsubj	7	SENT_206	[p13l11t1044r412b1123],
3	of	IN	O	of	_	0	SENT_206	[p13l464t1043r562b1123],
4	severe	JJ	O	severe	amod	6	SENT_206	[p13l591t1070r838b1123],
5	toxic	JJ	O	toxic	amod	6	SENT_206	[p13l885t1045r1083b1123],
6	effects	NNS	O	effect	prep_of	2	SENT_206	[p13l1129t1043r1398b1122],
7	(	VBP	O	(	_	0	SENT_206	[p13l1451t1050r1855b1135],
8	NCI	NN	ORGANIZATION	ncus	dobj	7	SENT_206	[p13l1451t1050r1855b1135],
9	.	.	O	.	_	0	SENT_206	[p13l1451t1050r1855b1135],

1	—	NN	O	—	_	0	SENT_207	[p13l1451t1050r1855b1135],
2	.	.	O	.	_	0	SENT_207	[p13l1451t1050r1855b1135],

1	CTC	NNP	ORGANIZATION	CTC	nn	2	SENT_208	[p13l1451t1050r1855b1135],
2	grade	NN	O	grade	nsubj	7	SENT_208	[p13l1903t1044r2133b1145],
3	23	CD	NUMBER	23	num	4	SENT_208	[p13l11t1178r139b1263],
4	)	NN	O	)	dep	2	SENT_208	[p13l11t1178r139b1263],
5	was	VBD	O	be	cop	7	SENT_208	[p13l176t1198r334b1251],
6	significantly	RB	O	significantly	advmod	7	SENT_208	[p13l373t1171r907b1273],
7	higher	JJR	O	higher	_	0	SENT_208	[p13l941t1172r1216b1273],
8	in	IN	O	in	_	0	SENT_208	[p13l1250t1173r1332b1250],
9	the	DT	O	the	det	11	SENT_208	[p13l1370t1172r1501b1250],
10	chemotherapy	NN	O	chemotherapy	nn	11	SENT_208	[p13l1540t1172r2139b1272],
11	group	NN	O	group	prep_in	7	SENT_208	[p13l12t1326r264b1401],
12	than	IN	O	than	advmod	7	SENT_208	[p13l327t1300r523b1378],
13	in	IN	O	in	_	0	SENT_208	[p13l582t1301r666b1378],
14	the	DT	O	the	det	16	SENT_208	[p13l727t1300r860b1378],
15	gefitinib	NN	O	gefitinib	nn	16	SENT_208	[p13l920t1299r1292b1401],
16	group	NN	O	group	prep_in	12	SENT_208	[p13l1353t1326r1605b1401],
17	(	CD	PERCENT	(	num	19	SENT_208	[p13l1672t1306r1964b1391],
18	71.7	CD	PERCENT	71.7	num	19	SENT_208	[p13l1672t1306r1964b1391],
19	%	NN	PERCENT	%	attr	7	SENT_208	[p13l1672t1306r1964b1391],
20	vs.	CC	O	vs.	_	0	SENT_208	[p13l2020t1326r2129b1379],
21	41.2	CD	NUMBER	41.2	number	22	SENT_208	[p13l11t1433r298b1523],
22	°	CD	NUMBER	°	amod	27	SENT_208	[p13l11t1433r298b1523],
23	/	:	O	/	punct	24	SENT_208	[p13l11t1433r298b1523],
24	o	NN	O	o	dep	22	SENT_208	[p13l11t1433r298b1523],
25	,	,	O	,	_	0	SENT_208	[p13l11t1433r298b1523],
26	P	NN	O	p	appos	24	SENT_208	[p13l335t1434r715b1518],
27	<	JJR	O	<	attr	7	SENT_208	[p13l335t1434r715b1518],
28	0.001	CD	NUMBER	0.001	num	29	SENT_208	[p13l335t1434r715b1518],
29	)	NN	O	)	dep	27	SENT_208	[p13l335t1434r715b1518],
30	.	.	O	.	_	0	SENT_208	[p13l335t1434r715b1518],

1	TREATMENT	NN	O	treatment	nsubjpass	16	SENT_209	[p13l9t1703r479b1751],
2	AFTER	IN	O	after	_	0	SENT_209	[p13l509t1703r748b1751],
3	PROTOCOL	NN	O	protocol	nn	5	SENT_209	[p13l787t1702r1213b1752],
4	DISCONTINUATION	NNP	O	DISCONTINUATION	nn	5	SENT_209	[p13l1250t1702r2009b1752],
5	Data	NNP	O	Data	prep_after	1	SENT_209	[p13l11t1808r211b1879],
6	on	IN	O	on	_	0	SENT_209	[p13l247t1827r353b1880],
7	treatment	NN	O	treatment	prep_on	5	SENT_209	[p13l390t1818r813b1879],
8	given	VBN	O	give	partmod	7	SENT_209	[p13l844t1802r1071b1902],
9	after	IN	O	after	mark	14	SENT_209	[p13l1107t1800r1309b1879],
10	the	DT	O	the	det	12	SENT_209	[p13l1343t1801r1475b1879],
11	study	NN	O	study	nn	12	SENT_209	[p13l1514t1801r1743b1901],
12	protocol	NN	O	protocol	nsubjpass	14	SENT_209	[p13l1774t1801r2135b1901],
13	Was	VBD	O	be	auxpass	14	SENT_209	[p13l7t1955r170b2008],
14	discontinued	VBN	O	discontinue	advcl	8	SENT_209	[p13l217t1929r776b2008],
15	were	VBD	O	be	auxpass	16	SENT_209	[p13l816t1955r1018b2008],
16	collected	VBN	O	collect	_	0	SENT_209	[p13l1063t1929r1443b2007],
17	retrospectively	RB	O	retrospectively	advmod	16	SENT_209	[p13l1487t1929r2129b2028],
18	.	.	O	.	_	0	SENT_209	[p13l1487t1929r2129b2028],

1	Though	IN	O	though	mark	5	SENT_210	[p13l8t2057r345b2158],
2	any	DT	O	any	det	3	SENT_210	[p13l380t2083r530b2157],
3	treatment	NN	O	treatment	nsubjpass	5	SENT_210	[p13l560t2074r984b2135],
4	was	VBD	O	be	auxpass	5	SENT_210	[p13l1010t2083r1172b2136],
5	permitted	VBN	O	permit	advcl	11	SENT_210	[p13l1209t2057r1658b2157],
6	,	,	O	,	_	0	SENT_210	[p13l1209t2057r1658b2157],
7	the	DT	O	the	det	10	SENT_210	[p13l1699t2057r1832b2135],
8	proto	NN	O	proto	nn	10	SENT_210	[p13l1867t2074r2133b2157],
9	—	NN	O	—	nn	10	SENT_210	[p13l1867t2074r2133b2157],
10	col	NN	O	col	nsubj	11	SENT_210	[p13l12t2185r135b2264],
11	recommended	VBD	O	recommend	_	0	SENT_210	[p13l172t2185r789b2264],
12	that	IN	O	that	complm	17	SENT_210	[p13l827t2185r999b2263],
13	the	DT	O	the	det	15	SENT_210	[p13l1032t2185r1165b2263],
14	crossover	NN	O	crossover	nn	15	SENT_210	[p13l1204t2211r1608b2264],
15	regimen	NN	O	regimen	nsubjpass	17	SENT_210	[p13l1643t2186r1999b2286],
16	be	VB	O	be	auxpass	17	SENT_210	[p13l2037t2185r2134b2264],
17	used	VBN	O	use	ccomp	11	SENT_210	[p13l12t2313r208b2392],
18	as	IN	O	as	_	0	SENT_210	[p13l238t2339r323b2391],
19	second-line	JJ	O	second-line	amod	20	SENT_210	[p13l356t2313r846b2392],
20	treatment	NN	O	treatment	prep_as	17	SENT_210	[p13l877t2330r1321b2392],
21	.	.	O	.	_	0	SENT_210	[p13l877t2330r1321b2392],

1	As	IN	O	as	_	0	SENT_211	[p13l1352t2321r1458b2391],
2	of	IN	O	of	prepc_as_of	15	SENT_211	[p13l1491t2312r1591b2392],
3	the	DT	O	the	det	6	SENT_211	[p13l1602t2313r1735b2391],
4	data	NNS	O	datum	nn	6	SENT_211	[p13l1766t2313r1949b2392],
5	cutoff	NN	O	cutoff	nn	6	SENT_211	[p13l1978t2330r2133b2392, p13l12t2440r152b2520],
6	point	NN	O	point	pobj	15	SENT_211	[p13l167t2442r423b2541],
7	,	,	O	,	_	0	SENT_211	[p13l167t2442r423b2541],
8	37	CD	NUMBER	37	num	9	SENT_211	[p13l464t2447r561b2520],
9	patients	NNS	O	patient	nsubj	15	SENT_211	[p13l595t2442r944b2541],
10	in	IN	O	in	_	0	SENT_211	[p13l979t2442r1064b2519],
11	the	DT	O	the	det	13	SENT_211	[p13l1098t2441r1234b2519],
12	gefitinib	JJ	O	gefitinib	amod	13	SENT_211	[p13l1268t2440r1648b2542],
13	group	NN	O	group	prep_in	9	SENT_211	[p13l1684t2467r1940b2542],
14	had	VBD	O	have	aux	15	SENT_211	[p13l1975t2441r2134b2520],
15	continued	VBN	O	continue	_	0	SENT_211	[p13l12t2569r433b2648],
16	their	PRP$	O	they	poss	21	SENT_211	[p13l461t2569r661b2647],
17	first	JJ	ORDINAL	first	amod	21	SENT_211	[p13l685t2568r1045b2647],
18	—	NN	O	—	nn	21	SENT_211	[p13l685t2568r1045b2647],
19	line	NN	O	line	nn	21	SENT_211	[p13l685t2568r1045b2647],
20	gefitinib	NN	O	gefitinib	nn	21	SENT_211	[p13l1072t2568r1436b2670],
21	therapy	NN	O	therapy	dobj	15	SENT_211	[p13l1465t2569r1792b2669],
22	.	.	O	.	_	0	SENT_211	[p13l1465t2569r1792b2669],

1	Among	IN	O	among	_	0	SENT_212	[p13l1822t2577r2138b2670],
2	the	DT	O	the	det	5	SENT_212	[p13l12t2697r145b2775],
3	remaining	VBG	O	remain	amod	5	SENT_212	[p13l186t2698r638b2798],
4	77	CD	NUMBER	77	num	5	SENT_212	[p13l676t2705r775b2776],
5	patients	NNS	O	patient	prep_among	22	SENT_212	[p13l816t2698r1157b2797],
6	in	IN	O	in	_	0	SENT_212	[p13l1199t2698r1283b2775],
7	the	DT	O	the	det	9	SENT_212	[p13l1324t2697r1456b2775],
8	gefitinb	JJ	O	gefitinb	amod	9	SENT_212	[p13l1497t2696r1839b2798],
9	group	NN	O	group	prep_in	5	SENT_212	[p13l1880t2723r2133b2798],
10	who	WP	O	who	nsubj	12	SENT_212	[p13l7t2825r190b2904],
11	had	VBD	O	have	aux	12	SENT_212	[p13l234t2825r390b2904],
12	stopped	VBN	O	stop	rcmod	9	SENT_212	[p13l434t2825r772b2925],
13	receiving	VBG	O	receive	xcomp	12	SENT_212	[p13l813t2826r1203b2926],
14	gefitinib	NN	O	gefitinib	dobj	13	SENT_212	[p13l1242t2824r1636b2926],
15	,	,	O	,	_	0	SENT_212	[p13l1242t2824r1636b2926],
16	52	CD	PERCENT	52	number	17	SENT_212	[p13l1685t2831r1780b2904],
17	(	CD	PERCENT	(	nsubj	22	SENT_212	[p13l1828t2830r2129b2916],
18	67.5	CD	PERCENT	67.5	num	19	SENT_212	[p13l1828t2830r2129b2916],
19	%	NN	PERCENT	%	dep	17	SENT_212	[p13l1828t2830r2129b2916],
20	)	CD	NUMBER	)	dep	17	SENT_212	[p13l1828t2830r2129b2916],
21	were	VBD	O	be	aux	22	SENT_212	[p13l7t2979r209b3032],
22	receiving	VBG	O	receive	_	0	SENT_212	[p13l249t2954r639b3054],
23	carboplatin	NN	O	carboplatin	nn	25	SENT_212	[p13l677t2953r1638b3053],
24	—	NN	O	—	nn	25	SENT_212	[p13l677t2953r1638b3053],
25	paclitaxel	NN	O	paclitaxel	dobj	22	SENT_212	[p13l677t2953r1638b3053],
26	as	IN	O	as	_	0	SENT_212	[p13l1676t2979r1761b3031],
27	secondline	NN	O	secondline	nn	28	SENT_212	[p13l1805t2953r2133b3032, p13l11t3080r170b3158],
28	treatment	NN	O	treatment	prep_as	25	SENT_212	[p13l222t3097r666b3176],
29	,	,	O	,	_	0	SENT_212	[p13l222t3097r666b3176],
30	with	IN	O	with	_	0	SENT_212	[p13l719t3080r914b3160],
31	a	DT	O	a	det	33	SENT_212	[p13l965t3106r1009b3158],
32	response	NN	O	response	nn	33	SENT_212	[p13l1059t3106r1439b3180],
33	rate	NN	O	rate	prep_with	22	SENT_212	[p13l1491t3097r1651b3158],
34	of	IN	O	of	_	0	SENT_212	[p13l1703t3079r1803b3159],
35	28.8	CD	NUMBER	28.8	number	36	SENT_212	[p13l1836t3085r2129b3160],
36	°	CD	NUMBER	°	prep_of	33	SENT_212	[p13l1836t3085r2129b3160],
37	/	:	O	/	punct	38	SENT_212	[p13l1836t3085r2129b3160],
38	o.	VB	O	o.	parataxis	22	SENT_212	[p13l1836t3085r2129b3160],
39	Sixteen	CD	NUMBER	sixteen	num	41	SENT_212	[p13l14t3210r322b3288],
40	other	JJ	O	other	amod	41	SENT_212	[p13l352t3209r580b3288],
41	patients	NNS	O	patient	nsubj	47	SENT_212	[p13l604t3210r946b3309],
42	in	IN	O	in	_	0	SENT_212	[p13l977t3210r1060b3287],
43	the	DT	O	the	det	45	SENT_212	[p13l1089t3209r1222b3287],
44	gefitinib	JJ	O	gefitinib	amod	45	SENT_212	[p13l1251t3208r1623b3310],
45	group	NN	O	group	prep_in	41	SENT_212	[p13l1654t3235r1906b3310],
46	were	VBD	O	be	aux	47	SENT_212	[p13l1932t3235r2134b3288],
47	receiving	VBG	O	receive	ccomp	38	SENT_212	[p13l12t3338r402b3438],
48	other	JJ	O	other	amod	49	SENT_212	[p13l457t3337r684b3416],
49	therapies	NNS	O	therapy	dobj	47	SENT_212	[p13l740t3337r1129b3437],
50	such	JJ	O	such	_	0	SENT_212	[p13l1191t3337r1385b3416],
51	as	IN	O	as	_	0	SENT_212	[p13l1441t3363r1527b3415],
52	carboplatingemcitabine	NN	O	carboplatingemcitabine	prep_such_as	49	SENT_212	[p13l1588t3337r2137b3437, p13l12t3465r561b3566],
53	.	.	O	.	_	0	SENT_212	[p13l1588t3337r2137b3437, p13l12t3465r561b3566],

1	Among	IN	O	among	_	0	SENT_213	[p13l611t3473r931b3566],
2	the	DT	O	the	det	4	SENT_213	[p13l977t3465r1109b3544],
3	112	CD	NUMBER	112	num	4	SENT_213	[p13l1161t3471r1310b3543],
4	patients	NNS	O	patient	pobj	1	SENT_213	[p13l1359t3466r1700b3565],
5	who	WP	O	who	nsubj	7	SENT_213	[p13l1746t3465r1929b3544],
6	had	VBD	O	have	aux	7	SENT_213	[p13l1978t3465r2134b3544],
7	completed	VBN	O	complete	rcmod	4	SENT_213	[p13l12t3592r457b3692],
8	first	RB	ORDINAL	first	advmod	11	SENT_213	[p13l512t3591r883b3670],
9	—	CD	NUMBER	—	num	11	SENT_213	[p13l512t3591r883b3670],
10	line	NN	O	line	nn	11	SENT_213	[p13l512t3591r883b3670],
11	carboplatin	NN	O	carboplatin	dobj	7	SENT_213	[p13l939t3592r1922b3692],
12	—	CD	NUMBER	—	num	13	SENT_213	[p13l939t3592r1922b3692],
13	paclitaxel	NN	O	paclitaxel	dep	11	SENT_213	[p13l939t3592r1922b3692],
14	,	,	O	,	_	0	SENT_213	[p13l939t3592r1922b3692],
15	106	CD	NUMBER	106	appos	11	SENT_213	[p13l1987t3598r2133b3671],

1	patients	NNS	O	patient	nsubj	6	SENT_214	[p14l11t23r352b122],
2	(	CD	PERCENT	(	number	3	SENT_214	[p14l413t28r728b113],
3	94.6	CD	PERCENT	94.6	num	4	SENT_214	[p14l413t28r728b113],
4	%	NN	PERCENT	%	dep	1	SENT_214	[p14l413t28r728b113],
5	)	CD	NUMBER	)	dep	1	SENT_214	[p14l413t28r728b113],
6	received	VBD	O	receive	_	0	SENT_214	[p14l788t22r1133b101],
7	second	JJ	ORDINAL	second	amod	10	SENT_214	[p14l1190t22r1679b101],
8	—	NN	O	—	nn	10	SENT_214	[p14l1190t22r1679b101],
9	line	NN	O	line	nn	10	SENT_214	[p14l1190t22r1679b101],
10	gefitinib	NN	O	gefitinib	dobj	6	SENT_214	[p14l1734t21r2130b123],
11	;	:	O	;	_	0	SENT_214	[p14l1734t21r2130b123],
12	58.5	CD	PERCENT	58.5	num	13	SENT_214	[p14l14t155r276b229],
13	%	NN	PERCENT	%	nsubj	17	SENT_214	[p14l14t155r276b229],
14	of	IN	O	of	_	0	SENT_214	[p14l310t148r411b228],
15	these	DT	O	these	det	16	SENT_214	[p14l427t149r651b227],
16	patients	NNS	O	patient	prep_of	13	SENT_214	[p14l684t150r1025b249],
17	had	VBD	O	have	parataxis	6	SENT_214	[p14l1062t149r1218b228],
18	a	DT	O	a	det	19	SENT_214	[p14l1252t175r1296b227],
19	response	NN	O	response	dobj	17	SENT_214	[p14l1329t175r1733b249],
20	.	.	O	.	_	0	SENT_214	[p14l1329t175r1733b249],

1	DISCUSSION	NN	O	discussion	_	0	SENT_215	[p14l734t446r1412b505],

1	Previous	JJ	O	previous	amod	2	SENT_216	[p14l11t664r380b742],
2	phase	NN	O	phase	nsubj	6	SENT_216	[p14l438t663r691b763],
3	2	CD	NUMBER	2	num	4	SENT_216	[p14l748t669r795b741],
4	studies	NNS	O	study	dep	2	SENT_216	[p14l854t663r1160b742],
5	have	VBP	O	have	aux	6	SENT_216	[p14l1219t663r1412b742],
6	suggested	VBN	O	suggest	_	0	SENT_216	[p14l1471t663r1906b764],
7	that	IN	O	that	complm	14	SENT_216	[p14l1964t663r2139b741],
8	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_216	[p14l11t797r266b874],
9	tyrosine	NN	O	tyrosine	nn	11	SENT_216	[p14l288t792r634b891],
10	kinase	NN	O	kinase	nn	11	SENT_216	[p14l667t791r946b870],
11	inhibitors	NNS	O	inhibitor	nsubj	14	SENT_216	[p14l978t791r1399b870],
12	are	VBP	O	be	cop	14	SENT_216	[p14l1433t817r1562b869],
13	highly	RB	O	highly	advmod	14	SENT_216	[p14l1595t791r1867b892],
14	effective	JJ	O	effective	ccomp	6	SENT_216	[p14l1896t790r2133b869, p14l12t920r159b998],
15	against	IN	O	against	_	0	SENT_216	[p14l209t920r525b1020],
16	mutated	VBN	O	mutate	prepc_against	14	SENT_216	[p14l570t919r1213b1002],
17	.	.	O	.	_	0	SENT_216	[p14l570t919r1213b1002],

1	—	NN	O	—	_	0	SENT_217	[p14l570t919r1213b1002],
2	.	.	O	.	_	0	SENT_217	[p14l570t919r1213b1002],

1	EGFR	NN	ORGANIZATION	egfr	_	0	SENT_218	[p14l570t919r1213b1002],
2	non	JJ	O	non	amod	1	SENT_218	[p14l1253t919r1895b998],
3	—	CD	NUMBER	—	num	8	SENT_218	[p14l1253t919r1895b998],
4	small	JJ	O	small	amod	8	SENT_218	[p14l1253t919r1895b998],
5	—	JJ	O	—	amod	8	SENT_218	[p14l1253t919r1895b998],
6	cell	NN	O	cell	nn	8	SENT_218	[p14l1253t919r1895b998],
7	lung	NN	O	lung	nn	8	SENT_218	[p14l1944t919r2137b1020],
8	cancer	NN	O	cancer	dep	1	SENT_218	[p14l12t1073r305b1125],
9	.	.	O	.	_	0	SENT_218	[p14l12t1073r305b1125],

1	The	DT	O	the	det	3	SENT_219	[p14l336t1047r495b1125],
2	current	JJ	DATE	current	amod	3	SENT_219	[p14l525t1064r833b1126],
3	phase	NN	O	phase	nsubj	10	SENT_219	[p14l856t1047r1100b1146],
4	3	CD	NUMBER	3	dep	3	SENT_219	[p14l1130t1053r1199b1142],
5	,	,	O	,	_	0	SENT_219	[p14l1130t1053r1199b1142],
6	prospective	JJ	O	prospective	amod	9	SENT_219	[p14l1232t1048r1733b1146],
7	,	,	O	,	_	0	SENT_219	[p14l1232t1048r1733b1146],
8	randomized	JJ	O	randomized	amod	9	SENT_219	[p14l1767t1047r2133b1125, p14l11t1175r185b1254],
9	study	NN	O	study	appos	3	SENT_219	[p14l217t1175r443b1275],
10	showed	VBD	O	show	_	0	SENT_219	[p14l471t1175r788b1254],
11	that	IN	O	that	complm	20	SENT_219	[p14l819t1175r988b1253],
12	the	DT	O	the	det	13	SENT_219	[p14l1014t1175r1145b1253],
13	use	NN	O	use	nsubj	20	SENT_219	[p14l1175t1201r1314b1254],
14	of	IN	O	of	_	0	SENT_219	[p14l1346t1174r1444b1254],
15	gefitinib	JJ	O	gefitinib	amod	16	SENT_219	[p14l1456t1174r1819b1276],
16	results	NNS	O	result	prep_of	13	SENT_219	[p14l1851t1175r2132b1254],
17	in	IN	O	in	_	0	SENT_219	[p14l11t1304r95b1381],
18	progression	NN	O	progression	prep_in	16	SENT_219	[p14l131t1302r839b1404],
19	—	CD	NUMBER	—	num	18	SENT_219	[p14l131t1302r839b1404],
20	free	JJ	O	free	ccomp	10	SENT_219	[p14l131t1302r839b1404],
21	survival	NN	O	survival	dobj	20	SENT_219	[p14l879t1303r1210b1382],
22	that	WDT	O	that	nsubj	26	SENT_219	[p14l1248t1303r1420b1381],
23	is	VBZ	O	be	cop	26	SENT_219	[p14l1452t1304r1518b1381],
24	twice	RB	O	twice	advmod	26	SENT_219	[p14l1558t1304r1785b1382],
25	as	RB	O	as	advmod	26	SENT_219	[p14l1822t1329r1907b1381],
26	long	JJ	O	long	rcmod	21	SENT_219	[p14l1947t1303r2138b1404],

1	2384	CD	DATE	2384	num	4	SENT_220	[p14l149t1462r226b1485],
2	N	NN	O	n	nn	4	SENT_220	[p14l963t1472r977b1487],
3	ENGLJ	NN	O	englj	nn	4	SENT_220	[p14l991t1472r1069b1494],
4	MED	NN	O	med	_	0	SENT_220	[p14l1084t1472r1136b1487],
5	362	CD	NUMBER	362	dep	4	SENT_220	[p14l1146t1466r1225b1494],
6	;	:	O	;	_	0	SENT_220	[p14l1146t1466r1225b1494],
7	25	CD	NUMBER	25	num	9	SENT_220	[p14l1146t1466r1225b1494],
8	NEJM.ORG	NN	O	nejm.org	nn	9	SENT_220	[p14l1260t1472r1384b1494],
9	JUNE	NN	DATE	june	dep	5	SENT_220	[p14l1415t1472r1479b1494],
10	24	CD	DATE	24	dep	9	SENT_220	[p14l1490t1472r1526b1494],
11	,	,	DATE	,	_	0	SENT_220	[p14l1490t1472r1526b1494],
12	2010	CD	DATE	2010	appos	10	SENT_220	[p14l1537t1472r1597b1488],

1	The	DT	O	the	det	4	SENT_221	[p14l936t1505r987b1529],
2	New	NNP	O	New	nn	4	SENT_221	[p14l996t1506r1058b1529],
3	England	NNP	O	England	nn	4	SENT_221	[p14l1067t1505r1178b1536],
4	Journal	NNP	O	Journal	_	0	SENT_221	[p14l1187t1505r1284b1529],
5	of	IN	O	of	_	0	SENT_221	[p14l1294t1505r1323b1529],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_221	[p14l1330t1505r1455b1529],

1	Copyright	NN	O	copyright	_	0	SENT_222	[p14l729t1587r863b1618],
2	©	CD	NUMBER	©	num	6	SENT_222	[p14l872t1587r896b1611],
3	2010	CD	DATE	2010	num	6	SENT_222	[p14l906t1587r971b1611],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_222	[p14l980t1587r1171b1611],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_222	[p14l1181t1587r1289b1611],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_222	[p14l1300t1587r1405b1618],
7	.	.	O	.	_	0	SENT_222	[p14l1300t1587r1405b1618],

1	All	DT	O	all	det	2	SENT_223	[p14l1416t1587r1457b1611],
2	rights	NNS	O	rights	nsubj	3	SENT_223	[p14l1466t1587r1541b1618],
3	reserved	VBN	O	reserve	_	0	SENT_223	[p14l1551t1587r1669b1611],
4	.	.	O	.	_	0	SENT_223	[p14l1551t1587r1669b1611],

1	GEFITINIB	NNP	O	GEFITINIB	nn	3	SENT_224	[p14l495t1693r671b1712],
2	OR	NN	O	or	nn	3	SENT_224	[p14l685t1693r730b1712],
3	CHEMOTHERAPY	NNP	O	CHEMOTHERAPY	_	0	SENT_224	[p14l742t1693r1019b1712],
4	FOR	IN	O	for	_	0	SENT_224	[p14l1032t1693r1096b1712],
5	NON	NNP	O	NON	prep_for	3	SENT_224	[p14l1109t1693r1412b1712],
6	.	.	O	.	_	0	SENT_224	[p14l1109t1693r1412b1712],

1	—	NN	O	—	_	0	SENT_225	[p14l1109t1693r1412b1712],
2	.	.	O	.	_	0	SENT_225	[p14l1109t1693r1412b1712],

1	SMALL-CELL	NN	O	small-cell	nn	2	SENT_226	[p14l1109t1693r1412b1712],
2	LUNG	NN	O	lung	_	0	SENT_226	[p14l1426t1693r1517b1712],
3	CANCER	NNP	O	CANCER	dep	2	SENT_226	[p14l1531t1693r1665b1712],

1	Figure	NN	O	figure	_	0	SENT_227	[p14l83t1976r301b2059],
2	2	CD	NUMBER	2	dep	1	SENT_227	[p14l328t1981r390b2039],
3	.	.	O	.	_	0	SENT_227	[p14l328t1981r390b2039],

1	Progression-free	JJ	O	progression-free	amod	2	SENT_228	[p14l425t1973r1008b2059],
2	Survival	NN	O	survival	_	0	SENT_228	[p14l1035t1974r1317b2039],
3	and	CC	O	and	_	0	SENT_228	[p14l1348t1974r1475b2039],
4	Overall	JJ	O	overall	amod	5	SENT_228	[p14l1506t1974r1759b2039],
5	Survival	NN	O	survival	conj_and	2	SENT_228	[p14l1789t1974r2071b2039],
6	among	IN	O	among	_	0	SENT_228	[p14l79t2103r325b2166],
7	the	DT	O	the	det	9	SENT_228	[p14l349t2082r462b2146],
8	Study	NNP	O	Study	nn	9	SENT_228	[p14l489t2082r691b2167],
9	Patients	NNPS	O	Patients	prep_among	2	SENT_228	[p14l722t2084r1027b2146],
10	.	.	O	.	_	0	SENT_228	[p14l722t2084r1027b2146],

1	Kaplan	NNP	PERSON	Kaplan	_	0	SENT_229	[p14l85t2211r585b2295],
2	.	.	O	.	_	0	SENT_229	[p14l85t2211r585b2295],

1	—	NN	O	—	_	0	SENT_230	[p14l85t2211r585b2295],
2	.	.	O	.	_	0	SENT_230	[p14l85t2211r585b2295],

1	Meier	NNP	PERSON	Meier	nn	2	SENT_231	[p14l85t2211r585b2295],
2	curves	NNS	O	curve	nsubjpass	7	SENT_231	[p14l612t2234r841b2275],
3	for	IN	O	for	_	0	SENT_231	[p14l871t2210r971b2275],
4	progression-free	JJ	O	progression-free	amod	5	SENT_231	[p14l1001t2210r1586b2296],
5	survival	NN	O	survival	prep_for	2	SENT_231	[p14l1617t2211r1885b2275],
6	are	VBP	O	be	auxpass	7	SENT_231	[p14l1920t2234r2024b2275],
7	shown	VBN	O	show	_	0	SENT_231	[p14l81t2319r308b2383],
8	for	IN	O	for	_	0	SENT_231	[p14l340t2317r439b2383],
9	the	DT	O	the	det	15	SENT_231	[p14l463t2319r575b2383],
10	progression	NN	O	progression	npadvmod	12	SENT_231	[p14l608t2317r1519b2404],
11	—	CD	NUMBER	—	num	10	SENT_231	[p14l608t2317r1519b2404],
12	free	JJ	O	free	amod	15	SENT_231	[p14l608t2317r1519b2404],
13	—	NN	O	—	nn	15	SENT_231	[p14l608t2317r1519b2404],
14	survival	NN	O	survival	nn	15	SENT_231	[p14l608t2317r1519b2404],
15	population	NN	O	population	prep_for	7	SENT_231	[p14l1556t2319r1937b2403],
16	(	CD	NUMBER	(	num	17	SENT_231	[p14l87t2426r301b2511],
17	Panel	NN	O	panel	dep	15	SENT_231	[p14l87t2426r301b2511],
18	A	DT	O	a	det	19	SENT_231	[p14l332t2430r403b2511],
19	)	NN	O	)	dep	17	SENT_231	[p14l332t2430r403b2511],
20	and	CC	O	and	_	0	SENT_231	[p14l441t2426r566b2491],
21	for	IN	O	for	_	0	SENT_231	[p14l598t2426r697b2491],
22	the	DT	O	the	det	24	SENT_231	[p14l721t2426r833b2491],
23	107	CD	NUMBER	107	num	24	SENT_231	[p14l867t2430r982b2491],
24	patients	NNS	O	patient	prep_for	7	SENT_231	[p14l1016t2432r1298b2510],
25	in	IN	O	in	_	0	SENT_231	[p14l1333t2432r1389b2489],
26	the	DT	O	the	det	28	SENT_231	[p14l1419t2426r1531b2491],
27	gefitinib	JJ	O	gefitinib	amod	28	SENT_231	[p14l1561t2426r1854b2511],
28	group	NN	O	group	prep_in	24	SENT_231	[p14l80t2556r287b2618],
29	with	IN	O	with	prep	7	SENT_231	[p14l314t2533r461b2598],
30	either	CC	O	either	dep	7	SENT_231	[p14l495t2533r701b2598],
31	ofthe	VB	O	ofthe	conj	7	SENT_231	[p14l727t2533r931b2598],
32	two	CD	NUMBER	two	num	35	SENT_231	[p14l958t2546r1088b2598],
33	most	RBS	O	most	advmod	34	SENT_231	[p14l1121t2546r1300b2598],
34	common	JJ	O	common	amod	35	SENT_231	[p14l1328t2556r1644b2598],
35	types	NNS	O	type	dobj	31	SENT_231	[p14l1675t2546r1863b2618],
36	of	IN	O	of	_	0	SENT_231	[p14l1895t2533r1972b2598],
37	epidermal	JJ	O	epidermal	amod	44	SENT_231	[p14l79t2641r435b2725],
38	growth	NN	O	growth	nn	44	SENT_231	[p14l470t2641r715b2726],
39	factor	NN	O	factor	nn	44	SENT_231	[p14l746t2640r956b2706],
40	receptor	NN	O	receptor	nn	44	SENT_231	[p14l987t2653r1282b2725],
41	(	CD	NUMBER	(	num	44	SENT_231	[p14l1316t2646r1558b2725],
42	EGFR	NN	ORGANIZATION	egfr	nn	44	SENT_231	[p14l1316t2646r1558b2725],
43	)	NN	O	)	nn	44	SENT_231	[p14l1316t2646r1558b2725],
44	mutation	NN	O	mutation	prep_of	35	SENT_231	[p14l1599t2647r1918b2706],
45	(	CD	NUMBER	(	num	48	SENT_231	[p14l87t2748r301b2833],
46	Panel	NN	O	panel	nn	48	SENT_231	[p14l87t2748r301b2833],
47	B	NN	O	b	nn	48	SENT_231	[p14l340t2754r426b2833],
48	)	NN	O	)	dep	44	SENT_231	[p14l340t2754r426b2833],
49	.	.	O	.	_	0	SENT_231	[p14l340t2754r426b2833],

1	Kaplan	NNP	PERSON	Kaplan	_	0	SENT_232	[p14l465t2748r964b2833],
2	.	.	O	.	_	0	SENT_232	[p14l465t2748r964b2833],

1	—	NN	O	—	_	0	SENT_233	[p14l465t2748r964b2833],
2	.	.	O	.	_	0	SENT_233	[p14l465t2748r964b2833],

1	Meier	NNP	PERSON	Meier	nn	2	SENT_234	[p14l465t2748r964b2833],
2	curves	NNS	O	curve	nsubjpass	11	SENT_234	[p14l991t2772r1221b2813],
3	for	IN	O	for	_	0	SENT_234	[p14l1251t2748r1348b2813],
4	overall	JJ	O	overall	amod	5	SENT_234	[p14l1374t2748r1598b2813],
5	survival	NN	O	survival	prep_for	2	SENT_234	[p14l1631t2748r1894b2813],
6	in	IN	O	in	_	0	SENT_234	[p14l1928t2755r1982b2812],
7	the	DT	O	the	det	9	SENT_234	[p14l77t2856r187b2920],
8	intention-to-treat	JJ	O	intention-to-treat	amod	9	SENT_234	[p14l217t2862r818b2920],
9	population	NN	O	population	prep_in	5	SENT_234	[p14l848t2856r1221b2940],
10	are	VBP	O	be	auxpass	11	SENT_234	[p14l1254t2879r1356b2920],
11	shown	VBN	O	show	dep	23	SENT_234	[p14l1386t2856r1609b2920],
12	in	IN	O	in	_	0	SENT_234	[p14l1644t2862r1698b2919],
13	Panel	NNP	O	Panel	nn	14	SENT_234	[p14l1736t2856r1916b2920],
14	C.	NNP	O	C.	prep_in	11	SENT_234	[p14l1949t2861r2016b2920],
15	In	IN	O	in	_	0	SENT_234	[p14l85t2969r142b3027],
16	Panels	NNPS	O	Panels	dep	17	SENT_234	[p14l181t2964r406b3028],
17	B	NN	O	b	prep_in	11	SENT_234	[p14l443t2969r480b3027],
18	and	CC	O	and	_	0	SENT_234	[p14l513t2964r638b3028],
19	C	NN	O	c	prep_in	11	SENT_234	[p14l671t2969r738b3040],
20	,	,	O	,	_	0	SENT_234	[p14l671t2969r738b3040],
21	tick	VB	O	tick	ccomp	11	SENT_234	[p14l769t2964r894b3028],
22	marks	NNS	O	mark	dobj	21	SENT_234	[p14l925t2964r1138b3028],
23	indicate	VBP	O	indicate	_	0	SENT_234	[p14l1173t2964r1450b3028],
24	patients	NNS	O	patient	dobj	23	SENT_234	[p14l1484t2969r1766b3048],
25	for	IN	O	for	_	0	SENT_234	[p14l1796t2963r1896b3028],
26	whom	WP	O	whom	dobj	29	SENT_234	[p14l77t3071r295b3136],
27	data	NNS	O	datum	nsubjpass	29	SENT_234	[p14l328t3071r479b3136],
28	were	VBD	O	be	auxpass	29	SENT_234	[p14l507t3094r674b3136],
29	censored	VBN	O	censor	prepc_for	23	SENT_234	[p14l703t3071r1025b3136],
30	at	IN	O	at	_	0	SENT_234	[p14l1059t3084r1122b3136],
31	the	DT	O	the	det	34	SENT_234	[p14l1147t3071r1259b3136],
32	data	NNS	O	datum	nn	34	SENT_234	[p14l1289t3071r1439b3136],
33	cutoff	NN	O	cutoff	nn	34	SENT_234	[p14l1470t3071r1688b3136],
34	point	NN	O	point	prep_at	29	SENT_234	[p14l1709t3077r1891b3155],
35	(	RB	O	(	advmod	36	SENT_234	[p14l87t3178r275b3263],
36	early	JJ	DATE	early	amod	34	SENT_234	[p14l87t3178r275b3263],
37	December	NNP	DATE	December	tmod	29	SENT_234	[p14l309t3178r675b3243],
38	2009	CD	DATE	2009	num	37	SENT_234	[p14l702t3183r923b3263],
39	)	CD	NUMBER	)	nsubj	23	SENT_234	[p14l702t3183r923b3263],
40	.	.	O	.	_	0	SENT_234	[p14l702t3183r923b3263],

1	as	IN	O	as	mark	3	SENT_235	[p14l11t3478r95b3529],
2	that	DT	O	that	nsubj	3	SENT_235	[p14l125t3452r294b3529],
3	obtained	VBN	O	obtain	_	0	SENT_235	[p14l317t3452r687b3530],
4	with	IN	O	with	_	0	SENT_235	[p14l710t3452r902b3531],
5	the	DT	O	the	det	6	SENT_235	[p14l930t3452r1061b3530],
6	use	NN	O	use	prep_with	3	SENT_235	[p14l1088t3478r1226b3531],
7	of	IN	O	of	_	0	SENT_235	[p14l1254t3451r1353b3530],
8	carboplatin	NN	O	carboplatin	nn	10	SENT_235	[p14l1363t3452r2132b3551],
9	—	NN	O	—	nn	10	SENT_235	[p14l1363t3452r2132b3551],
10	pacli	NN	O	paclus	prep_of	6	SENT_235	[p14l1363t3452r2132b3551],
11	—	CD	NUMBER	—	num	12	SENT_235	[p14l1363t3452r2132b3551],
12	taxel	NN	O	taxel	dep	10	SENT_235	[p14l12t3581r215b3659],
13	in	IN	O	in	_	0	SENT_235	[p14l249t3582r333b3658],
14	patients	NNS	O	patient	prep_in	12	SENT_235	[p14l368t3582r709b3680],
15	with	IN	O	with	_	0	SENT_235	[p14l743t3581r938b3660],
16	mutated-EGFR	NN	O	mutated-egfr	prep_with	14	SENT_235	[p14l974t3581r1617b3664],
17	non	JJ	O	non	amod	21	SENT_235	[p14l1642t3581r2132b3659, p14l12t3709r157b3787],
18	—	NN	O	—	nn	21	SENT_235	[p14l1642t3581r2132b3659, p14l12t3709r157b3787],
19	smallcell	NN	O	smallcell	nn	21	SENT_235	[p14l1642t3581r2132b3659, p14l12t3709r157b3787],
20	lung	NN	O	lung	nn	21	SENT_235	[p14l191t3709r385b3810],
21	cancer	NN	O	cancer	dobj	3	SENT_235	[p14l418t3735r717b3805],
22	,	,	O	,	_	0	SENT_235	[p14l418t3735r717b3805],
23	with	IN	O	with	_	0	SENT_235	[p14l754t3709r949b3788],
24	a	DT	O	a	det	27	SENT_235	[p14l985t3735r1029b3787],
25	tolerable	JJ	O	tolerable	amod	27	SENT_235	[p14l1064t3709r1433b3788],
26	toxicity	NN	O	toxicity	nn	27	SENT_235	[p14l1470t3710r1787b3809],
27	profile	NN	O	profile	prep_with	21	SENT_235	[p14l1817t3708r2128b3809],
28	,	,	O	,	_	0	SENT_235	[p14l1817t3708r2128b3809],

1	including	VBG	O	include	_	0	SENT_236	[p15l11t22r412b123],
2	less	JJR	O	less	amod	4	SENT_236	[p15l444t22r597b100],
3	hematologic	JJ	O	hematologic	amod	4	SENT_236	[p15l635t22r1158b123],
4	toxicity	NN	O	toxicity	prep_including	11	SENT_236	[p15l1194t23r1503b122],
5	and	CC	O	and	_	0	SENT_236	[p15l1535t22r1690b101],
6	neurotoX	NN	O	neurotox	conj_and	4	SENT_236	[p15l1727t39r2132b101],
7	—	NN	O	—	nn	8	SENT_236	[p15l1727t39r2132b101],
8	icity	NN	O	icity	nsubjpass	11	SENT_236	[p15l11t151r190b249],
9	than	IN	O	than	advmod	11	SENT_236	[p15l221t150r417b227],
10	is	VBZ	O	be	auxpass	11	SENT_236	[p15l452t151r517b227],
11	seen	VBN	O	see	_	0	SENT_236	[p15l555t176r744b228],
12	with	IN	O	with	_	0	SENT_236	[p15l774t150r969b229],
13	chemotherapy	NN	O	chemotherapy	prep_with	11	SENT_236	[p15l1004t150r1628b249],
14	.	.	O	.	_	0	SENT_236	[p15l1004t150r1628b249],

1	The	DT	O	the	dep	147	SENT_237	[p15l137t277r295b354],
2	IPASS	NNP	O	IPASS	dep	147	SENT_237	[p15l325t283r590b372],
3	,	,	O	,	_	0	SENT_237	[p15l325t283r590b372],
4	which	WDT	O	which	dep	147	SENT_237	[p15l623t277r882b356],
5	was	VBD	O	be	dep	147	SENT_237	[p15l909t303r1069b356],
6	conducted	VBN	O	conduct	dep	147	SENT_237	[p15l1103t277r1537b356],
7	in	IN	O	in	dep	147	SENT_237	[p15l1567t278r1649b354],
8	Asia	NNP	LOCATION	Asia	dep	147	SENT_237	[p15l1677t278r1881b372],
9	,	,	O	,	_	0	SENT_237	[p15l1677t278r1881b372],
10	compared	VBN	O	compare	dep	147	SENT_237	[p15l1919t302r2132b355, p15l10t405r248b505],
11	gefitinib	NN	O	gefitinib	dep	147	SENT_237	[p15l283t404r646b506],
12	with	IN	O	with	dep	147	SENT_237	[p15l678t405r870b484],
13	carboplatin	NN	O	carboplatin	dep	147	SENT_237	[p15l906t405r1844b505],
14	—	CD	NUMBER	—	dep	147	SENT_237	[p15l906t405r1844b505],
15	paclitaXel	NN	O	paclitaxel	dep	147	SENT_237	[p15l906t405r1844b505],
16	as	IN	O	as	dep	147	SENT_237	[p15l1878t431r1962b483],
17	the	DT	O	the	dep	147	SENT_237	[p15l2000t405r2133b483],
18	first	JJ	ORDINAL	first	dep	147	SENT_237	[p15l11t532r381b611],
19	—	NN	O	—	dep	147	SENT_237	[p15l11t532r381b611],
20	line	NN	O	line	dep	147	SENT_237	[p15l11t532r381b611],
21	treatment	NN	O	treatment	dep	147	SENT_237	[p15l426t550r849b611],
22	for	IN	O	for	dep	147	SENT_237	[p15l888t532r1011b612],
23	advanced	JJ	O	advanced	dep	147	SENT_237	[p15l1052t533r1448b612],
24	non	JJ	O	non	dep	147	SENT_237	[p15l1491t533r2134b612],
25	—	NN	O	—	dep	147	SENT_237	[p15l1491t533r2134b612],
26	small	JJ	O	small	dep	147	SENT_237	[p15l1491t533r2134b612],
27	—	NN	O	—	dep	147	SENT_237	[p15l1491t533r2134b612],
28	cell	NN	O	cell	dep	147	SENT_237	[p15l1491t533r2134b612],
29	lung	NN	O	lung	dep	147	SENT_237	[p15l10t661r207b762],
30	cancer	NN	O	cancer	dep	147	SENT_237	[p15l244t687r530b739],
31	in	IN	O	in	dep	147	SENT_237	[p15l566t662r651b739],
32	patients	NNS	O	patient	dep	147	SENT_237	[p15l689t662r1038b761],
33	selected	VBN	O	select	dep	147	SENT_237	[p15l1081t661r1429b740],
34	on	IN	O	on	dep	147	SENT_237	[p15l1469t687r1576b740],
35	the	DT	O	the	dep	147	SENT_237	[p15l1616t661r1751b739],
36	basis	NN	O	basis	dep	147	SENT_237	[p15l1792t661r2008b740],
37	of	IN	O	of	dep	147	SENT_237	[p15l2050t660r2151b740],
38	clinical	JJ	O	clinical	dep	147	SENT_237	[p15l12t788r325b866],
39	characteristics	NNS	O	characteristic	dep	147	SENT_237	[p15l363t788r984b866],
40	that	WDT	O	that	dep	147	SENT_237	[p15l1025t788r1197b866],
41	included	VBD	O	include	dep	147	SENT_237	[p15l1229t788r1596b867],
42	a	DT	O	a	dep	147	SENT_237	[p15l1633t814r1677b866],
43	history	NN	O	history	dep	147	SENT_237	[p15l1713t788r2018b888],
44	of	IN	O	of	dep	147	SENT_237	[p15l2051t787r2151b867],
45	no	DT	O	no	dep	147	SENT_237	[p15l11t943r114b996],
46	smoking	NN	O	smoking	dep	147	SENT_237	[p15l151t917r515b1018],
47	or	CC	O	or	dep	147	SENT_237	[p15l546t943r633b996],
48	light	JJ	O	light	dep	147	SENT_237	[p15l663t917r856b1018],
49	smoking	NN	O	smoking	dep	147	SENT_237	[p15l886t917r1251b1018],
50	as	IN	O	as	dep	147	SENT_237	[p15l1281t943r1364b995],
51	Well	NNP	O	Well	dep	147	SENT_237	[p15l1396t917r1567b996],
52	as	IN	O	as	dep	147	SENT_237	[p15l1600t943r1683b995],
53	histologic	JJ	O	histologic	dep	147	SENT_237	[p15l1720t917r2134b1018],
54	evidence	NN	O	evidence	dep	147	SENT_237	[p15l12t1045r386b1124],
55	of	IN	O	of	dep	147	SENT_237	[p15l438t1044r540b1124],
56	adenocarcinoma	NN	O	adenocarcinoma	dep	147	SENT_237	[p15l572t1045r1367b1124],
57	.7	CD	NUMBER	.7	dep	147	SENT_237	[p15l572t1045r1367b1124],
58	Although	IN	O	although	dep	147	SENT_237	[p15l1414t1045r1830b1146],
59	IPASS	NNS	ORGANIZATION	ipass	dep	147	SENT_237	[p15l1880t1051r2130b1124],
60	showed	VBD	O	show	dep	147	SENT_237	[p15l12t1173r330b1252],
61	the	DT	O	the	dep	147	SENT_237	[p15l363t1173r493b1251],
62	overall	JJ	O	overall	dep	147	SENT_237	[p15l527t1173r806b1252],
63	superiority	NN	O	superiority	dep	147	SENT_237	[p15l839t1174r1293b1273],
64	of	IN	O	of	dep	147	SENT_237	[p15l1322t1172r1421b1252],
65	geﬁtinib	NN	O	geﬁtinib	dep	147	SENT_237	[p15l1435t1172r1798b1274],
66	(	CD	NUMBER	(	dep	147	SENT_237	[p15l1837t1180r2018b1264],
67	rate	NN	O	rate	dep	147	SENT_237	[p15l1837t1180r2018b1264],
68	of	IN	O	of	dep	147	SENT_237	[p15l2051t1172r2152b1252],
69	1-year	JJ	DURATION	1-year	dep	147	SENT_237	[p15l15t1307r266b1401],
70	progression	NN	O	progression	dep	147	SENT_237	[p15l300t1300r1008b1402],
71	—	CD	NUMBER	—	dep	147	SENT_237	[p15l300t1300r1008b1402],
72	free	JJ	O	free	dep	147	SENT_237	[p15l300t1300r1008b1402],
73	survival	NN	O	survival	dep	147	SENT_237	[p15l1048t1301r1402b1397],
74	,	,	O	,	_	0	SENT_237	[p15l1048t1301r1402b1397],
75	24.9	CD	PERCENT	24.9	dep	147	SENT_237	[p15l1445t1307r1730b1397],
76	%	NN	PERCENT	%	dep	147	SENT_237	[p15l1445t1307r1730b1397],
77	,	,	O	,	_	0	SENT_237	[p15l1445t1307r1730b1397],
78	vs.	FW	O	vs.	dep	147	SENT_237	[p15l1770t1327r1879b1380],
79	6.7	CD	PERCENT	6.7	dep	147	SENT_237	[p15l1922t1307r2134b1380],
80	%	NN	PERCENT	%	dep	147	SENT_237	[p15l1922t1307r2134b1380],
81	with	IN	O	with	dep	147	SENT_237	[p15l7t1428r195b1508],
82	chemotherapy	NN	O	chemotherapy	dep	147	SENT_237	[p15l234t1428r837b1528],
83	;	:	O	;	_	0	SENT_237	[p15l234t1428r837b1528],
84	hazard	NN	O	hazard	dep	147	SENT_237	[p15l880t1428r1165b1507],
85	ratio	NN	O	ratio	dep	147	SENT_237	[p15l1204t1429r1391b1507],
86	for	IN	O	for	dep	147	SENT_237	[p15l1431t1427r1550b1507],
87	death	NN	O	death	dep	147	SENT_237	[p15l1586t1428r1814b1507],
88	or	CC	O	or	dep	147	SENT_237	[p15l1854t1454r1940b1507],
89	disease	NN	O	disease	dep	147	SENT_237	[p15l1976t1428r2132b1507, p15l12t1583r185b1635],
90	progression	NN	O	progression	dep	147	SENT_237	[p15l220t1558r730b1658],
91	,	,	O	,	_	0	SENT_237	[p15l220t1558r730b1658],
92	0.74	CD	NUMBER	0.74	dep	147	SENT_237	[p15l771t1563r955b1652],
93	;	:	O	;	_	0	SENT_237	[p15l771t1563r955b1652],
94	P	NN	O	p	dep	147	SENT_237	[p15l993t1563r1364b1653],
95	<	JJR	O	<	dep	147	SENT_237	[p15l993t1563r1364b1653],
96	0.001	CD	NUMBER	0.001	dep	147	SENT_237	[p15l993t1563r1364b1653],
97	)	NN	O	)	dep	147	SENT_237	[p15l993t1563r1364b1653],
98	,	,	O	,	_	0	SENT_237	[p15l993t1563r1364b1653],
99	the	DT	O	the	dep	147	SENT_237	[p15l1405t1557r1534b1635],
100	most	RBS	O	most	dep	147	SENT_237	[p15l1569t1574r1779b1636],
101	impressive	JJ	O	impressive	dep	147	SENT_237	[p15l1809t1558r2132b1657, p15l12t1686r169b1764],
102	result	NN	O	result	dep	147	SENT_237	[p15l211t1685r461b1764],
103	emerged	VBD	O	emerge	dep	147	SENT_237	[p15l497t1685r874b1786],
104	from	IN	O	from	dep	147	SENT_237	[p15l915t1684r1128b1764],
105	subgroup	NN	O	subgroup	dep	147	SENT_237	[p15l1171t1685r1583b1786],
106	analysis	NN	O	analysis	dep	147	SENT_237	[p15l1626t1685r2000b1785],
107	:	:	O	:	_	0	SENT_237	[p15l1626t1685r2000b1785],
108	as	IN	O	as	dep	147	SENT_237	[p15l2045t1711r2131b1763],
109	compared	VBN	O	compare	dep	147	SENT_237	[p15l12t1813r423b1913],
110	with	IN	O	with	dep	147	SENT_237	[p15l453t1813r642b1892],
111	chemotherapy	NN	O	chemotherapy	dep	147	SENT_237	[p15l678t1813r1276b1913],
112	,	,	O	,	_	0	SENT_237	[p15l678t1813r1276b1913],
113	geﬁtinib	NN	O	geﬁtinib	dep	147	SENT_237	[p15l1316t1812r1671b1914],
114	was	VBD	O	be	dep	147	SENT_237	[p15l1703t1839r1861b1892],
115	effective	JJ	O	effective	dep	147	SENT_237	[p15l1899t1812r2132b1891, p15l12t1942r158b2020],
116	in	IN	O	in	dep	147	SENT_237	[p15l198t1942r281b2018],
117	patients	NNS	O	patient	dep	147	SENT_237	[p15l319t1942r661b2040],
118	with	IN	O	with	dep	147	SENT_237	[p15l698t1941r893b2020],
119	mutant	JJ	O	mutant	dep	147	SENT_237	[p15l933t1958r1247b2020],
120	EGFR	NN	ORGANIZATION	egfr	dep	147	SENT_237	[p15l1280t1947r1536b2024],
121	(	NN	O	(	dep	147	SENT_237	[p15l1570t1941r1896b2031],
122	hazard	NN	O	hazard	dep	147	SENT_237	[p15l1570t1941r1896b2031],
123	ratio	NN	O	ratio	dep	147	SENT_237	[p15l1935t1942r2132b2019],
124	for	IN	O	for	dep	147	SENT_237	[p15l11t2068r137b2148],
125	death	NN	O	death	dep	147	SENT_237	[p15l175t2069r417b2148],
126	or	CC	O	or	dep	147	SENT_237	[p15l458t2095r548b2148],
127	disease	NN	O	disease	dep	147	SENT_237	[p15l586t2069r904b2148],
128	progression	NN	O	progression	dep	147	SENT_237	[p15l942t2070r1491b2170],
129	,	,	O	,	_	0	SENT_237	[p15l942t2070r1491b2170],
130	0.48	CD	NUMBER	0.48	dep	147	SENT_237	[p15l1537t2075r1747b2160],
131	)	NN	O	)	dep	147	SENT_237	[p15l1537t2075r1747b2160],
132	but	CC	O	but	dep	147	SENT_237	[p15l1793t2069r1935b2148],
133	was	VBD	O	be	dep	147	SENT_237	[p15l1966t2095r2131b2148],
134	ineffective	JJ	O	ineffective	dep	147	SENT_237	[p15l11t2195r469b2275],
135	in	IN	O	in	dep	147	SENT_237	[p15l513t2197r598b2274],
136	those	DT	O	those	dep	147	SENT_237	[p15l642t2196r879b2275],
137	with	IN	O	with	dep	147	SENT_237	[p15l919t2196r1118b2276],
138	Wild	NNP	O	Wild	dep	147	SENT_237	[p15l1157t2196r1573b2296],
139	—	CD	NUMBER	—	dep	147	SENT_237	[p15l1157t2196r1573b2296],
140	type	NN	O	type	dep	147	SENT_237	[p15l1157t2196r1573b2296],
141	EGFR	NN	ORGANIZATION	egfr	dep	147	SENT_237	[p15l1616t2202r1876b2280],
142	(	CD	NUMBER	(	dep	147	SENT_237	[p15l1914t2196r2132b2287, p15l11t2325r152b2404],
143	hazard	NN	O	hazard	dep	147	SENT_237	[p15l1914t2196r2132b2287, p15l11t2325r152b2404],
144	ratio	NN	O	ratio	dep	147	SENT_237	[p15l185t2326r411b2421],
145	,	,	O	,	_	0	SENT_237	[p15l185t2326r411b2421],
146	2.85	CD	NUMBER	2.85	dep	147	SENT_237	[p15l451t2331r691b2416],
147	)	NN	O	)	_	0	SENT_237	[p15l451t2331r691b2416],
148	.	.	O	.	_	0	SENT_237	[p15l451t2331r691b2416],

1	This	DT	O	this	det	2	SENT_238	[p15l728t2325r919b2403],
2	finding	NN	O	finding	nsubj	3	SENT_238	[p15l955t2324r1288b2426],
3	suggested	VBD	O	suggest	_	0	SENT_238	[p15l1320t2325r1757b2426],
4	that	IN	O	that	complm	13	SENT_238	[p15l1792t2325r1968b2403],
5	the	DT	O	the	det	6	SENT_238	[p15l1997t2325r2133b2403],
6	presence	NN	O	presence	nsubj	13	SENT_238	[p15l9t2478r385b2552],
7	of	IN	O	of	_	0	SENT_238	[p15l421t2451r521b2531],
8	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_238	[p15l537t2458r793b2536],
9	mutations	NNS	O	mutation	prep_of	6	SENT_238	[p15l817t2453r1252b2531],
10	is	VBZ	O	be	cop	13	SENT_238	[p15l1289t2453r1354b2530],
11	the	DT	O	the	det	13	SENT_238	[p15l1392t2452r1525b2530],
12	best	JJS	O	best	amod	13	SENT_238	[p15l1561t2452r1738b2531],
13	criterion	NN	O	criterion	ccomp	3	SENT_238	[p15l1769t2453r2133b2531],
14	for	IN	O	for	_	0	SENT_238	[p15l11t2580r134b2660],
15	selection	NN	O	selection	prep_for	13	SENT_238	[p15l177t2581r555b2660],
16	of	IN	O	of	_	0	SENT_238	[p15l600t2580r700b2660],
17	patients	NNS	O	patient	prep_of	15	SENT_238	[p15l724t2582r1066b2681],
18	who	WP	O	who	nsubj	19	SENT_238	[p15l1108t2581r1291b2660],
19	benefit	VBP	O	benefit	rcmod	17	SENT_238	[p15l1337t2580r1642b2660],
20	from	IN	O	from	_	0	SENT_238	[p15l1681t2580r1891b2660],
21	gefi	FW	O	gefi	nn	23	SENT_238	[p15l1935t2580r2132b2682],
22	—	FW	O	—	nn	23	SENT_238	[p15l1935t2580r2132b2682],
23	tinib	NN	O	tinib	prep_from	19	SENT_238	[p15l12t2709r241b2804],
24	,	,	O	,	_	0	SENT_238	[p15l12t2709r241b2804],
25	an	DT	O	a	det	26	SENT_238	[p15l299t2735r403b2786],
26	idea	NN	O	idea	appos	23	SENT_238	[p15l456t2709r634b2787],
27	that	WDT	O	that	nsubjpass	29	SENT_238	[p15l685t2709r861b2786],
28	is	VBZ	O	be	auxpass	29	SENT_238	[p15l909t2710r976b2786],
29	validated	VBN	O	validate	rcmod	26	SENT_238	[p15l1026t2709r1425b2788],
30	by	IN	O	by	_	0	SENT_238	[p15l1478t2709r1577b2808],
31	the	DT	O	the	det	34	SENT_238	[p15l1626t2709r1760b2787],
32	present	JJ	DATE	present	amod	34	SENT_238	[p15l1813t2726r2138b2808],
33	study	NN	O	study	nn	34	SENT_238	[p15l13t2837r329b2936],
34	.2	NN	NUMBER	.2	agent	29	SENT_238	[p15l13t2837r329b2936],
35	°	CD	NUMBER	°	tmod	29	SENT_238	[p15l13t2837r329b2936],
36	Recently	RB	DATE	recently	advmod	35	SENT_238	[p15l365t2837r739b2936],
37	,	,	O	,	_	0	SENT_238	[p15l365t2837r739b2936],
38	another	DT	O	another	det	40	SENT_238	[p15l781t2837r1110b2915],
39	Japanese	JJ	MISC	japanese	amod	40	SENT_238	[p15l1134t2844r1507b2936],
40	phase	NN	O	phase	appos	13	SENT_238	[p15l1543t2837r1788b2936],
41	3	CD	NUMBER	3	num	42	SENT_238	[p15l1827t2843r1870b2916],
42	study	NN	O	study	dep	40	SENT_238	[p15l1913t2837r2138b2936],
43	(	CD	NUMBER	(	num	44	SENT_238	[p15l16t2971r629b3060],
44	WJTOG3405	NN	O	wjtog3405	dep	40	SENT_238	[p15l16t2971r629b3060],
45	;	:	O	;	_	0	SENT_238	[p15l16t2971r629b3060],
46	University	NNP	ORGANIZATION	University	nn	52	SENT_238	[p15l686t2966r1132b3064],
47	Hospital	NNP	ORGANIZATION	Hospital	nn	52	SENT_238	[p15l1181t2965r1556b3064],
48	Medical	NNP	ORGANIZATION	Medical	nn	52	SENT_238	[p15l1607t2965r1956b3043],
49	Information	NNP	ORGANIZATION	Information	nn	52	SENT_238	[p15l2009t2972r2132b3042, p15l11t3092r455b3172],
50	Network	NNP	ORGANIZATION	Network	nn	52	SENT_238	[p15l538t3093r923b3172],
51	Clinical	JJ	ORGANIZATION	clinical	amod	52	SENT_238	[p15l1005t3093r1346b3172],
52	Trials	NNS	ORGANIZATION	trial	dep	13	SENT_238	[p15l1429t3093r1680b3171],
53	Registry	NN	ORGANIZATION	registry	nn	55	SENT_238	[p15l1767t3094r2138b3194],
54	[	CD	NUMBER	[	num	55	SENT_238	[p15l20t3226r479b3310],
55	UMIN	NNP	O	UMIN	dep	13	SENT_238	[p15l20t3226r479b3310],
56	.	.	O	.	_	0	SENT_238	[p15l20t3226r479b3310],

1	—	NN	O	—	_	0	SENT_239	[p15l20t3226r479b3310],
2	.	.	O	.	_	0	SENT_239	[p15l20t3226r479b3310],

1	CT	NN	O	ct	nn	2	SENT_240	[p15l20t3226r479b3310],
2	R	NN	O	r	_	0	SENT_240	[p15l483t3226r576b3310],
3	]	CD	NUMBER	]	num	4	SENT_240	[p15l483t3226r576b3310],
4	number	NN	O	number	dep	2	SENT_240	[p15l643t3220r1005b3315],
5	,	,	O	,	_	0	SENT_240	[p15l643t3220r1005b3315],
6	UMINOOOOO0539	NN	O	uminooooo0539	nn	7	SENT_240	[p15l1068t3226r1851b3310],
7	)	NN	O	)	appos	2	SENT_240	[p15l1068t3226r1851b3310],
8	compared	VBN	O	compare	partmod	7	SENT_240	[p15l1916t3245r2132b3298, p15l9t3348r247b3448],
9	geﬁtinib	NN	O	geﬁtinib	dobj	8	SENT_240	[p15l282t3347r643b3449],
10	to	TO	O	to	_	0	SENT_240	[p15l681t3365r761b3427],
11	cisplatin	NN	O	cisplatin	nn	13	SENT_240	[p15l799t3348r1608b3448],
12	—	CD	NUMBER	—	num	13	SENT_240	[p15l799t3348r1608b3448],
13	docetaXel	NN	O	docetaxel	prep_to	8	SENT_240	[p15l799t3348r1608b3448],
14	as	IN	O	as	_	0	SENT_240	[p15l1642t3374r1727b3426],
15	the	DT	O	the	det	17	SENT_240	[p15l1765t3348r1894b3426],
16	firstline	NN	O	firstline	nn	17	SENT_240	[p15l1930t3347r2132b3426, p15l10t3476r172b3554],
17	treatment	NN	O	treatment	prep_as	8	SENT_240	[p15l214t3493r638b3554],
18	for	IN	O	for	_	0	SENT_240	[p15l672t3475r795b3555],
19	advanced	JJ	O	advanced	amod	21	SENT_240	[p15l830t3476r1226b3555],
20	non	JJ	O	non	amod	21	SENT_240	[p15l1264t3476r1907b3555],
21	—	NN	O	—	prep_for	17	SENT_240	[p15l1264t3476r1907b3555],
22	small	JJ	O	small	amod	26	SENT_240	[p15l1264t3476r1907b3555],
23	—	NN	O	—	nn	26	SENT_240	[p15l1264t3476r1907b3555],
24	cell	NN	O	cell	nn	26	SENT_240	[p15l1264t3476r1907b3555],
25	lung	NN	O	lung	nn	26	SENT_240	[p15l1943t3476r2137b3577],
26	cancer	NN	O	cancer	dep	21	SENT_240	[p15l12t3630r297b3682],
27	with	IN	O	with	_	0	SENT_240	[p15l345t3604r544b3683],
28	EGFR	NN	ORGANIZATION	egfr	nn	29	SENT_240	[p15l596t3610r856b3687],
29	mutations	NNS	O	mutation	prep_with	8	SENT_240	[p15l899t3605r1449b3683],
30	.	.	O	.	_	0	SENT_240	[p15l899t3605r1449b3683],

1	”	NN	O	”	dep	6	SENT_241	[p15l899t3605r1449b3683],
2	Although	IN	O	although	dep	6	SENT_241	[p15l1499t3604r1914b3705],
3	this	DT	O	this	det	4	SENT_241	[p15l1969t3604r2131b3682],
4	study	NN	O	study	nsubj	6	SENT_241	[p16l12t21r238b121],
5	also	RB	O	also	advmod	6	SENT_241	[p16l263t21r431b100],
6	showed	VBD	O	show	advcl	29	SENT_241	[p16l465t21r781b100],
7	the	DT	O	the	det	8	SENT_241	[p16l812t21r942b99],
8	superiority	NN	O	superiority	dobj	6	SENT_241	[p16l974t22r1429b121],
9	of	IN	O	of	_	0	SENT_241	[p16l1455t20r1555b100],
10	gefitinib	NN	O	gefitinib	prep_of	8	SENT_241	[p16l1566t20r1929b122],
11	over	IN	O	over	_	0	SENT_241	[p16l1961t47r2136b100],
12	standard	JJ	O	standard	amod	13	SENT_241	[p16l12t149r391b228],
13	chemotherapy	NN	O	chemotherapy	prep_over	10	SENT_241	[p16l431t149r1042b249],
14	with	IN	O	with	_	0	SENT_241	[p16l1072t149r1267b228],
15	respect	NN	O	respect	prep_with	6	SENT_241	[p16l1307t166r1616b249],
16	to	TO	O	to	_	0	SENT_241	[p16l1650t166r1732b228],
17	progression	NN	O	progression	npadvmod	19	SENT_241	[p16l1771t175r2132b250, p16l12t276r388b356],
18	—	CD	NUMBER	—	num	17	SENT_241	[p16l1771t175r2132b250, p16l12t276r388b356],
19	free	JJ	O	free	amod	20	SENT_241	[p16l1771t175r2132b250, p16l12t276r388b356],
20	survival	NN	O	survival	prep_to	6	SENT_241	[p16l430t277r793b373],
21	,	,	O	,	_	0	SENT_241	[p16l430t277r793b373],
22	the	DT	O	the	det	23	SENT_241	[p16l839t277r973b355],
23	magnitude	NN	O	magnitude	nsubj	29	SENT_241	[p16l1013t277r1488b378],
24	of	IN	O	of	_	0	SENT_241	[p16l1529t276r1630b356],
25	the	DT	O	the	det	26	SENT_241	[p16l1651t277r1786b355],
26	benefit	NN	O	benefit	prep_of	23	SENT_241	[p16l1827t276r2138b356],
27	was	VBD	O	be	cop	29	SENT_241	[p16l7t431r167b484],
28	somewhat	RB	O	somewhat	advmod	29	SENT_241	[p16l202t405r637b484],
29	smaller	JJR	O	smaller	_	0	SENT_241	[p16l665t405r978b483],
30	than	IN	O	than	prep	29	SENT_241	[p16l1007t405r1200b482],
31	in	IN	O	in	pcomp	30	SENT_241	[p16l1231t406r1314b482],
32	our	PRP$	O	we	poss	33	SENT_241	[p16l1346t431r1489b484],
33	study	NN	O	study	pobj	31	SENT_241	[p16l1520t405r1756b504],
34	,	,	O	,	_	0	SENT_241	[p16l1520t405r1756b504],
35	possibly	RB	O	possibly	advmod	29	SENT_241	[p16l1792t405r2138b504],
36	because	IN	O	because	_	0	SENT_241	[p16l12t533r341b612],
37	of	IN	O	of	_	0	SENT_241	[p16l372t532r471b612],
38	differences	NNS	O	difference	prep_because_of	29	SENT_241	[p16l484t532r947b612],
39	in	IN	O	in	_	0	SENT_241	[p16l979t534r1061b611],
40	the	DT	O	the	det	41	SENT_241	[p16l1092t533r1222b611],
41	characteristics	NNS	O	characteristic	prep_in	38	SENT_241	[p16l1253t533r1859b611],
42	of	IN	O	of	_	0	SENT_241	[p16l1892t532r1991b612],
43	the	DT	O	the	det	44	SENT_241	[p16l2003t533r2133b611],
44	patients	NNS	O	patient	prep_of	41	SENT_241	[p16l9t661r358b760],
45	(	RB	O	(	advmod	54	SENT_241	[p16l411t661r657b751],
46	since	IN	O	since	dep	54	SENT_241	[p16l411t661r657b751],
47	41	CD	PERCENT	41	num	48	SENT_241	[p16l702t665r882b739],
48	%	NN	PERCENT	%	nsubj	54	SENT_241	[p16l702t665r882b739],
49	of	IN	O	of	_	0	SENT_241	[p16l927t659r1028b739],
50	patients	NNS	O	patient	prep_of	48	SENT_241	[p16l1054t661r1403b760],
51	in	IN	O	in	_	0	SENT_241	[p16l1449t661r1533b738],
52	WJTOG3405	NN	O	wjtog3405	prep_in	50	SENT_241	[p16l1575t666r2129b751],
53	had	VBD	O	have	aux	54	SENT_241	[p16l11t789r170b868],
54	had	VBN	O	have	ccomp	29	SENT_241	[p16l211t789r370b868],
55	surgery	NN	O	surgery	dobj	54	SENT_241	[p16l412t815r755b890],
56	,	,	O	,	_	0	SENT_241	[p16l412t815r755b890],
57	VS.	NNP	O	VS.	appos	55	SENT_241	[p16l797t815r908b868],
58	only	RB	O	only	advmod	57	SENT_241	[p16l956t789r1143b889],
59	9	CD	PERCENT	9	num	60	SENT_241	[p16l1180t794r1316b868],
60	%	NN	PERCENT	%	pobj	58	SENT_241	[p16l1180t794r1316b868],
61	in	IN	O	in	_	0	SENT_241	[p16l1356t790r1440b867],
62	our	PRP$	O	we	poss	64	SENT_241	[p16l1482t815r1631b868],
63	study	NN	O	study	nn	64	SENT_241	[p16l1671t789r1927b889],
64	)	NN	O	)	prep_in	58	SENT_241	[p16l1671t789r1927b889],
65	and	CC	O	and	_	0	SENT_241	[p16l1973t789r2133b868],
66	the	DT	O	the	det	67	SENT_241	[p16l12t916r146b994],
67	duration	NN	O	duration	conj_and	64	SENT_241	[p16l197t916r570b995],
68	of	IN	O	of	_	0	SENT_241	[p16l621t915r722b995],
69	folloW	NN	O	follow	prep_of	57	SENT_241	[p16l753t915r1169b1016],
70	—	CD	NUMBER	—	num	69	SENT_241	[p16l753t915r1169b1016],
71	up	IN	O	up	advmod	69	SENT_241	[p16l753t915r1169b1016],
72	(	CD	NUMBER	(	num	73	SENT_241	[p16l1226t916r1605b1012],
73	median	NN	O	median	pobj	71	SENT_241	[p16l1226t916r1605b1012],
74	,	,	O	,	_	0	SENT_241	[p16l1226t916r1605b1012],
75	81	CD	DURATION	81	num	76	SENT_241	[p16l1661t922r1759b995],
76	days	NNS	NUMBER	day	tmod	54	SENT_241	[p16l1810t916r1998b1016],
77	in	IN	O	in	_	0	SENT_241	[p16l2049t917r2133b994],
78	WJTOG3405	NNP	O	WJTOG3405	nn	79	SENT_241	[p16l7t1051r561b1135],
79	VS.	NNP	O	VS.	prep_in	54	SENT_241	[p16l602t1071r713b1124],
80	527	CD	DURATION	527	num	81	SENT_241	[p16l763t1051r910b1123],
81	days	NNS	NUMBER	day	tmod	79	SENT_241	[p16l954t1045r1141b1144],
82	in	IN	O	in	_	0	SENT_241	[p16l1184t1046r1269b1122],
83	our	PRP$	O	we	poss	85	SENT_241	[p16l1311t1071r1459b1124],
84	study	NN	O	study	nn	85	SENT_241	[p16l1499t1045r1782b1144],
85	)	NN	O	)	prep_in	79	SENT_241	[p16l1499t1045r1782b1144],
86	.	.	O	.	_	0	SENT_241	[p16l1499t1045r1782b1144],

1	A	DT	O	a	det	2	SENT_242	[p17l39t78r81b126],
2	Progression-free	JJ	O	progression-free	_	0	SENT_242	[p17l128t81r756b141],
3	.	.	O	.	_	0	SENT_242	[p17l128t81r756b141],

1	—	NN	O	—	_	0	SENT_243	[p17l128t81r756b141],
2	.	.	O	.	_	0	SENT_243	[p17l128t81r756b141],

1	Survival	NNP	O	Survival	nn	2	SENT_244	[p17l128t81r756b141],
2	Population	NNP	O	Population	_	0	SENT_244	[p17l779t82r1041b140],

1	100	CD	NUMBER	100	number	2	SENT_245	[p17l193t176r271b216],
2	90	CD	NUMBER	90	num	4	SENT_245	[p17l219t285r271b325],
3	80	CD	NUMBER	80	number	4	SENT_245	[p17l219t394r271b434],
4	70	CD	NUMBER	70	_	0	SENT_245	[p17l221t503r271b543],
5	60	CD	NUMBER	60	number	6	SENT_245	[p17l219t613r271b652],
6	50	CD	NUMBER	50	num	8	SENT_245	[p17l219t722r271b762],
7	40	CD	NUMBER	40	number	8	SENT_245	[p17l217t831r271b871],
8	30	CD	NUMBER	30	dep	4	SENT_245	[p17l219t941r271b980],
9	Geﬁtinib	NNP	O	Geﬁtinib	nn	12	SENT_245	[p17l1642t975r1839b1018],
10	20	CD	NUMBER	20	num	12	SENT_245	[p17l218t1050r271b1089],
11	Standard	NNP	O	Standard	nn	12	SENT_245	[p17l960t1020r1164b1062],
12	Rdr	NNP	O	Rdr	dep	4	SENT_245	[p17l1644t1044r1837b1095],
13	+	CC	O	+	rcmod	12	SENT_245	[p17l1644t1044r1837b1095],

1	chemotherapy	NN	O	chemotherapy	_	0	SENT_246	[p17l899t1084r1228b1140],

1	10	CD	NUMBER	10	_	0	SENT_247	[p17l222t1159r271b1199],
2	(	CD	NUMBER	(	num	3	SENT_247	[p17l966t1151r1159b1204],
3	N	NN	O	n	dep	1	SENT_247	[p17l966t1151r1159b1204],
4	=	JJ	O	=	amod	6	SENT_247	[p17l966t1151r1159b1204],
5	1lO	NN	O	1lo	nn	6	SENT_247	[p17l966t1151r1159b1204],
6	)	NN	O	)	dep	1	SENT_247	[p17l966t1151r1159b1204],

1	Progression-free	JJ	O	progression-free	amod	2	SENT_248	[p17l75t701r135b1102],
2	Survival	NN	O	survival	_	0	SENT_248	[p17l76t489r121b684],
3	(	CD	PERCENT	(	num	4	SENT_248	[p17l78t387r135b466],
4	%	NN	PERCENT	%	dep	2	SENT_248	[p17l78t387r135b466],
5	)	CD	NUMBER	)	dep	2	SENT_248	[p17l78t387r135b466],

1	Months	NNS	DURATION	month	_	0	SENT_249	[p17l801t1426r988b1471],
2	since	IN	O	since	_	0	SENT_249	[p17l1007t1427r1134b1471],
3	Randomization	NN	O	randomization	prep_since	1	SENT_249	[p17l1155t1426r1523b1471],

1	B	NN	O	b	nn	2	SENT_250	[p17l44t1599r79b1648],
2	Patients	NNS	O	patient	_	0	SENT_250	[p17l127t1604r322b1648],
3	Receiving	VBG	O	receive	dep	2	SENT_250	[p17l344t1604r578b1662],
4	Geﬁtinib	NN	O	geﬁtinib	dobj	3	SENT_250	[p17l595t1602r808b1648],

1	Exon	NN	O	exon	_	0	SENT_251	[p17l1328t2318r1431b2356],
2	19	CD	NUMBER	19	num	3	SENT_251	[p17l1455t2318r1503b2356],
3	deletion	NN	O	deletion	dep	1	SENT_251	[p17l1522t2314r1703b2356],

1	40	CD	NUMBER	40	num	2	SENT_252	[p17l217t2357r271b2396],
2	30	CD	NUMBER	30	_	0	SENT_252	[p17l219t2466r271b2506],
3	20	CD	NUMBER	20	number	4	SENT_252	[p17l218t2575r271b2615],
4	10	CD	NUMBER	10	dep	2	SENT_252	[p17l222t2685r271b2724],
5	L858R	NN	O	l858r	nn	6	SENT_252	[p17l1073t2661r1211b2701],
6	mutation	NN	O	mutation	dep	4	SENT_252	[p17l1231t2662r1436b2701],

1	(	NN	O	(	nn	2	SENT_253	[p17l1171t2726r1337b2778],
2	N	NN	O	n	_	0	SENT_253	[p17l1171t2726r1337b2778],
3	=	JJ	O	=	dep	2	SENT_253	[p17l1171t2726r1337b2778],
4	49	CD	NUMBER	49	num	5	SENT_253	[p17l1171t2726r1337b2778],
5	)	NN	O	)	dep	2	SENT_253	[p17l1171t2726r1337b2778],

1	Progression-free	JJ	O	progression-free	amod	2	SENT_254	[p17l75t2226r135b2627],
2	Survival	NN	O	survival	_	0	SENT_254	[p17l76t2015r121b2209],
3	(	CD	PERCENT	(	num	4	SENT_254	[p17l78t1912r135b1992],
4	%	NN	PERCENT	%	dep	2	SENT_254	[p17l78t1912r135b1992],
5	)	CD	NUMBER	)	dep	2	SENT_254	[p17l78t1912r135b1992],

1	Months	NNS	DURATION	month	_	0	SENT_255	[p17l801t2951r988b2996],
2	since	IN	O	since	_	0	SENT_255	[p17l1007t2952r1134b2996],
3	Randomization	NN	O	randomization	prep_since	1	SENT_255	[p17l1155t2951r1523b2996],

1	C	NN	O	c	_	0	SENT_256	[p17l40t3124r80b3174],
2	Intention-to-Treat	JJ	O	intention-to-treat	amod	3	SENT_256	[p17l127t3129r561b3174],
3	Population	NNP	O	Population	dep	1	SENT_256	[p17l581t3128r842b3187],

1	100	CD	NUMBER	100	number	2	SENT_257	[p17l193t3227r271b3266],
2	90	CD	NUMBER	90	dep	16	SENT_257	[p17l219t3336r271b3376],
3	so	IN	O	so	dep	9	SENT_257	[p17l219t3445r271b3485],
4	3	CD	NUMBER	3	num	5	SENT_257	[p17l78t3551r135b3630],
5	70	CD	NUMBER	70	pobj	3	SENT_257	[p17l221t3555r271b3594],
6	3	CD	NUMBER	3	number	7	SENT_257	[p17l76t3653r121b3733],
7	6	CD	NUMBER	6	num	9	SENT_257	[p17l219t3664r271b3703],
8	°	NN	O	°	nn	9	SENT_257	[p17l219t3664r271b3703],
9	Geﬁtinib	NN	O	geﬁtinib	dep	2	SENT_257	[p17l1745t3687r1941b3730],
10	3	CD	NUMBER	3	number	11	SENT_257	[p17l79t3736r121b3834],
11	50	CD	NUMBER	50	num	13	SENT_257	[p17l219t3773r271b3812],
12	(	CD	NUMBER	(	number	13	SENT_257	[p17l1747t3755r1940b3807],
13	N	NN	O	n	npadvmod	14	SENT_257	[p17l1747t3755r1940b3807],
14	=	JJ	O	=	amod	2	SENT_257	[p17l1747t3755r1940b3807],
15	114	CD	NUMBER	114	npadvmod	16	SENT_257	[p17l1747t3755r1940b3807],
16	>	JJR	O	>	_	0	SENT_257	[p17l1747t3755r1940b3807],

1	:	:	O	:	_	0	SENT_258	[p18l76t6r121b47],
2	l.	VB	O	l.	_	0	SENT_258	[p18l1659t6r1997b42],
3	|	CD	NUMBER	|	amod	2	SENT_258	[p18l1659t6r1997b42],
4	_	CD	NUMBER	_	number	5	SENT_258	[p18l1659t6r1997b42],
5	|	NN	O	|	amod	2	SENT_258	[p18l1659t6r1997b42],
6	.	.	O	.	_	0	SENT_258	[p18l1659t6r1997b42],

1	I.	NN	O	i.	_	0	SENT_259	[p18l1659t6r1997b42],
2	Ij	NN	O	ij	nn	3	SENT_259	[p18l1659t6r1997b42],
3	|	NN	O	|	dep	1	SENT_259	[p18l1659t6r1997b42],
4	.	.	O	.	_	0	SENT_259	[p18l1659t6r1997b42],

1	|	NN	O	|	_	0	SENT_260	[p18l1659t6r1997b42],
2	.	.	O	.	_	0	SENT_260	[p18l1659t6r1997b42],

1	|	RB	O	|	amod	5	SENT_261	[p18l1659t6r1997b42],
2	_	CD	NUMBER	_	tmod	1	SENT_261	[p18l1659t6r1997b42],
3	|	CD	NUMBER	|	number	4	SENT_261	[p18l1659t6r1997b42],
4	_	CD	NUMBER	_	num	5	SENT_261	[p18l1659t6r1997b42],
5	|	NNS	O	|	_	0	SENT_261	[p18l1659t6r1997b42],
6	"	``	O	"	punct	5	SENT_261	[p18l76t54r121b111],
7	E	NN	O	e	nn	9	SENT_261	[p18l76t54r121b111],
8	40	CD	NUMBER	40	num	9	SENT_261	[p18l217t54r271b93],
9	“	NN	O	“	dep	10	SENT_261	[p18l91t114r121b170],
10	>	JJR	O	>	dep	5	SENT_261	[p18l91t114r121b170],
11	’	CD	NUMBER	’	num	12	SENT_261	[p18l91t114r121b170],
12	C	NN	O	c	dep	10	SENT_261	[p18l79t172r121b214],
13	)	CD	NUMBER	)	number	14	SENT_261	[p18l79t172r121b214],
14	30	CD	NUMBER	30	dep	5	SENT_261	[p18l219t163r271b203],
15	Standard	NNP	O	Standard	nn	16	SENT_261	[p18l1440t152r1644b194],
16	chemotherapy	NN	O	chemotherapy	dep	14	SENT_261	[p18l1379t216r1708b272],

1	20	CD	NUMBER	20	number	2	SENT_262	[p18l218t272r271b312],
2	(	CD	NUMBER	(	dep	10	SENT_262	[p18l1446t284r1640b336],
3	N	NN	O	n	prep	2	SENT_262	[p18l1446t284r1640b336],
4	=	JJ	O	=	amod	6	SENT_262	[p18l1446t284r1640b336],
5	114	CD	NUMBER	114	num	6	SENT_262	[p18l1446t284r1640b336],
6	)	NN	O	)	dep	3	SENT_262	[p18l1446t284r1640b336],
7	o	NN	O	o	dep	10	SENT_262	[p18l293t554r318b594],
8	3	CD	NUMBER	3	num	7	SENT_262	[p18l416t555r436b593],
9	6	CD	DATE	6	num	10	SENT_262	[p18l538t555r562b594],
10	9	CD	DATE	9	dep	16	SENT_262	[p18l660t555r683b594],
11	12	CD	DATE	12	number	12	SENT_262	[p18l772t555r819b593],
12	15	CD	DATE	15	dep	10	SENT_262	[p18l894t555r940b593],
13	18	CD	DATE	18	num	14	SENT_262	[p18l1016t554r1064b594],
14	21	CD	DATE	21	dep	12	SENT_262	[p18l1135t555r1185b593],
15	24	CD	DATE	24	num	16	SENT_262	[p18l1257t555r1309b593],
16	27	CD	DATE	27	dep	21	SENT_262	[p18l1380t555r1432b593],
17	30	CD	DATE	30	number	18	SENT_262	[p18l1503t554r1555b594],
18	33	CD	DATE	33	dep	16	SENT_262	[p18l1625t555r1673b593],
19	36	CD	DATE	36	dep	18	SENT_262	[p18l1747t555r1799b594],
20	39	CD	DATE	39	num	21	SENT_262	[p18l1870t555r1920b594],
21	42	CD	DATE	42	_	0	SENT_262	[p18l1990t555r2042b593],

1	Months	NNS	DURATION	month	_	0	SENT_263	[p18l801t648r988b693],
2	since	IN	O	since	_	0	SENT_263	[p18l1007t649r1134b693],
3	Randomization	NN	O	randomization	prep_since	1	SENT_263	[p18l1155t648r1523b693],

1	The	DT	O	the	det	4	SENT_264	[p18l105t884r225b942],
2	standard	JJ	O	standard	amod	4	SENT_264	[p18l263t884r546b943],
3	end	NN	O	end	nn	4	SENT_264	[p18l583t884r697b943],
4	point	NN	O	point	nsubj	23	SENT_264	[p18l733t885r905b958],
5	of	IN	O	of	_	0	SENT_264	[p18l939t883r1014b943],
6	phase	NN	O	phase	nn	8	SENT_264	[p18l1036t884r1222b958],
7	3	CD	NUMBER	3	num	8	SENT_264	[p18l1260t888r1292b943],
8	trials	NNS	O	trial	prep_of	4	SENT_264	[p18l1332t884r1495b942],
9	of	IN	O	of	_	0	SENT_264	[p18l1535t883r1609b943],
10	treatments	NNS	O	treatment	prep_of	4	SENT_264	[p18l12t991r350b1037],
11	for	IN	O	for	_	0	SENT_264	[p18l376t978r466b1038],
12	advanced	JJ	O	advanced	amod	14	SENT_264	[p18l488t979r778b1038],
13	non	JJ	O	non	amod	14	SENT_264	[p18l803t979r1272b1038],
14	—	NN	O	—	prep_for	10	SENT_264	[p18l803t979r1272b1038],
15	small	JJ	O	small	amod	19	SENT_264	[p18l803t979r1272b1038],
16	—	NN	O	—	nn	19	SENT_264	[p18l803t979r1272b1038],
17	cell	NN	O	cell	nn	19	SENT_264	[p18l803t979r1272b1038],
18	lung	NN	O	lung	nn	19	SENT_264	[p18l1296t979r1438b1054],
19	cancer	NN	O	cancer	dep	14	SENT_264	[p18l1460t998r1595b1037, p18l12t1093r106b1132],
20	has	VBZ	O	have	aux	23	SENT_264	[p18l128t1074r236b1132],
21	been	VBN	O	be	cop	23	SENT_264	[p18l263t1074r413b1132],
22	overall	JJ	O	overall	amod	23	SENT_264	[p18l438t1074r651b1133],
23	survival	NN	O	survival	_	0	SENT_264	[p18l676t1074r941b1133],
24	.	.	O	.	_	0	SENT_264	[p18l676t1074r941b1133],

1	However	RB	O	however	advmod	12	SENT_265	[p18l969t1080r1264b1145],
2	,	,	O	,	_	0	SENT_265	[p18l969t1080r1264b1145],
3	when	WRB	O	when	advmod	7	SENT_265	[p18l1290t1074r1464b1133],
4	our	PRP$	O	we	poss	5	SENT_265	[p18l1489t1093r1597b1133],
5	trial	NN	O	trial	nsubjpass	7	SENT_265	[p18l12t1169r148b1227],
6	was	VBD	O	be	auxpass	7	SENT_265	[p18l179t1188r303b1228],
7	begun	VBN	O	begin	advcl	12	SENT_265	[p18l340t1169r545b1244],
8	in	IN	O	in	_	0	SENT_265	[p18l579t1170r643b1227],
9	2006	CD	DATE	2006	prep_in	7	SENT_265	[p18l678t1173r855b1240],
10	,	,	O	,	_	0	SENT_265	[p18l678t1173r855b1240],
11	we	PRP	O	we	nsubj	12	SENT_265	[p18l890t1188r980b1228],
12	had	VBD	O	have	_	0	SENT_265	[p18l1015t1169r1133b1228],
13	data	NNS	O	datum	dobj	12	SENT_265	[p18l1169t1169r1308b1228],
14	only	RB	O	only	advmod	13	SENT_265	[p18l1343t1169r1484b1243],
15	on	IN	O	on	prep	12	SENT_265	[p18l1516t1188r1596b1228],

1	N	NN	O	n	nn	3	SENT_266	[p18l570t1312r584b1327],
2	ENGLJ	NN	O	englj	nn	3	SENT_266	[p18l599t1312r677b1334],
3	MED	NN	O	med	_	0	SENT_266	[p18l691t1312r743b1327],
4	362	CD	NUMBER	362	dep	3	SENT_266	[p18l753t1306r832b1334],
5	;	:	O	;	_	0	SENT_266	[p18l753t1306r832b1334],
6	25	CD	NUMBER	25	num	8	SENT_266	[p18l753t1306r832b1334],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_266	[p18l868t1312r992b1334],
8	JUNE	NN	DATE	june	dep	4	SENT_266	[p18l1023t1312r1087b1334],
9	24	CD	DATE	24	dep	8	SENT_266	[p18l1097t1312r1133b1334],
10	,	,	DATE	,	_	0	SENT_266	[p18l1097t1312r1133b1334],
11	2010	CD	DATE	2010	num	12	SENT_266	[p18l1145t1312r1205b1328],
12	2335	CD	DATE	2335	appos	9	SENT_266	[p18l1940t1302r2015b1325],

1	The	DT	O	the	det	4	SENT_267	[p18l702t1345r753b1369],
2	New	NNP	O	New	nn	4	SENT_267	[p18l762t1346r824b1369],
3	England	NNP	O	England	nn	4	SENT_267	[p18l833t1345r944b1376],
4	Joumal	NNP	O	Joumal	_	0	SENT_267	[p18l953t1345r1050b1369],
5	of	IN	O	of	_	0	SENT_267	[p18l1060t1345r1089b1369],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_267	[p18l1095t1345r1220b1369],

1	Copyright	NN	O	copyright	_	0	SENT_268	[p18l494t1427r629b1458],
2	©	CD	NUMBER	©	num	6	SENT_268	[p18l638t1427r661b1451],
3	2010	CD	DATE	2010	num	6	SENT_268	[p18l672t1427r737b1451],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_268	[p18l746t1427r937b1451],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_268	[p18l947t1427r1055b1451],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_268	[p18l1065t1427r1170b1458],
7	.	.	O	.	_	0	SENT_268	[p18l1065t1427r1170b1458],

1	All	DT	O	all	det	2	SENT_269	[p18l1181t1427r1223b1451],
2	rights	NNS	O	rights	nsubj	3	SENT_269	[p18l1232t1427r1307b1458],
3	reserved	VBN	O	reserve	_	0	SENT_269	[p18l1316t1427r1435b1451],
4	.	.	O	.	_	0	SENT_269	[p18l1316t1427r1435b1451],

1	The	DT	O	the	det	4	SENT_270	[p18l673t1533r719b1554],
2	NEW	NNP	O	NEW	nn	4	SENT_270	[p18l737t1535r822b1554],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_270	[p18l841t1535r1030b1554],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_270	[p18l1049t1535r1228b1561],
5	of	IN	O	of	_	0	SENT_270	[p18l1248t1533r1276b1560],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_270	[p18l1288t1535r1487b1554],

1	Table	NNP	O	Table	_	0	SENT_271	[p18l59t1756r201b1804],
2	2	CD	NUMBER	2	dep	1	SENT_271	[p18l218t1760r262b1804],
3	.	.	O	.	_	0	SENT_271	[p18l218t1760r262b1804],

1	Response	NN	O	response	dep	3	SENT_272	[p18l285t1761r536b1819],
2	to	TO	O	to	dep	3	SENT_272	[p18l551t1764r603b1804],
3	Treatment	NN	O	treatment	_	0	SENT_272	[p18l619t1761r894b1804],
4	in	IN	O	in	_	0	SENT_272	[p18l912t1757r955b1803],
5	the	DT	O	the	det	7	SENT_272	[p18l974t1756r1058b1804],
6	Intention-to-Treat	NNP	O	Intention-to-Treat	nn	7	SENT_272	[p18l1079t1757r1541b1804],
7	Population	NNP	O	Population	prep_in	3	SENT_272	[p18l1561t1756r1857b1819],
8	,	,	O	,	_	0	SENT_272	[p18l1561t1756r1857b1819],
9	According	VBG	O	accord	_	0	SENT_272	[p18l58t1836r325b1899],
10	to	TO	O	to	prepc_according_to	7	SENT_272	[p18l340t1844r392b1884],
11	Treatment	NNP	ORGANIZATION	Treatment	nn	12	SENT_272	[p18l408t1840r683b1884],
12	Group	NNP	ORGANIZATION	Group	pobj	7	SENT_272	[p18l699t1839r914b1898],
13	.	.	O	.	_	0	SENT_272	[p18l699t1839r914b1898],

1	*	NN	O	*	_	0	SENT_273	[p18l699t1839r914b1898],

1	Gefitinib	NNP	O	Gefitinib	nn	4	SENT_274	[p18l1099t1978r1325b2027],
2	Carbop	NNP	O	Carbop	nn	4	SENT_274	[p18l1479t1979r2065b2041],
3	|	NN	O	|	nn	4	SENT_274	[p18l1479t1979r2065b2041],
4	atin	NN	O	atin	_	0	SENT_274	[p18l1479t1979r2065b2041],
5	.	.	O	.	_	0	SENT_274	[p18l1479t1979r2065b2041],

1	—	NN	O	—	_	0	SENT_275	[p18l1479t1979r2065b2041],
2	.	.	O	.	_	0	SENT_275	[p18l1479t1979r2065b2041],

1	Pac	NN	O	pac	_	0	SENT_276	[p18l1479t1979r2065b2041],
2	|	SYM	O	|	dep	3	SENT_276	[p18l1479t1979r2065b2041],
3	itaxe	FW	O	itaxe	rcmod	1	SENT_276	[p18l1479t1979r2065b2041],
4	|	FW	O	|	dep	1	SENT_276	[p18l1479t1979r2065b2041],

1	Response	NN	O	response	nn	3	SENT_277	[p18l64t2056r315b2113],
2	(	CD	NUMBER	(	num	3	SENT_277	[p18l1099t2056r1157b2115],
3	N	NN	O	n	_	0	SENT_277	[p18l1099t2056r1157b2115],
4	=	JJ	O	=	quantmod	6	SENT_277	[p18l1172t2055r1325b2115],
5	114	CD	NUMBER	114	number	6	SENT_277	[p18l1172t2055r1325b2115],
6	)	CD	NUMBER	)	num	12	SENT_277	[p18l1172t2055r1325b2115],
7	(	NN	O	(	nn	12	SENT_277	[p18l1660t2055r1718b2115],
8	N	NN	O	n	nn	12	SENT_277	[p18l1660t2055r1718b2115],
9	=	JJ	O	=	amod	12	SENT_277	[p18l1733t2055r1886b2115],
10	114	CD	NUMBER	114	num	12	SENT_277	[p18l1733t2055r1886b2115],
11	)	NN	O	)	nn	12	SENT_277	[p18l1733t2055r1886b2115],
12	number	NN	O	number	dep	3	SENT_277	[p18l1197t2162r1396b2211],
13	of	IN	O	of	_	0	SENT_277	[p18l1410t2161r1468b2226],
14	patients	NNS	O	patient	prep_of	12	SENT_277	[p18l1469t2164r1669b2225],
15	(	CD	PERCENT	(	num	17	SENT_277	[p18l1692t2166r1908b2225],
16	percent	NN	PERCENT	percent	nn	17	SENT_277	[p18l1692t2166r1908b2225],
17	)	NN	O	)	dep	3	SENT_277	[p18l1692t2166r1908b2225],

1	Complete	JJ	O	complete	amod	2	SENT_278	[p18l61t2273r314b2336],
2	response	NN	O	response	_	0	SENT_278	[p18l336t2290r571b2336],
3	Partial	JJ	O	partial	amod	4	SENT_278	[p18l65t2384r223b2432],
4	response	NN	O	response	dep	2	SENT_278	[p18l247t2401r483b2447],
5	Complete	JJ	O	complete	amod	4	SENT_278	[p18l61t2495r314b2557],
6	or	CC	O	or	_	0	SENT_278	[p18l333t2512r386b2543],
7	partial	JJ	O	partial	amod	8	SENT_278	[p18l406t2495r565b2558],
8	response'i	NN	O	response'us	conj_or	2	SENT_278	[p18l590t2499r861b2558],
9	'	''	O	'	_	0	SENT_278	[p18l590t2499r861b2558],
10	Stable	JJ	O	stable	amod	14	SENT_278	[p18l62t2606r220b2654],
11	disease	NN	O	disease	nn	14	SENT_278	[p18l239t2606r433b2654],
12	Progressive	JJ	O	progressive	amod	14	SENT_278	[p18l65t2721r364b2780],
13	disease	NN	O	disease	nn	14	SENT_278	[p18l383t2716r577b2765],
14	Response	NN	O	response	dep	8	SENT_278	[p18l65t2832r315b2890],
15	that	WDT	O	that	nsubjpass	19	SENT_278	[p18l333t2827r435b2875],
16	could	MD	O	could	aux	19	SENT_278	[p18l454t2827r594b2875],
17	not	RB	O	not	neg	19	SENT_278	[p18l618t2836r701b2875],
18	be	VB	O	be	auxpass	19	SENT_278	[p18l722t2827r779b2875],
19	evaluated	VBN	O	evaluate	dep	2	SENT_278	[p18l157t2899r404b2947],

1	*	NN	O	*	_	0	SENT_279	[p18l9t3067r38b3095],
2	All	DT	O	all	det	3	SENT_279	[p18l56t3062r119b3110],
3	responses	NNS	O	response	nsubj	4	SENT_279	[p18l147t3080r410b3125],
4	differed	VBD	O	differ	rcmod	1	SENT_279	[p18l434t3062r629b3111],
5	signiﬁcantly	RB	O	signiﬁcantly	advmod	4	SENT_279	[p18l655t3062r968b3126],
6	between	IN	O	between	_	0	SENT_279	[p18l990t3063r1202b3111],
7	the	DT	O	the	det	9	SENT_279	[p18l1225t3062r1307b3111],
8	two	CD	NUMBER	two	num	9	SENT_279	[p18l1327t3072r1421b3111],
9	groups	NNS	O	group	prep_between	4	SENT_279	[p18l1444t3080r1624b3126],
10	(	CD	NUMBER	(	num	11	SENT_279	[p18l1653t3066r1879b3126],
11	P	NN	O	p	npadvmod	12	SENT_279	[p18l1653t3066r1879b3126],
12	<	JJR	O	<	amod	9	SENT_279	[p18l1653t3066r1879b3126],
13	0.001	CD	NUMBER	0.001	dep	12	SENT_279	[p18l1653t3066r1879b3126],
14	by	IN	O	by	dep	13	SENT_279	[p18l1906t3062r1960b3126],

1	Fisher	NNP	PERSON	Fisher	_	0	SENT_280	[p18l62t3135r260b3183],
2	’s	POS	O	’s	possessive	1	SENT_280	[p18l62t3135r260b3183],
3	exact	JJ	O	exact	amod	1	SENT_280	[p18l284t3144r415b3183],
4	test	NN	O	test	prep	1	SENT_280	[p18l435t3139r568b3198],
5	)	NN	O	)	dep	4	SENT_280	[p18l435t3139r568b3198],
6	.	.	O	.	_	0	SENT_280	[p18l435t3139r568b3198],
7	'	''	O	'	_	0	SENT_280	[p18l11t3211r41b3269],

1	i	LS	O	i	dep	4	SENT_281	[p18l11t3211r41b3269],
2	'	''	O	'	_	0	SENT_281	[p18l11t3211r41b3269],
3	The	DT	O	the	det	4	SENT_281	[p18l55t3206r152b3254],
4	percentage	NN	O	percentage	csubjpass	19	SENT_281	[p18l177t3215r463b3269],
5	of	IN	O	of	_	0	SENT_281	[p18l485t3206r542b3254],
6	patients	NNS	O	patient	prep_of	4	SENT_281	[p18l557t3211r763b3268],
7	in	IN	O	in	_	0	SENT_281	[p18l789t3211r830b3253],
8	whom	WP	O	whom	rel	10	SENT_281	[p18l853t3206r1013b3254],
9	there	EX	O	there	expl	10	SENT_281	[p18l1037t3206r1170b3254],
10	was	VBD	O	be	rcmod	6	SENT_281	[p18l1190t3223r1288b3254],
11	either	CC	O	either	preconj	13	SENT_281	[p18l1312t3206r1461b3254],
12	a	DT	O	a	det	13	SENT_281	[p18l1482t3223r1506b3254],
13	complete	JJ	O	complete	nsubj	10	SENT_281	[p18l1529t3206r1771b3268],
14	or	CC	O	or	_	0	SENT_281	[p18l1793t3223r1847b3254],
15	a	DT	O	a	det	17	SENT_281	[p18l1868t3223r1892b3254],
16	partial	JJ	O	partial	amod	17	SENT_281	[p18l1918t3206r2076b3268],
17	response	NN	O	response	conj_or	13	SENT_281	[p18l61t3294r296b3339],
18	was	VBD	O	be	auxpass	19	SENT_281	[p18l316t3294r414b3325],
19	considered	VBN	O	consider	_	0	SENT_281	[p18l438t3277r724b3325],
20	to	TO	O	to	aux	23	SENT_281	[p18l746t3286r797b3325],
21	be	VB	O	be	cop	23	SENT_281	[p18l822t3277r879b3325],
22	the	DT	O	the	det	23	SENT_281	[p18l900t3277r981b3325],
23	rate	NN	O	rate	xcomp	19	SENT_281	[p18l1006t3286r1101b3325],
24	of	IN	O	of	_	0	SENT_281	[p18l1123t3277r1180b3325],
25	objective	JJ	O	objective	amod	26	SENT_281	[p18l1193t3277r1425b3340],
26	response	NN	O	response	prep_of	23	SENT_281	[p18l1450t3294r1699b3339],
27	.	.	O	.	_	0	SENT_281	[p18l1450t3294r1699b3339],

1	progression	NN	O	progression	_	0	SENT_282	[p18l561t3528r1065b3603],
2	—	CD	NUMBER	—	num	4	SENT_282	[p18l561t3528r1065b3603],
3	free	JJ	O	free	amod	4	SENT_282	[p18l561t3528r1065b3603],
4	survival	NN	O	survival	dep	1	SENT_282	[p18l1092t3528r1328b3587],
5	from	IN	O	from	_	0	SENT_282	[p18l1353t3528r1505b3587],
6	our	PRP$	O	we	poss	7	SENT_282	[p18l1531t3547r1637b3587],
7	phase	NN	O	phase	prep_from	4	SENT_282	[p18l1659t3528r1838b3603],
8	2	CD	NUMBER	2	num	9	SENT_282	[p18l1863t3533r1898b3586],
9	studies	NNS	O	study	dep	1	SENT_282	[p18l1926t3528r2143b3587],
10	in	IN	O	in	_	0	SENT_282	[p18l562t3624r624b3681],
11	patients	NNS	O	patient	prep_in	9	SENT_282	[p18l653t3624r907b3698],
12	with	IN	O	with	_	0	SENT_282	[p18l936t3623r1081b3682],
13	non	JJ	O	non	amod	19	SENT_282	[p18l1111t3623r1590b3682],
14	—	JJ	O	—	amod	19	SENT_282	[p18l1111t3623r1590b3682],
15	small	JJ	O	small	amod	19	SENT_282	[p18l1111t3623r1590b3682],
16	—	NN	O	—	nn	19	SENT_282	[p18l1111t3623r1590b3682],
17	cell	NN	O	cell	nn	19	SENT_282	[p18l1111t3623r1590b3682],
18	lung	NN	O	lung	nn	19	SENT_282	[p18l1618t3623r1763b3698],
19	cancer	NN	O	cancer	prep_with	11	SENT_282	[p18l1791t3642r2000b3682],
20	and	CC	O	and	_	0	SENT_282	[p18l2027t3623r2145b3682],
21	EGFR	NN	ORGANIZATION	egfr	nn	22	SENT_282	[p18l562t3723r747b3780],
22	mutations	NNS	O	mutation	conj_and	19	SENT_282	[p18l765t3719r1093b3777],
23	.	.	O	.	_	0	SENT_282	[p18l765t3719r1093b3777],

1	The	DT	O	the	det	2	SENT_283	[p18l1119t3718r1236b3776],
2	data	NNS	O	datum	nsubj	8	SENT_283	[p18l1262t3718r1393b3776],
3	on	IN	O	on	_	0	SENT_283	[p18l1418t3737r1495b3776],
4	overall	JJ	O	overall	amod	5	SENT_283	[p18l1521t3718r1724b3777],
5	survival	NN	O	survival	prep_on	2	SENT_283	[p18l1750t3718r1986b3777],
6	first	JJ	ORDINAL	first	amod	5	SENT_283	[p18l2011t3718r2148b3776],
7	became	VBD	O	become	cop	8	SENT_283	[p19l563t23r811b82],
8	available	JJ	O	available	_	0	SENT_283	[p19l846t23r1129b82],
9	in	IN	O	in	_	0	SENT_283	[p19l1164t24r1227b81],
10	2008	CD	DATE	2008	prep_in	8	SENT_283	[p19l1262t28r1438b94],
11	,	,	O	,	_	0	SENT_283	[p19l1262t28r1438b94],
12	when	WRB	O	when	advmod	21	SENT_283	[p19l1474t23r1650b82],
13	the	DT	O	the	det	15	SENT_283	[p19l1686t23r1786b81],
14	combined	JJ	O	combined	amod	15	SENT_283	[p19l1822t23r2144b82],
15	analysis	NN	O	analysis	nsubj	21	SENT_283	[p19l562t118r822b193],
16	of	IN	O	of	_	0	SENT_283	[p19l857t118r932b177],
17	Japanese	JJ	MISC	japanese	amod	18	SENT_283	[p19l943t124r1233b193],
18	phase	NN	O	phase	prep_of	15	SENT_283	[p19l1264t118r1454b193],
19	2	CD	NUMBER	2	num	20	SENT_283	[p19l1486t123r1522b176],
20	studies	NNS	O	study	dep	18	SENT_283	[p19l1556t118r1785b177],
21	(	VBP	O	(	advcl	8	SENT_283	[p19l1822t123r2039b186],
22	Iressa	NNP	MISC	Iressa	nn	25	SENT_283	[p19l1822t123r2039b186],
23	—	NNP	MISC	—	nn	25	SENT_283	[p19l2067t152r2148b158],
24	Combined	NNP	MISC	Combined	nn	25	SENT_283	[p19l563t213r883b272],
25	Analysis	NN	MISC	analysis	nsubj	29	SENT_283	[p19l895t213r1152b288],
26	of	IN	MISC	of	_	0	SENT_283	[p19l1169t213r1242b272],
27	Mutation	NN	MISC	mutation	nn	28	SENT_283	[p19l1241t214r1524b272],
28	Positives	NNS	MISC	positive	prep_of	25	SENT_283	[p19l1538t214r1801b272],
29	[	VBP	O	[	ccomp	21	SENT_283	[p19l1824t218r2141b281],
30	I	PRP	O	I	dobj	29	SENT_283	[p19l1824t218r2141b281],
31	.	.	O	.	_	0	SENT_283	[p19l1824t218r2141b281],

1	—	NN	O	—	_	0	SENT_284	[p19l1824t218r2141b281],
2	.	.	O	.	_	0	SENT_284	[p19l1824t218r2141b281],

1	CAMP	NN	O	camp	nn	3	SENT_285	[p19l1824t218r2141b281],
2	]	CD	NUMBER	]	num	3	SENT_285	[p19l1824t218r2141b281],
3	)	NN	O	)	nsubjpass	11	SENT_285	[p19l1824t218r2141b281],
4	and	CC	O	and	_	0	SENT_285	[p19l562t308r678b367],
5	the	DT	O	the	det	7	SENT_285	[p19l708t308r805b367],
6	subgroup	NN	O	subgroup	nn	7	SENT_285	[p19l836t308r1131b383],
7	analyses	NNS	O	analysis	nsubjpass	11	SENT_285	[p19l1161t308r1423b383],
8	of	IN	O	of	_	0	SENT_285	[p19l1454t308r1528b367],
9	IPASS	NNP	ORGANIZATION	IPASS	prep_of	7	SENT_285	[p19l1542t313r1722b367],
10	were	VBD	O	be	auxpass	11	SENT_285	[p19l1751t327r1899b367],
11	reported	VBN	O	report	_	0	SENT_285	[p19l1928t320r2144b383, p19l563t403r750b462],
12	.7	CD	NUMBER	.7	npadvmod	13	SENT_285	[p19l1928t320r2144b383, p19l563t403r750b462],
13	>	JJR	O	>	acomp	11	SENT_285	[p19l1928t320r2144b383, p19l563t403r750b462],
14	22	CD	NUMBER	22	dep	13	SENT_285	[p19l1928t320r2144b383, p19l563t403r750b462],
15	We	PRP	O	we	nsubj	17	SENT_285	[p19l776t409r875b462],
16	thus	RB	O	thus	advmod	17	SENT_285	[p19l904t403r1040b462],
17	planned	VBD	O	plan	rcmod	14	SENT_285	[p19l1069t403r1330b478],
18	to	TO	O	to	aux	19	SENT_285	[p19l1358t415r1419b462],
19	have	VB	O	have	xcomp	17	SENT_285	[p19l1448t403r1589b462],
20	progression-free	JJ	O	progression-free	amod	21	SENT_285	[p19l1616t403r2144b478],
21	survival	NN	O	survival	dobj	19	SENT_285	[p19l564t498r811b557],
22	as	IN	O	as	_	0	SENT_285	[p19l840t518r904b556],
23	the	DT	O	the	det	26	SENT_285	[p19l936t498r1035b557],
24	primary	JJ	O	primary	amod	26	SENT_285	[p19l1064t499r1325b573],
25	end	NN	O	end	nn	26	SENT_285	[p19l1352t498r1466b557],
26	point	NN	O	point	prep_as	19	SENT_285	[p19l1495t499r1667b573],
27	in	IN	O	in	_	0	SENT_285	[p19l1692t499r1754b556],
28	the	DT	O	the	det	30	SENT_285	[p19l1785t498r1884b557],
29	current	JJ	DATE	current	amod	30	SENT_285	[p19l1914t510r2149b557],
30	study	NN	O	study	prep_in	19	SENT_285	[p19l564t593r744b668],
31	,	,	O	,	_	0	SENT_285	[p19l564t593r744b668],
32	because	IN	O	because	mark	34	SENT_285	[p19l778t593r1028b652],
33	it	PRP	O	it	nsubj	34	SENT_285	[p19l1056t594r1100b651],
34	allowed	VBD	O	allow	advcl	19	SENT_285	[p19l1124t593r1373b652],
35	us	PRP	O	we	nsubj	37	SENT_285	[p19l1401t613r1470b652],
36	to	TO	O	to	aux	37	SENT_285	[p19l1501t605r1562b652],
37	calculate	VB	O	calculate	xcomp	34	SENT_285	[p19l1591t593r1873b652],
38	the	DT	O	the	det	40	SENT_285	[p19l1903t593r2001b652],
39	statistical	JJ	O	statistical	amod	40	SENT_285	[p19l2031t605r2143b651, p19l563t688r780b746],
40	power	NN	O	power	dobj	37	SENT_285	[p19l808t707r1007b763],
41	of	IN	O	of	_	0	SENT_285	[p19l1035t688r1109b747],
42	the	DT	O	the	det	43	SENT_285	[p19l1125t688r1224b747],
43	study	NN	O	study	prep_of	40	SENT_285	[p19l1255t688r1436b763],
44	.	.	O	.	_	0	SENT_285	[p19l1255t688r1436b763],

1	Several	JJ	O	several	amod	2	SENT_286	[p19l660t783r883b842],
2	studies	NNS	O	study	nsubj	4	SENT_286	[p19l912t783r1135b842],
3	have	VBP	O	have	aux	4	SENT_286	[p19l1165t783r1307b842],
4	suggested	VBN	O	suggest	_	0	SENT_286	[p19l1336t783r1654b858],
5	that	IN	O	that	complm	15	SENT_286	[p19l1682t783r1811b841],
6	the	DT	O	the	det	9	SENT_286	[p19l1835t783r1934b842],
7	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_286	[p19l1961t788r2152b845],
8	copy	NN	O	copy	nn	9	SENT_286	[p19l563t897r708b953],
9	number	NN	O	number	nsubj	15	SENT_286	[p19l731t878r979b937],
10	may	MD	O	may	aux	15	SENT_286	[p19l1004t897r1136b953],
11	be	VB	O	be	cop	15	SENT_286	[p19l1160t878r1231b937],
12	a	DT	O	a	det	15	SENT_286	[p19l1257t898r1291b936],
13	better	JJR	O	better	amod	15	SENT_286	[p19l1317t878r1500b937],
14	predictive	JJ	O	predictive	amod	15	SENT_286	[p19l1524t878r1830b953],
15	biomarl	NN	O	biomarl	ccomp	4	SENT_286	[p19l1858t878r2143b937, p19l563t993r622b1032],
16	<	JJR	O	<	amod	17	SENT_286	[p19l1858t878r2143b937, p19l563t993r622b1032],
17	er	NN	O	er	dep	15	SENT_286	[p19l1858t878r2143b937, p19l563t993r622b1032],
18	for	IN	O	for	_	0	SENT_286	[p19l646t973r735b1032],
19	the	DT	O	the	det	20	SENT_286	[p19l759t973r855b1032],
20	efficacy	NN	O	efficacy	prep_for	17	SENT_286	[p19l882t973r1122b1048],
21	of	IN	O	of	_	0	SENT_286	[p19l1145t973r1218b1032],
22	EGFR	NN	ORGANIZATION	egfr	nn	25	SENT_286	[p19l1230t978r1416b1035],
23	tyrosine	NN	O	tyrosine	nn	25	SENT_286	[p19l1435t974r1681b1048],
24	kinase	NN	O	kinase	nn	25	SENT_286	[p19l1708t973r1908b1032],
25	inhibitors	NNS	O	inhibitor	prep_of	20	SENT_286	[p19l1934t973r2143b1032, p19l563t1080r687b1127],
26	than	IN	O	than	_	0	SENT_286	[p19l720t1068r869b1126],
27	the	DT	O	the	det	28	SENT_286	[p19l900t1068r1001b1127],
28	presence	NN	O	presence	prep_than	15	SENT_286	[p19l1031t1087r1318b1143],
29	of	IN	O	of	_	0	SENT_286	[p19l1350t1068r1425b1127],
30	an	DT	O	a	det	32	SENT_286	[p19l1442t1087r1520b1126],
31	EGFR	NN	ORGANIZATION	egfr	nn	32	SENT_286	[p19l1550t1073r1744b1130],
32	mutation	NN	O	mutation	prep_of	28	SENT_286	[p19l1766t1069r2144b1127],
33	.	.	O	.	_	0	SENT_286	[p19l1766t1069r2144b1127],

1	”	NN	O	”	ccomp	9	SENT_287	[p19l1766t1069r2144b1127],
2	However	RB	O	however	advmod	1	SENT_287	[p19l562t1169r851b1234],
3	,	,	O	,	_	0	SENT_287	[p19l562t1169r851b1234],
4	its	PRP$	O	its	poss	6	SENT_287	[p19l877t1164r948b1221],
5	predictive	JJ	O	predictive	amod	6	SENT_287	[p19l971t1163r1277b1238],
6	capacity	NN	O	capacity	nsubjpass	9	SENT_287	[p19l1300t1164r1554b1238],
7	has	VBZ	O	have	aux	9	SENT_287	[p19l1573t1163r1679b1221],
8	been	VBN	O	be	auxpass	9	SENT_287	[p19l1703t1163r1851b1222],
9	reported	VBN	O	report	dep	14	SENT_287	[p19l1873t1163r2144b1238],
10	only	RB	O	only	advmod	9	SENT_287	[p19l563t1258r700b1333],
11	in	IN	O	in	_	0	SENT_287	[p19l726t1259r789b1316],
12	placebo-controlled	JJ	O	placebo-controlled	amod	13	SENT_287	[p19l817t1258r1421b1333],
13	trials	NNS	O	trial	prep_in	9	SENT_287	[p19l1451t1258r1615b1316],
14	(	VBP	O	(	_	0	SENT_287	[p19l1650t1263r1861b1326],
15	Iressa	NNP	O	Iressa	nn	17	SENT_287	[p19l1650t1263r1861b1326],
16	Survival	NNP	O	Survival	nn	17	SENT_287	[p19l1892t1258r2145b1317],
17	Evaluation	NN	O	evaluation	dobj	14	SENT_287	[p19l562t1353r891b1412],
18	in	IN	O	in	_	0	SENT_287	[p19l915t1354r976b1411],
19	Lung	NN	O	lung	nn	20	SENT_287	[p19l1000t1359r1162b1428],
20	Cancer	NN	O	cancer	prep_in	17	SENT_287	[p19l1184t1358r1402b1412],
21	[	CD	NUMBER	[	num	22	SENT_287	[p19l1432t1357r1668b1420],
22	ISEL	NN	O	isel	nsubj	14	SENT_287	[p19l1432t1357r1668b1420],
23	]	CD	NUMBER	]	num	24	SENT_287	[p19l1432t1357r1668b1420],
24	24	CD	NUMBER	24	dep	22	SENT_287	[p19l1432t1357r1668b1420],
25	and	CC	O	and	_	0	SENT_287	[p19l1692t1353r1808b1412],
26	the	DT	O	the	det	30	SENT_287	[p19l1833t1353r1930b1412],
27	BR	NN	O	br	nn	30	SENT_287	[p19l1954t1358r2144b1415],
28	.21	CD	NUMBER	.21	num	30	SENT_287	[p19l1954t1358r2144b1415],
29	study23	NN	O	study23	nn	30	SENT_287	[p19l564t1448r812b1523],
30	)	NN	O	)	dep	22	SENT_287	[p19l564t1448r812b1523],
31	.	.	O	.	_	0	SENT_287	[p19l564t1448r812b1523],

1	Moreover	RB	O	moreover	advmod	8	SENT_288	[p19l840t1454r1143b1519],
2	,	,	O	,	_	0	SENT_288	[p19l840t1454r1143b1519],
3	the	DT	O	the	det	5	SENT_288	[p19l1173t1448r1268b1507],
4	subgroup	NN	O	subgroup	nn	5	SENT_288	[p19l1295t1448r1584b1523],
5	analysis	NN	O	analysis	nsubj	8	SENT_288	[p19l1610t1448r1852b1523],
6	in	IN	O	in	_	0	SENT_288	[p19l1878t1449r1938b1506],
7	IPASS	NNP	ORGANIZATION	IPASS	prep_in	5	SENT_288	[p19l1962t1453r2142b1507],
8	showed	VBD	O	show	_	0	SENT_288	[p19l564t1543r804b1602],
9	that	IN	O	that	complm	15	SENT_288	[p19l828t1543r957b1601],
10	longer	JJR	O	longer	dep	11	SENT_288	[p19l976t1543r1181b1618],
11	progression-free	JJ	O	progression-free	amod	12	SENT_288	[p19l1201t1543r1729b1618],
12	survival	NN	O	survival	nsubjpass	15	SENT_288	[p19l1755t1543r2001b1602],
13	was	VBD	O	be	auxpass	15	SENT_288	[p19l2022t1563r2143b1602],
14	significantly	RB	O	significantly	advmod	15	SENT_288	[p19l564t1638r969b1713],
15	associated	VBN	O	associate	ccomp	8	SENT_288	[p19l990t1638r1321b1697],
16	with	IN	O	with	_	0	SENT_288	[p19l1343t1638r1489b1697],
17	sensitive	JJ	O	sensitive	amod	19	SENT_288	[p19l1515t1639r1786b1697],
18	EGFR	NN	ORGANIZATION	egfr	nn	19	SENT_288	[p19l1811t1643r2001b1700],
19	mutations	NNS	O	mutation	prep_with	15	SENT_288	[p19l2019t1657r2143b1697, p19l563t1734r782b1792],
20	but	CC	O	but	_	0	SENT_288	[p19l814t1733r919b1792],
21	not	RB	O	not	_	0	SENT_288	[p19l945t1745r1051b1792],
22	with	IN	O	with	_	0	SENT_288	[p19l1075t1733r1220b1792],
23	a	DT	O	a	det	27	SENT_288	[p19l1250t1753r1284b1791],
24	high	JJ	O	high	amod	27	SENT_288	[p19l1313t1733r1458b1808],
25	EGFR	NN	ORGANIZATION	egfr	nn	27	SENT_288	[p19l1487t1738r1678b1795],
26	copy	NN	O	copy	nn	27	SENT_288	[p19l1701t1752r1848b1808],
27	number	NN	O	number	prep_with	15	SENT_288	[p19l1875t1733r2141b1792],
28	.	.	O	.	_	0	SENT_288	[p19l1875t1733r2141b1792],

1	We	PRP	O	we	nsubj	3	SENT_289	[p19l560t1834r659b1887],
2	therefore	RB	O	therefore	advmod	3	SENT_289	[p19l690t1828r980b1887],
3	believe	VBP	O	believe	_	0	SENT_289	[p19l1012t1828r1229b1887],
4	that	IN	O	that	complm	12	SENT_289	[p19l1261t1828r1390b1886],
5	evaluation	NN	O	evaluation	nsubj	12	SENT_289	[p19l1417t1828r1746b1887],
6	of	IN	O	of	_	0	SENT_289	[p19l1778t1828r1852b1887],
7	the	DT	O	the	det	9	SENT_289	[p19l1870t1828r1969b1887],
8	copy	NN	O	copy	nn	9	SENT_289	[p19l2001t1847r2148b1903],
9	number	NN	O	number	prep_of	5	SENT_289	[p19l563t1923r814b1982],
10	is	VBZ	O	be	cop	12	SENT_289	[p19l848t1924r897b1981],
11	not	RB	O	not	neg	12	SENT_289	[p19l935t1935r1041b1982],
12	necessary	JJ	O	necessary	ccomp	3	SENT_289	[p19l1074t1942r1387b1998],
13	when	WRB	O	when	advmod	19	SENT_289	[p19l1416t1923r1591b1982],
14	an	DT	O	a	det	17	SENT_289	[p19l1627t1942r1703b1981],
15	EGFR	NN	ORGANIZATION	egfr	nn	17	SENT_289	[p19l1739t1928r1929b1985],
16	mutation	NN	O	mutation	nn	17	SENT_289	[p19l1958t1935r2143b1982, p19l563t2019r689b2077],
17	test	NN	O	test	nsubj	19	SENT_289	[p19l718t2030r833b2077],
18	is	VBZ	O	be	cop	19	SENT_289	[p19l858t2019r907b2076],
19	available	JJ	O	available	advcl	12	SENT_289	[p19l937t2018r1231b2077],
20	.	.	O	.	_	0	SENT_289	[p19l937t2018r1231b2077],

1	In	IN	O	in	_	0	SENT_290	[p19l1264t2024r1330b2076],
2	the	DT	O	the	det	4	SENT_290	[p19l1359t2018r1458b2077],
3	current	JJ	DATE	current	amod	4	SENT_290	[p19l1488t2030r1722b2077],
4	study	NN	O	study	prep_in	38	SENT_290	[p19l1749t2018r1929b2093],
5	,	,	O	,	_	0	SENT_290	[p19l1749t2018r1929b2093],
6	EGFR	NN	ORGANIZATION	egfr	nn	7	SENT_290	[p19l1961t2023r2152b2080],
7	mutations	NNS	O	mutation	nsubjpass	9	SENT_290	[p19l563t2115r880b2173],
8	were	VBD	O	be	auxpass	9	SENT_290	[p19l903t2134r1050b2173],
9	detected	VBN	O	detect	parataxis	38	SENT_290	[p19l1076t2114r1337b2173],
10	with	IN	O	with	_	0	SENT_290	[p19l1358t2114r1501b2173],
11	the	DT	O	the	det	12	SENT_290	[p19l1526t2114r1623b2173],
12	use	NN	O	use	prep_with	9	SENT_290	[p19l1648t2134r1751b2173],
13	of	IN	O	of	_	0	SENT_290	[p19l1776t2114r1850b2173],
14	the	DT	O	the	det	18	SENT_290	[p19l1861t2114r1958b2173],
15	PNALNA	NNP	O	PNALNA	nn	18	SENT_290	[p19l1982t2119r2144b2173, p19l562t2215r703b2268],
16	PCR	NN	O	pcr	nn	18	SENT_290	[p19l724t2214r866b2271],
17	clamp	NN	O	clamp	nn	18	SENT_290	[p19l883t2209r1073b2284],
18	method	NN	O	method	prep_of	12	SENT_290	[p19l1099t2209r1358b2280],
19	,	,	O	,	_	0	SENT_290	[p19l1099t2209r1358b2280],
20	the	DT	O	the	det	21	SENT_290	[p19l1387t2209r1485b2268],
21	usefulness	NN	O	usefulness	nsubjpass	26	SENT_290	[p19l1509t2209r1841b2268],
22	of	IN	O	of	_	0	SENT_290	[p19l1868t2209r1942b2268],
23	which	WDT	O	which	prep_of	21	SENT_290	[p19l1949t2209r2145b2268],
24	has	VBZ	O	have	aux	26	SENT_290	[p19l563t2304r670b2362],
25	been	VBN	O	be	auxpass	26	SENT_290	[p19l699t2304r849b2363],
26	validated	VBN	O	validate	rcmod	18	SENT_290	[p19l873t2304r1308b2363],
27	.15	CD	NUMBER	.15	number	28	SENT_290	[p19l873t2304r1308b2363],
28	»	CD	NUMBER	»	num	29	SENT_290	[p19l873t2304r1308b2363],
29	16	CD	NUMBER	16	dobj	26	SENT_290	[p19l873t2304r1308b2363],
30	With	IN	O	with	_	0	SENT_290	[p19l1333t2304r1492b2362],
31	this	DT	O	this	det	32	SENT_290	[p19l1519t2304r1638b2362],
32	method	NN	O	method	prep_with	26	SENT_290	[p19l1667t2304r1931b2375],
33	,	,	O	,	_	0	SENT_290	[p19l1667t2304r1931b2375],
34	EGFR	NN	ORGANIZATION	egfr	nn	35	SENT_290	[p19l1962t2309r2152b2366],
35	mutations	NNS	O	mutation	nsubjpass	38	SENT_290	[p19l563t2400r886b2458],
36	can	MD	O	can	aux	38	SENT_290	[p19l919t2418r1030b2457],
37	be	VB	O	be	auxpass	38	SENT_290	[p19l1062t2399r1133b2458],
38	detected	VBN	O	detect	_	0	SENT_290	[p19l1165t2399r1432b2458],
39	from	IN	O	from	_	0	SENT_290	[p19l1462t2399r1619b2458],
40	small	JJ	O	small	amod	42	SENT_290	[p19l1651t2399r1825b2457],
41	cytologic	JJ	O	cytologic	amod	42	SENT_290	[p19l1856t2399r2145b2474],
42	specimens	NNS	O	specimen	prep_from	38	SENT_290	[p19l564t2495r916b2569],
43	,	,	O	,	_	0	SENT_290	[p19l564t2495r916b2569],
44	such	JJ	O	such	_	0	SENT_290	[p19l953t2494r1097b2553],
45	as	IN	O	as	_	0	SENT_290	[p19l1129t2514r1193b2552],
46	those	DT	O	those	prep_such_as	42	SENT_290	[p19l1227t2494r1399b2553],
47	from	IN	O	from	_	0	SENT_290	[p19l1432t2494r1588b2553],
48	bronchial	JJ	O	bronchial	amod	49	SENT_290	[p19l1621t2494r1927b2553],
49	washings	NNS	O	washing	prep_from	46	SENT_290	[p19l1956t2494r2144b2553, p19l562t2590r717b2664],
50	,	,	O	,	_	0	SENT_290	[p19l1956t2494r2144b2553, p19l562t2590r717b2664],
51	pleural	JJ	O	pleural	amod	52	SENT_290	[p19l753t2589r981b2664],
52	effusions	NNS	O	effusion	prep_from	46	SENT_290	[p19l1014t2589r1334b2660],
53	,	,	O	,	_	0	SENT_290	[p19l1014t2589r1334b2660],
54	and	CC	O	and	_	0	SENT_290	[p19l1370t2589r1490b2648],
55	sputum	NN	O	sputum	nn	56	SENT_290	[p19l1523t2601r1770b2664],
56	collection	NN	O	collection	prep_from	46	SENT_290	[p19l1803t2589r2140b2660],
57	,	,	O	,	_	0	SENT_290	[p19l1803t2589r2140b2660],
58	which	WDT	O	which	nsubjpass	61	SENT_290	[p19l559t2684r749b2743],
59	are	VBP	O	be	auxpass	61	SENT_290	[p19l775t2704r868b2743],
60	frequently	RB	O	frequently	advmod	61	SENT_290	[p19l895t2684r1209b2759],
61	used	VBN	O	use	rcmod	46	SENT_290	[p19l1233t2684r1374b2743],
62	for	IN	O	for	_	0	SENT_290	[p19l1401t2684r1490b2743],
63	the	DT	O	the	det	64	SENT_290	[p19l1515t2684r1611b2743],
64	diagnosis	NN	O	diagnosis	prep_for	61	SENT_290	[p19l1639t2684r1932b2759],
65	of	IN	O	of	_	0	SENT_290	[p19l1961t2684r2034b2743],
66	advanced	JJ	O	advanced	amod	71	SENT_290	[p19l2047t2684r2144b2743, p19l559t2779r781b2838],
67	non	JJ	O	non	amod	71	SENT_290	[p19l818t2779r1297b2838],
68	—	NN	O	—	nn	71	SENT_290	[p19l818t2779r1297b2838],
69	small-cell	NN	O	small-cell	nn	71	SENT_290	[p19l818t2779r1297b2838],
70	lung	NN	O	lung	nn	71	SENT_290	[p19l1333t2779r1477b2854],
71	cancer	NN	O	cancer	prep_of	64	SENT_290	[p19l1513t2798r1736b2838],
72	.	.	O	.	_	0	SENT_290	[p19l1513t2798r1736b2838],

1	The	DT	O	the	det	2	SENT_291	[p19l1775t2779r1894b2838],
2	results	NNS	O	result	nsubjpass	7	SENT_291	[p19l1932t2779r2143b2838],
3	of	IN	O	of	_	0	SENT_291	[p19l12t3047r113b3127],
4	the	DT	O	the	det	5	SENT_291	[p19l131t3048r263b3126],
5	analyses	NNS	O	analysis	prep_of	2	SENT_291	[p19l298t3048r657b3148],
6	are	VBP	O	be	auxpass	7	SENT_291	[p19l695t3074r824b3126],
7	obtained	VBN	O	obtain	_	0	SENT_291	[p19l861t3048r1239b3127],
8	within	IN	O	within	_	0	SENT_291	[p19l1270t3048r1555b3128],
9	several	JJ	DURATION	several	amod	10	SENT_291	[p19l1592t3048r1884b3128],
10	days	NNS	DURATION	day	prep_within	7	SENT_291	[p19l1920t3048r2129b3148],
11	,	,	O	,	_	0	SENT_291	[p19l1920t3048r2129b3148],
12	so	IN	O	so	dep	7	SENT_291	[p19l13t3203r103b3255],
13	the	DT	O	the	det	14	SENT_291	[p19l140t3177r270b3255],
14	treatment	NN	O	treatment	nsubjpass	18	SENT_291	[p19l305t3193r720b3255],
15	is	VBZ	O	be	auxpass	18	SENT_291	[p19l750t3178r814b3254],
16	usually	RB	O	usually	advmod	18	SENT_291	[p19l851t3177r1151b3276],
17	not	RB	O	not	neg	18	SENT_291	[p19l1182t3194r1323b3255],
18	delayed	VBN	O	delay	ccomp	7	SENT_291	[p19l1353t3177r1687b3276],
19	.	.	O	.	_	0	SENT_291	[p19l1353t3177r1687b3276],

1	The	DT	O	the	det	5	SENT_292	[p19l1724t3177r1882b3255],
2	PNALNA	NNP	O	PNALNA	nn	5	SENT_292	[p19l1916t3183r2133b3256, p19l11t3312r201b3384],
3	PCR	NN	O	pcr	nn	5	SENT_292	[p19l231t3311r421b3388],
4	clamp	NN	O	clamp	nn	5	SENT_292	[p19l447t3305r702b3404],
5	approach	NN	O	approach	nsubjpass	11	SENT_292	[p19l739t3305r1126b3404],
6	is	VBZ	O	be	cop	8	SENT_292	[p19l1161t3306r1226b3382],
7	readily	RB	O	readily	advmod	8	SENT_292	[p19l1263t3305r1548b3404],
8	available	JJ	O	available	_	0	SENT_292	[p19l1579t3305r1942b3384],
9	and	CC	O	and	_	0	SENT_292	[p19l1976t3305r2134b3383],
10	is	VBZ	O	be	auxpass	11	SENT_292	[p19l11t3434r77b3511],
11	covered	VBN	O	cover	conj_and	8	SENT_292	[p19l119t3433r443b3512],
12	by	IN	O	by	_	0	SENT_292	[p19l483t3433r580b3532],
13	health	NN	O	health	nn	14	SENT_292	[p19l615t3433r885b3511],
14	insurance	NN	O	insurance	agent	11	SENT_292	[p19l924t3434r1345b3512],
15	in	IN	O	in	_	0	SENT_292	[p19l1383t3434r1467b3510],
16	Japan	NNP	LOCATION	Japan	prep_in	14	SENT_292	[p19l1496t3440r1764b3532],
17	.	.	O	.	_	0	SENT_292	[p19l1496t3440r1764b3532],

1	The	DT	O	the	det	3	SENT_293	[p19l137t3561r298b3639],
2	best	JJS	O	best	amod	3	SENT_293	[p19l346t3561r523b3640],
3	timing	NN	O	timing	_	0	SENT_293	[p19l567t3562r860b3662],
4	of	IN	O	of	_	0	SENT_293	[p19l906t3560r1005b3640],
5	treatment	NN	O	treatment	prep_of	3	SENT_293	[p19l1035t3578r1459b3639],
6	with	IN	O	with	dep	3	SENT_293	[p19l1497t3561r1693b3640],
7	an	DT	O	a	det	11	SENT_293	[p19l1739t3587r1843b3639],
8	EGFR	NN	ORGANIZATION	egfr	nn	11	SENT_293	[p19l1889t3567r2145b3644],
9	tyrosine	NN	O	tyrosine	nn	11	SENT_293	[p19l12t3689r358b3788],
10	kinase	NN	O	kinase	nn	11	SENT_293	[p19l395t3688r674b3768],
11	inhibitor	NN	O	inhibitor	pobj	6	SENT_293	[p19l711t3688r1093b3767],
12	for	IN	O	for	_	0	SENT_293	[p19l1126t3687r1249b3767],
13	patients	NNS	O	patient	prep_for	11	SENT_293	[p19l1282t3689r1623b3788],
14	with	IN	O	with	dep	3	SENT_293	[p19l1658t3688r1853b3768],
15	EGFR	NN	ORGANIZATION	egfr	pobj	14	SENT_293	[p19l1889t3694r2144b3772],

1	mutations	NNS	O	mutation	nsubj	3	SENT_294	[p20l12t22r446b100],
2	remains	VBZ	O	remain	cop	3	SENT_294	[p20l479t22r826b99],
3	undetermined	JJ	O	undetermined	_	0	SENT_294	[p20l859t21r1491b100],
4	.	.	O	.	_	0	SENT_294	[p20l859t21r1491b100],

1	A	DT	O	a	det	3	SENT_295	[p20l1524t28r1590b98],
2	recent	JJ	O	recent	amod	3	SENT_295	[p20l1617t37r1882b99],
3	study	NN	O	study	nsubj	4	SENT_295	[p20l1909t21r2138b120],
4	showed	VBD	O	show	_	0	SENT_295	[p20l13t149r326b228],
5	that	IN	O	that	complm	10	SENT_295	[p20l363t149r528b227],
6	overall	JJ	O	overall	amod	7	SENT_295	[p20l561t149r834b228],
7	survival	NN	O	survival	nsubj	10	SENT_295	[p20l872t149r1189b228],
8	did	VBD	O	do	aux	10	SENT_295	[p20l1226t149r1356b228],
9	not	RB	O	not	neg	10	SENT_295	[p20l1393t166r1532b228],
10	differ	VB	O	differ	ccomp	4	SENT_295	[p20l1564t148r1794b228],
11	significantly	RB	O	significantly	advmod	10	SENT_295	[p20l1829t148r2133b250, p20l12t276r279b376],
12	between	IN	O	between	_	0	SENT_295	[p20l318t276r683b356],
13	first	JJ	ORDINAL	first	amod	15	SENT_295	[p20l727t275r1109b354],
14	—	NN	O	—	nn	15	SENT_295	[p20l727t275r1109b354],
15	line	NN	O	line	prep_between	10	SENT_295	[p20l727t275r1109b354],
16	and	CC	O	and	_	0	SENT_295	[p20l1152t276r1312b355],
17	second	JJ	ORDINAL	second	amod	20	SENT_295	[p20l1357t276r1859b355],
18	—	NN	O	—	nn	20	SENT_295	[p20l1357t276r1859b355],
19	line	NN	O	line	nn	20	SENT_295	[p20l1357t276r1859b355],
20	treatments	NNS	O	treatment	prep_between	10	SENT_295	[p20l1904t293r2133b354, p20l12t423r268b485],
21	with	IN	O	with	_	0	SENT_295	[p20l302t406r494b485],
22	erlotinib	NN	O	erlotinib	prep_with	10	SENT_295	[p20l531t406r985b485],
23	.25	CD	NUMBER	.25	num	25	SENT_295	[p20l531t406r985b485],
24	Overall	JJ	O	overall	amod	25	SENT_295	[p20l1025t406r1326b485],
25	survival	NN	O	survival	nsubjpass	27	SENT_295	[p20l1364t406r1688b485],
26	is	VBZ	O	be	auxpass	27	SENT_295	[p20l1722t407r1787b484],
27	considered	VBN	O	consider	rcmod	22	SENT_295	[p20l1827t406r2133b485, p20l12t533r193b612],

1	to	TO	O	to	aux	3	SENT_296	[p20l232t550r313b612],
2	be	VB	O	be	auxpass	3	SENT_296	[p20l354t533r451b612],
3	influenced	VBN	O	influence	_	0	SENT_296	[p20l488t532r949b613],
4	by	IN	O	by	_	0	SENT_296	[p20l988t533r1085b633],
5	the	DT	O	the	det	8	SENT_296	[p20l1120t533r1252b611],
6	second	JJ	ORDINAL	second	amod	8	SENT_296	[p20l1293t533r1782b612],
7	—	NN	O	—	nn	8	SENT_296	[p20l1293t533r1782b612],
8	line	NN	O	line	agent	3	SENT_296	[p20l1293t533r1782b612],
9	or	CC	O	or	_	0	SENT_296	[p20l1822t559r1911b612],
10	later	JJ	O	later	amod	11	SENT_296	[p20l1945t533r2138b611],
11	treatment	NN	O	treatment	agent	3	SENT_296	[p20l12t678r456b740],
12	.	.	O	.	_	0	SENT_296	[p20l12t678r456b740],

1	In	IN	O	in	_	0	SENT_297	[p20l506t669r595b739],
2	the	DT	O	the	det	4	SENT_297	[p20l640t661r773b739],
3	current	JJ	DATE	current	amod	4	SENT_297	[p20l819t678r1133b741],
4	study	NN	O	study	prep_in	13	SENT_297	[p20l1175t661r1417b761],
5	,	,	O	,	_	0	SENT_297	[p20l1175t661r1417b761],
6	95	CD	PERCENT	95	num	7	SENT_297	[p20l1468t667r1653b740],
7	%	NN	PERCENT	%	nsubj	13	SENT_297	[p20l1468t667r1653b740],
8	of	IN	O	of	_	0	SENT_297	[p20l1698t660r1798b740],
9	the	DT	O	the	det	10	SENT_297	[p20l1825t661r1957b739],
10	patients	NNS	O	patient	prep_of	7	SENT_297	[p20l2001t687r2133b761, p20l12t790r248b867],
11	in	IN	O	in	_	0	SENT_297	[p20l301t790r384b867],
12	whom	WP	O	whom	prep_in	10	SENT_297	[p20l430t789r701b868],
13	f1rst	VBP	O	f1rst	_	0	SENT_297	[p20l752t788r1123b867],
14	—	CD	NUMBER	—	num	16	SENT_297	[p20l752t788r1123b867],
15	line	NN	O	line	nn	16	SENT_297	[p20l752t788r1123b867],
16	carboplatin	NN	O	carboplatin	dobj	13	SENT_297	[p20l1174t789r2134b889],
17	—	CD	NUMBER	—	num	18	SENT_297	[p20l1174t789r2134b889],
18	paclitaXel	NN	O	paclitaxel	nsubj	19	SENT_297	[p20l1174t789r2134b889],
19	failed	VBD	O	fail	rcmod	16	SENT_297	[p20l12t917r257b997],
20	crossed	VBN	O	cross	dep	19	SENT_297	[p20l301t918r630b997],
21	over	IN	O	over	prep	20	SENT_297	[p20l674t944r856b997],
22	to	TO	O	to	pcomp	21	SENT_297	[p20l897t935r979b997],
23	gefitinib	NN	O	gefitinib	nn	24	SENT_297	[p20l1024t917r1404b1019],
24	therapy	NN	O	therapy	pobj	22	SENT_297	[p20l1450t918r1792b1018],
25	.	.	O	.	_	0	SENT_297	[p20l1450t918r1792b1018],

1	Such	PDT	O	such	predet	5	SENT_298	[p20l1843t918r2048b997],
2	a	DT	O	a	det	5	SENT_298	[p20l2091t944r2135b996],
3	high	JJ	O	high	amod	5	SENT_298	[p20l12t1046r203b1147],
4	crossover	NN	O	crossover	nn	5	SENT_298	[p20l241t1072r636b1125],
5	rate	NN	O	rate	nsubjpass	9	SENT_298	[p20l670t1063r826b1124],
6	has	VBZ	O	have	aux	9	SENT_298	[p20l863t1046r1005b1124],
7	not	RB	O	not	neg	9	SENT_298	[p20l1044t1063r1184b1125],
8	been	VBN	O	be	auxpass	9	SENT_298	[p20l1217t1046r1414b1125],
9	reported	VBN	O	report	_	0	SENT_298	[p20l1451t1046r1810b1146],
10	in	IN	O	in	_	0	SENT_298	[p20l1845t1047r1928b1124],
11	previous	JJ	O	previous	amod	12	SENT_298	[p20l1963t1072r2133b1146, p20l7t1174r231b1253],
12	studies	NNS	O	study	prep_in	9	SENT_298	[p20l267t1173r567b1253],
13	of	IN	O	of	_	0	SENT_298	[p20l602t1172r702b1252],
14	EGFR	NN	ORGANIZATION	egfr	nn	17	SENT_298	[p20l715t1179r971b1257],
15	tyrosine	NN	O	tyrosine	nn	17	SENT_298	[p20l993t1174r1339b1273],
16	kinase	NN	O	kinase	nn	17	SENT_298	[p20l1371t1173r1650b1253],
17	inhibitors	NNS	O	inhibitor	prep_of	12	SENT_298	[p20l1682t1173r2129b1252],
18	.	.	O	.	_	0	SENT_298	[p20l1682t1173r2129b1252],

1	For	IN	O	for	_	0	SENT_299	[p20l11t1309r153b1380],
2	example	NN	O	example	prep_for	20	SENT_299	[p20l197t1301r576b1401],
3	,	,	O	,	_	0	SENT_299	[p20l197t1301r576b1401],
4	in	IN	O	in	_	0	SENT_299	[p20l627t1302r710b1379],
5	IPASS	NNP	ORGANIZATION	IPASS	prep_in	20	SENT_299	[p20l755t1307r1026b1397],
6	,	,	O	,	_	0	SENT_299	[p20l755t1307r1026b1397],
7	only	RB	O	only	quantmod	8	SENT_299	[p20l1079t1301r1262b1401],
8	39	CD	PERCENT	39	num	9	SENT_299	[p20l1305t1307r1489b1381],
9	%	NN	PERCENT	%	nsubj	20	SENT_299	[p20l1305t1307r1489b1381],
10	of	IN	O	of	_	0	SENT_299	[p20l1536t1300r1636b1380],
11	patients	NNS	O	patient	prep_of	9	SENT_299	[p20l1662t1302r2004b1401],
12	in	IN	O	in	_	0	SENT_299	[p20l2051t1302r2134b1379],
13	the	DT	O	the	det	18	SENT_299	[p20l12t1430r140b1508],
14	first	JJ	ORDINAL	first	amod	18	SENT_299	[p20l175t1429r525b1508],
15	—	NN	O	—	nn	18	SENT_299	[p20l175t1429r525b1508],
16	line	NN	O	line	nn	18	SENT_299	[p20l175t1429r525b1508],
17	chemotherapy	NN	O	chemotherapy	nn	18	SENT_299	[p20l560t1430r1147b1530],
18	group	NN	O	group	prep_in	11	SENT_299	[p20l1176t1456r1420b1531],
19	later	RB	O	later	advmod	20	SENT_299	[p20l1454t1430r1637b1508],
20	received	VBD	O	receive	_	0	SENT_299	[p20l1668t1430r1999b1509],
21	an	DT	O	a	det	24	SENT_299	[p20l2032t1456r2134b1508],
22	EGFR	NN	O	egfr	nn	24	SENT_299	[p20l11t1559r633b1658],
23	—	NN	O	—	nn	24	SENT_299	[p20l11t1559r633b1658],
24	tyrosine	NN	O	tyrosine	iobj	20	SENT_299	[p20l11t1559r633b1658],
25	kinase	NN	O	kinase	nn	26	SENT_299	[p20l665t1558r944b1637],
26	inhibitor	NN	O	inhibitor	dobj	20	SENT_299	[p20l975t1558r1374b1637],
27	.	.	O	.	_	0	SENT_299	[p20l975t1558r1374b1637],

1	Considering	VBG	O	consider	dep	86	SENT_300	[p20l1412t1558r1938b1659],
2	that	IN	O	that	dep	26	SENT_300	[p20l1967t1558r2139b1636],
3	in	IN	O	in	_	0	SENT_300	[p20l11t1687r96b1763],
4	our	PRP$	O	we	poss	5	SENT_300	[p20l139t1712r287b1765],
5	study	NN	O	study	prep_in	26	SENT_300	[p20l328t1686r563b1785],
6	the	DT	O	the	det	9	SENT_300	[p20l601t1686r737b1764],
7	median	JJ	O	median	amod	9	SENT_300	[p20l779t1686r1109b1764],
8	overall	JJ	O	overall	amod	9	SENT_300	[p20l1152t1686r1445b1765],
9	survival	NN	O	survival	nsubj	26	SENT_300	[p20l1489t1686r1830b1765],
10	in	IN	O	in	_	0	SENT_300	[p20l1871t1687r1955b1763],
11	the	DT	O	the	det	13	SENT_300	[p20l1998t1686r2134b1764],
12	gefitinib	JJ	O	gefitinib	amod	13	SENT_300	[p20l12t1813r375b1915],
13	group	NN	O	group	prep_in	9	SENT_300	[p20l410t1840r658b1915],
14	was	VBD	O	be	cop	26	SENT_300	[p20l689t1840r849b1893],
15	7	CD	DURATION	7	num	16	SENT_300	[p20l887t1822r933b1893],
16	months	NNS	NUMBER	month	npadvmod	17	SENT_300	[p20l968t1814r1289b1893],
17	longer	JJR	O	longer	advmod	26	SENT_300	[p20l1325t1814r1594b1915],
18	than	IN	O	than	_	0	SENT_300	[p20l1626t1814r1819b1892],
19	that	DT	O	that	prep_than	17	SENT_300	[p20l1854t1814r2022b1892],
20	in	IN	O	in	_	0	SENT_300	[p20l2051t1815r2134b1892],
21	the	DT	O	the	det	23	SENT_300	[p20l12t1942r147b2020],
22	chemotherapy	NN	O	chemotherapy	nn	23	SENT_300	[p20l192t1942r815b2042],
23	group	NN	O	group	prep_in	19	SENT_300	[p20l854t1968r1111b2043],
24	(	CD	NUMBER	(	number	25	SENT_300	[p20l1161t1948r1368b2033],
25	30.5	CD	DURATION	30.5	num	26	SENT_300	[p20l1161t1948r1368b2033],
26	months	NNS	NUMBER	month	pcomp	1	SENT_300	[p20l1416t1942r1748b2021],
27	vs.	CC	O	vs.	prep	26	SENT_300	[p20l1791t1968r1901b2021],
28	23.6	CD	DURATION	23.6	num	29	SENT_300	[p20l1951t1948r2133b2021],
29	months	NNS	NUMBER	month	dep	27	SENT_300	[p20l12t2070r382b2166],
30	)	RB	O	)	advmod	26	SENT_300	[p20l12t2070r382b2166],
31	,	,	O	,	_	0	SENT_300	[p20l12t2070r382b2166],
32	in	IN	O	in	dep	38	SENT_300	[p20l417t2071r499b2148],
33	which	WDT	O	which	pobj	32	SENT_300	[p20l524t2070r782b2149],
34	virtually	RB	O	virtually	advmod	36	SENT_300	[p20l808t2070r1163b2170],
35	all	DT	O	all	det	36	SENT_300	[p20l1187t2070r1290b2148],
36	patients	NNS	O	patient	nsubjpass	38	SENT_300	[p20l1318t2071r1652b2170],
37	were	VBD	O	be	auxpass	38	SENT_300	[p20l1680t2096r1878b2149],
38	given	VBN	O	give	dep	26	SENT_300	[p20l1908t2071r2134b2171],
39	gefitinib	NN	O	gefitinib	dobj	38	SENT_300	[p20l12t2197r366b2299],
40	as	IN	O	as	_	0	SENT_300	[p20l396t2224r479b2276],
41	the	DT	O	the	det	45	SENT_300	[p20l511t2198r639b2276],
42	second	JJ	ORDINAL	second	amod	45	SENT_300	[p20l671t2198r1139b2277],
43	—	NN	O	—	nn	45	SENT_300	[p20l671t2198r1139b2277],
44	line	NN	O	line	nn	45	SENT_300	[p20l671t2198r1139b2277],
45	treatment	NN	O	treatment	prep_as	38	SENT_300	[p20l1169t2215r1594b2294],
46	,	,	O	,	_	0	SENT_300	[p20l1169t2215r1594b2294],
47	and	CC	O	and	_	0	SENT_300	[p20l1628t2198r1782b2277],
48	that	IN	O	that	complm	57	SENT_300	[p20l1811t2198r1977b2276],
49	the	DT	O	the	det	50	SENT_300	[p20l2001t2198r2134b2276],
50	rate	NN	O	rate	nsubj	57	SENT_300	[p20l12t2343r175b2404],
51	of	IN	O	of	_	0	SENT_300	[p20l216t2325r317b2405],
52	response	NN	O	response	prep_of	50	SENT_300	[p20l339t2352r728b2426],
53	to	TO	O	to	_	0	SENT_300	[p20l769t2343r851b2405],
54	gefitinib	NN	O	gefitinib	prep_to	52	SENT_300	[p20l893t2325r1273b2427],
55	was	VBD	O	be	cop	57	SENT_300	[p20l1311t2352r1475b2405],
56	slightly	RB	O	slightly	advmod	57	SENT_300	[p20l1519t2326r1844b2427],
57	worse	JJR	O	worse	pcomp	1	SENT_300	[p20l1876t2352r2133b2405],
58	in	IN	O	in	_	0	SENT_300	[p20l11t2455r96b2532],
59	the	DT	O	the	det	63	SENT_300	[p20l139t2454r274b2532],
60	second	JJ	ORDINAL	second	amod	63	SENT_300	[p20l318t2454r818b2533],
61	—	NN	O	—	nn	63	SENT_300	[p20l318t2454r818b2533],
62	line	NN	O	line	nn	63	SENT_300	[p20l318t2454r818b2533],
63	setting	NN	O	setting	prep_in	57	SENT_300	[p20l863t2455r1168b2555],
64	than	IN	O	than	dep	57	SENT_300	[p20l1208t2454r1407b2532],
65	in	IN	O	in	_	0	SENT_300	[p20l1449t2455r1533b2532],
66	the	DT	O	the	det	69	SENT_300	[p20l1577t2454r1711b2532],
67	first	JJ	ORDINAL	first	amod	69	SENT_300	[p20l1755t2453r2134b2532],
68	—	NN	O	—	nn	69	SENT_300	[p20l1755t2453r2134b2532],
69	line	NN	O	line	prep_in	57	SENT_300	[p20l1755t2453r2134b2532],
70	setting	VBG	O	set	partmod	69	SENT_300	[p20l13t2583r305b2683],
71	(	CD	PERCENT	(	number	72	SENT_300	[p20l345t2588r630b2673],
72	58.5	CD	PERCENT	58.5	num	73	SENT_300	[p20l345t2588r630b2673],
73	%	NN	PERCENT	%	dobj	70	SENT_300	[p20l345t2588r630b2673],
74	vs.	CC	O	vs.	prep	73	SENT_300	[p20l663t2608r770b2661],
75	73.7	CD	PERCENT	73.7	num	76	SENT_300	[p20l814t2587r1116b2678],
76	%	NN	PERCENT	%	dep	74	SENT_300	[p20l814t2587r1116b2678],
77	)	CD	NUMBER	)	dep	76	SENT_300	[p20l814t2587r1116b2678],
78	,	,	O	,	_	0	SENT_300	[p20l814t2587r1116b2678],
79	ﬁrst	IN	O	ﬁrst	_	0	SENT_300	[p20l1160t2581r1520b2660],
80	—	CD	NUMBER	—	prep_ﬁrst	57	SENT_300	[p20l1160t2581r1520b2660],
81	line	NN	O	line	nn	82	SENT_300	[p20l1160t2581r1520b2660],
82	gefitinib	NN	O	gefitinib	nsubj	86	SENT_300	[p20l1557t2581r1920b2683],
83	may	MD	O	may	aux	86	SENT_300	[p20l1960t2608r2139b2682],
84	be	VB	O	be	cop	86	SENT_300	[p20l12t2710r108b2789],
85	more	RBR	O	more	advmod	86	SENT_300	[p20l144t2736r359b2789],
86	effective	JJ	O	effective	_	0	SENT_300	[p20l396t2709r745b2789],
87	than	IN	O	than	_	0	SENT_300	[p20l782t2710r975b2788],
88	gefitinib	NN	O	gefitinib	prep_than	86	SENT_300	[p20l1010t2709r1373b2811],
89	as	IN	O	as	_	0	SENT_300	[p20l1409t2736r1493b2788],
90	second	JJ	ORDINAL	second	amod	92	SENT_300	[p20l1533t2710r2012b2789],
91	—	NN	O	—	nn	92	SENT_300	[p20l1533t2710r2012b2789],
92	line	NN	O	line	prep_as	86	SENT_300	[p20l1533t2710r2012b2789],
93	or	CC	O	or	_	0	SENT_300	[p20l2049t2736r2137b2789],
94	later	RB	O	later	advmod	95	SENT_300	[p20l11t2838r199b2916],
95	therapy	NN	O	therapy	prep_as	86	SENT_300	[p20l229t2838r555b2937],
96	.	.	O	.	_	0	SENT_300	[p20l229t2838r555b2937],

1	This	DT	O	this	det	2	SENT_301	[p20l590t2838r773b2915],
2	idea	NN	O	idea	nsubj	3	SENT_301	[p20l807t2838r978b2916],
3	needs	VBZ	O	need	_	0	SENT_301	[p20l1009t2838r1248b2916],
4	to	TO	O	to	aux	6	SENT_301	[p20l1282t2854r1363b2916],
5	be	VB	O	be	auxpass	6	SENT_301	[p20l1396t2838r1492b2916],
6	tested	VBN	O	test	xcomp	3	SENT_301	[p20l1524t2838r1773b2916],
7	in	IN	O	in	_	0	SENT_301	[p20l1804t2839r1885b2915],
8	studies	NNS	O	study	prep_in	6	SENT_301	[p20l1919t2838r2133b2917, p20l11t2967r123b3045],
9	with	IN	O	with	_	0	SENT_301	[p20l160t2966r355b3045],
10	large	JJ	O	large	amod	11	SENT_301	[p20l394t2966r608b3067],
11	samples	NNS	O	sample	prep_with	8	SENT_301	[p20l649t2966r994b3066],
12	or	CC	O	or	_	0	SENT_301	[p20l1036t2992r1124b3045],
13	in	IN	O	in	_	0	SENT_301	[p20l1160t2967r1244b3044],
14	a	DT	O	a	det	17	SENT_301	[p20l1282t2992r1327b3044],
15	meta	NN	O	meta	nn	17	SENT_301	[p20l1365t2966r1977b3066],
16	—	NN	O	—	nn	17	SENT_301	[p20l1365t2966r1977b3066],
17	analysis	NN	O	analysis	prep_in	6	SENT_301	[p20l1365t2966r1977b3066],
18	.	.	O	.	_	0	SENT_301	[p20l1365t2966r1977b3066],

1	We	PRP	O	we	nsubj	2	SENT_302	[p20l137t3102r269b3172],
2	believe	VBP	O	believe	_	0	SENT_302	[p20l302t3094r587b3173],
3	that	IN	O	that	complm	18	SENT_302	[p20l620t3094r789b3172],
4	the	DT	O	the	det	9	SENT_302	[p20l817t3094r947b3173],
5	prolonged	JJ	O	prolonged	amod	9	SENT_302	[p20l978t3094r1408b3195],
6	progression	NN	O	progression	nn	9	SENT_302	[p20l1439t3093r2134b3195],
7	—	CD	NUMBER	—	num	9	SENT_302	[p20l1439t3093r2134b3195],
8	free	JJ	O	free	amod	9	SENT_302	[p20l1439t3093r2134b3195],
9	survival	NN	O	survival	nsubj	18	SENT_302	[p20l13t3222r345b3301],
10	provided	VBN	O	provide	partmod	9	SENT_302	[p20l375t3222r750b3322],
11	by	IN	O	by	_	0	SENT_302	[p20l782t3222r879b3322],
12	the	DT	O	the	det	13	SENT_302	[p20l907t3222r1040b3300],
13	use	NN	O	use	agent	10	SENT_302	[p20l1072t3248r1213b3301],
14	of	IN	O	of	_	0	SENT_302	[p20l1246t3221r1346b3301],
15	first-line	JJ	O	first-line	amod	16	SENT_302	[p20l1359t3221r1729b3300],
16	gefitinib	NN	O	gefitinib	prep_of	13	SENT_302	[p20l1761t3221r2133b3323],
17	is	VBZ	O	be	cop	18	SENT_302	[p20l11t3350r76b3427],
18	valuable	JJ	O	valuable	ccomp	2	SENT_302	[p20l107t3349r451b3429],
19	for	IN	O	for	_	0	SENT_302	[p20l485t3348r606b3428],
20	patients	NNS	O	patient	prep_for	18	SENT_302	[p20l635t3350r969b3449],
21	with	IN	O	with	_	0	SENT_302	[p20l1001t3349r1193b3429],
22	advanced	JJ	O	advanced	amod	24	SENT_302	[p20l1226t3349r1615b3429],
23	non	JJ	O	non	amod	24	SENT_302	[p20l1649t3349r2133b3428],
24	—	NN	O	—	prep_with	18	SENT_302	[p20l1649t3349r2133b3428],
25	small	JJ	O	small	amod	29	SENT_302	[p20l1649t3349r2133b3428],
26	—	NN	O	—	nn	29	SENT_302	[p20l1649t3349r2133b3428],
27	cell	NN	O	cell	nn	29	SENT_302	[p20l12t3478r158b3556],
28	lung	NN	O	lung	nn	29	SENT_302	[p20l201t3478r394b3579],
29	cancer	NN	O	cancer	tmod	18	SENT_302	[p20l436t3504r735b3574],
30	,	,	O	,	_	0	SENT_302	[p20l436t3504r735b3574],
31	who	WP	O	who	nsubj	32	SENT_302	[p20l780t3478r963b3557],
32	have	VBP	O	have	rcmod	29	SENT_302	[p20l1009t3478r1198b3557],
33	a	DT	O	a	det	35	SENT_302	[p20l1242t3504r1287b3556],
34	poor	JJ	O	poor	amod	35	SENT_302	[p20l1328t3504r1531b3578],
35	prognosis	NN	O	prognosis	dobj	32	SENT_302	[p20l1571t3479r2022b3579],
36	.	.	O	.	_	0	SENT_302	[p20l1571t3479r2022b3579],

1	If	IN	O	if	mark	4	SENT_303	[p20l2070t3477r2152b3556],
2	gefitinib	NN	O	gefitinib	nsubjpass	4	SENT_303	[p20l12t3605r383b3707],
3	is	VBZ	O	be	auxpass	4	SENT_303	[p20l418t3607r483b3684],
4	administered	VBN	O	administer	_	0	SENT_303	[p20l519t3606r1089b3685],
5	as	IN	O	as	_	0	SENT_303	[p20l1122t3632r1207b3684],
6	second	JJ	ORDINAL	second	amod	8	SENT_303	[p20l1245t3606r1734b3685],
7	—	NN	O	—	nn	8	SENT_303	[p20l1245t3606r1734b3685],
8	line	NN	O	line	prep_as	4	SENT_303	[p20l1245t3606r1734b3685],
9	or	CC	O	or	_	0	SENT_303	[p20l1769t3632r1858b3685],
10	thirdline	NN	O	thirdline	conj_or	8	SENT_303	[p20l1889t3606r2133b3685, p21l11t20r167b98],

1	treatment	NN	O	treatment	nsubj	5	SENT_304	[p21l198t37r633b115],
2	,	,	O	,	_	0	SENT_304	[p21l198t37r633b115],
3	patients	NNS	O	patient	appos	1	SENT_304	[p21l667t21r1002b119],
4	may	MD	O	may	aux	5	SENT_304	[p21l1034t46r1211b119],
5	miss	VB	O	miss	_	0	SENT_304	[p21l1237t21r1432b98],
6	the	DT	O	the	det	7	SENT_304	[p21l1466t20r1596b98],
7	opportunity	NN	O	opportunity	dobj	5	SENT_304	[p21l1628t21r2138b119],
8	to	TO	O	to	aux	9	SENT_304	[p21l12t165r91b227],
9	receive	VB	O	receive	conj_or	9	SENT_304	[p21l128t149r404b227],
10	treatment	NN	O	treatment	dobj	9	SENT_304	[p21l440t165r847b227],
11	with	IN	O	with	_	0	SENT_304	[p21l873t148r1061b227],
12	gefitinib	NN	O	gefitinib	prep_with	10	SENT_304	[p21l1097t147r1451b249],
13	because	IN	O	because	_	0	SENT_304	[p21l1489t148r1812b227],
14	of	IN	O	of	prepc_because_of	9	SENT_304	[p21l1849t147r1946b227],
15	rapidly	RB	O	rapidly	advmod	9	SENT_304	[p21l1963t174r2133b248, p21l11t276r167b376],
16	progressive	JJ	O	progressive	amod	17	SENT_304	[p21l200t277r689b377],
17	disease	NN	O	disease	pobj	9	SENT_304	[p21l729t276r1039b355],
18	during	IN	O	during	_	0	SENT_304	[p21l1079t276r1367b377],
19	or	CC	O	or	_	0	SENT_304	[p21l1403t302r1492b355],
20	after	IN	O	after	_	0	SENT_304	[p21l1526t275r1729b354],
21	first	JJ	ORDINAL	first	amod	24	SENT_304	[p21l1764t275r2134b354],
22	—	NN	O	—	nn	24	SENT_304	[p21l1764t275r2134b354],
23	line	NN	O	line	nn	24	SENT_304	[p21l1764t275r2134b354],
24	treatment	NN	O	treatment	prep_during	9	SENT_304	[p21l12t420r456b482],
25	.	.	O	.	_	0	SENT_304	[p21l12t420r456b482],

1	We	PRP	O	we	nsubj	2	SENT_305	[p21l502t411r635b482],
2	believe	VBP	O	believe	_	0	SENT_305	[p21l680t404r972b483],
3	that	IN	O	that	complm	17	SENT_305	[p21l1016t404r1188b482],
4	the	DT	O	the	det	6	SENT_305	[p21l1227t404r1360b482],
5	current	JJ	DATE	current	amod	6	SENT_305	[p21l1405t421r1719b483],
6	study	NN	O	study	nsubj	17	SENT_305	[p21l1760t404r2002b503],
7	,	,	O	,	_	0	SENT_305	[p21l1760t404r2002b503],
8	in	IN	O	in	_	0	SENT_305	[p21l2051t405r2134b481],
9	combination	NN	O	combination	prep_in	6	SENT_305	[p21l12t531r559b610],
10	with	IN	O	with	_	0	SENT_305	[p21l592t531r788b611],
11	our	PRP$	O	we	poss	13	SENT_305	[p21l826t557r972b610],
12	previous	JJ	O	previous	amod	13	SENT_305	[p21l1005t532r1368b631],
13	study	NN	O	study	prep_with	9	SENT_305	[p21l1409t531r1639b631],
14	of	IN	O	of	_	0	SENT_305	[p21l1673t530r1773b610],
15	patients	NNS	O	patient	prep_of	13	SENT_305	[p21l1791t532r2133b631],
16	with	IN	O	with	prep	15	SENT_305	[p21l7t660r203b739],
17	mutated	VBN	O	mutate	ccomp	2	SENT_305	[p21l250t660r893b743],
18	.	.	O	.	_	0	SENT_305	[p21l250t660r893b743],

1	—	NN	O	—	_	0	SENT_306	[p21l250t660r893b743],
2	.	.	O	.	_	0	SENT_306	[p21l250t660r893b743],

1	EGFR	NN	ORGANIZATION	egfr	nsubj	15	SENT_307	[p21l250t660r893b743],
2	non	JJ	O	non	amod	1	SENT_307	[p21l930t660r1572b739],
3	—	CD	NUMBER	—	num	8	SENT_307	[p21l930t660r1572b739],
4	small	JJ	O	small	amod	8	SENT_307	[p21l930t660r1572b739],
5	—	JJ	O	—	amod	8	SENT_307	[p21l930t660r1572b739],
6	cell	NN	O	cell	nn	8	SENT_307	[p21l930t660r1572b739],
7	lung	NN	O	lung	nn	8	SENT_307	[p21l1618t660r1812b761],
8	cancer	NN	O	cancer	tmod	2	SENT_307	[p21l1856t686r2137b739],
9	and	CC	O	and	_	0	SENT_307	[p21l11t787r169b866],
10	poor	JJ	O	poor	amod	12	SENT_307	[p21l217t813r421b887],
11	performance	NN	O	performance	nn	12	SENT_307	[p21l466t786r1021b887],
12	status	NN	O	status	tmod	2	SENT_307	[p21l1073t791r1427b883],
13	,	,	O	,	_	0	SENT_307	[p21l1073t791r1427b883],
14	”	NN	O	”	appos	8	SENT_307	[p21l1073t791r1427b883],
15	establishes	VBZ	O	establish	_	0	SENT_307	[p21l1480t787r1948b866],
16	the	DT	O	the	det	18	SENT_307	[p21l2001t787r2134b865],
17	clinical	JJ	O	clinical	amod	18	SENT_307	[p21l12t915r326b993],
18	benefit	NN	O	benefit	dobj	15	SENT_307	[p21l374t914r679b994],
19	of	IN	O	of	_	0	SENT_307	[p21l723t914r823b994],
20	an	DT	O	a	det	24	SENT_307	[p21l853t941r955b993],
21	EGFR	NN	ORGANIZATION	egfr	nn	24	SENT_307	[p21l1003t921r1258b999],
22	tyrosine	NN	O	tyrosine	nn	24	SENT_307	[p21l1297t916r1643b1015],
23	kinase	NN	O	kinase	nn	24	SENT_307	[p21l1691t915r1970b995],
24	inhibitor	NN	O	inhibitor	prep_of	18	SENT_307	[p21l2018t916r2133b993, p21l12t1043r291b1122],
25	as	IN	O	as	_	0	SENT_307	[p21l316t1069r399b1121],
26	first	JJ	ORDINAL	first	amod	29	SENT_307	[p21l430t1042r781b1121],
27	—	NN	O	—	nn	29	SENT_307	[p21l430t1042r781b1121],
28	line	NN	O	line	nn	29	SENT_307	[p21l430t1042r781b1121],
29	treatment	NN	O	treatment	prep_as	15	SENT_307	[p21l810t1060r1217b1121],
30	in	IN	O	in	_	0	SENT_307	[p21l1240t1044r1320b1121],
31	patients	NNS	O	patient	prep_in	29	SENT_307	[p21l1348t1044r1675b1143],
32	with	IN	O	with	_	0	SENT_307	[p21l1700t1043r1889b1123],
33	nonsmall	JJ	O	nonsmall	amod	37	SENT_307	[p21l1918t1069r2138b1122, p21l13t1172r432b1250],
34	—	NN	O	—	nn	37	SENT_307	[p21l1918t1069r2138b1122, p21l13t1172r432b1250],
35	cell	NN	O	cell	nn	37	SENT_307	[p21l1918t1069r2138b1122, p21l13t1172r432b1250],
36	lung	NN	O	lung	nn	37	SENT_307	[p21l466t1172r660b1273],
37	cancer	NN	O	cancer	prep_with	31	SENT_307	[p21l693t1198r974b1250],
38	and	CC	O	and	_	0	SENT_307	[p21l1008t1172r1165b1251],
39	sensitive	JJ	O	sensitive	amod	41	SENT_307	[p21l1203t1173r1566b1251],
40	EGFR	NN	ORGANIZATION	egfr	nn	41	SENT_307	[p21l1601t1178r1858b1255],
41	mutations	NNS	O	mutation	prep_with	31	SENT_307	[p21l1884t1189r2133b1251, p21l12t1301r248b1378],
42	.	.	O	.	_	0	SENT_307	[p21l1884t1189r2133b1251, p21l12t1301r248b1378],

1	Predictable	JJ	O	predictable	amod	3	SENT_308	[p21l140t1426r596b1505],
2	toxicity	NN	O	toxicity	nn	3	SENT_308	[p21l631t1427r934b1526],
3	profiles	NNS	O	profile	nsubjpass	5	SENT_308	[p21l963t1425r1279b1526],
4	were	VBD	O	be	auxpass	5	SENT_308	[p21l1311t1452r1507b1506],
5	observed	VBN	O	observe	_	0	SENT_308	[p21l1543t1426r1908b1505],
6	with	IN	O	with	_	0	SENT_308	[p21l1939t1426r2134b1506],
7	gefitinib	NN	O	gefitinib	prep_with	5	SENT_308	[p21l12t1554r392b1656],
8	and	CC	O	and	_	0	SENT_308	[p21l430t1555r590b1634],
9	with	IN	O	with	_	0	SENT_308	[p21l622t1555r820b1634],
10	carboplatin	NN	O	carboplatin	nn	12	SENT_308	[p21l858t1555r1841b1655],
11	—	CD	NUMBER	—	num	12	SENT_308	[p21l858t1555r1841b1655],
12	paclitaxel	NN	O	paclitaxel	prep_with	5	SENT_308	[p21l858t1555r1841b1655],
13	in	IN	O	in	_	0	SENT_308	[p21l1877t1556r1961b1633],
14	the	DT	O	the	det	16	SENT_308	[p21l1999t1555r2134b1633],
15	current	JJ	DATE	current	amod	16	SENT_308	[p21l12t1700r327b1762],
16	study	NN	O	study	prep_in	12	SENT_308	[p21l355t1683r598b1782],
17	.	.	O	.	_	0	SENT_308	[p21l355t1683r598b1782],

1	Diarrhea	NNP	MISC	Diarrhea	nsubjpass	5	SENT_309	[p21l634t1683r1013b1761],
2	and	CC	O	and	_	0	SENT_309	[p21l1043t1683r1200b1761],
3	rash	NN	O	rash	nsubjpass	5	SENT_309	[p21l1232t1683r1414b1760],
4	were	VBD	O	be	auxpass	5	SENT_309	[p21l1442t1709r1648b1762],
5	seen	VBN	O	see	_	0	SENT_309	[p21l1684t1709r1876b1761],
6	more	RBR	O	more	advmod	7	SENT_309	[p21l1911t1709r2134b1761],
7	often	RB	O	often	advmod	5	SENT_309	[p21l12t1810r230b1890],
8	in	IN	O	in	_	0	SENT_309	[p21l261t1812r344b1889],
9	the	DT	O	the	det	11	SENT_309	[p21l376t1811r505b1889],
10	gefitinib	JJ	O	gefitinib	amod	11	SENT_309	[p21l537t1810r900b1912],
11	group	NN	O	group	prep_in	5	SENT_309	[p21l933t1837r1202b1912],
12	,	,	O	,	_	0	SENT_309	[p21l933t1837r1202b1912],
13	Whereas	IN	O	whereas	mark	21	SENT_309	[p21l1235t1811r1579b1890],
14	hematologic	JJ	O	hematologic	amod	18	SENT_309	[p21l1613t1811r2135b1912],
15	and	CC	O	and	_	0	SENT_309	[p21l11t1939r167b2018],
16	neurologic	JJ	O	neurologic	conj_and	14	SENT_309	[p21l205t1939r654b2040],
17	toxic	JJ	O	toxic	amod	18	SENT_309	[p21l692t1940r894b2018],
18	effects	NNS	O	effect	nsubj	21	SENT_309	[p21l932t1938r1211b2017],
19	were	VBD	O	be	cop	21	SENT_309	[p21l1249t1965r1451b2018],
20	more	RBR	O	more	advmod	21	SENT_309	[p21l1492t1965r1711b2018],
21	common	JJ	O	common	dep	5	SENT_309	[p21l1753t1965r2134b2018],
22	in	IN	O	in	_	0	SENT_309	[p21l11t2068r95b2145],
23	the	DT	O	the	det	25	SENT_309	[p21l133t2067r265b2145],
24	chemotherapy	NN	O	chemotherapy	nn	25	SENT_309	[p21l305t2067r915b2167],
25	group	NN	O	group	prep_in	21	SENT_309	[p21l949t2093r1223b2168],
26	.	.	O	.	_	0	SENT_309	[p21l949t2093r1223b2168],

1	Geﬁtinib	NN	O	geﬁtinib	nsubj	2	SENT_310	[p21l1267t2066r1652b2146],
2	appears	VBZ	O	appear	_	0	SENT_310	[p21l1689t2093r2014b2167],
3	to	TO	O	to	prep	2	SENT_310	[p21l2053t2084r2133b2146],

1	2386	CD	DATE	2386	num	4	SENT_311	[p21l149t2243r226b2267],
2	N	NN	O	n	nn	4	SENT_311	[p21l963t2254r977b2269],
3	ENGL	NN	ORGANIZATION	engl	nn	4	SENT_311	[p21l991t2254r1055b2270],
4	MED	NN	O	med	_	0	SENT_311	[p21l1084t2254r1136b2269],
5	362	CD	NUMBER	362	dep	4	SENT_311	[p21l1146t2248r1225b2276],
6	;	:	O	;	_	0	SENT_311	[p21l1146t2248r1225b2276],
7	25	CD	NUMBER	25	num	8	SENT_311	[p21l1146t2248r1225b2276],
8	NE	NNS	O	ne	dep	5	SENT_311	[p21l1260t2254r1290b2269],
9	M.ORG	NNP	O	M.ORG	nn	10	SENT_311	[p21l1305t2254r1384b2270],
10	JUNE	NNP	DATE	JUNE	dep	8	SENT_311	[p21l1415t2254r1479b2276],
11	24	CD	DATE	24	num	10	SENT_311	[p21l1490t2254r1526b2276],
12	,	,	DATE	,	_	0	SENT_311	[p21l1490t2254r1526b2276],
13	2010	CD	DATE	2010	num	10	SENT_311	[p21l1537t2254r1597b2270],

1	The	DT	O	the	det	3	SENT_312	[p21l936t2287r987b2311],
2	New	JJ	O	new	amod	3	SENT_312	[p21l996t2288r1058b2311],
3	land	NN	O	land	_	0	SENT_312	[p21l1122t2287r1178b2311],
4	Journ	NNP	O	Journ	nn	5	SENT_312	[p21l1187t2288r1260b2311],
5	Medicine	NNP	O	Medicine	dep	3	SENT_312	[p21l1330t2287r1455b2311],

1	Copyright	NN	O	copyright	_	0	SENT_313	[p21l729t2369r863b2400],
2	©	CD	NUMBER	©	num	6	SENT_313	[p21l872t2369r896b2393],
3	2010	CD	DATE	2010	num	6	SENT_313	[p21l906t2369r971b2393],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_313	[p21l980t2369r1171b2393],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_313	[p21l1181t2369r1289b2393],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_313	[p21l1300t2369r1405b2400],
7	.	.	O	.	_	0	SENT_313	[p21l1300t2369r1405b2400],

1	All	DT	O	all	det	2	SENT_314	[p21l1416t2369r1457b2393],
2	rights	NNS	O	rights	nsubj	3	SENT_314	[p21l1466t2369r1541b2400],
3	reserved	VBN	O	reserve	_	0	SENT_314	[p21l1551t2369r1669b2393],
4	.	.	O	.	_	0	SENT_314	[p21l1551t2369r1669b2393],

1	GEFITINIB	NNP	O	GEFITINIB	nn	3	SENT_315	[p21l352t2412r528b2431],
2	OR	NN	O	or	nn	3	SENT_315	[p21l542t2412r587b2431],
3	CHEMOTHERAPY	NNP	O	CHEMOTHERAPY	_	0	SENT_315	[p21l599t2412r876b2431],
4	FOR	IN	O	for	_	0	SENT_315	[p21l889t2412r954b2431],
5	NON	NNP	O	NON	prep_for	3	SENT_315	[p21l967t2412r1269b2431],
6	.	.	O	.	_	0	SENT_315	[p21l967t2412r1269b2431],

1	—	NN	O	—	_	0	SENT_316	[p21l967t2412r1269b2431],
2	.	.	O	.	_	0	SENT_316	[p21l967t2412r1269b2431],

1	SMALL-CELL	NN	O	small-cell	nn	2	SENT_317	[p21l967t2412r1269b2431],
2	LUNG	NN	O	lung	_	0	SENT_317	[p21l1283t2412r1375b2431],
3	CANCER	NNP	O	CANCER	dep	2	SENT_317	[p21l1388t2412r1522b2431],

1	Table	NNP	O	Table	_	0	SENT_318	[p21l119t2533r193b2558],
2	3	CD	NUMBER	3	dep	1	SENT_318	[p21l202t2535r225b2558],
3	.	.	O	.	_	0	SENT_318	[p21l202t2535r225b2558],

1	Common	JJ	O	common	amod	3	SENT_319	[p21l234t2535r360b2558],
2	Toxic	JJ	O	toxic	amod	3	SENT_319	[p21l370t2534r443b2558],
3	Effects	NNS	O	effect	_	0	SENT_319	[p21l454t2533r543b2558],
4	in	IN	O	in	_	0	SENT_319	[p21l553t2534r576b2558],
5	the	DT	O	the	det	7	SENT_319	[p21l585t2533r629b2558],
6	Safety	NN	ORGANIZATION	safety	nn	7	SENT_319	[p21l638t2533r721b2566],
7	Population	NNP	ORGANIZATION	Population	prep_in	3	SENT_319	[p21l731t2533r885b2566],
8	,	,	O	,	_	0	SENT_319	[p21l731t2533r885b2566],
9	According	VBG	O	accord	_	0	SENT_319	[p21l894t2533r1033b2566],
10	to	TO	O	to	prepc_according_to	3	SENT_319	[p21l1041t2537r1068b2558],
11	Treatment	NNP	ORGANIZATION	Treatment	nn	12	SENT_319	[p21l1076t2536r1219b2558],
12	Group	NNP	ORGANIZATION	Group	pobj	3	SENT_319	[p21l1228t2535r1340b2566],
13	.	.	O	.	_	0	SENT_319	[p21l1228t2535r1340b2566],

1	*	NN	O	*	_	0	SENT_320	[p21l1228t2535r1340b2566],

1	P	NN	O	p	nn	2	SENT_321	[p21l1895t2611r1911b2633],
2	Value	NN	O	value	_	0	SENT_321	[p21l1920t2608r1997b2634],
3	for	IN	O	for	_	0	SENT_321	[p21l2006t2608r2045b2634],
4	Toxic	JJ	O	toxic	amod	6	SENT_321	[p21l119t2647r192b2671],
5	Effect	NN	O	effect	nn	6	SENT_321	[p21l204t2646r279b2671],
6	Geﬁtinib	NN	O	geﬁtinib	prep_for	2	SENT_321	[p21l723t2646r841b2671],
7	(	CD	NUMBER	(	num	8	SENT_321	[p21l854t2648r884b2679],
8	N	NN	O	n	dep	2	SENT_321	[p21l854t2648r884b2679],
9	=	JJ	O	=	quantmod	11	SENT_321	[p21l891t2658r909b2667],
10	114	CD	NUMBER	114	number	11	SENT_321	[p21l916t2648r971b2679],
11	)	CD	NUMBER	)	num	14	SENT_321	[p21l916t2648r971b2679],
12	Carbop	NNP	O	Carbop	nn	14	SENT_321	[p21l1305t2646r1609b2678],
13	|	CD	NUMBER	|	num	14	SENT_321	[p21l1305t2646r1609b2678],
14	atin	NN	O	atin	dep	8	SENT_321	[p21l1305t2646r1609b2678],
15	.	.	O	.	_	0	SENT_321	[p21l1305t2646r1609b2678],

1	—	NN	O	—	_	0	SENT_322	[p21l1305t2646r1609b2678],
2	.	.	O	.	_	0	SENT_322	[p21l1305t2646r1609b2678],

1	Pac	NN	O	pac	_	0	SENT_323	[p21l1305t2646r1609b2678],
2	|	SYM	O	|	dep	5	SENT_323	[p21l1305t2646r1609b2678],
3	itaxe	FW	O	itaxe	nn	5	SENT_323	[p21l1305t2646r1609b2678],
4	|	FW	O	|	nn	5	SENT_323	[p21l1305t2646r1609b2678],
5	(	FW	O	(	rcmod	1	SENT_323	[p21l1623t2648r1653b2679],
6	N	NN	O	n	dep	7	SENT_323	[p21l1623t2648r1653b2679],
7	=	JJ	O	=	amod	1	SENT_323	[p21l1661t2658r1678b2667],
8	113	CD	NUMBER	113	number	9	SENT_323	[p21l1685t2648r1741b2679],
9	)	CD	NUMBER	)	dep	1	SENT_323	[p21l1685t2648r1741b2679],
10	Grade	NNP	O	Grade	dep	9	SENT_323	[p21l1905t2646r1988b2671],
11	23	CD	NUMBER	23	num	10	SENT_323	[p21l1999t2648r2030b2671],

1	Grade	NNP	O	Grade	dep	28	SENT_324	[p21l533t2704r615b2729],
2	1	CD	NUMBER	1	num	21	SENT_324	[p21l626t2706r638b2728],
3	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l658t2704r740b2729],
4	2	CD	NUMBER	2	num	21	SENT_324	[p21l750t2706r763b2728],
5	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l783t2704r865b2729],
6	3	CD	NUMBER	3	num	21	SENT_324	[p21l875t2706r887b2729],
7	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l908t2704r990b2729],
8	4	CD	NUMBER	4	num	21	SENT_324	[p21l999t2706r1014b2728],
9	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l1036t2704r1118b2729],
10	23	CD	NUMBER	23	num	21	SENT_324	[p21l1128t2706r1159b2729],
11	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l1208t2704r1290b2729],
12	1	CD	NUMBER	1	num	21	SENT_324	[p21l1302t2706r1313b2728],
13	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l1333t2704r1415b2729],
14	2	CD	NUMBER	2	num	21	SENT_324	[p21l1425t2706r1439b2728],
15	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l1458t2704r1540b2729],
16	3	CD	NUMBER	3	num	21	SENT_324	[p21l1550t2706r1562b2729],
17	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l1583t2704r1665b2729],
18	4	CD	NUMBER	4	num	21	SENT_324	[p21l1674t2706r1689b2728],
19	Grade	NNP	O	Grade	nn	21	SENT_324	[p21l1711t2704r1793b2729],
20	23	CD	NUMBER	23	num	21	SENT_324	[p21l1803t2706r1834b2729],
21	no.	NN	O	no.	rcmod	1	SENT_324	[p21l682t2770r719b2787],
22	of	IN	O	of	_	0	SENT_324	[p21l731t2761r761b2795],
23	patients	NNS	O	patient	prep_of	1	SENT_324	[p21l762t2762r866b2794],
24	no.	IN	O	no.	_	0	SENT_324	[p21l1049t2770r1086b2787],
25	(	CD	PERCENT	(	num	26	SENT_324	[p21l1100t2763r1146b2794],
26	%	NN	PERCENT	%	prep_no.	23	SENT_324	[p21l1100t2763r1146b2794],
27	)	CD	NUMBER	)	dep	28	SENT_324	[p21l1100t2763r1146b2794],
28	no.	NN	O	no.	dep	34	SENT_324	[p21l1357t2770r1394b2787],
29	of	IN	O	of	_	0	SENT_324	[p21l1406t2761r1436b2795],
30	patients	NNS	O	patient	prep_of	28	SENT_324	[p21l1437t2763r1541b2794],
31	no.	IN	O	no.	_	0	SENT_324	[p21l1724t2770r1761b2787],
32	(	CD	PERCENT	(	num	33	SENT_324	[p21l1776t2763r1821b2794],
33	%	NN	PERCENT	%	prep_no.	30	SENT_324	[p21l1776t2763r1821b2794],
34	)	CD	NUMBER	)	_	0	SENT_324	[p21l1776t2763r1821b2794],

1	1	CD	NUMBER	1	num	3	SENT_325	[p21l843t2821r854b2844],
2	1	CD	NUMBER	1	num	3	SENT_325	[p21l1056t2821r1067b2844],
3	(	NN	O	(	_	0	SENT_325	[p21l1082t2821r1140b2852],
4	0.9	CD	NUMBER	0.9	num	5	SENT_325	[p21l1082t2821r1140b2852],
5	)	NN	O	)	dep	3	SENT_325	[p21l1082t2821r1140b2852],
6	7	CD	NUMBER	7	num	9	SENT_325	[p21l1264t2821r1276b2844],
7	o	NN	O	o	nn	9	SENT_325	[p21l1391t2821r1406b2844],
8	o	NN	O	o	nn	9	SENT_325	[p21l1516t2821r1531b2844],
9	o	NN	O	o	dep	3	SENT_325	[p21l1733t2821r1748b2844],

1	1	LS	NUMBER	1	_	0	SENT_326	[p21l971t3167r987b3198],
2	-	:	O	-	_	0	SENT_326	[p21l971t3167r987b3198],
3	3	CD	DATE	3	number	4	SENT_326	[p21l1055t3167r1067b3190],
4	(	NN	O	(	amod	8	SENT_326	[p21l1082t3167r1140b3198],
5	2.5	CD	NUMBER	2.5	number	7	SENT_326	[p21l1082t3167r1140b3198],
6	)	NN	O	)	dep	7	SENT_326	[p21l1082t3167r1140b3198],
7	o	NN	O	o	amod	8	SENT_326	[p21l1516t3166r1531b3190],
8	o	NN	O	o	dep	1	SENT_326	[p21l1733t3166r1748b3190],

1	Diarrhea	NNP	O	Diarrhea	_	0	SENT_327	[p21l122t2819r237b2844],
2	32	CD	NUMBER	32	num	4	SENT_327	[p21l575t2821r605b2844],
3	Appetite	NN	O	appetite	nn	4	SENT_327	[p21l119t2878r234b2910],
4	loss	NN	O	loss	dep	1	SENT_327	[p21l245t2877r297b2902],

1	\	RB	O	\	advmod	2	SENT_328	[p21l715t2821r730b3017],
2	|	CD	NUMBER	|	nsubj	3	SENT_328	[p21l715t2821r730b3017],
3	i	LS	O	i	_	0	SENT_328	[p21l715t2821r730b3017],
4	.	.	O	.	_	0	SENT_328	[p21l715t2821r730b3017],

1	—	NN	O	—	_	0	SENT_329	[p21l715t2821r730b3017],
2	.	.	O	.	_	0	SENT_329	[p21l715t2821r730b3017],

1	I.	NN	O	i.	nn	2	SENT_330	[p21l715t2821r730b3017],
2	l	NN	O	l	dep	11	SENT_330	[p21l715t2821r730b3017],
3	>	JJR	O	>	amod	5	SENT_330	[p21l715t2821r730b3017],
4	O	NN	O	o	nn	5	SENT_330	[p21l715t2821r730b3017],
5	\	NN	O	\	dep	2	SENT_330	[p21l715t2821r730b3017],
6	7	CD	NUMBER	7	num	7	SENT_330	[p21l593t2879r605b2902],
7	Fatigue	NN	O	fatigue	dep	11	SENT_330	[p21l122t2937r220b2968],
8	8	CD	NUMBER	8	num	11	SENT_330	[p21l591t2936r605b2960],
9	Rash	NNP	O	Rash	nn	11	SENT_330	[p21l122t2992r185b3017],
10	38	CD	NUMBER	38	num	11	SENT_330	[p21l575t2994r605b3017],
11	Neuropathy	NNP	O	Neuropathy	dep	16	SENT_330	[p21l122t3050r282b3083],
12	(	CD	NUMBER	(	num	15	SENT_330	[p21l294t3052r417b3083],
13	sensory	JJ	O	sensory	amod	15	SENT_330	[p21l294t3052r417b3083],
14	)	NN	O	)	nn	15	SENT_330	[p21l294t3052r417b3083],
15	o	NN	O	o	dep	11	SENT_330	[p21l591t3051r606b3075],
16	Arthralgia	NN	ORGANIZATION	arthralgium	dep	18	SENT_330	[p21l119t3107r253b3140],
17	1	CD	NUMBER	1	num	16	SENT_330	[p21l593t3110r604b3132],
18	Pneumonitis	NN	ORGANIZATION	pneumonitis	dep	20	SENT_330	[p21l122t3167r293b3190],
19	3	CD	NUMBER	3	num	18	SENT_330	[p21l592t3167r604b3190],
20	o	NN	O	o	_	0	SENT_330	[p21l591t3224r606b3248],
21	EN	IN	O	en	dep	20	SENT_330	[p21l700t2994r712b3017],

1	Aminotransferase	NN	O	aminotransferase	nn	2	SENT_331	[p21l119t3222r364b3248],
2	elevation	NN	O	elevation	_	0	SENT_331	[p21l373t3223r494b3248],
3	2	CD	NUMBER	2	num	4	SENT_331	[p21l575t3225r588b3247],
4	2	CD	NUMBER	2	dep	2	SENT_331	[p21l825t3225r838b3247],

1	D	NN	O	d	_	0	SENT_332	[p21l1625t3282r1638b3305],
2	)	CD	NUMBER	)	num	1	SENT_332	[p21l1625t3282r1638b3305],
3	I	PRP	O	I	dep	1	SENT_332	[p21l1641t2821r1656b3420],
4	.	.	O	.	_	0	SENT_332	[p21l1641t2821r1656b3420],

1	—	NN	O	—	_	0	SENT_333	[p21l1641t2821r1656b3420],
2	.	.	O	.	_	0	SENT_333	[p21l1641t2821r1656b3420],

1	|	NN	O	|	nn	2	SENT_334	[p21l1641t2821r1656b3420],
2	O	NN	O	o	_	0	SENT_334	[p21l1641t2821r1656b3420],
3	\	CD	NUMBER	\	num	4	SENT_334	[p21l1641t2821r1656b3420],
4	l	NN	O	l	dep	2	SENT_334	[p21l1641t2821r1656b3420],
5	|	NN	O	|	dep	4	SENT_334	[p21l1641t2821r1656b3420],
6	.	.	O	.	_	0	SENT_334	[p21l1641t2821r1656b3420],

1	—	NN	O	—	_	0	SENT_335	[p21l1641t2821r1656b3420],
2	.	.	O	.	_	0	SENT_335	[p21l1641t2821r1656b3420],
3	'	''	O	'	_	0	SENT_335	[p21l1641t2821r1656b3420],

1	OOOOOOO	NNP	O	OOOOOOO	_	0	SENT_336	[p21l1641t2821r1656b3420],

1	Neutropenia	NN	O	neutropenia	nn	3	SENT_337	[p21l122t3282r292b3313],
2	5	CD	NUMBER	5	num	3	SENT_337	[p21l592t3282r604b3305],
3	Anemia	NN	O	anemia	dep	13	SENT_337	[p21l119t3339r223b3363],
4	19	CD	NUMBER	19	num	5	SENT_337	[p21l577t3340r605b3363],
5	Thrombocytopenia	NN	ORGANIZATION	thrombocytopenia	dep	3	SENT_337	[p21l119t3395r378b3428],
6	8	CD	NUMBER	8	num	8	SENT_337	[p21l591t3397r605b3421],
7	o	NN	O	o	nn	8	SENT_337	[p21l841t3397r856b3421],
8	o	NN	O	o	dep	5	SENT_337	[p21l954t3397r969b3421],
9	o	NN	O	o	dep	13	SENT_337	[p21l1054t3397r1069b3421],
10	25	CD	NUMBER	25	num	9	SENT_337	[p21l1246t3398r1275b3421],
11	Any	DT	O	any	det	13	SENT_337	[p21l119t3455r170b3486],
12	17	CD	NUMBER	17	num	13	SENT_337	[p21l577t3455r606b3478],
13	44	CD	NUMBER	44	dep	22	SENT_337	[p21l699t3455r730b3478],
14	43	CD	NUMBER	43	num	15	SENT_337	[p21l824t3455r854b3478],
15	4	CD	NUMBER	4	dep	13	SENT_337	[p21l953t3455r987b3486],
16	'	''	O	'	_	0	SENT_337	[p21l953t3455r987b3486],
17	)	CD	NUMBER	)	dep	15	SENT_337	[p21l953t3455r987b3486],
18	‘	CD	NUMBER	‘	number	19	SENT_337	[p21l953t3455r987b3486],
19	47	CD	NUMBER	47	num	21	SENT_337	[p21l1037t3455r1069b3478],
20	(	CD	NUMBER	(	number	21	SENT_337	[p21l1082t3455r1156b3486],
21	41.2	CD	NUMBER	41.2	dep	15	SENT_337	[p21l1082t3455r1156b3486],
22	)	NN	O	)	_	0	SENT_337	[p21l1082t3455r1156b3486],
23	4	CD	NUMBER	4	num	22	SENT_337	[p21l1262t3455r1277b3478],

1	©	NN	O	©	_	0	SENT_338	[p21l953t2821r969b3363],
2	I	NN	O	i	dep	1	SENT_338	[p21l953t2821r969b3363],
3	.	.	O	.	_	0	SENT_338	[p21l953t2821r969b3363],

1	—	NN	O	—	_	0	SENT_339	[p21l953t2821r969b3363],
2	.	.	O	.	_	0	SENT_339	[p21l953t2821r969b3363],
3	'	''	O	'	_	0	SENT_339	[p21l953t2821r969b3363],

1	|	NN	O	|	_	0	SENT_340	[p21l953t2821r969b3363],
2	.	.	O	.	_	0	SENT_340	[p21l953t2821r969b3363],

1	—	NN	O	—	_	0	SENT_341	[p21l953t2821r969b3363],
2	.	.	O	.	_	0	SENT_341	[p21l953t2821r969b3363],
3	'	''	O	'	_	0	SENT_341	[p21l953t2821r969b3363],

1	|	NN	O	|	_	0	SENT_342	[p21l953t2821r969b3363],
2	.	.	O	.	_	0	SENT_342	[p21l953t2821r969b3363],

1	—	NN	O	—	_	0	SENT_343	[p21l953t2821r969b3363],
2	.	.	O	.	_	0	SENT_343	[p21l953t2821r969b3363],
3	'	''	O	'	_	0	SENT_343	[p21l953t2821r969b3363],

1	©	NN	O	©	nn	2	SENT_344	[p21l953t2821r969b3363],
2	C	NN	O	c	_	0	SENT_344	[p21l953t2821r969b3363],
3	©	CD	NUMBER	©	dep	2	SENT_344	[p21l953t2821r969b3363],
4	$	$	MONEY	$	amod	6	SENT_344	[p21l953t2821r969b3363],
5	3	CD	MONEY	3	number	4	SENT_344	[p21l953t2821r969b3363],
6	©	NN	O	©	dep	3	SENT_344	[p21l953t2821r969b3363],
7	6	CD	NUMBER	6	number	8	SENT_344	[p21l842t2879r855b2902],
8	3	CD	NUMBER	3	dep	2	SENT_344	[p21l842t2936r854b2959],
9	6	CD	NUMBER	6	num	10	SENT_344	[p21l842t2994r856b3017],
10	o	NN	O	o	dep	8	SENT_344	[p21l841t3051r856b3075],
11	1	CD	NUMBER	1	number	12	SENT_344	[p21l843t3110r854b3132],
12	2	CD	NUMBER	2	dep	2	SENT_344	[p21l841t3167r855b3190],
13	9	CD	NUMBER	9	num	15	SENT_344	[p21l842t3225r855b3248],
14	O	NN	O	o	nn	15	SENT_344	[p21l841t3282r856b3305],
15	o	NN	O	o	dep	12	SENT_344	[p21l841t3339r856b3363],
16	1-4	CD	NUMBER	1-4	num	17	SENT_344	[p21l701t3225r713b3247],
17	OM1-LaJOI	NN	O	om1-lajous	dep	2	SENT_344	[p21l716t3052r731b3421],
18	\	CD	NUMBER	\	number	19	SENT_344	[p21l716t3052r731b3421],
19	)	CD	NUMBER	)	dep	17	SENT_344	[p21l716t3052r731b3421],
20	i	LS	O	i	dep	19	SENT_344	[p21l716t3052r731b3421],
21	.	.	O	.	_	0	SENT_344	[p21l716t3052r731b3421],

1	—	NN	O	—	_	0	SENT_345	[p21l716t3052r731b3421],
2	.	.	O	.	_	0	SENT_345	[p21l716t3052r731b3421],

1	I	PRP	O	I	_	0	SENT_346	[p21l716t3052r731b3421],
2	-	:	O	-	_	0	SENT_346	[p21l1624t3455r1639b3478],
3	Ix	NN	O	ix	nn	4	SENT_346	[p21l1624t3455r1639b3478],
4	O	NN	O	o	dep	1	SENT_346	[p21l1641t3455r1656b3478],

1	*	NN	O	*	nn	3	SENT_347	[p21l93t3540r109b3555],
2	Toxic-effect	JJ	O	toxic-effect	amod	3	SENT_347	[p21l118t3538r274b3563],
3	grades	NNS	O	grade	nsubj	5	SENT_347	[p21l285t3538r374b3571],
4	are	VBP	O	be	cop	5	SENT_347	[p21l387t3547r427b3563],
5	ba	NN	O	ba	_	0	SENT_347	[p21l439t3538r469b3563],
6	on	IN	O	on	_	0	SENT_347	[p21l529t3547r561b3563],
7	th	DT	O	th	det	15	SENT_347	[p21l573t3538r599b3563],
8	ational	JJ	O	ational	amod	15	SENT_347	[p21l653t3538r743b3563],
9	Cancer	NNP	ORGANIZATION	Cancer	nn	15	SENT_347	[p21l756t3540r851b3563],
10	Institute	NNP	ORGANIZATION	Institute	nn	15	SENT_347	[p21l863t3540r975b3563],
11	Common	NNP	O	Common	nn	15	SENT_347	[p21l986t3540r1113b3563],
12	Terminology	NNP	O	Terminology	nn	15	SENT_347	[p21l1124t3538r1298b3571],
13	Criteria	NNP	O	Criteria	nn	15	SENT_347	[p21l1308t3540r1406b3563],
14	(	CD	NUMBER	(	num	15	SENT_347	[p21l1421t3540r1528b3571],
15	version	NN	O	version	prep_on	5	SENT_347	[p21l1421t3540r1528b3571],
16	3.0	CD	NUMBER	3.0	num	17	SENT_347	[p21l1541t3540r1599b3571],
17	)	NN	O	)	dep	15	SENT_347	[p21l1541t3540r1599b3571],
18	.	.	O	.	_	0	SENT_347	[p21l1541t3540r1599b3571],

1	T	NN	O	t	nsubj	4	SENT_348	[p21l94t3577r110b3608],
2	One	CD	NUMBER	one	num	3	SENT_348	[p21l119t3577r176b3600],
3	patient	NN	O	patient	dep	1	SENT_348	[p21l188t3577r282b3608],
4	counted	VBD	O	count	_	0	SENT_348	[p21l293t3575r402b3600],
5	her	PRP$	O	she	poss	6	SENT_348	[p21l416t3575r458b3600],
6	d	NN	O	d	nsubj	11	SENT_348	[p21l518t3575r532b3600],
7	a	DT	O	a	det	11	SENT_348	[p21l545t3584r558b3600],
8	gr	NN	O	gr	nn	11	SENT_348	[p21l570t3584r597b3608],
9	5	CD	NUMBER	5	num	11	SENT_348	[p21l657t3577r670b3600],
10	toxic	JJ	O	toxic	amod	11	SENT_348	[p21l682t3577r746b3600],
11	effect	NN	O	effect	xcomp	4	SENT_348	[p21l756t3575r836b3600],
12	.	.	O	.	_	0	SENT_348	[p21l756t3575r836b3600],

1	be	VB	O	be	cop	3	SENT_349	[p22l11t98r106b176],
2	less	RBR	O	less	advmod	3	SENT_349	[p22l135t97r288b176],
3	toxic	JJ	O	toxic	_	0	SENT_349	[p22l321t98r523b176],
4	than	IN	O	than	_	0	SENT_349	[p22l553t98r748b176],
5	carboplatin	NN	O	carboplatin	nn	7	SENT_349	[p22l778t98r1744b198],
6	—	CD	NUMBER	—	num	7	SENT_349	[p22l778t98r1744b198],
7	paclitaxel	NN	O	paclitaxel	prep_than	3	SENT_349	[p22l778t98r1744b198],
8	.	.	O	.	_	0	SENT_349	[p22l778t98r1744b198],

1	The	DT	O	the	det	3	SENT_350	[p22l1776t98r1935b176],
2	only	JJ	O	only	amod	3	SENT_350	[p22l1966t98r2148b198],
3	exception	NN	O	exception	nsubj	7	SENT_350	[p22l11t226r414b326],
4	was	VBD	O	be	cop	7	SENT_350	[p22l443t252r604b305],
5	interstitial	JJ	O	interstitial	amod	7	SENT_350	[p22l638t225r1082b304],
6	lung	NN	O	lung	nn	7	SENT_350	[p22l1115t226r1306b326],
7	disease	NN	O	disease	_	0	SENT_350	[p22l1336t225r1664b321],
8	;	:	O	;	_	0	SENT_350	[p22l1336t225r1664b321],
9	there	EX	O	there	expl	10	SENT_350	[p22l1702t226r1915b304],
10	were	VBD	O	be	parataxis	7	SENT_350	[p22l1943t252r2143b305],
11	three	CD	NUMBER	three	num	12	SENT_350	[p22l11t353r226b432],
12	cases	NNS	O	case	nsubj	10	SENT_350	[p22l295t380r513b432],
13	of	IN	O	of	_	0	SENT_350	[p22l583t353r682b432],
14	severe	JJ	O	severe	amod	17	SENT_350	[p22l732t380r985b433],
15	interstitial	JJ	O	interstitial	amod	17	SENT_350	[p22l1051t354r1504b432],
16	lung	NN	O	lung	nn	17	SENT_350	[p22l1571t354r1765b454],
17	disease	NN	O	disease	prep_of	12	SENT_350	[p22l1831t353r2143b432],
18	(	CD	NUMBER	(	num	19	SENT_350	[p22l15t481r339b582],
19	Zgrade	NN	O	zgrade	dep	17	SENT_350	[p22l15t481r339b582],
20	3	CD	NUMBER	3	num	21	SENT_350	[p22l374t487r446b573],
21	)	NN	O	)	dep	17	SENT_350	[p22l374t487r446b573],
22	in	IN	O	in	_	0	SENT_350	[p22l484t482r567b559],
23	the	DT	O	the	det	25	SENT_350	[p22l600t482r733b560],
24	gefitinib	JJ	O	gefitinib	amod	25	SENT_350	[p22l766t481r1139b582],
25	group	NN	O	group	prep_in	21	SENT_350	[p22l1174t507r1427b582],
26	and	CC	O	and	_	0	SENT_350	[p22l1460t482r1619b560],
27	none	NN	O	none	conj_and	17	SENT_350	[p22l1651t507r1861b560],
28	in	IN	O	in	_	0	SENT_350	[p22l1893t482r1977b559],
29	the	DT	O	the	det	31	SENT_350	[p22l2010t482r2143b560],
30	chemotherapy	NN	O	chemotherapy	nn	31	SENT_350	[p22l11t610r624b710],
31	group	NN	O	group	prep_in	27	SENT_350	[p22l658t635r936b710],
32	;	:	O	;	_	0	SENT_350	[p22l658t635r936b710],
33	one	CD	NUMBER	one	nsubj	38	SENT_350	[p22l978t635r1130b688],
34	of	IN	O	of	_	0	SENT_350	[p22l1169t609r1269b688],
35	the	DT	O	the	det	36	SENT_350	[p22l1289t609r1422b688],
36	cases	NNS	O	case	prep_of	33	SENT_350	[p22l1461t636r1684b688],
37	Was	VBD	O	be	cop	38	SENT_350	[p22l1720t636r1883b689],
38	fatal	JJ	O	fatal	parataxis	7	SENT_350	[p22l1923t609r2138b688],
39	.	.	O	.	_	0	SENT_350	[p22l1923t609r2138b688],

1	The	DT	O	the	det	2	SENT_351	[p22l7t738r168b816],
2	patient	NN	O	patient	nsubj	7	SENT_351	[p22l205t738r509b838],
3	who	WP	O	who	nsubj	4	SENT_351	[p22l537t737r722b817],
4	died	VBD	O	die	rcmod	2	SENT_351	[p22l762t738r945b816],
5	was	VBD	O	be	cop	7	SENT_351	[p22l978t764r1142b817],
6	a	DT	O	a	det	7	SENT_351	[p22l1182t764r1226b816],
7	woman	NN	O	woman	_	0	SENT_351	[p22l1259t763r1583b817],
8	who	WP	O	who	nsubj	16	SENT_351	[p22l1616t738r1800b817],
9	had	VBD	O	have	rcmod	7	SENT_351	[p22l1840t738r1998b816],
10	no	DT	O	no	det	11	SENT_351	[p22l2036t763r2141b816],
11	history	NN	O	history	dobj	9	SENT_351	[p22l10t866r316b966],
12	of	IN	O	of	_	0	SENT_351	[p22l348t865r449b944],
13	smoking	NN	O	smoking	prep_of	11	SENT_351	[p22l469t866r847b966],
14	and	CC	O	and	_	0	SENT_351	[p22l881t866r1039b944],
15	thus	RB	O	thus	advmod	9	SENT_351	[p22l1077t865r1260b945],
16	had	VBD	O	have	rcmod	7	SENT_351	[p22l1299t865r1457b944],
17	a	DT	O	a	det	20	SENT_351	[p22l1493t892r1537b944],
18	relatively	RB	O	relatively	advmod	19	SENT_351	[p22l1572t865r1960b966],
19	low	JJ	O	low	amod	20	SENT_351	[p22l1991t866r2147b945],
20	risk	NN	O	risk	dobj	16	SENT_351	[p22l10t994r174b1073],
21	of	IN	O	of	_	0	SENT_351	[p22l212t993r312b1072],
22	interstitial	JJ	O	interstitial	amod	24	SENT_351	[p22l335t994r788b1072],
23	lung	NN	O	lung	nn	24	SENT_351	[p22l827t994r1021b1094],
24	disease	NN	O	disease	prep_of	20	SENT_351	[p22l1061t994r1396b1072],
25	.	.	O	.	_	0	SENT_351	[p22l1061t994r1396b1072],

1	Gefitinib	NN	O	gefitinib	nsubj	3	SENT_352	[p22l1443t993r1838b1072],
2	sometimes	RB	O	sometimes	advmod	3	SENT_352	[p22l1882t1019r2142b1072, p22l11t1122r247b1200],
3	causes	VBZ	O	cause	_	0	SENT_352	[p22l295t1148r571b1201],
4	diffuse	JJ	O	diffuse	amod	8	SENT_352	[p22l620t1121r923b1201],
5	alveolar	JJ	O	alveolar	amod	8	SENT_352	[p22l968t1121r1295b1201],
6	or	CC	O	or	_	0	SENT_352	[p22l1333t1147r1421b1200],
7	interstitial	JJ	O	interstitial	conj_or	5	SENT_352	[p22l1458t1122r1886b1200],
8	damage	NN	O	damage	dobj	3	SENT_352	[p22l1927t1121r2142b1200, p22l9t1276r169b1350],
9	,	,	O	,	_	0	SENT_352	[p22l1927t1121r2142b1200, p22l9t1276r169b1350],

1	especially	RB	O	especially	advmod	2	SENT_353	[p22l213t1249r615b1350],
2	during	IN	O	during	_	0	SENT_353	[p22l648t1250r928b1350],
3	the	DT	DURATION	the	det	6	SENT_353	[p22l961t1250r1094b1328],
4	first	JJ	DURATION	first	amod	6	SENT_353	[p22l1136t1249r1317b1328],
5	3	CD	DURATION	3	num	6	SENT_353	[p22l1351t1255r1395b1328],
6	months	NNS	NUMBER	month	pobj	2	SENT_353	[p22l1437t1250r1761b1328],
7	of	IN	O	of	_	0	SENT_353	[p22l1803t1249r1902b1328],
8	treatment	NN	O	treatment	prep_of	6	SENT_353	[p22l1923t1266r2142b1328, p22l10t1384r325b1457],
9	.	.	O	.	_	0	SENT_353	[p22l1923t1266r2142b1328, p22l10t1384r325b1457],

1	”	NN	O	”	nsubj	14	SENT_354	[p22l1923t1266r2142b1328, p22l10t1384r325b1457],
2	The	DT	O	the	det	4	SENT_354	[p22l387t1379r545b1457],
3	estimated	VBN	O	estimate	amod	4	SENT_354	[p22l611t1379r1027b1457],
4	incidence	NN	O	incidence	nsubj	10	SENT_354	[p22l1091t1378r1492b1457],
5	of	IN	O	of	_	0	SENT_354	[p22l1558t1378r1657b1457],
6	interstitial	JJ	O	interstitial	amod	8	SENT_354	[p22l1703t1378r2144b1457],
7	lung	NN	O	lung	nn	8	SENT_354	[p22l8t1508r199b1608],
8	disease	NN	O	disease	prep_of	4	SENT_354	[p22l230t1508r535b1586],
9	is	VBZ	O	be	cop	10	SENT_354	[p22l567t1508r632b1586],
10	low	JJ	O	low	rcmod	1	SENT_354	[p22l665t1508r819b1587],
11	in	IN	O	in	_	0	SENT_354	[p22l847t1508r930b1585],
12	many	JJ	O	many	amod	13	SENT_354	[p22l962t1533r1202b1608],
13	countries	NNS	O	country	prep_in	10	SENT_354	[p22l1233t1508r1642b1587],
14	(	VBP	O	(	_	0	SENT_354	[p22l1686t1514r1886b1608],
15	e.g.	FW	O	e.g.	dobj	14	SENT_354	[p22l1686t1514r1886b1608],
16	,	,	O	,	_	0	SENT_354	[p22l1686t1514r1886b1608],
17	0.3	CD	PERCENT	0.3	num	18	SENT_354	[p22l1929t1513r2144b1586],
18	%	NN	PERCENT	%	appos	15	SENT_354	[p22l1929t1513r2144b1586],
19	in	IN	O	in	_	0	SENT_354	[p22l9t1636r92b1713],
20	United	NNP	LOCATION	United	nn	21	SENT_354	[p22l128t1636r412b1714],
21	States	NNPS	LOCATION	States	prep_in	18	SENT_354	[p22l451t1641r695b1714],
22	28	CD	NUMBER	28	dep	18	SENT_354	[p22l728t1641r798b1681],
23	but	CC	O	but	_	0	SENT_354	[p22l837t1636r975b1715],
24	is	VBZ	O	be	cop	26	SENT_354	[p22l1007t1636r1072b1714],
25	relatively	RB	O	relatively	advmod	26	SENT_354	[p22l1111t1636r1488b1736],
26	high	JJ	O	high	dep	18	SENT_354	[p22l1521t1635r1714b1736],
27	(	NN	O	(	dep	26	SENT_354	[p22l1756t1641r1828b1727],
28	4	CD	NUMBER	4	num	27	SENT_354	[p22l1756t1641r1828b1727],
29	to	TO	O	to	_	0	SENT_354	[p22l1865t1652r1946b1714],
30	6	CD	PERCENT	6	number	31	SENT_354	[p22l1984t1641r2138b1727],
31	%	NN	PERCENT	%	amod	38	SENT_354	[p22l1984t1641r2138b1727],
32	)	CD	NUMBER	)	npadvmod	36	SENT_354	[p22l1984t1641r2138b1727],
33	in	IN	O	in	_	0	SENT_354	[p22l9t1764r93b1841],
34	Japan	NNP	LOCATION	Japan	prep_in	32	SENT_354	[p22l127t1769r570b1864],
35	.29	CD	NUMBER	.29	num	34	SENT_354	[p22l127t1769r570b1864],
36	>	JJR	O	>	amod	38	SENT_354	[p22l127t1769r570b1864],
37	3	CD	NUMBER	3	dep	36	SENT_354	[p22l127t1769r570b1864],
38	°	NN	O	°	prep_to	26	SENT_354	[p22l127t1769r570b1864],
39	Every	DT	O	every	det	40	SENT_354	[p22l612t1771r845b1864],
40	patient	NN	O	patient	nsubjpass	51	SENT_354	[p22l882t1764r1178b1864],
41	treated	VBN	O	treat	partmod	40	SENT_354	[p22l1213t1764r1500b1842],
42	with	IN	O	with	_	0	SENT_354	[p22l1534t1764r1724b1843],
43	an	DT	O	a	det	47	SENT_354	[p22l1764t1789r1864b1842],
44	EGFR	NN	ORGANIZATION	egfr	nn	47	SENT_354	[p22l1903t1769r2153b1847],
45	tyrosine	NN	O	tyrosine	nn	47	SENT_354	[p22l11t1892r343b1992],
46	kinase	NN	O	kinase	nn	47	SENT_354	[p22l419t1892r688b1971],
47	inhibitor	NN	O	inhibitor	prep_with	41	SENT_354	[p22l764t1892r1143b1970],
48	should	MD	O	should	aux	51	SENT_354	[p22l1222t1891r1510b1971],
49	be	VB	O	be	auxpass	51	SENT_354	[p22l1591t1892r1688b1970],
50	carefully	RB	O	carefully	advmod	51	SENT_354	[p22l1769t1891r2148b1992],
51	monitored	VBN	O	monitor	ccomp	26	SENT_354	[p22l10t2021r462b2099],
52	for	IN	O	for	_	0	SENT_354	[p22l502t2020r626b2099],
53	this	DT	O	this	det	55	SENT_354	[p22l663t2021r823b2099],
54	toxic	JJ	O	toxic	amod	55	SENT_354	[p22l865t2021r1072b2099],
55	effect	NN	O	effect	prep_for	51	SENT_354	[p22l1112t2020r1375b2099],
56	.	.	O	.	_	0	SENT_354	[p22l1112t2020r1375b2099],

1	In	IN	O	in	_	0	SENT_355	[p22l139t2156r229b2226],
2	conclusion	NN	O	conclusion	prep_in	14	SENT_355	[p22l280t2148r767b2244],
3	,	,	O	,	_	0	SENT_355	[p22l280t2148r767b2244],
4	the	DT	O	the	det	5	SENT_355	[p22l823t2148r956b2227],
5	efficacy	NN	O	efficacy	nsubj	14	SENT_355	[p22l1008t2148r1346b2249],
6	of	IN	O	of	_	0	SENT_355	[p22l1392t2148r1493b2227],
7	first	JJ	ORDINAL	first	amod	12	SENT_355	[p22l1525t2148r1897b2227],
8	—	NN	O	—	nn	12	SENT_355	[p22l1525t2148r1897b2227],
9	line	NN	O	line	nn	12	SENT_355	[p22l1525t2148r1897b2227],
10	gefi	NN	O	gefus	nn	12	SENT_355	[p22l1948t2148r2145b2249],
11	—	NN	O	—	nn	12	SENT_355	[p22l1948t2148r2145b2249],
12	tinib	NN	O	tinib	prep_of	5	SENT_355	[p22l12t2277r206b2355],
13	was	VBD	O	be	cop	14	SENT_355	[p22l241t2303r399b2356],
14	superior	JJ	O	superior	_	0	SENT_355	[p22l442t2277r783b2377],
15	to	TO	O	to	_	0	SENT_355	[p22l818t2293r898b2355],
16	that	DT	O	that	prep_to	14	SENT_355	[p22l938t2276r1105b2355],
17	of	IN	O	of	_	0	SENT_355	[p22l1139t2276r1237b2355],
18	standard	JJ	O	standard	amod	19	SENT_355	[p22l1258t2277r1624b2355],
19	chemotherapy	NN	O	chemotherapy	prep_of	16	SENT_355	[p22l1663t2277r2145b2355, p22l11t2431r167b2505],
20	,	,	O	,	_	0	SENT_355	[p22l1663t2277r2145b2355, p22l11t2431r167b2505],
21	with	IN	O	with	_	0	SENT_355	[p22l208t2404r401b2484],
22	acceptable	JJ	O	acceptable	amod	35	SENT_355	[p22l440t2405r880b2505],
23	toxicity	NN	O	toxicity	tmod	22	SENT_355	[p22l921t2405r1244b2505],
24	,	,	O	,	_	0	SENT_355	[p22l921t2405r1244b2505],
25	in	IN	O	in	_	0	SENT_355	[p22l1289t2405r1372b2482],
26	patients	NNS	O	patient	prep_in	23	SENT_355	[p22l1410t2405r1746b2505],
27	with	IN	O	with	_	0	SENT_355	[p22l1784t2404r1977b2484],
28	advanced	JJ	O	advanced	amod	30	SENT_355	[p22l2016t2405r2145b2483, p22l7t2533r312b2612],
29	non	JJ	O	non	amod	30	SENT_355	[p22l373t2533r1037b2611],
30	—	NN	O	—	prep_with	26	SENT_355	[p22l373t2533r1037b2611],
31	small	JJ	O	small	amod	35	SENT_355	[p22l373t2533r1037b2611],
32	—	NN	O	—	nn	35	SENT_355	[p22l373t2533r1037b2611],
33	cell	NN	O	cell	nn	35	SENT_355	[p22l373t2533r1037b2611],
34	lung	NN	O	lung	nn	35	SENT_355	[p22l1097t2533r1295b2633],
35	cancer	NN	O	cancer	nsubj	36	SENT_355	[p22l1355t2558r1644b2611],
36	harboring	VBG	O	harbor	prepc_with	14	SENT_355	[p22l1702t2533r2151b2633],
37	sensitive	JJ	O	sensitive	amod	39	SENT_355	[p22l13t2661r378b2740],
38	EGFR	NN	ORGANIZATION	egfr	nn	39	SENT_355	[p22l425t2666r682b2744],
39	mutations	NNS	O	mutation	dobj	36	SENT_355	[p22l719t2661r1181b2740],
40	.	.	O	.	_	0	SENT_355	[p22l719t2661r1181b2740],

1	Selection	NN	O	selection	nsubjpass	12	SENT_356	[p22l1236t2661r1625b2739],
2	of	IN	O	of	_	0	SENT_356	[p22l1674t2660r1774b2739],
3	patients	NNS	O	patient	prep_of	1	SENT_356	[p22l1801t2661r2145b2761],
4	on	IN	O	on	_	0	SENT_356	[p22l12t2814r119b2867],
5	the	DT	O	the	det	6	SENT_356	[p22l155t2789r288b2867],
6	basis	NN	O	basis	prep_on	3	SENT_356	[p22l325t2789r537b2867],
7	of	IN	O	of	_	0	SENT_356	[p22l577t2788r677b2867],
8	EGFR-mutation	NN	O	egfr-mutation	nn	9	SENT_356	[p22l692t2789r1365b2872],
9	status	NN	O	status	prep_of	6	SENT_356	[p22l1402t2805r1656b2868],
10	is	VBZ	O	be	auxpass	12	SENT_356	[p22l1693t2789r1759b2867],
11	strongly	RB	O	strongly	advmod	12	SENT_356	[p22l1798t2789r2152b2889],
12	recommended	VBN	O	recommend	_	0	SENT_356	[p22l11t2917r655b2996],
13	.	.	O	.	_	0	SENT_356	[p22l11t2917r655b2996],

1	Supported	VBN	O	support	_	0	SENT_357	[p22l98t3098r437b3174],
2	by	IN	O	by	_	0	SENT_357	[p22l462t3098r536b3174],
3	grants	NNS	O	grant	prep_by	1	SENT_357	[p22l556t3098r989b3175],
4	—	CD	NUMBER	—	num	5	SENT_357	[p22l556t3098r989b3175],
5	in-aid	NN	O	in-aid	dep	3	SENT_357	[p22l556t3098r989b3175],
6	from	IN	O	from	_	0	SENT_357	[p22l1013t3098r1174b3158],
7	the	DT	O	the	det	9	SENT_357	[p22l1198t3098r1300b3158],
8	Japan	NNP	ORGANIZATION	Japan	nn	9	SENT_357	[p22l1317t3104r1505b3174],
9	Society	NNP	ORGANIZATION	Society	prep_from	1	SENT_357	[p22l1531t3099r1765b3174],
10	for	IN	ORGANIZATION	for	_	0	SENT_357	[p22l1787t3098r1881b3158],
11	Promotion	NNP	ORGANIZATION	Promotion	prep_for	1	SENT_357	[p22l1902t3103r2147b3158, p22l11t3195r141b3254],
12	of	IN	ORGANIZATION	of	_	0	SENT_357	[p22l170t3194r246b3254],
13	Science	NNP	ORGANIZATION	Science	prep_of	11	SENT_357	[p22l263t3195r504b3254],
14	and	CC	O	and	_	0	SENT_357	[p22l533t3194r654b3254],
15	the	DT	O	the	det	17	SENT_357	[p22l683t3194r785b3253],
16	Japanese	JJ	MISC	japanese	amod	17	SENT_357	[p22l806t3200r1099b3269],
17	Foundation	NNP	MISC	Foundation	conj_and	11	SENT_357	[p22l1127t3194r1508b3254],
18	for	IN	O	for	_	0	SENT_357	[p22l1537t3194r1632b3254],
19	the	DT	O	the	det	21	SENT_357	[p22l1659t3194r1761b3253],
20	Multidisciplinary	NNP	O	Multidisciplinary	nn	21	SENT_357	[p22l1787t3194r2147b3254, p22l9t3291r249b3367],
21	Treatment	NN	O	treatment	prep_for	17	SENT_357	[p22l271t3296r616b3351],
22	of	IN	O	of	_	0	SENT_357	[p22l642t3291r718b3351],
23	Cancer	NN	O	cancer	prep_of	21	SENT_357	[p22l732t3296r962b3351],
24	and	CC	O	and	_	0	SENT_357	[p22l987t3291r1108b3351],
25	a	DT	O	a	det	26	SENT_357	[p22l1136t3311r1169b3351],
26	grant	NN	O	grant	prep_for	17	SENT_357	[p22l1196t3304r1377b3368],
27	from	IN	O	from	_	0	SENT_357	[p22l1401t3291r1562b3351],
28	the	DT	O	the	det	32	SENT_357	[p22l1591t3291r1692b3351],
29	Tokyo	NNP	ORGANIZATION	Tokyo	nn	32	SENT_357	[p22l1718t3291r1918b3367],
30	Cooperative	NNP	ORGANIZATION	Cooperative	nn	32	SENT_357	[p22l1948t3296r2147b3367, p22l11t3389r226b3448],
31	Oncology	NNP	ORGANIZATION	Oncology	nn	32	SENT_357	[p22l252t3388r571b3465],
32	Group	NNP	ORGANIZATION	Group	prep_from	26	SENT_357	[p22l593t3393r818b3464],
33	.	.	O	.	_	0	SENT_357	[p22l593t3393r818b3464],

1	Disclosure	NN	O	disclosure	nsubj	2	SENT_358	[p22l95t3484r445b3544],
2	forms	VBZ	O	form	_	0	SENT_358	[p22l478t3484r672b3544],
3	provided	VBN	O	provide	csubj	8	SENT_358	[p22l705t3484r994b3559],
4	by	IN	O	by	_	0	SENT_358	[p22l1028t3484r1102b3559],
5	the	DT	O	the	det	6	SENT_358	[p22l1132t3484r1234b3543],
6	authors	NNS	O	author	prep_by	3	SENT_358	[p22l1266t3484r1515b3544],
7	are	VBP	O	be	cop	8	SENT_358	[p22l1549t3504r1648b3543],
8	available	JJ	O	available	ccomp	2	SENT_358	[p22l1681t3484r1968b3544],
9	with	IN	O	with	_	0	SENT_358	[p22l1998t3484r2148b3544],
10	the	DT	O	the	det	12	SENT_358	[p22l11t3581r112b3641],
11	full	JJ	O	full	amod	12	SENT_358	[p22l138t3581r253b3641],
12	text	NN	O	text	prep_with	8	SENT_358	[p22l278t3594r402b3641],
13	of	IN	O	of	_	0	SENT_358	[p22l424t3581r501b3641],
14	this	DT	O	this	det	15	SENT_358	[p22l512t3581r636b3641],
15	article	NN	O	article	prep_of	12	SENT_358	[p22l662t3581r869b3641],
16	at	IN	O	at	_	0	SENT_358	[p22l895t3594r955b3641],
17	N	NN	O	n	nn	18	SENT_358	[p22l975t3587r1032b3641],
18	EJM.org	NN	O	ejm.org	prep_at	15	SENT_358	[p22l1035t3587r1317b3658],
19	.	.	O	.	_	0	SENT_358	[p22l1035t3587r1317b3658],

1	We	PRP	O	we	nsubj	2	SENT_359	[p22l94t3683r195b3736],
2	thank	VBP	O	thank	_	0	SENT_359	[p22l220t3677r417b3737],
3	all	DT	O	all	dobj	2	SENT_359	[p22l437t3677r518b3736],
4	our	PRP$	O	we	poss	5	SENT_359	[p22l542t3696r654b3737],
5	patients	NNS	O	patient	dep	3	SENT_359	[p22l675t3678r938b3752],
6	and	CC	O	and	_	0	SENT_359	[p22l964t3677r1085b3737],
7	their	PRP$	O	they	poss	8	SENT_359	[p22l1109t3677r1266b3736],
8	families	NNS	O	family	conj_and	3	SENT_359	[p22l1288t3677r1574b3749],
9	,	,	O	,	_	0	SENT_359	[p22l1288t3677r1574b3749],
10	as	RB	O	as	_	0	SENT_359	[p22l1602t3697r1668b3736],
11	well	RB	O	well	_	0	SENT_359	[p22l1690t3677r1826b3737],
12	as	IN	O	as	_	0	SENT_359	[p22l1850t3697r1916b3736],
13	all	PDT	O	all	predet	16	SENT_359	[p22l1941t3677r2022b3736],
14	the	DT	O	the	det	16	SENT_359	[p22l2045t3677r2148b3736],
15	site	NN	O	site	nn	16	SENT_359	[p23l11t19r121b78],
16	investigators	NNS	O	investigator	conj_and	3	SENT_359	[p23l155t19r598b95],
17	;	:	O	;	_	0	SENT_359	[p23l155t19r598b95],
18	and	CC	O	and	_	0	SENT_359	[p23l634t18r755b78],
19	Dr.	NNP	O	Dr.	nn	24	SENT_359	[p23l787t23r884b78],
20	Koichi	NNP	PERSON	Koichi	nn	24	SENT_359	[p23l921t18r1134b80],
21	Yamazaki	NNP	PERSON	Yamazaki	nn	24	SENT_359	[p23l1165t18r1490b78],
22	(	CD	NUMBER	(	num	24	SENT_359	[p23l1526t18r1884b91],
23	deceased	JJ	O	deceased	amod	24	SENT_359	[p23l1526t18r1884b91],
24	)	NN	O	)	dobj	2	SENT_359	[p23l1526t18r1884b91],
25	,	,	O	,	_	0	SENT_359	[p23l1526t18r1884b91],
26	former	JJ	O	former	amod	28	SENT_359	[p23l1922t18r2149b78],
27	associate	JJ	O	associate	amod	28	SENT_359	[p23l10t115r310b174],
28	professor	NN	O	professor	appos	24	SENT_359	[p23l342t114r656b189],
29	of	IN	O	of	_	0	SENT_359	[p23l689t114r765b174],
30	the	DT	O	the	det	32	SENT_359	[p23l786t114r887b173],
31	First	NNP	ORGANIZATION	First	nn	32	SENT_359	[p23l921t115r1072b173],
32	Department	NNP	ORGANIZATION	Department	prep_of	28	SENT_359	[p23l1101t119r1504b189],
33	of	IN	ORGANIZATION	of	_	0	SENT_359	[p23l1535t114r1611b174],
34	Medicine	NNP	ORGANIZATION	Medicine	nn	38	SENT_359	[p23l1628t114r1951b186],
35	,	,	O	,	_	0	SENT_359	[p23l1628t114r1951b186],
36	Hokkaido	NNP	ORGANIZATION	Hokkaido	appos	38	SENT_359	[p23l1988t114r2147b174, p23l10t210r191b270],
37	University	NNP	ORGANIZATION	University	nn	38	SENT_359	[p23l218t211r554b284],
38	School	NNP	ORGANIZATION	School	prep_of	32	SENT_359	[p23l578t210r798b270],
39	of	IN	ORGANIZATION	of	_	0	SENT_359	[p23l824t210r900b270],
40	Medicine	NNP	ORGANIZATION	Medicine	prep_of	38	SENT_359	[p23l910t210r1232b270],
41	.	.	O	.	_	0	SENT_359	[p23l910t210r1232b270],

1	APPE	NNP	O	APPE	nn	3	SENT_360	[p23l873t396r934b412],
2	N	NNP	O	N	nn	3	SENT_360	[p23l939t396r953b412],
3	D	NNP	O	D	_	0	SENT_360	[p23l959t396r974b412],
4	IX	CD	NUMBER	ix	dep	3	SENT_360	[p23l979t396r1001b412],

1	The	DT	O	the	dep	138	SENT_361	[p23l93t429r140b452],
2	authors	NNS	O	author	dep	138	SENT_361	[p23l151t429r252b453],
3	’	VBP	O	’	dep	138	SENT_361	[p23l151t429r252b453],
4	affiliations	NNS	O	affiliation	dep	138	SENT_361	[p23l264t429r395b453],
5	are	VBP	O	be	dep	138	SENT_361	[p23l407t437r443b452],
6	as	IN	O	as	dep	138	SENT_361	[p23l454t437r479b452],
7	follows	VBZ	O	follow	dep	138	SENT_361	[p23l490t429r588b453],
8	:	:	O	:	_	0	SENT_361	[p23l490t429r588b453],
9	Miyagi	NNP	ORGANIZATION	Miyagi	dep	138	SENT_361	[p23l599t429r682b459],
10	Cancer	NNP	ORGANIZATION	Cancer	dep	138	SENT_361	[p23l693t431r779b453],
11	Center	NNP	ORGANIZATION	Center	dep	138	SENT_361	[p23l789t431r877b457],
12	,	,	O	,	_	0	SENT_361	[p23l789t431r877b457],
13	Miyagi	NNP	PERSON	Miyagi	dep	138	SENT_361	[p23l889t429r972b459],
14	(	NNP	O	(	dep	138	SENT_361	[p23l984t431r1076b457],
15	M.M.	NNP	LOCATION	M.M.	dep	138	SENT_361	[p23l984t431r1076b457],
16	)	NNP	O	)	dep	138	SENT_361	[p23l984t431r1076b457],
17	;	:	O	;	_	0	SENT_361	[p23l984t431r1076b457],
18	Tohoku	NNP	ORGANIZATION	Tohoku	dep	138	SENT_361	[p23l1087t429r1184b453],
19	University	NNP	ORGANIZATION	University	dep	138	SENT_361	[p23l1195t429r1320b459],
20	Hospital	NNP	ORGANIZATION	Hospital	dep	138	SENT_361	[p23l1329t429r1434b459],
21	(	CD	NUMBER	(	dep	138	SENT_361	[p23l1447t431r1506b458],
22	A.I.	NNP	LOCATION	A.I.	dep	138	SENT_361	[p23l1447t431r1506b458],
23	,	,	O	,	_	0	SENT_361	[p23l1447t431r1506b458],
24	T.N.	NNP	PERSON	T.N.	dep	138	SENT_361	[p23l1518t431r1591b457],
25	)	NNP	O	)	dep	138	SENT_361	[p23l1518t431r1591b457],
26	;	:	O	;	_	0	SENT_361	[p23l1518t431r1591b457],
27	Sendai	NN	ORGANIZATION	sendaus	dep	138	SENT_361	[p23l1604t429r1685b453],
28	Kousei	NNP	ORGANIZATION	Kousei	dep	138	SENT_361	[p23l1696t430r1780b453],
29	Hospital	NNP	ORGANIZATION	Hospital	dep	138	SENT_361	[p23l94t466r199b496],
30	(	CD	NUMBER	(	dep	138	SENT_361	[p23l211t468r283b494],
31	S.S.	NNP	LOCATION	S.S.	dep	138	SENT_361	[p23l211t468r283b494],
32	)	CD	NUMBER	)	dep	138	SENT_361	[p23l211t468r283b494],
33	;	:	O	;	_	0	SENT_361	[p23l211t468r283b494],
34	and	CC	O	and	dep	138	SENT_361	[p23l295t466r340b490],
35	Tohoku	NNP	ORGANIZATION	Tohoku	dep	138	SENT_361	[p23l350t466r447b490],
36	University	NNP	ORGANIZATION	University	dep	138	SENT_361	[p23l458t466r582b496],
37	Graduate	NNP	ORGANIZATION	Graduate	dep	138	SENT_361	[p23l592t466r705b490],
38	School	NNP	ORGANIZATION	School	dep	138	SENT_361	[p23l716t466r799b490],
39	of	IN	ORGANIZATION	of	dep	138	SENT_361	[p23l810t466r840b490],
40	Medicine	NNP	ORGANIZATION	Medicine	dep	138	SENT_361	[p23l844t466r958b490],
41	(	CD	NUMBER	(	dep	138	SENT_361	[p23l970t468r1042b493],
42	T.N.	NNP	LOCATION	T.N.	dep	138	SENT_361	[p23l970t468r1042b493],
43	)	CD	NUMBER	)	dep	138	SENT_361	[p23l970t468r1042b493],
44	—	CD	NUMBER	—	dep	138	SENT_361	[p23l1053t479r1087b482],
45	all	DT	O	all	dep	138	SENT_361	[p23l1096t466r1125b489],
46	in	IN	O	in	dep	138	SENT_361	[p23l1135t466r1159b489],
47	Sendai	NN	LOCATION	sendaus	dep	138	SENT_361	[p23l1170t466r1259b494],
48	;	:	O	;	_	0	SENT_361	[p23l1170t466r1259b494],
49	Saitama	NNP	ORGANIZATION	Saitama	dep	138	SENT_361	[p23l1272t466r1369b490],
50	Medical	NNP	ORGANIZATION	Medical	dep	138	SENT_361	[p23l1378t466r1476b490],
51	University	NNP	ORGANIZATION	University	dep	138	SENT_361	[p23l1486t466r1611b496],
52	International	NNP	ORGANIZATION	International	dep	138	SENT_361	[p23l1620t466r1780b490],
53	Medical	NNP	ORGANIZATION	Medical	dep	138	SENT_361	[p23l93t503r191b527],
54	Center	NNP	ORGANIZATION	Center	dep	138	SENT_361	[p23l201t505r282b527],
55	(	CD	NUMBER	(	dep	138	SENT_361	[p23l293t505r365b530],
56	K.K.	NNP	ORGANIZATION	K.K.	dep	138	SENT_361	[p23l293t505r365b530],
57	)	NN	O	)	dep	138	SENT_361	[p23l293t505r365b530],
58	and	CC	O	and	dep	138	SENT_361	[p23l376t503r422b527],
59	Saitama	NNP	ORGANIZATION	Saitama	dep	138	SENT_361	[p23l432t503r530b527],
60	Medical	NNP	ORGANIZATION	Medical	dep	138	SENT_361	[p23l538t503r636b527],
61	University	NNP	ORGANIZATION	University	dep	138	SENT_361	[p23l646t503r770b533],
62	(	NNP	O	(	dep	138	SENT_361	[p23l780t505r859b531],
63	H.M.	NNP	LOCATION	H.M.	dep	138	SENT_361	[p23l780t505r859b531],
64	,	,	O	,	_	0	SENT_361	[p23l780t505r859b531],
65	T.T.	NNP	O	T.T.	dep	138	SENT_361	[p23l870t505r928b532],
66	,	,	O	,	_	0	SENT_361	[p23l870t505r928b532],
67	K.H.	NNP	LOCATION	K.H.	dep	138	SENT_361	[p23l939t505r1006b530],
68	)	CD	NUMBER	)	dep	138	SENT_361	[p23l939t505r1006b530],
69	—	CD	NUMBER	—	dep	138	SENT_361	[p23l1016t516r1049b519],
70	boﬂi	NNS	O	boﬂi	dep	138	SENT_361	[p23l1059t503r1115b527],
71	in	IN	O	in	dep	138	SENT_361	[p23l1125t503r1148b526],
72	Saitama	NNP	LOCATION	Saitama	dep	138	SENT_361	[p23l1159t504r1263b531],
73	;	:	O	;	_	0	SENT_361	[p23l1159t504r1263b531],
74	Hokkaido	NNP	ORGANIZATION	Hokkaido	dep	138	SENT_361	[p23l1274t503r1396b527],
75	University	NNP	ORGANIZATION	University	dep	138	SENT_361	[p23l1406t503r1531b533],
76	School	NNP	ORGANIZATION	School	dep	138	SENT_361	[p23l1540t503r1623b527],
77	of	IN	ORGANIZATION	of	dep	138	SENT_361	[p23l1633t503r1662b527],
78	Medicine	NNP	ORGANIZATION	Medicine	dep	138	SENT_361	[p23l1666t503r1780b527],
79	(	NNP	O	(	dep	138	SENT_361	[p23l96t542r125b567],
80	S.	NNP	PERSON	S.	dep	138	SENT_361	[p23l96t542r125b567],
81	Oizumi	NNP	PERSON	Oizumi	dep	138	SENT_361	[p23l136t540r245b568],
82	)	NN	O	)	dep	138	SENT_361	[p23l136t540r245b568],
83	,	,	O	,	_	0	SENT_361	[p23l136t540r245b568],
84	Kokka	FW	O	kokka	dep	138	SENT_361	[p23l256t540r442b564],
85	—	FW	O	—	dep	138	SENT_361	[p23l256t540r442b564],
86	komuin	FW	O	komuin	dep	138	SENT_361	[p23l256t540r442b564],
87	Kyosai	FW	O	kyosai	dep	138	SENT_361	[p23l452t540r630b570],
88	—	FW	O	—	dep	138	SENT_361	[p23l452t540r630b570],
89	kumiai	FW	O	kumiai	dep	138	SENT_361	[p23l452t540r630b570],
90	Rengokai	FW	ORGANIZATION	rengokai	dep	138	SENT_361	[p23l639t540r756b570],
91	Sapporo	NNP	ORGANIZATION	Sapporo	dep	138	SENT_361	[p23l767t542r868b570],
92	Medical	NNP	ORGANIZATION	Medical	dep	138	SENT_361	[p23l877t540r975b564],
93	Center	NNP	ORGANIZATION	Center	dep	138	SENT_361	[p23l984t542r1066b564],
94	(	CD	NUMBER	(	dep	138	SENT_361	[p23l1076t542r1150b568],
95	H.I.	NNP	LOCATION	H.I.	dep	138	SENT_361	[p23l1076t542r1150b568],
96	)	NNP	O	)	dep	138	SENT_361	[p23l1076t542r1150b568],
97	,	,	O	,	_	0	SENT_361	[p23l1076t542r1150b568],
98	National	NNP	ORGANIZATION	National	dep	138	SENT_361	[p23l1160t540r1267b564],
99	Hospital	NNP	ORGANIZATION	Hospital	dep	138	SENT_361	[p23l1276t540r1382b570],
100	Organization	NNP	ORGANIZATION	Organization	dep	138	SENT_361	[p23l1391t540r1554b570],
101	Hokkaido	NNP	ORGANIZATION	Hokkaido	dep	138	SENT_361	[p23l1563t540r1685b564],
102	Cancer	NNP	ORGANIZATION	Cancer	dep	138	SENT_361	[p23l1695t542r1781b564],
103	Center	NNP	ORGANIZATION	Center	dep	138	SENT_361	[p23l94t579r176b601],
104	(	NNP	O	(	dep	138	SENT_361	[p23l187t579r276b605],
105	M.H.	NNP	LOCATION	M.H.	dep	138	SENT_361	[p23l187t579r276b605],
106	)	NNP	O	)	dep	138	SENT_361	[p23l187t579r276b605],
107	,	,	O	,	_	0	SENT_361	[p23l187t579r276b605],
108	Hokkaido	NNP	ORGANIZATION	Hokkaido	dep	138	SENT_361	[p23l287t577r409b601],
109	University	NNP	ORGANIZATION	University	dep	138	SENT_361	[p23l419t577r544b607],
110	Graduate	NNP	ORGANIZATION	Graduate	dep	138	SENT_361	[p23l552t577r666b601],
111	School	NNP	ORGANIZATION	School	dep	138	SENT_361	[p23l677t577r760b601],
112	of	IN	ORGANIZATION	of	dep	138	SENT_361	[p23l770t577r799b601],
113	Medicine	NNP	ORGANIZATION	Medicine	dep	138	SENT_361	[p23l803t577r917b601],
114	(	CD	NUMBER	(	dep	138	SENT_361	[p23l928t579r999b605],
115	I.K.	NNP	LOCATION	I.K.	dep	138	SENT_361	[p23l928t579r999b605],
116	)	NNP	O	)	dep	138	SENT_361	[p23l928t579r999b605],
117	,	,	O	,	_	0	SENT_361	[p23l928t579r999b605],
118	and	CC	O	and	dep	138	SENT_361	[p23l1010t577r1055b601],
119	Hokkaido	NNP	ORGANIZATION	Hokkaido	dep	138	SENT_361	[p23l1065t577r1187b601],
120	Social	NNP	ORGANIZATION	Social	dep	138	SENT_361	[p23l1198t577r1270b601],
121	Insurance	NNP	ORGANIZATION	Insurance	dep	138	SENT_361	[p23l1280t579r1401b601],
122	Hospital	NNP	ORGANIZATION	Hospital	dep	138	SENT_361	[p23l1411t577r1517b607],
123	(	CD	NUMBER	(	dep	138	SENT_361	[p23l1528t579r1601b604],
124	T.H.	NNP	LOCATION	T.H.	dep	138	SENT_361	[p23l1528t579r1601b604],
125	)	CD	NUMBER	)	dep	138	SENT_361	[p23l1528t579r1601b604],
126	—	CD	NUMBER	—	dep	138	SENT_361	[p23l1611t590r1645b593],
127	all	DT	O	all	dep	138	SENT_361	[p23l1654t577r1682b600],
128	in	IN	O	in	dep	138	SENT_361	[p23l1692t578r1716b600],
129	Sapporo	NNP	LOCATION	Sapporo	dep	138	SENT_361	[p23l1727t579r1780b607, p23l94t622r159b644],
130	;	:	O	;	_	0	SENT_361	[p23l1727t579r1780b607, p23l94t622r159b644],
131	Nippon	NNP	ORGANIZATION	Nippon	dep	138	SENT_361	[p23l171t615r265b644],
132	Medical	NNP	ORGANIZATION	Medical	dep	138	SENT_361	[p23l275t614r373b638],
133	School	NNP	ORGANIZATION	School	dep	138	SENT_361	[p23l384t614r467b638],
134	(	NNP	O	(	dep	138	SENT_361	[p23l480t616r553b641],
135	A.G.	NNP	LOCATION	A.G.	dep	138	SENT_361	[p23l480t616r553b641],
136	)	NNP	O	)	dep	138	SENT_361	[p23l480t616r553b641],
137	and	CC	O	and	dep	138	SENT_361	[p23l566t614r611b638],
138	Anti	NNP	O	Anti	_	0	SENT_361	[p23l621t614r843b638],
139	.	.	O	.	_	0	SENT_361	[p23l621t614r843b638],

1	—	NN	O	—	_	0	SENT_362	[p23l621t614r843b638],
2	.	.	O	.	_	0	SENT_362	[p23l621t614r843b638],

1	Tuberculosis	NN	ORGANIZATION	tuberculosis	_	0	SENT_363	[p23l621t614r843b638],
2	Association	NNP	ORGANIZATION	Association	nn	6	SENT_363	[p23l853t614r997b638],
3	Fukujuji	NNP	ORGANIZATION	Fukujuji	nn	6	SENT_363	[p23l1008t614r1108b644],
4	Hospital	NNP	ORGANIZATION	Hospital	nn	6	SENT_363	[p23l1119t614r1224b644],
5	(	CD	NUMBER	(	num	6	SENT_363	[p23l1236t616r1304b641],
6	K.Y.	NNP	LOCATION	K.Y.	dep	1	SENT_363	[p23l1236t616r1304b641],
7	)	CD	NUMBER	)	number	8	SENT_363	[p23l1236t616r1304b641],
8	—	CD	NUMBER	—	dep	6	SENT_363	[p23l1316t627r1349b630],
9	both	DT	O	both	dep	1	SENT_363	[p23l1360t614r1416b638],
10	in	IN	O	in	_	0	SENT_363	[p23l1427t614r1450b637],
11	Tokyo	NNP	LOCATION	Tokyo	prep_in	9	SENT_363	[p23l1460t614r1544b644],
12	;	:	O	;	_	0	SENT_363	[p23l1460t614r1544b644],
13	Niigata	NNP	ORGANIZATION	Niigata	nn	15	SENT_363	[p23l1556t614r1646b644],
14	University	NNP	ORGANIZATION	University	nn	15	SENT_363	[p23l1657t614r1781b644],
15	Medical	NNP	ORGANIZATION	Medical	dep	9	SENT_363	[p23l93t651r191b675],
16	and	CC	ORGANIZATION	and	_	0	SENT_363	[p23l200t651r245b675],
17	Dental	NNP	ORGANIZATION	Dental	nn	18	SENT_363	[p23l254t651r336b674],
18	Hospital	NNP	ORGANIZATION	Hospital	dep	9	SENT_363	[p23l345t651r457b681],
19	,	,	O	,	_	0	SENT_363	[p23l345t651r457b681],
20	Niigata	NNP	LOCATION	Niigata	appos	15	SENT_363	[p23l467t651r557b681],
21	(	CD	NUMBER	(	num	20	SENT_363	[p23l568t653r647b679],
22	H.Y.	NNP	LOCATION	H.Y.	dep	20	SENT_363	[p23l568t653r647b679],
23	)	CD	NUMBER	)	num	22	SENT_363	[p23l568t653r647b679],
24	;	:	O	;	_	0	SENT_363	[p23l568t653r647b679],
25	National	NNP	ORGANIZATION	National	nn	30	SENT_363	[p23l657t651r764b675],
26	Hospital	NNP	ORGANIZATION	Hospital	nn	30	SENT_363	[p23l773t651r878b681],
27	Organization	NNP	ORGANIZATION	Organization	nn	30	SENT_363	[p23l888t651r1050b681],
28	Dohoku	NNP	ORGANIZATION	Dohoku	nn	30	SENT_363	[p23l1059t651r1159b675],
29	National	NNP	ORGANIZATION	National	nn	30	SENT_363	[p23l1168t651r1275b675],
30	Hospital	NNP	ORGANIZATION	Hospital	dep	9	SENT_363	[p23l1284t651r1396b681],
31	,	,	O	,	_	0	SENT_363	[p23l1284t651r1396b681],
32	Asahikawa	NNP	LOCATION	Asahikawa	nn	34	SENT_363	[p23l1406t651r1540b675],
33	(	CD	NUMBER	(	num	34	SENT_363	[p23l1551t653r1575b678],
34	Y	NN	O	y	appos	30	SENT_363	[p23l1551t653r1575b678],
35	.	.	O	.	_	0	SENT_363	[p23l1576t653r1623b679],

1	F.	NNP	O	F.	nn	2	SENT_364	[p23l1576t653r1623b679],
2	)	NNP	O	)	_	0	SENT_364	[p23l1576t653r1623b679],
3	;	:	O	;	_	0	SENT_364	[p23l1576t653r1623b679],
4	Kesennuma	NNP	LOCATION	Kesennuma	nn	6	SENT_364	[p23l1634t653r1780b675],
5	City	NNP	LOCATION	City	nn	6	SENT_364	[p23l94t688r143b718],
6	Hospital	NNP	LOCATION	Hospital	dep	2	SENT_364	[p23l151t688r263b718],
7	,	,	O	,	_	0	SENT_364	[p23l151t688r263b718],
8	Miyagi	NNP	PERSON	Miyagi	nn	11	SENT_364	[p23l273t688r356b718],
9	(	NNP	O	(	nn	11	SENT_364	[p23l367t690r396b715],
10	S.	NNP	PERSON	S.	nn	11	SENT_364	[p23l367t690r396b715],
11	Okinaga	NNP	PERSON	Okinaga	appos	2	SENT_364	[p23l407t688r528b718],
12	)	NN	O	)	dep	11	SENT_364	[p23l407t688r528b718],
13	;	:	O	;	_	0	SENT_364	[p23l407t688r528b718],
14	Iwate	NNP	ORGANIZATION	Iwate	nn	17	SENT_364	[p23l538t690r604b712],
15	Prefectural	NNP	ORGANIZATION	Prefectural	nn	17	SENT_364	[p23l613t688r746b712],
16	Central	NNP	ORGANIZATION	Central	nn	17	SENT_364	[p23l756t688r845b712],
17	Hospital	NNP	ORGANIZATION	Hospital	dep	11	SENT_364	[p23l854t688r966b718],
18	,	,	O	,	_	0	SENT_364	[p23l854t688r966b718],
19	Morioka	NNP	LOCATION	Morioka	nn	22	SENT_364	[p23l976t688r1082b712],
20	(	NNP	O	(	nn	22	SENT_364	[p23l1092t690r1179b716],
21	H.H.	NNP	LOCATION	H.H.	nn	22	SENT_364	[p23l1092t690r1179b716],
22	)	NNP	O	)	appos	17	SENT_364	[p23l1092t690r1179b716],
23	;	:	O	;	_	0	SENT_364	[p23l1092t690r1179b716],
24	Kanagawa	NNP	LOCATION	Kanagawa	nn	25	SENT_364	[p23l1189t690r1317b718],
25	Cardiovascular	NNP	LOCATION	Cardiovascular	dep	11	SENT_364	[p23l1325t688r1509b712],
26	and	CC	O	and	_	0	SENT_364	[p23l1517t688r1563b712],
27	Respiratory	NNP	ORGANIZATION	Respiratory	nn	28	SENT_364	[p23l1572t688r1714b718],
28	Center	NNP	ORGANIZATION	Center	dep	11	SENT_364	[p23l1722t690r1780b712, p23l94t730r127b748],
29	(	CD	NUMBER	(	num	31	SENT_364	[p23l136t727r208b752],
30	T.O.	NNP	ORGANIZATION	T.O.	nn	31	SENT_364	[p23l136t727r208b752],
31	)	NN	O	)	dep	2	SENT_364	[p23l136t727r208b752],
32	and	CC	O	and	_	0	SENT_364	[p23l218t725r263b749],
33	Yokohama	NNP	ORGANIZATION	Yokohama	nn	39	SENT_364	[p23l271t725r404b749],
34	City	NNP	ORGANIZATION	City	nn	39	SENT_364	[p23l412t725r460b755],
35	University	NNP	ORGANIZATION	University	nn	39	SENT_364	[p23l468t725r592b755],
36	Medical	NNP	ORGANIZATION	Medical	nn	39	SENT_364	[p23l599t725r696b749],
37	Center	NNP	ORGANIZATION	Center	nn	39	SENT_364	[p23l705t727r787b749],
38	(	NNP	O	(	nn	39	SENT_364	[p23l796t727r869b752],
39	S.M.	NNP	LOCATION	S.M.	dep	2	SENT_364	[p23l796t727r869b752],
40	)	CD	NUMBER	)	number	41	SENT_364	[p23l796t727r869b752],
41	—	CD	NUMBER	—	num	42	SENT_364	[p23l879t738r912b741],
42	boﬂi	NNS	O	boﬂi	dep	2	SENT_364	[p23l920t725r976b749],
43	in	IN	O	in	_	0	SENT_364	[p23l985t725r1009b748],
44	Yokohama	NNP	LOCATION	Yokohama	prep_in	42	SENT_364	[p23l1016t725r1156b753],
45	;	:	O	;	_	0	SENT_364	[p23l1016t725r1156b753],
46	Tsuboi	NNP	ORGANIZATION	Tsuboi	nn	49	SENT_364	[p23l1165t725r1250b749],
47	Cancer	NNP	ORGANIZATION	Cancer	nn	49	SENT_364	[p23l1259t727r1345b749],
48	Center	NNP	ORGANIZATION	Center	nn	49	SENT_364	[p23l1353t727r1435b749],
49	Hospital	NNP	ORGANIZATION	Hospital	dep	2	SENT_364	[p23l1443t725r1555b755],
50	,	,	O	,	_	0	SENT_364	[p23l1443t725r1555b755],
51	Koriyama	NNP	LOCATION	Koriyama	nn	54	SENT_364	[p23l1565t725r1684b755],
52	(	NNP	O	(	nn	54	SENT_364	[p23l1693t727r1779b753],
53	M.A.	NNP	LOCATION	M.A.	nn	54	SENT_364	[p23l1693t727r1779b753],
54	)	NNP	O	)	appos	49	SENT_364	[p23l1693t727r1779b753],
55	;	:	O	;	_	0	SENT_364	[p23l1693t727r1779b753],
56	and	CC	O	and	_	0	SENT_364	[p23l94t762r139b786],
57	Graduate	NNP	ORGANIZATION	Graduate	nn	58	SENT_364	[p23l149t762r263b786],
58	School	NNP	ORGANIZATION	School	conj_and	42	SENT_364	[p23l273t762r356b786],
59	of	IN	ORGANIZATION	of	_	0	SENT_364	[p23l366t762r396b786],
60	Medicine	NNP	ORGANIZATION	Medicine	prep_of	58	SENT_364	[p23l399t762r520b790],
61	,	,	O	,	_	0	SENT_364	[p23l399t762r520b790],
62	Hirosaki	NNP	ORGANIZATION	Hirosaki	nn	67	SENT_364	[p23l531t762r638b786],
63	University	NNP	ORGANIZATION	University	nn	67	SENT_364	[p23l647t762r777b792],
64	,	,	O	,	_	0	SENT_364	[p23l647t762r777b792],
65	Hirosaki	NNP	LOCATION	Hirosaki	appos	67	SENT_364	[p23l789t762r895b786],
66	(	CD	NUMBER	(	num	67	SENT_364	[p23l906t764r970b789],
67	Y.S.	NNP	LOCATION	Y.S.	appos	2	SENT_364	[p23l906t764r970b789],
68	)	CD	NUMBER	)	number	69	SENT_364	[p23l906t764r970b789],
69	—	CD	NUMBER	—	dep	67	SENT_364	[p23l980t775r1014b778],
70	all	DT	O	all	dep	2	SENT_364	[p23l1022t762r1051b785],
71	in	IN	O	in	_	0	SENT_364	[p23l1061t762r1085b785],
72	Japan	NNP	LOCATION	Japan	prep_in	70	SENT_364	[p23l1092t764r1169b792],
73	.	.	O	.	_	0	SENT_364	[p23l1092t764r1169b792],

1	Contributing	VBG	O	contribute	_	0	SENT_365	[p23l125t799r290b829],
2	members	NNS	O	member	dobj	1	SENT_365	[p23l300t799r417b823],
3	of	IN	O	of	_	0	SENT_365	[p23l428t799r458b823],
4	the	DT	O	the	det	6	SENT_365	[p23l464t799r502b822],
5	N	NN	O	n	nn	6	SENT_365	[p23l512t801r534b823],
6	orth	NN	O	orth	prep_of	2	SENT_365	[p23l536t799r653b823],
7	.	.	O	.	_	0	SENT_365	[p23l536t799r653b823],

1	—	NN	O	—	_	0	SENT_366	[p23l536t799r653b823],
2	.	.	O	.	_	0	SENT_366	[p23l536t799r653b823],

1	East	NNP	ORGANIZATION	East	nn	4	SENT_367	[p23l536t799r653b823],
2	Japan	NNP	ORGANIZATION	Japan	nn	4	SENT_367	[p23l659t801r731b829],
3	Study	NNP	ORGANIZATION	Study	nn	4	SENT_367	[p23l743t799r812b829],
4	Group	NNP	ORGANIZATION	Group	nsubj	5	SENT_367	[p23l822t801r902b829],
5	were	VBD	O	be	_	0	SENT_367	[p23l912t807r972b823],
6	as	IN	O	as	mark	7	SENT_367	[p23l983t807r1008b822],
7	follows	VBZ	O	follow	advcl	5	SENT_367	[p23l1019t799r1119b823],
8	:	:	O	:	_	0	SENT_367	[p23l1019t799r1119b823],
9	Steering	NNP	O	Steering	nn	13	SENT_367	[p23l1131t799r1237b829],
10	Committee	NNP	O	Committee	nn	13	SENT_367	[p23l1244t799r1384b823],
11	—	NNP	O	—	nn	13	SENT_367	[p23l1394t812r1427b815],
12	K.	NNP	PERSON	K.	nn	13	SENT_367	[p23l1437t801r1463b823],
13	Kobayashi	NNP	PERSON	Kobayashi	dobj	7	SENT_367	[p23l1475t799r1612b829],
14	,	,	O	,	_	0	SENT_367	[p23l1475t799r1612b829],
15	A.	NNP	PERSON	A.	nn	16	SENT_367	[p23l1624t801r1649b823],
16	Inoue	NNP	PERSON	Inoue	appos	13	SENT_367	[p23l1661t801r1741b827],
17	,	,	O	,	_	0	SENT_367	[p23l1661t801r1741b827],
18	K.	NNP	PERSON	K.	nn	19	SENT_367	[p23l1753t801r1778b823],
19	Yamazaki	NNP	PERSON	Yamazaki	appos	13	SENT_367	[p23l93t836r222b864],
20	,	,	O	,	_	0	SENT_367	[p23l93t836r222b864],
21	S.	NNP	PERSON	S.	nn	22	SENT_367	[p23l237t838r258b860],
22	Oizumi	NNP	PERSON	Oizumi	appos	13	SENT_367	[p23l272t836r373b865],
23	,	,	O	,	_	0	SENT_367	[p23l272t836r373b865],
24	H.	NNP	PERSON	H.	nn	25	SENT_367	[p23l387t838r416b860],
25	Isobe	NNP	PERSON	Isobe	appos	13	SENT_367	[p23l430t836r505b864],
26	,	,	O	,	_	0	SENT_367	[p23l430t836r505b864],
27	Y.	NNP	PERSON	Y.	nn	28	SENT_367	[p23l519t838r542b860],
28	Saijo	NNP	PERSON	Saijo	appos	13	SENT_367	[p23l557t836r624b866],
29	,	,	O	,	_	0	SENT_367	[p23l557t836r624b866],
30	K.	NNP	PERSON	K.	nn	31	SENT_367	[p23l638t838r664b860],
31	Hagiwara	NNP	PERSON	Hagiwara	appos	13	SENT_367	[p23l678t836r806b866],
32	,	,	O	,	_	0	SENT_367	[p23l678t836r806b866],
33	A.	NNP	PERSON	A.	nn	34	SENT_367	[p23l820t838r846b860],
34	Gemma	NNP	PERSON	Gemma	appos	13	SENT_367	[p23l860t838r967b864],
35	,	,	O	,	_	0	SENT_367	[p23l860t838r967b864],
36	T.	NNP	PERSON	T.	nn	37	SENT_367	[p23l981t838r1005b860],
37	Nukiwa	NNP	PERSON	Nukiwa	appos	13	SENT_367	[p23l1020t836r1125b864],
38	;	:	O	;	_	0	SENT_367	[p23l1020t836r1125b864],
39	Advisers	NNP	O	Advisers	dep	13	SENT_367	[p23l1138t836r1246b860],
40	to	TO	O	to	_	0	SENT_367	[p23l1259t841r1283b860],
41	Steering	NNP	O	Steering	nn	45	SENT_367	[p23l1293t836r1399b866],
42	Committee	NNP	O	Committee	nn	45	SENT_367	[p23l1407t836r1548b860],
43	—	NNP	O	—	nn	45	SENT_367	[p23l1560t849r1593b852],
44	S.	NNP	PERSON	S.	nn	45	SENT_367	[p23l1606t838r1626b860],
45	Kudoh	NNP	PERSON	Kudoh	prep_to	39	SENT_367	[p23l1641t836r1733b864],
46	,	,	O	,	_	0	SENT_367	[p23l1641t836r1733b864],
47	M.	NNP	PERSON	M.	nn	48	SENT_367	[p23l1746t838r1779b860],
48	Kanazawa	NNP	PERSON	Kanazawa	appos	45	SENT_367	[p23l94t875r229b901],
49	;	:	O	;	_	0	SENT_367	[p23l94t875r229b901],
50	Independent	NNP	ORGANIZATION	Independent	nn	51	SENT_367	[p23l244t873r406b903],
51	Data	NNP	ORGANIZATION	Data	dep	13	SENT_367	[p23l415t875r474b897],
52	and	CC	O	and	_	0	SENT_367	[p23l484t873r530b897],
53	Safety	NNP	ORGANIZATION	Safety	dep	13	SENT_367	[p23l542t873r617b903],
54	Monitoring	VBG	ORGANIZATION	monitor	partmod	13	SENT_367	[p23l626t873r774b903],
55	Committee	NNP	ORGANIZATION	Committee	nn	58	SENT_367	[p23l783t873r924b897],
56	—	NNP	O	—	nn	58	SENT_367	[p23l937t886r971b889],
57	K.	NNP	PERSON	K.	nn	58	SENT_367	[p23l984t875r1010b897],
58	Nagao	NNP	PERSON	Nagao	dobj	54	SENT_367	[p23l1026t875r1115b903],
59	,	,	O	,	_	0	SENT_367	[p23l1026t875r1115b903],
60	Y.	NNP	PERSON	Y.	nn	61	SENT_367	[p23l1130t875r1152b897],
61	Nakai	NNP	PERSON	Nakai	appos	58	SENT_367	[p23l1168t873r1249b901],
62	,	,	O	,	_	0	SENT_367	[p23l1168t873r1249b901],
63	M.	NNP	PERSON	M.	nn	64	SENT_367	[p23l1265t875r1297b897],
64	Shibuya	NNP	PERSON	Shibuya	appos	61	SENT_367	[p23l1314t873r1419b903],
65	;	:	O	;	_	0	SENT_367	[p23l1314t873r1419b903],
66	Study	NNP	O	Study	nn	68	SENT_367	[p23l1436t873r1507b903],
67	Site	NN	O	site	nn	68	SENT_367	[p23l1517t873r1563b897],
68	Investigators	NNS	O	investigator	nsubj	69	SENT_367	[p23l1573t873r1738b903],
69	—	VBP	O	—	parataxis	5	SENT_367	[p23l1748t886r1781b889],

1	NENGLJ	NN	O	nenglj	nn	2	SENT_368	[p23l621t988r727b1010],
2	MED362	NN	O	med362	_	0	SENT_368	[p23l742t982r883b1010],
3	;	:	O	;	_	0	SENT_368	[p23l742t982r883b1010],
4	25	CD	NUMBER	25	num	6	SENT_368	[p23l742t982r883b1010],
5	NEJM.ORG	NN	O	nejm.org	nn	6	SENT_368	[p23l918t988r1042b1010],
6	jUNE24	NN	O	june24	dep	2	SENT_368	[p23l1073t988r1255b1010],
7	,2010	CD	NUMBER	,2010	number	8	SENT_368	[p23l1073t988r1255b1010],
8	2337	CD	DATE	2337	dep	6	SENT_368	[p23l1990t978r2067b1001],

1	The	DT	O	the	det	5	SENT_369	[p23l753t1045r804b1069],
2	New	NNP	O	New	nn	5	SENT_369	[p23l813t1046r875b1069],
3	England	NNP	O	England	nn	5	SENT_369	[p23l884t1045r995b1076],
4	J	NNP	O	J	nn	5	SENT_369	[p23l1003t1046r1016b1069],
5	oumal	NN	O	oumal	_	0	SENT_369	[p23l1017t1045r1101b1069],
6	of	IN	O	of	_	0	SENT_369	[p23l1110t1045r1139b1069],
7	Medicine	NN	O	medicine	prep_of	5	SENT_369	[p23l1146t1045r1271b1069],

1	Copyright	NN	O	copyright	_	0	SENT_370	[p23l545t1127r680b1158],
2	©	CD	NUMBER	©	num	6	SENT_370	[p23l689t1127r712b1151],
3	2010	CD	DATE	2010	num	6	SENT_370	[p23l722t1127r788b1151],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_370	[p23l797t1127r988b1151],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_370	[p23l998t1127r1106b1151],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_370	[p23l1116t1127r1221b1158],
7	.	.	O	.	_	0	SENT_370	[p23l1116t1127r1221b1158],

1	All	DT	O	all	det	2	SENT_371	[p23l1232t1127r1274b1151],
2	rights	NNS	O	rights	nsubj	3	SENT_371	[p23l1283t1127r1357b1158],
3	reserved	VBN	O	reserve	_	0	SENT_371	[p23l1367t1127r1486b1151],
4	.	.	O	.	_	0	SENT_371	[p23l1367t1127r1486b1151],

1	GEFITINIB	NNP	O	GEFITINIB	nn	3	SENT_372	[p23l496t1170r672b1189],
2	OR	NN	O	or	nn	3	SENT_372	[p23l686t1170r731b1189],
3	CHEMOTHERAPY	NNP	O	CHEMOTHERAPY	_	0	SENT_372	[p23l743t1170r1020b1189],
4	FOR	IN	O	for	_	0	SENT_372	[p23l1033t1170r1097b1189],
5	NON	NNP	O	NON	prep_for	3	SENT_372	[p23l1110t1170r1413b1189],
6	.	.	O	.	_	0	SENT_372	[p23l1110t1170r1413b1189],

1	—	NN	O	—	_	0	SENT_373	[p23l1110t1170r1413b1189],
2	.	.	O	.	_	0	SENT_373	[p23l1110t1170r1413b1189],

1	SMALL-CELL	NN	O	small-cell	nn	2	SENT_374	[p23l1110t1170r1413b1189],
2	LUNG	NN	O	lung	_	0	SENT_374	[p23l1427t1170r1519b1189],
3	CANCER	NNP	O	CANCER	dep	2	SENT_374	[p23l1532t1170r1666b1189],

1	K.	NNP	PERSON	K.	dep	101	SENT_375	[p23l237t1266r262b1288],
2	Akie	NNP	PERSON	Akie	dep	101	SENT_375	[p23l274t1264r338b1292],
3	,	,	O	,	_	0	SENT_375	[p23l274t1264r338b1292],
4	N.	NNP	PERSON	N.	dep	101	SENT_375	[p23l350t1266r378b1287],
5	Chonabayashi	NNP	PERSON	Chonabayashi	dep	101	SENT_375	[p23l391t1264r575b1294],
6	,	,	O	,	_	0	SENT_375	[p23l391t1264r575b1294],
7	Y.	NNP	PERSON	Y.	dep	101	SENT_375	[p23l587t1266r609b1287],
8	Hasegawa	NNP	PERSON	Hasegawa	dep	101	SENT_375	[p23l622t1266r757b1294],
9	,	,	O	,	_	0	SENT_375	[p23l622t1266r757b1294],
10	K.	NNP	PERSON	K.	dep	101	SENT_375	[p23l769t1266r795b1288],
11	Hayashibara	NNP	PERSON	Hayashibara	dep	101	SENT_375	[p23l808t1264r971b1294],
12	,	,	O	,	_	0	SENT_375	[p23l808t1264r971b1294],
13	M.	NNP	PERSON	M.	dep	101	SENT_375	[p23l983t1266r1015b1287],
14	Hino	NNP	PERSON	Hino	dep	101	SENT_375	[p23l1027t1264r1097b1292],
15	,	,	O	,	_	0	SENT_375	[p23l1027t1264r1097b1292],
16	T.	NNP	PERSON	T.	dep	101	SENT_375	[p23l1109t1266r1133b1287],
17	Hino	NNP	PERSON	Hino	dep	101	SENT_375	[p23l1146t1264r1216b1292],
18	,	,	O	,	_	0	SENT_375	[p23l1146t1264r1216b1292],
19	K.	NNP	PERSON	K.	dep	101	SENT_375	[p23l1228t1266r1254b1288],
20	Ikebuchi	NNP	PERSON	Ikebuchi	dep	101	SENT_375	[p23l1266t1264r1383b1292],
21	,	,	O	,	_	0	SENT_375	[p23l1266t1264r1383b1292],
22	Y.	NNP	PERSON	Y.	dep	101	SENT_375	[p23l1395t1266r1417b1287],
23	Ishii	NNP	PERSON	Ishii	dep	101	SENT_375	[p23l1430t1264r1492b1292],
24	,	,	O	,	_	0	SENT_375	[p23l1430t1264r1492b1292],
25	N.	NNP	PERSON	N.	dep	101	SENT_375	[p23l1504t1266r1533b1287],
26	Kaneko	NNP	PERSON	Kaneko	dep	101	SENT_375	[p23l1545t1264r1648b1292],
27	,	,	O	,	_	0	SENT_375	[p23l1545t1264r1648b1292],
28	Y.	NNP	PERSON	Y.	dep	101	SENT_375	[p23l1660t1266r1682b1287],
29	Kimura	NNP	PERSON	Kimura	dep	101	SENT_375	[p23l1695t1264r1796b1292],
30	,	,	O	,	_	0	SENT_375	[p23l1695t1264r1796b1292],
31	H.	NNP	PERSON	H.	dep	101	SENT_375	[p23l1808t1266r1837b1287],
32	Koba	NNP	PERSON	Koba	dep	101	SENT_375	[p23l1849t1264r1922b1292],
33	,	,	O	,	_	0	SENT_375	[p23l1849t1264r1922b1292],
34	T.	NNP	PERSON	T.	dep	101	SENT_375	[p23l236t1303r260b1324],
35	Kojima	NNP	PERSON	Kojima	dep	101	SENT_375	[p23l272t1301r369b1331],
36	,	,	O	,	_	0	SENT_375	[p23l272t1301r369b1331],
37	S.	NNP	PERSON	S.	dep	101	SENT_375	[p23l382t1303r402b1324],
38	Kosaihira	NNP	PERSON	Kosaihira	dep	101	SENT_375	[p23l414t1301r542b1329],
39	,	,	O	,	_	0	SENT_375	[p23l414t1301r542b1329],
40	N.	NNP	PERSON	N.	dep	101	SENT_375	[p23l554t1303r582b1324],
41	Koyama	NNP	PERSON	Koyama	dep	101	SENT_375	[p23l594t1303r702b1331],
42	,	,	O	,	_	0	SENT_375	[p23l594t1303r702b1331],
43	H.	NNP	PERSON	H.	dep	101	SENT_375	[p23l714t1303r743b1324],
44	Miki	NNP	PERSON	Miki	dep	101	SENT_375	[p23l754t1301r819b1329],
45	,	,	O	,	_	0	SENT_375	[p23l754t1301r819b1329],
46	Y.	NNP	PERSON	Y.	dep	101	SENT_375	[p23l830t1303r852b1324],
47	Minegishi	NNP	PERSON	Minegishi	dep	101	SENT_375	[p23l863t1301r997b1331],
48	,	,	O	,	_	0	SENT_375	[p23l863t1301r997b1331],
49	N.	NNP	PERSON	N.	dep	101	SENT_375	[p23l1009t1303r1037b1324],
50	Morikawa	NNP	PERSON	Morikawa	dep	101	SENT_375	[p23l1049t1301r1182b1329],
51	,	,	O	,	_	0	SENT_375	[p23l1049t1301r1182b1329],
52	G.	NNP	PERSON	G.	dep	101	SENT_375	[p23l1194t1303r1222b1324],
53	Moriyama	NNP	PERSON	Moriyama	dep	101	SENT_375	[p23l1233t1301r1367b1331],
54	,	,	O	,	_	0	SENT_375	[p23l1233t1301r1367b1331],
55	Y.	NNP	PERSON	Y.	dep	101	SENT_375	[p23l1378t1303r1401b1324],
56	Murayama	NNP	PERSON	Murayama	dep	101	SENT_375	[p23l1412t1303r1552b1331],
57	,	,	O	,	_	0	SENT_375	[p23l1412t1303r1552b1331],
58	M.	NNP	PERSON	M.	dep	101	SENT_375	[p23l1563t1303r1595b1324],
59	Nagashima	NNP	PERSON	Nagashima	dep	101	SENT_375	[p23l1607t1301r1757b1331],
60	,	,	O	,	_	0	SENT_375	[p23l1607t1301r1757b1331],
61	K.	NNP	PERSON	K.	dep	101	SENT_375	[p23l1769t1303r1795b1325],
62	Niizuma	NNP	PERSON	Niizuma	dep	101	SENT_375	[p23l1806t1301r1922b1329],
63	,	,	O	,	_	0	SENT_375	[p23l1806t1301r1922b1329],
64	H.	NNP	PERSON	H.	dep	101	SENT_375	[p23l237t1340r265b1361],
65	Nitanai	NNP	PERSON	Nitanai	dep	101	SENT_375	[p23l278t1338r378b1366],
66	,	,	O	,	_	0	SENT_375	[p23l278t1338r378b1366],
67	S.	NNP	PERSON	S.	dep	101	SENT_375	[p23l392t1340r413b1361],
68	Ogura	NNP	PERSON	Ogura	dep	101	SENT_375	[p23l426t1340r511b1368],
69	,	,	O	,	_	0	SENT_375	[p23l426t1340r511b1368],
70	Y.	NNP	PERSON	Y.	dep	101	SENT_375	[p23l523t1340r546b1361],
71	Okamoto	NNP	PERSON	Okamoto	dep	101	SENT_375	[p23l560t1338r684b1366],
72	,	,	O	,	_	0	SENT_375	[p23l560t1338r684b1366],
73	Y.	NNP	PERSON	Y.	dep	101	SENT_375	[p23l697t1340r719b1361],
74	Osaki	NNP	PERSON	Osaki	dep	101	SENT_375	[p23l733t1338r811b1366],
75	,	,	O	,	_	0	SENT_375	[p23l733t1338r811b1366],
76	H.	NNP	PERSON	H.	dep	101	SENT_375	[p23l825t1340r853b1361],
77	Sakai	NNP	PERSON	Sakai	dep	101	SENT_375	[p23l867t1338r940b1366],
78	,	,	O	,	_	0	SENT_375	[p23l867t1338r940b1366],
79	H.	NNP	PERSON	H.	dep	101	SENT_375	[p23l953t1340r982b1361],
80	Sugita	NNP	PERSON	Sugita	dep	101	SENT_375	[p23l996t1338r1081b1368],
81	,	,	O	,	_	0	SENT_375	[p23l996t1338r1081b1368],
82	T.	NNP	PERSON	T.	dep	101	SENT_375	[p23l1093t1340r1117b1361],
83	Suzuki	NNP	PERSON	Suzuki	dep	101	SENT_375	[p23l1132t1338r1223b1366],
84	,	,	O	,	_	0	SENT_375	[p23l1132t1338r1223b1366],
85	J.	NNP	PERSON	J.	dep	101	SENT_375	[p23l1234t1340r1251b1365],
86	Tanaka	NNP	PERSON	Tanaka	dep	101	SENT_375	[p23l1264t1338r1363b1366],
87	,	,	O	,	_	0	SENT_375	[p23l1264t1338r1363b1366],
88	H.	NNP	PERSON	H.	dep	101	SENT_375	[p23l1376t1340r1405b1361],
89	Tokunaga	NNP	PERSON	Tokunaga	dep	101	SENT_375	[p23l1417t1338r1551b1368],
90	,	,	O	,	_	0	SENT_375	[p23l1417t1338r1551b1368],
91	T.	NNP	PERSON	T.	dep	101	SENT_375	[p23l1563t1340r1588b1361],
92	Tsukamoto	NNP	PERSON	Tsukamoto	dep	101	SENT_375	[p23l1600t1338r1751b1366],
93	,	,	O	,	_	0	SENT_375	[p23l1600t1338r1751b1366],
94	K.	NNP	PERSON	K.	dep	101	SENT_375	[p23l1764t1340r1790b1362],
95	Uematsu	NNP	PERSON	Uematsu	dep	101	SENT_375	[p23l1803t1340r1922b1366],
96	,	,	O	,	_	0	SENT_375	[p23l1803t1340r1922b1366],
97	K.	NNP	PERSON	K.	dep	101	SENT_375	[p23l237t1377r262b1399],
98	Usui	NNP	PERSON	Usui	dep	101	SENT_375	[p23l274t1375r339b1403],
99	,	,	O	,	_	0	SENT_375	[p23l274t1375r339b1403],
100	K.	NNP	PERSON	K.	dep	101	SENT_375	[p23l351t1377r377b1399],
101	Yasuda	NNP	PERSON	Yasuda	_	0	SENT_375	[p23l388t1375r484b1399],
102	.	.	O	.	_	0	SENT_375	[p23l388t1375r484b1399],

1	REFERENCES	NNS	O	reference	_	0	SENT_376	[p23l26t1573r690b1638],

1	1	LS	NUMBER	1	_	0	SENT_377	[p23l23t1808r98b1887],
2	.	.	O	.	_	0	SENT_377	[p23l23t1808r98b1887],

1	Schiller	NNP	PERSON	Schiller	nn	2	SENT_378	[p23l219t1796r601b1887],
2	JH	NNP	O	JH	_	0	SENT_378	[p23l632t1804r793b1907],
3	,	,	O	,	_	0	SENT_378	[p23l632t1804r793b1907],
4	Harrington	NNP	PERSON	Harrington	nn	5	SENT_378	[p23l844t1798r1421b1913],
5	D	NNP	O	D	appos	2	SENT_378	[p23l1466t1804r1569b1907],
6	,	,	O	,	_	0	SENT_378	[p23l1466t1804r1569b1907],
7	Belani	NNP	PERSON	Belani	nn	8	SENT_378	[p23l1619t1796r1939b1887],
8	CP	NNP	O	CP	appos	2	SENT_378	[p23l1983t1804r2133b1907],
9	,	,	O	,	_	0	SENT_378	[p23l1983t1804r2133b1907],
10	et	FW	O	et	nn	11	SENT_378	[p23l20t1965r110b2036],
11	al.	FW	O	al.	appos	2	SENT_378	[p23l159t1945r273b2036],
12	.	.	O	.	_	0	SENT_378	[p23l159t1945r273b2036],

1	Comparison	NN	O	comparison	_	0	SENT_379	[p23l335t1947r957b2060],
2	of	IN	O	of	_	0	SENT_379	[p23l1013t1945r1130b2036],
3	four	CD	NUMBER	four	num	5	SENT_379	[p23l1163t1945r1375b2036],
4	chemotherapy	NN	O	chemotherapy	nn	5	SENT_379	[p23l1428t1945r2145b2060],
5	regimens	NNS	O	regimen	prep_of	1	SENT_379	[p23l19t2096r469b2211],
6	for	IN	O	for	_	0	SENT_379	[p23l506t2094r647b2185],
7	advanced	JJ	O	advanced	amod	9	SENT_379	[p23l678t2094r1126b2185],
8	non	JJ	O	non	amod	9	SENT_379	[p23l1161t2094r1884b2185],
9	—	NN	O	—	prep_for	1	SENT_379	[p23l1161t2094r1884b2185],
10	small	JJ	O	small	amod	14	SENT_379	[p23l1161t2094r1884b2185],
11	—	NN	O	—	nn	14	SENT_379	[p23l1161t2094r1884b2185],
12	cell	NN	O	cell	nn	14	SENT_379	[p23l1161t2094r1884b2185],
13	lung	NN	O	lung	nn	14	SENT_379	[p23l1917t2094r2145b2211],
14	cancer	NN	O	cancer	dep	9	SENT_379	[p23l21t2273r371b2334],
15	.	.	O	.	_	0	SENT_379	[p23l21t2273r371b2334],

1	N	NN	O	n	nn	3	SENT_380	[p23l415t2251r502b2334],
2	Engl	NNP	O	Engl	nn	3	SENT_380	[p23l538t2243r765b2360],
3	J	NNP	O	J	nsubj	4	SENT_380	[p23l793t2253r837b2348],
4	Med	VBD	O	med	_	0	SENT_380	[p23l870t2243r1088b2334],
5	2002	CD	DATE	2002	dobj	4	SENT_380	[p23l1127t2251r1864b2352],
6	;	:	O	;	_	0	SENT_380	[p23l1127t2251r1864b2352],
7	346:92	CD	NUMBER	346:92	number	8	SENT_380	[p23l1127t2251r1864b2352],
8	—	CD	NUMBER	—	dep	5	SENT_380	[p23l1127t2251r1864b2352],
9	8	CD	NUMBER	8	dep	8	SENT_380	[p23l1127t2251r1864b2352],
10	.	.	O	.	_	0	SENT_380	[p23l1127t2251r1864b2352],

1	2	LS	NUMBER	2	_	0	SENT_381	[p23l17t2404r102b2483],
2	.	.	O	.	_	0	SENT_381	[p23l17t2404r102b2483],

1	Ohe	NNP	O	Ohe	nn	2	SENT_382	[p23l217t2392r419b2483],
2	Y	NN	O	y	_	0	SENT_382	[p23l486t2400r571b2503],
3	,	,	O	,	_	0	SENT_382	[p23l486t2400r571b2503],
4	Ohashi	NNP	PERSON	Ohashi	nn	5	SENT_382	[p23l648t2392r1015b2483],
5	Y	NN	PERSON	y	appos	2	SENT_382	[p23l1080t2402r1165b2503],
6	,	,	O	,	_	0	SENT_382	[p23l1080t2402r1165b2503],
7	Kubota	NNP	PERSON	Kubota	nn	8	SENT_382	[p23l1242t2392r1613b2485],
8	K	NNP	PERSON	K	appos	2	SENT_382	[p23l1682t2400r1783b2503],
9	,	,	O	,	_	0	SENT_382	[p23l1682t2400r1783b2503],
10	et	FW	O	et	nn	11	SENT_382	[p23l1862t2412r1953b2483],
11	al.	FW	O	al.	appos	2	SENT_382	[p23l2018t2392r2134b2483],
12	.	.	O	.	_	0	SENT_382	[p23l2018t2392r2134b2483],

1	Randomized	VBN	O	randomize	_	0	SENT_383	[p23l17t2541r676b2638],
2	phase	NN	O	phase	nn	4	SENT_383	[p23l722t2541r1019b2656],
3	TII	NNP	ORGANIZATION	TII	nn	4	SENT_383	[p23l1066t2549r1187b2630],
4	study	NN	O	study	dobj	1	SENT_383	[p23l1236t2541r1510b2656],
5	of	IN	O	of	_	0	SENT_383	[p23l1553t2541r1672b2632],
6	cisplatin	NN	O	cisplatin	prep_of	4	SENT_383	[p23l1699t2541r2141b2656],
7	plus	CC	O	plus	_	0	SENT_383	[p23l17t2690r227b2805],
8	irinotecan	NN	O	irinotecan	dobj	1	SENT_383	[p23l294t2692r825b2781],
9	versus	CC	O	versus	prep	8	SENT_383	[p23l884t2720r1203b2781],
10	carboplatin	NN	O	carboplatin	dep	9	SENT_383	[p23l1272t2690r1864b2805],
11	plus	CC	O	plus	_	0	SENT_383	[p23l1929t2690r2138b2805],
12	paclitaxel	NN	O	paclitaxel	dep	9	SENT_383	[p23l17t2839r542b2954],
13	,	,	O	,	_	0	SENT_383	[p23l17t2839r542b2954],
14	cisplatin	NN	O	cisplatin	conj_plus	10	SENT_383	[p23l640t2839r1082b2954],
15	plus	CC	O	plus	_	0	SENT_383	[p23l1171t2839r1381b2954],
16	gemcitabine	NN	O	gemcitabine	conj_plus	10	SENT_383	[p23l1474t2839r2135b2956],
17	,	,	O	,	_	0	SENT_383	[p23l1474t2839r2135b2956],
18	and	CC	O	and	_	0	SENT_383	[p23l19t2988r205b3079],
19	cisplatin	NN	O	cisplatin	conj_and	4	SENT_383	[p23l288t2988r728b3103],
20	plus	CC	O	plus	prep	19	SENT_383	[p23l807t2988r1017b3103],
21	vinorelbine	NN	O	vinorelbine	dep	20	SENT_383	[p23l1096t2988r1680b3079],
22	for	IN	O	for	_	0	SENT_383	[p23l1761t2988r1908b3079],
23	advanced	JJ	O	advanced	amod	28	SENT_383	[p23l1985t2988r2139b3079, p23l15t3137r369b3228],
24	non-small	JJ	O	non-small	amod	28	SENT_383	[p23l409t3137r1155b3228],
25	—	NN	O	—	nn	28	SENT_383	[p23l409t3137r1155b3228],
26	cell	NN	O	cell	nn	28	SENT_383	[p23l409t3137r1155b3228],
27	lung	NN	O	lung	nn	28	SENT_383	[p23l1193t3137r1424b3254],
28	cancer	NN	O	cancer	prep_for	21	SENT_383	[p23l1460t3167r1823b3228],
29	:	:	O	:	_	0	SENT_383	[p23l1460t3167r1823b3228],
30	FourArm	NN	O	fourarm	nn	32	SENT_383	[p23l1866t3145r2139b3228, p23l15t3294r242b3375],
31	Cooperative	NNP	O	Cooperative	nn	32	SENT_383	[p23l318t3288r930b3401],
32	Study	NNP	O	Study	dep	19	SENT_383	[p23l1009t3286r1292b3401],
33	in	IN	O	in	_	0	SENT_383	[p23l1363t3288r1462b3375],
34	Japan	NNP	LOCATION	Japan	prep_in	32	SENT_383	[p23l1525t3294r1846b3401],
35	.	.	O	.	_	0	SENT_383	[p23l1525t3294r1846b3401],

1	Ann	NNP	PERSON	Ann	nn	2	SENT_384	[p23l1925t3294r2141b3375],
2	Oncol	NNP	PERSON	Oncol	_	0	SENT_384	[p23l19t3435r322b3526],
3	2007	CD	DATE	2007	num	2	SENT_384	[p23l363t3443r1151b3544],
4	;	:	O	;	_	0	SENT_384	[p23l363t3443r1151b3544],
5	18:317	CD	NUMBER	18:317	number	6	SENT_384	[p23l363t3443r1151b3544],
6	—	CD	NUMBER	—	dep	2	SENT_384	[p23l363t3443r1151b3544],
7	23	CD	NUMBER	23	dep	6	SENT_384	[p23l363t3443r1151b3544],
8	.	.	O	.	_	0	SENT_384	[p23l363t3443r1151b3544],

1	3	LS	NUMBER	3	_	0	SENT_385	[p23l19t3596r96b3675],
2	.	.	O	.	_	0	SENT_385	[p23l19t3596r96b3675],

1	Fukuoka	NNP	LOCATION	Fukuoka	nn	2	SENT_386	[p23l215t3584r655b3675],
2	M	NNP	O	M	_	0	SENT_386	[p23l684t3592r811b3695],
3	,	,	O	,	_	0	SENT_386	[p23l684t3592r811b3695],
4	Yano	NNP	PERSON	Yano	nn	5	SENT_386	[p23l848t3592r1094b3675],
5	S	NNP	O	S	appos	2	SENT_386	[p23l1133t3592r1213b3693],
6	,	,	O	,	_	0	SENT_386	[p23l1133t3592r1213b3693],
7	Giaccone	NNP	PERSON	Giaccone	nn	8	SENT_386	[p23l1254t3586r1716b3675],
8	G	NNP	O	G	appos	2	SENT_386	[p23l1751t3592r1858b3695],
9	,	,	O	,	_	0	SENT_386	[p23l1751t3592r1858b3695],
10	et	FW	O	et	nn	11	SENT_386	[p23l1901t3604r1991b3675],
11	al.	FW	O	al.	appos	2	SENT_386	[p23l2020t3584r2133b3675],
12	.	.	O	.	_	0	SENT_386	[p23l2020t3584r2133b3675],

1	Multi	JJ	O	multi	dep	2	SENT_387	[p24l15t26r959b117],
2	—	NN	O	—	amod	7	SENT_387	[p24l15t26r959b117],
3	institutional	JJ	O	institutional	amod	7	SENT_387	[p24l15t26r959b117],
4	randomized	JJ	O	randomized	amod	7	SENT_387	[p24l1028t26r1639b117],
5	phase	NN	O	phase	nn	7	SENT_387	[p24l1705t26r1997b141],
6	ii	LS	O	ii	dep	7	SENT_387	[p24l2066t34r2141b115],
7	trial	NN	O	trial	nsubj	23	SENT_387	[p24l19t175r229b266],
8	of	IN	O	of	_	0	SENT_387	[p24l266t175r383b266],
9	gefitinib	NN	O	gefitinib	prep_of	7	SENT_387	[p24l397t175r835b292],
10	for	IN	O	for	prep	9	SENT_387	[p24l874t175r1019b266],
11	previously	RB	DATE	previously	pcomp	10	SENT_387	[p24l1050t175r1567b290],
12	treated	VBN	O	treat	partmod	7	SENT_387	[p24l1599t175r1949b266],
13	patients	NNS	O	patient	dobj	12	SENT_387	[p24l1985t205r2139b290, p24l19t326r298b415],
14	with	IN	O	with	_	0	SENT_387	[p24l345t324r573b415],
15	advanced	JJ	O	advanced	amod	17	SENT_387	[p24l623t324r1088b415],
16	non	JJ	O	non	amod	17	SENT_387	[p24l1139t324r1868b415],
17	—	NN	O	—	prep_with	12	SENT_387	[p24l1139t324r1868b415],
18	small	JJ	O	small	amod	22	SENT_387	[p24l1139t324r1868b415],
19	—	NN	O	—	nn	22	SENT_387	[p24l1139t324r1868b415],
20	cell	NN	O	cell	nn	22	SENT_387	[p24l1139t324r1868b415],
21	lung	NN	O	lung	nn	22	SENT_387	[p24l1917t324r2145b441],
22	cancer	NN	O	cancer	dep	17	SENT_387	[p24l20t503r350b564],
23	(	VBD	O	(	_	0	SENT_387	[p24l407t473r591b578],
24	the	DT	O	the	det	28	SENT_387	[p24l407t473r591b578],
25	IDEAL	NNP	O	IDEAL	nn	28	SENT_387	[p24l646t481r975b562],
26	1	CD	NUMBER	1	num	28	SENT_387	[p24l1032t481r1082b562],
27	Trial	NN	O	trial	nn	28	SENT_387	[p24l1133t473r1437b578],
28	)	NN	O	)	dobj	23	SENT_387	[p24l1133t473r1437b578],
29	.	.	O	.	_	0	SENT_387	[p24l1133t473r1437b578],

1	J	NNP	O	J	nn	3	SENT_388	[p24l1486t483r1530b578],
2	Clin	NNP	O	Clin	nn	3	SENT_388	[p24l1581t473r1789b564],
3	Oncol	NNP	O	Oncol	_	0	SENT_388	[p24l1844t473r2141b564],
4	2003	CD	DATE	2003	num	3	SENT_388	[p24l19t630r878b731],
5	;	:	O	;	_	0	SENT_388	[p24l19t630r878b731],
6	21:2237	CD	NUMBER	21:2237	number	7	SENT_388	[p24l19t630r878b731],
7	—	CD	NUMBER	—	dep	3	SENT_388	[p24l19t630r878b731],
8	46	CD	NUMBER	46	dep	7	SENT_388	[p24l19t630r878b731],
9	.	.	O	.	_	0	SENT_388	[p24l19t630r878b731],

1	[	NNP	O	[	_	0	SENT_389	[p24l951t630r1433b733],
2	Erratum	NNP	O	Erratum	nn	6	SENT_389	[p24l951t630r1433b733],
3	,	,	O	,	_	0	SENT_389	[p24l951t630r1433b733],
4	J	NNP	O	J	appos	6	SENT_389	[p24l1484t632r1527b727],
5	Clin	NNP	O	Clin	nn	6	SENT_389	[p24l1581t622r1787b713],
6	Oncol	NNP	O	Oncol	dep	1	SENT_389	[p24l1844t622r2141b713],
7	2004	CD	DATE	2004	rcmod	6	SENT_389	[p24l19t779r757b880],
8	;	:	O	;	_	0	SENT_389	[p24l19t779r757b880],
9	22:811	CD	NUMBER	22:811	dep	7	SENT_389	[p24l19t779r757b880],
10	.	.	O	.	_	0	SENT_389	[p24l19t779r757b880],
11	]	SYM	O	]	dep	7	SENT_389	[p24l19t779r757b880],

1	4	LS	NUMBER	4	_	0	SENT_390	[p24l17t932r98b1011],
2	.	.	O	.	_	0	SENT_390	[p24l17t932r98b1011],

1	Kris	NNP	PERSON	Kris	nn	2	SENT_391	[p24l217t922r423b1013],
2	MG	NN	PERSON	mg	_	0	SENT_391	[p24l463t928r674b1031],
3	,	,	O	,	_	0	SENT_391	[p24l463t928r674b1031],
4	Natale	NNP	PERSON	Natale	nn	5	SENT_391	[p24l719t920r1045b1011],
5	RB	NN	O	rb	appos	2	SENT_391	[p24l1086t928r1262b1031],
6	,	,	O	,	_	0	SENT_391	[p24l1086t928r1262b1031],
7	Herbst	NNP	ORGANIZATION	Herbst	nn	8	SENT_391	[p24l1309t920r1650b1011],
8	RS	NN	ORGANIZATION	r	appos	2	SENT_391	[p24l1684t928r1846b1031],
9	,	,	O	,	_	0	SENT_391	[p24l1684t928r1846b1031],
10	et	FW	O	et	nn	11	SENT_391	[p24l1894t940r1985b1011],
11	al.	FW	O	al.	appos	2	SENT_391	[p24l2020t920r2133b1011],
12	.	.	O	.	_	0	SENT_391	[p24l2020t920r2133b1011],

1	Efficacy	NN	O	efficacy	_	0	SENT_392	[p24l17t1069r427b1184],
2	of	IN	O	of	_	0	SENT_392	[p24l478t1069r595b1160],
3	gefitinib	NN	O	gefitinib	prep_of	1	SENT_392	[p24l629t1069r1094b1186],
4	,	,	O	,	_	0	SENT_392	[p24l629t1069r1094b1186],
5	an	DT	O	a	det	6	SENT_392	[p24l1155t1099r1276b1160],
6	inhibitor	NN	O	inhibitor	appos	3	SENT_392	[p24l1331t1069r1781b1160],
7	of	IN	O	of	_	0	SENT_392	[p24l1834t1069r1949b1160],
8	the	DT	O	the	det	14	SENT_392	[p24l1985t1069r2139b1160],
9	epidermal	JJ	O	epidermal	amod	14	SENT_392	[p24l21t1218r528b1333],
10	growth	NN	O	growth	nn	14	SENT_392	[p24l559t1218r928b1335],
11	factor	NN	O	factor	nn	14	SENT_392	[p24l961t1218r1254b1309],
12	receptor	NN	O	receptor	nn	14	SENT_392	[p24l1284t1238r1702b1333],
13	tyrosine	NN	O	tyrosine	nn	14	SENT_392	[p24l1733t1220r2140b1333],
14	kinase	NN	O	kinase	prep_of	6	SENT_392	[p24l19t1367r367b1478],
15	,	,	O	,	_	0	SENT_392	[p24l19t1367r367b1478],
16	in	IN	O	in	_	0	SENT_392	[p24l409t1369r506b1456],
17	symptomatic	JJ	O	symptomatic	amod	18	SENT_392	[p24l543t1369r1187b1482],
18	patients	NNS	O	patient	prep_in	3	SENT_392	[p24l1220t1369r1615b1482],
19	with	IN	O	with	_	0	SENT_392	[p24l1648t1367r1874b1458],
20	nonsmall	JJ	O	nonsmall	amod	23	SENT_392	[p24l1911t1397r2139b1458, p24l21t1516r296b1607],
21	cell	NN	O	cell	nn	23	SENT_392	[p24l327t1516r498b1607],
22	lung	NN	O	lung	nn	23	SENT_392	[p24l528t1516r755b1633],
23	cancer	NN	O	cancer	prep_with	18	SENT_392	[p24l783t1546r1138b1607],
24	:	:	O	:	_	0	SENT_392	[p24l783t1546r1138b1607],
25	a	DT	O	a	det	27	SENT_392	[p24l1173t1546r1225b1607],
26	randomized	JJ	O	randomized	amod	27	SENT_392	[p24l1254t1516r1866b1607],
27	trial	NN	O	trial	dep	1	SENT_392	[p24l1897t1516r2134b1607],
28	.	.	O	.	_	0	SENT_392	[p24l1897t1516r2134b1607],

1	JAMA	NNP	O	JAMA	_	0	SENT_393	[p24l7t1675r308b1770],
2	2003	CD	DATE	2003	num	1	SENT_393	[p24l345t1673r1264b1774],
3	;	:	O	;	_	0	SENT_393	[p24l345t1673r1264b1774],
4	290:2149	CD	NUMBER	290:2149	dep	1	SENT_393	[p24l345t1673r1264b1774],
5	.	.	O	.	_	0	SENT_393	[p24l345t1673r1264b1774],

1	—	NN	O	—	_	0	SENT_394	[p24l345t1673r1264b1774],
2	.	.	O	.	_	0	SENT_394	[p24l345t1673r1264b1774],

1	S8	NN	O	s8	_	0	SENT_395	[p24l345t1673r1264b1774],
2	.	.	O	.	_	0	SENT_395	[p24l345t1673r1264b1774],

1	5	CD	NUMBER	5	_	0	SENT_396	[p24l21t1826r94b1905],
2	.	.	O	.	_	0	SENT_396	[p24l21t1826r94b1905],

1	Kim	NNP	PERSON	Kim	nn	2	SENT_397	[p24l217t1816r427b1907],
2	ES	NN	O	e	_	0	SENT_397	[p24l456t1822r601b1925],
3	,	,	O	,	_	0	SENT_397	[p24l456t1822r601b1925],
4	Hirsh	NNP	PERSON	Hirsh	nn	5	SENT_397	[p24l637t1814r916b1905],
5	V	NNP	PERSON	V	appos	2	SENT_397	[p24l941t1822r1026b1923],
6	,	,	O	,	_	0	SENT_397	[p24l941t1822r1026b1923],
7	Mok	NNP	ORGANIZATION	Mok	nn	8	SENT_397	[p24l1058t1814r1284b1905],
8	T	NN	ORGANIZATION	t	appos	2	SENT_397	[p24l1304t1822r1393b1925],
9	,	,	O	,	_	0	SENT_397	[p24l1304t1822r1393b1925],
10	et	FW	O	et	nn	11	SENT_397	[p24l1429t1834r1518b1905],
11	al.	FW	O	al.	appos	2	SENT_397	[p24l1541t1814r1652b1905],
12	.	.	O	.	_	0	SENT_397	[p24l1541t1814r1652b1905],

1	Gefitinib	JJ	O	gefitinib	_	0	SENT_398	[p24l1688t1814r2139b1905],
2	versus	CC	O	versus	prep	1	SENT_398	[p24l15t1993r320b2054],
3	docetaxel	NN	O	docetaxel	dep	2	SENT_398	[p24l361t1963r829b2054],
4	in	IN	O	in	prep	3	SENT_398	[p24l864t1965r959b2052],
5	previously	RB	DATE	previously	pcomp	4	SENT_398	[p24l995t1963r1502b2078],
6	treated	VBN	O	treat	partmod	1	SENT_398	[p24l1533t1963r1878b2054],
7	nonsmall	JJ	O	nonsmall	amod	11	SENT_398	[p24l1914t1993r2139b2054, p24l21t2112r514b2203],
8	—	NN	O	—	nn	11	SENT_398	[p24l1914t1993r2139b2054, p24l21t2112r514b2203],
9	cell	NN	O	cell	nn	11	SENT_398	[p24l1914t1993r2139b2054, p24l21t2112r514b2203],
10	lung	NN	O	lung	nn	11	SENT_398	[p24l545t2112r771b2229],
11	cancer	NN	O	cancer	dobj	6	SENT_398	[p24l803t2142r1132b2203],
12	(	CD	NUMBER	(	num	13	SENT_398	[p24l1167t2120r1816b2217],
13	INTEREST	NN	O	interest	dep	1	SENT_398	[p24l1167t2120r1816b2217],
14	)	CD	NUMBER	)	dep	13	SENT_398	[p24l1167t2120r1816b2217],
15	:	:	O	:	_	0	SENT_398	[p24l1167t2120r1816b2217],
16	a	DT	O	a	det	18	SENT_398	[p24l1854t2142r1904b2203],
17	randomised	JJ	O	randomised	amod	18	SENT_398	[p24l1935t2142r2139b2203, p24l21t2261r451b2352],
18	phase	NN	O	phase	dep	1	SENT_398	[p24l494t2261r785b2376],
19	ITT	NNP	ORGANIZATION	ITT	nn	20	SENT_398	[p24l828t2269r947b2350],
20	trial	NN	O	trial	dep	18	SENT_398	[p24l991t2261r1227b2352],
21	.	.	O	.	_	0	SENT_398	[p24l991t2261r1227b2352],

1	Lancet	NNP	O	Lancet	_	0	SENT_399	[p24l1276t2269r1614b2352],
2	2008	CD	DATE	2008	num	1	SENT_399	[p24l1652t2269r2135b2370],
3	;	:	O	;	_	0	SENT_399	[p24l1652t2269r2135b2370],
4	372	CD	NUMBER	372	num	6	SENT_399	[p24l1652t2269r2135b2370],
5	:	:	O	:	_	0	SENT_399	[p24l1652t2269r2135b2370],
6	1809-18	CD	NUMBER	1809-18	dep	1	SENT_399	[p24l23t2417r444b2500],
7	.	.	O	.	_	0	SENT_399	[p24l23t2417r444b2500],

1	6	CD	NUMBER	6	_	0	SENT_400	[p24l19t2570r98b2649],
2	.	.	O	.	_	0	SENT_400	[p24l19t2570r98b2649],

1	Maruyama	NNP	PERSON	Maruyama	nn	2	SENT_401	[p24l213t2566r755b2673],
2	R	NNP	PERSON	R	_	0	SENT_401	[p24l793t2566r894b2669],
3	,	,	O	,	_	0	SENT_401	[p24l793t2566r894b2669],
4	Nishiwaki	NNP	LOCATION	Nishiwaki	nn	5	SENT_401	[p24l937t2558r1456b2649],
5	Y	NN	O	y	appos	2	SENT_401	[p24l1491t2566r1575b2669],
6	,	,	O	,	_	0	SENT_401	[p24l1491t2566r1575b2669],
7	Tamura	NNP	PERSON	Tamura	nn	8	SENT_401	[p24l1618t2566r2009b2649],
8	T	NN	O	t	appos	2	SENT_401	[p24l2044t2566r2134b2669],
9	,	,	O	,	_	0	SENT_401	[p24l2044t2566r2134b2669],
10	et	FW	O	et	nn	11	SENT_401	[p24l21t2727r110b2798],
11	al.	FW	O	al.	appos	2	SENT_401	[p24l143t2707r258b2798],
12	.	.	O	.	_	0	SENT_401	[p24l143t2707r258b2798],

1	Phase	NN	O	phase	nn	3	SENT_402	[p24l302t2707r591b2798],
2	TH	NN	O	th	nn	3	SENT_402	[p24l629t2715r748b2796],
3	study	NN	O	study	_	0	SENT_402	[p24l789t2707r1074b2822],
4	,	,	O	,	_	0	SENT_402	[p24l789t2707r1074b2822],
5	V	NN	O	v	appos	3	SENT_402	[p24l1116t2715r1519b2818],
6	—	CD	NUMBER	—	number	7	SENT_402	[p24l1116t2715r1519b2818],
7	15	CD	NUMBER	15	dep	5	SENT_402	[p24l1116t2715r1519b2818],
8	—	NN	O	—	dep	7	SENT_402	[p24l1116t2715r1519b2818],
9	32	CD	NUMBER	32	num	8	SENT_402	[p24l1116t2715r1519b2818],
10	,	,	O	,	_	0	SENT_402	[p24l1116t2715r1519b2818],
11	of	IN	O	of	_	0	SENT_402	[p24l1567t2707r1682b2798],
12	gefitinib	NN	O	gefitinib	prep_of	3	SENT_402	[p24l1701t2707r2139b2824],
13	versus	CC	O	versus	prep	12	SENT_402	[p24l15t2886r320b2947],
14	docetaxel	NN	O	docetaxel	dep	13	SENT_402	[p24l357t2856r825b2947],
15	in	IN	O	in	prep	14	SENT_402	[p24l856t2858r953b2945],
16	previously	RB	DATE	previously	pcomp	15	SENT_402	[p24l985t2856r1492b2971],
17	treated	VBN	O	treat	partmod	12	SENT_402	[p24l1519t2856r1864b2947],
18	Japanese	JJ	MISC	japanese	amod	19	SENT_402	[p24l1886t2866r2139b2971, p24l19t3035r233b3096],
19	patients	NNS	O	patient	dobj	17	SENT_402	[p24l267t3007r652b3120],
20	with	IN	O	with	_	0	SENT_402	[p24l686t3005r906b3096],
21	non	JJ	O	non	amod	27	SENT_402	[p24l943t3005r1641b3096],
22	—	JJ	O	—	amod	27	SENT_402	[p24l943t3005r1641b3096],
23	small	JJ	O	small	amod	27	SENT_402	[p24l943t3005r1641b3096],
24	—	NN	O	—	nn	27	SENT_402	[p24l943t3005r1641b3096],
25	cell	NN	O	cell	nn	27	SENT_402	[p24l943t3005r1641b3096],
26	lung	NN	O	lung	nn	27	SENT_402	[p24l1676t3005r1894b3122],
27	cancer	NN	O	cancer	prep_with	19	SENT_402	[p24l1927t3035r2139b3096, p24l21t3184r191b3245],
28	.	.	O	.	_	0	SENT_402	[p24l1927t3035r2139b3096, p24l21t3184r191b3245],
29	]	SYM	O	]	dep	19	SENT_402	[p24l225t3164r269b3259],

1	Clin	NNP	O	Clin	nn	2	SENT_403	[p24l306t3154r512b3245],
2	Oncol	NNP	O	Oncol	_	0	SENT_403	[p24l553t3154r850b3245],
3	2008	CD	DATE	2008	num	2	SENT_403	[p24l890t3162r1751b3263],
4	;	:	O	;	_	0	SENT_403	[p24l890t3162r1751b3263],
5	26:4244	CD	NUMBER	26:4244	dep	2	SENT_403	[p24l890t3162r1751b3263],
6	—	CD	NUMBER	—	dep	5	SENT_403	[p24l890t3162r1751b3263],
7	'S	POS	O	's	possessive	6	SENT_403	[p24l890t3162r1751b3263],
8	2	CD	NUMBER	2	num	6	SENT_403	[p24l890t3162r1751b3263],
9	.	.	O	.	_	0	SENT_403	[p24l890t3162r1751b3263],

1	7	CD	NUMBER	7	_	0	SENT_404	[p24l21t3315r88b3394],
2	.	.	O	.	_	0	SENT_404	[p24l21t3315r88b3394],

1	Mok	NN	O	mok	nn	2	SENT_405	[p24l213t3303r442b3395],
2	TS	NN	O	t	_	0	SENT_405	[p24l490t3311r645b3414],
3	,	,	O	,	_	0	SENT_405	[p24l490t3311r645b3414],
4	Wu	NNP	O	Wu	nn	5	SENT_405	[p24l704t3311r872b3394],
5	Y	NN	O	y	appos	2	SENT_405	[p24l923t3311r1108b3414],
6	.	.	O	.	_	0	SENT_405	[p24l923t3311r1108b3414],

1	—	NN	O	—	_	0	SENT_406	[p24l923t3311r1108b3414],
2	.	.	O	.	_	0	SENT_406	[p24l923t3311r1108b3414],

1	L	NN	O	l	_	0	SENT_407	[p24l923t3311r1108b3414],
2	,	,	O	,	_	0	SENT_407	[p24l923t3311r1108b3414],
3	Thongprasert	NNP	O	Thongprasert	nn	4	SENT_407	[p24l1165t3303r1860b3420],
4	S	NNP	O	S	appos	1	SENT_407	[p24l1913t3311r1993b3414],
5	,	,	O	,	_	0	SENT_407	[p24l1913t3311r1993b3414],
6	et	FW	O	et	nn	7	SENT_407	[p24l2056t3323r2147b3394],
7	al.	FW	O	al.	appos	4	SENT_407	[p24l19t3452r132b3543],
8	.	.	O	.	_	0	SENT_407	[p24l19t3452r132b3543],

1	Gefitinib	NN	O	gefitinib	_	0	SENT_408	[p24l191t3452r653b3543],
2	or	CC	O	or	_	0	SENT_408	[p24l708t3482r811b3543],
3	carboplatin	NN	O	carboplatin	conj_or	1	SENT_408	[p24l860t3452r1993b3567],
4	—	CD	NUMBER	—	num	5	SENT_408	[p24l860t3452r1993b3567],
5	paclitaxel	NN	O	paclitaxel	dep	1	SENT_408	[p24l860t3452r1993b3567],
6	in	IN	O	in	_	0	SENT_408	[p24l2044t3454r2141b3541],
7	pulmonary	JJ	O	pulmonary	amod	8	SENT_408	[p24l17t3601r569b3716],
8	adenocarcinoma	NN	O	adenocarcinoma	prep_in	5	SENT_408	[p24l599t3601r1447b3692],
9	.	.	O	.	_	0	SENT_408	[p24l599t3601r1447b3692],

1	N	NN	O	n	nn	3	SENT_409	[p24l1486t3609r1573b3692],
2	Engl	NNP	O	Engl	nn	3	SENT_409	[p24l1604t3601r1894b3718],
3	]	NNP	O	]	nsubj	4	SENT_409	[p24l1604t3601r1894b3718],
4	Med	VBD	O	med	_	0	SENT_409	[p24l1923t3601r2141b3692],

1	2009	CD	DATE	2009	_	0	SENT_410	[p25l19t27r856b128],
2	;	:	O	;	_	0	SENT_410	[p25l19t27r856b128],
3	361:947	CD	NUMBER	361:947	number	4	SENT_410	[p25l19t27r856b128],
4	—	CD	NUMBER	—	dep	1	SENT_410	[p25l19t27r856b128],
5	57	CD	NUMBER	57	dep	4	SENT_410	[p25l19t27r856b128],
6	.	.	O	.	_	0	SENT_410	[p25l19t27r856b128],

1	8	CD	NUMBER	8	_	0	SENT_411	[p25l17t178r98b259],
2	.	.	O	.	_	0	SENT_411	[p25l17t178r98b259],

1	Lynch	NNP	PERSON	Lynch	nn	3	SENT_412	[p25l215t168r512b283],
2	T	NN	O	t	nn	3	SENT_412	[p25l563t176r694b279],
3	]	NN	O	]	_	0	SENT_412	[p25l563t176r694b279],
4	,	,	O	,	_	0	SENT_412	[p25l563t176r694b279],
5	Bell	NNP	ORGANIZATION	Bell	nn	6	SENT_412	[p25l753t168r944b259],
6	DW	NNP	ORGANIZATION	DW	appos	3	SENT_412	[p25l997t176r1199b279],
7	,	,	O	,	_	0	SENT_412	[p25l997t176r1199b279],
8	Sordella	NNP	PERSON	Sordella	nn	9	SENT_412	[p25l1262t168r1670b259],
9	R	NNP	PERSON	R	appos	3	SENT_412	[p25l1721t176r1821b279],
10	,	,	O	,	_	0	SENT_412	[p25l1721t176r1821b279],
11	et	FW	O	et	nn	12	SENT_412	[p25l1882t188r1973b259],
12	al.	FW	O	al.	appos	3	SENT_412	[p25l2020t168r2134b259],
13	.	.	O	.	_	0	SENT_412	[p25l2020t168r2134b259],

1	Activating	VBG	O	activate	amod	2	SENT_413	[p25l15t319r536b434],
2	mutations	NNS	O	mutation	_	0	SENT_413	[p25l615t319r1126b408],
3	in	IN	O	in	_	0	SENT_413	[p25l1211t319r1308b406],
4	the	DT	O	the	det	7	SENT_413	[p25l1393t317r1549b408],
5	epidermal	JJ	O	epidermal	amod	7	SENT_413	[p25l1634t317r2141b432],
6	growth	NN	O	growth	nn	7	SENT_413	[p25l19t466r381b583],
7	factor	NN	O	factor	prep_in	2	SENT_413	[p25l421t466r708b557],
8	receptor	NN	O	receptor	nn	10	SENT_413	[p25l745t486r1155b581],
9	underlying	VBG	O	underlie	amod	10	SENT_413	[p25l1191t466r1727b583],
10	responsiveness	NN	O	responsiveness	dep	2	SENT_413	[p25l1763t496r2139b581, p25l21t617r425b706],
11	of	IN	O	of	_	0	SENT_413	[p25l472t615r587b706],
12	non	JJ	O	non	amod	18	SENT_413	[p25l609t615r1365b706],
13	—	JJ	O	—	amod	18	SENT_413	[p25l609t615r1365b706],
14	small	JJ	O	small	amod	18	SENT_413	[p25l609t615r1365b706],
15	—	NN	O	—	nn	18	SENT_413	[p25l609t615r1365b706],
16	cell	NN	O	cell	nn	18	SENT_413	[p25l609t615r1365b706],
17	lung	NN	O	lung	nn	18	SENT_413	[p25l1407t615r1634b732],
18	cancer	NN	O	cancer	prep_of	10	SENT_413	[p25l1674t645r2003b706],
19	to	TO	O	to	_	0	SENT_413	[p25l2044t635r2139b706],
20	gefitinib	NN	O	gefitinib	prep_to	10	SENT_413	[p25l19t764r496b881],
21	.	.	O	.	_	0	SENT_413	[p25l19t764r496b881],

1	N	NN	O	n	nn	3	SENT_414	[p25l557t772r643b855],
2	Engl	NNP	O	Engl	nn	3	SENT_414	[p25l696t764r928b881],
3	J	NNP	O	J	nsubj	4	SENT_414	[p25l973t774r1017b869],
4	Med	VBD	O	med	_	0	SENT_414	[p25l1068t764r1288b855],
5	2004	CD	DATE	2004	dobj	4	SENT_414	[p25l1345t772r2139b873, p25l21t918r160b1001],
6	;	:	O	;	_	0	SENT_414	[p25l1345t772r2139b873, p25l21t918r160b1001],
7	330:212939	CD	NUMBER	330:212939	dep	5	SENT_414	[p25l1345t772r2139b873, p25l21t918r160b1001],
8	.	.	O	.	_	0	SENT_414	[p25l1345t772r2139b873, p25l21t918r160b1001],

1	9	CD	NUMBER	9	_	0	SENT_415	[p25l19t1073r96b1152],
2	.	.	O	.	_	0	SENT_415	[p25l19t1073r96b1152],

1	Paez	NNP	PERSON	Paez	nn	2	SENT_416	[p25l215t1069r441b1152],
2	TG	NN	PERSON	tg	_	0	SENT_416	[p25l470t1069r623b1172],
3	,	,	O	,	_	0	SENT_416	[p25l470t1069r623b1172],
4	Iéinne	NNP	ORGANIZATION	Iéinne	nn	5	SENT_416	[p25l658t1069r946b1166],
5	PA	NN	ORGANIZATION	pa	appos	2	SENT_416	[p25l985t1069r1141b1172],
6	,	,	O	,	_	0	SENT_416	[p25l985t1069r1141b1172],
7	Lee	NNP	PERSON	Lee	nn	8	SENT_416	[p25l1185t1069r1355b1152],
8	JC	NNP	PERSON	JC	appos	2	SENT_416	[p25l1383t1069r1526b1172],
9	,	,	O	,	_	0	SENT_416	[p25l1383t1069r1526b1172],
10	et	FW	O	et	nn	11	SENT_416	[p25l1573t1081r1662b1152],
11	al.	FW	O	al.	appos	2	SENT_416	[p25l1696t1061r1811b1152],
12	.	.	O	.	_	0	SENT_416	[p25l1696t1061r1811b1152],

1	EGFR	NN	ORGANIZATION	egfr	nn	2	SENT_417	[p25l1854t1069r2153b1158],
2	mutations	NNS	O	mutation	_	0	SENT_417	[p25l19t1212r520b1301],
3	in	IN	O	in	_	0	SENT_417	[p25l559t1212r655b1299],
4	lung	NN	O	lung	nn	5	SENT_417	[p25l692t1210r914b1327],
5	cancer	NN	O	cancer	prep_in	2	SENT_417	[p25l949t1240r1296b1301],
6	:	:	O	:	_	0	SENT_417	[p25l949t1240r1296b1301],
7	correlation	NN	O	correlation	dep	2	SENT_417	[p25l1339t1210r1880b1301],
8	with	IN	O	with	_	0	SENT_417	[p25l1912t1210r2141b1301],
9	clinical	JJ	O	clinical	amod	10	SENT_417	[p25l21t1359r389b1450],
10	response	NN	O	response	prep_with	7	SENT_417	[p25l426t1389r874b1474],
11	to	TO	O	to	_	0	SENT_417	[p25l912t1379r1007b1450],
12	gefitinib	NN	O	gefitinib	nn	13	SENT_417	[p25l1044t1359r1482b1476],
13	therapy	NN	O	therapy	prep_to	10	SENT_417	[p25l1521t1359r1916b1474],
14	.	.	O	.	_	0	SENT_417	[p25l1521t1359r1916b1474],

1	Science	NNP	O	Science	_	0	SENT_418	[p25l1963t1361r2139b1450, p25l21t1538r241b1599],
2	2004	CD	DATE	2004	num	1	SENT_418	[p25l282t1516r1256b1617],
3	;	:	O	;	_	0	SENT_418	[p25l282t1516r1256b1617],
4	304:1497	CD	NUMBER	304:1497	dep	1	SENT_418	[p25l282t1516r1256b1617],
5	.	.	O	.	_	0	SENT_418	[p25l282t1516r1256b1617],

1	—	NN	O	—	_	0	SENT_419	[p25l282t1516r1256b1617],
2	.	.	O	.	_	0	SENT_419	[p25l282t1516r1256b1617],

1	SO0	NN	O	so0	_	0	SENT_420	[p25l282t1516r1256b1617],
2	.	.	O	.	_	0	SENT_420	[p25l282t1516r1256b1617],

1	10	CD	NUMBER	10	_	0	SENT_421	[p25l23t1667r148b1748],
2	.	.	O	.	_	0	SENT_421	[p25l23t1667r148b1748],

1	Mitsudomi	JJ	ORGANIZATION	mitsudomi	amod	2	SENT_422	[p25l213t1657r748b1748],
2	T	NN	ORGANIZATION	t	_	0	SENT_422	[p25l777t1665r862b1768],
3	,	,	O	,	_	0	SENT_422	[p25l777t1665r862b1768],
4	Kosaka	NNP	PERSON	Kosaka	nn	5	SENT_422	[p25l902t1657r1258b1750],
5	T	NN	PERSON	t	appos	2	SENT_422	[p25l1286t1665r1373b1768],
6	,	,	O	,	_	0	SENT_422	[p25l1286t1665r1373b1768],
7	Endoh	NN	PERSON	endoh	nn	8	SENT_422	[p25l1410t1657r1724b1748],
8	H	NN	O	h	appos	2	SENT_422	[p25l1757t1665r1864b1768],
9	,	,	O	,	_	0	SENT_422	[p25l1757t1665r1864b1768],
10	et	FW	O	et	nn	11	SENT_422	[p25l1905t1677r1993b1748],
11	al.	FW	O	al.	appos	2	SENT_422	[p25l2020t1657r2133b1748],
12	.	.	O	.	_	0	SENT_422	[p25l2020t1657r2133b1748],

1	Mutations	NNS	O	mutation	nsubj	9	SENT_423	[p25l15t1808r530b1897],
2	of	IN	O	of	_	0	SENT_423	[p25l571t1806r686b1897],
3	the	DT	O	the	det	8	SENT_423	[p25l704t1806r859b1897],
4	epidermal	JJ	O	epidermal	amod	8	SENT_423	[p25l898t1806r1407b1921],
5	growth	NN	O	growth	nn	8	SENT_423	[p25l1444t1806r1811b1923],
6	factor	NN	O	factor	nn	8	SENT_423	[p25l1850t1806r2145b1897],
7	receptor	NN	O	receptor	nn	8	SENT_423	[p25l19t1975r437b2070],
8	gene	NN	O	gene	prep_of	1	SENT_423	[p25l488t1985r722b2072],
9	predict	VBP	O	predict	_	0	SENT_423	[p25l775t1955r1133b2070],
10	prolonged	JJ	O	prolonged	amod	11	SENT_423	[p25l1179t1955r1694b2072],
11	survival	NN	O	survival	dobj	9	SENT_423	[p25l1751t1955r2141b2046],
12	after	IN	O	after	_	0	SENT_423	[p25l19t2104r256b2195],
13	gefitinib	NN	O	gefitinib	nn	14	SENT_423	[p25l300t2104r737b2221],
14	treatment	NN	O	treatment	prep_after	9	SENT_423	[p25l785t2124r1284b2195],
15	in	IN	O	in	_	0	SENT_423	[p25l1323t2106r1421b2193],
16	patients	NNS	O	patient	prep_in	14	SENT_423	[p25l1466t2106r1868b2219],
17	with	IN	O	with	_	0	SENT_423	[p25l1912t2104r2141b2196],
18	non	JJ	O	non	amod	24	SENT_423	[p25l19t2253r734b2344],
19	—	JJ	O	—	amod	24	SENT_423	[p25l19t2253r734b2344],
20	small	JJ	O	small	amod	24	SENT_423	[p25l19t2253r734b2344],
21	—	NN	O	—	nn	24	SENT_423	[p25l19t2253r734b2344],
22	cell	NN	O	cell	nn	24	SENT_423	[p25l19t2253r734b2344],
23	lung	NN	O	lung	nn	24	SENT_423	[p25l775t2253r999b2370],
24	cancer	NN	O	cancer	prep_with	16	SENT_423	[p25l1038t2283r1363b2344],
25	with	IN	O	with	_	0	SENT_423	[p25l1397t2253r1621b2344],
26	postoperative	JJ	O	postoperative	amod	27	SENT_423	[p25l1662t2273r2139b2368, p25l19t2404r248b2493],
27	recurrence	NN	O	recurrence	prep_with	24	SENT_423	[p25l320t2432r884b2493],
28	.	.	O	.	_	0	SENT_423	[p25l320t2432r884b2493],

1	J	NNP	O	J	nn	3	SENT_424	[p25l951t2412r993b2507],
2	Clin	NNP	O	Clin	nn	3	SENT_424	[p25l1064t2402r1270b2493],
3	Oncol	NNP	O	Oncol	_	0	SENT_424	[p25l1343t2402r1640b2493],
4	2005	CD	DATE	2005	num	3	SENT_424	[p25l1711t2410r2135b2511],
5	;	:	O	;	_	0	SENT_424	[p25l1711t2410r2135b2511],
6	23	CD	NUMBER	23	dep	3	SENT_424	[p25l1711t2410r2135b2511],
7	:	:	O	:	_	0	SENT_424	[p25l1711t2410r2135b2511],

1	11	CD	NUMBER	11	_	0	SENT_425	[p25l15t2791r78b2829],
2	.	.	O	.	_	0	SENT_425	[p25l15t2791r78b2829],

1	Toyooka	FW	LOCATION	toyooka	_	0	SENT_426	[p25l107t2785r313b2841],
2	S	NN	LOCATION	s	dep	1	SENT_426	[p25l334t2789r372b2839],
3	,	,	O	,	_	0	SENT_426	[p25l334t2789r372b2839],
4	Takano	NNP	PERSON	Takano	nn	5	SENT_426	[p25l393t2785r575b2830],
5	T	NN	O	t	appos	2	SENT_426	[p25l594t2789r638b2839],
6	,	,	O	,	_	0	SENT_426	[p25l594t2789r638b2839],
7	Kosaka	NNP	PERSON	Kosaka	nn	8	SENT_426	[p25l660t2785r839b2831],
8	T	NN	O	t	appos	2	SENT_426	[p25l857t2789r900b2839],
9	,	,	O	,	_	0	SENT_426	[p25l857t2789r900b2839],
10	et	FW	O	et	nn	11	SENT_426	[p25l924t2794r968b2829],
11	al.	FW	O	al.	appos	2	SENT_426	[p25l985t2785r1040b2829],
12	.	.	O	.	_	0	SENT_426	[p25l985t2785r1040b2829],

1	Epidermal	JJ	O	epidermal	amod	5	SENT_427	[p25l12t2855r265b2911],
2	growth	NN	O	growth	nn	5	SENT_427	[p25l293t2855r472b2912],
3	factor	NN	O	factor	nn	5	SENT_427	[p25l500t2855r644b2899],
4	receptor	NN	O	receptor	nn	5	SENT_427	[p25l670t2864r874b2911],
5	mutation	NN	O	mutation	nsubjpass	15	SENT_427	[p25l900t2864r1043b2900, p25l13t2927r123b2980],
6	,	,	O	,	_	0	SENT_427	[p25l900t2864r1043b2900, p25l13t2927r123b2980],
7	but	CC	O	but	_	0	SENT_427	[p25l143t2926r223b2971],
8	not	RB	O	not	_	0	SENT_427	[p25l236t2935r317b2970],
9	sex	NN	O	sex	nsubjpass	15	SENT_427	[p25l331t2941r408b2970],
10	and	CC	O	and	_	0	SENT_427	[p25l422t2926r512b2970],
11	smoking	NN	O	smoking	conj_negcc	5	SENT_427	[p25l528t2926r754b2983],
12	,	,	O	,	_	0	SENT_427	[p25l528t2926r754b2983],
13	is	VBZ	O	be	auxpass	15	SENT_427	[p25l773t2927r811b2970],
14	independently	RB	O	independently	advmod	15	SENT_427	[p25l828t2926r1042b2982, p25l13t2997r161b3053],
15	associated	VBN	O	associate	_	0	SENT_427	[p25l176t2997r425b3041],
16	with	IN	O	with	_	0	SENT_427	[p25l441t2997r550b3042],
17	favorable	JJ	O	favorable	amod	18	SENT_427	[p25l568t2997r785b3042],
18	prognosis	NN	O	prognosis	prep_with	15	SENT_427	[p25l802t2998r1042b3054],
19	of	IN	O	of	_	0	SENT_427	[p25l13t3068r70b3112],
20	gefitinib-treated	JJ	O	gefitinib-treated	amod	21	SENT_427	[p25l78t3068r485b3125],
21	patients	NNS	O	patient	prep_of	18	SENT_427	[p25l502t3069r697b3124],
22	with	IN	O	with	_	0	SENT_427	[p25l714t3068r825b3113],
23	lung	NN	O	lung	nn	24	SENT_427	[p25l843t3068r953b3125],
24	adenocarcinoma	NN	O	adenocarcinoma	prep_with	15	SENT_427	[p25l969t3068r1042b3113, p25l13t3140r382b3183],
25	.	.	O	.	_	0	SENT_427	[p25l969t3068r1042b3113, p25l13t3140r382b3183],

1	Cancer	NN	O	cancer	_	0	SENT_428	[p25l416t3143r590b3183],
2	Sci	NNP	O	Sci	dep	1	SENT_428	[p25l620t3140r689b3183],
3	2008	CD	DATE	2008	num	2	SENT_428	[p25l719t3143r1043b3193, p25l13t3214r54b3255],
4	;	:	O	;	_	0	SENT_428	[p25l719t3143r1043b3193, p25l13t3214r54b3255],
5	99:3038	CD	NUMBER	99:3038	dep	1	SENT_428	[p25l719t3143r1043b3193, p25l13t3214r54b3255],
6	.	.	O	.	_	0	SENT_428	[p25l719t3143r1043b3193, p25l13t3214r54b3255],

1	12	CD	NUMBER	12	_	0	SENT_429	[p25l15t3288r79b3326],
2	.	.	O	.	_	0	SENT_429	[p25l15t3288r79b3326],

1	Inoue	NNP	PERSON	Inoue	nn	2	SENT_430	[p25l108t3286r247b3327],
2	A	NNP	O	A	_	0	SENT_430	[p25l266t3286r316b3336],
3	,	,	O	,	_	0	SENT_430	[p25l266t3286r316b3336],
4	Suzuki	NNP	ORGANIZATION	Suzuki	nn	5	SENT_430	[p25l342t3282r509b3327],
5	T	NN	ORGANIZATION	t	appos	2	SENT_430	[p25l529t3286r572b3336],
6	,	,	O	,	_	0	SENT_430	[p25l529t3286r572b3336],
7	Fukuhara	NNP	ORGANIZATION	Fukuhara	nn	8	SENT_430	[p25l597t3282r834b3327],
8	T	NN	ORGANIZATION	t	appos	2	SENT_430	[p25l853t3286r896b3336],
9	,	,	O	,	_	0	SENT_430	[p25l853t3286r896b3336],
10	et	FW	O	et	nn	11	SENT_430	[p25l922t3291r966b3326],
11	al.	FW	O	al.	appos	2	SENT_430	[p25l985t3282r1040b3326],
12	.	.	O	.	_	0	SENT_430	[p25l985t3282r1040b3326],

1	Prospective	JJ	O	prospective	amod	2	SENT_431	[p25l12t3353r292b3408],
2	phase	NN	O	phase	_	0	SENT_431	[p25l310t3352r452b3408],
3	II	CD	NUMBER	ii	num	4	SENT_431	[p25l471t3356r508b3396],
4	study	NN	O	study	dep	2	SENT_431	[p25l528t3352r659b3408],
5	of	IN	O	of	_	0	SENT_431	[p25l676t3352r733b3396],
6	gefitinib	NN	O	gefitinib	prep_of	4	SENT_431	[p25l742t3352r954b3409],
7	for	IN	O	for	_	0	SENT_431	[p25l974t3352r1045b3396],
8	chemotherapy	NN	O	chemotherapy	nn	9	SENT_431	[p25l13t3424r486b3480],
9	—	NN	O	—	prep_for	6	SENT_431	[p25l13t3424r486b3480],
10	naive	JJ	O	naive	amod	11	SENT_431	[p25l13t3424r486b3480],
11	patients	NNS	O	patient	dep	2	SENT_431	[p25l499t3425r686b3480],
12	with	IN	O	with	_	0	SENT_431	[p25l699t3424r806b3469],
13	advanced	JJ	O	advanced	amod	15	SENT_431	[p25l820t3424r1043b3469],
14	non	JJ	O	non	amod	15	SENT_431	[p25l13t3494r360b3539],
15	—	NN	O	—	prep_with	11	SENT_431	[p25l13t3494r360b3539],
16	small	JJ	O	small	amod	20	SENT_431	[p25l13t3494r360b3539],
17	—	NN	O	—	nn	20	SENT_431	[p25l13t3494r360b3539],
18	cell	NN	O	cell	nn	20	SENT_431	[p25l13t3494r360b3539],
19	lung	NN	O	lung	nn	20	SENT_431	[p25l377t3494r485b3551],
20	cancer	NN	O	cancer	dep	2	SENT_431	[p25l502t3509r659b3538],
21	with	IN	O	with	_	0	SENT_431	[p25l673t3494r782b3539],
22	epidermal	JJ	O	epidermal	amod	27	SENT_431	[p25l800t3494r1043b3550],
23	growth	NN	O	growth	nn	27	SENT_431	[p25l13t3565r192b3622],
24	factor	NN	O	factor	nn	27	SENT_431	[p25l224t3565r367b3610],
25	receptor	NN	O	receptor	nn	27	SENT_431	[p25l398t3574r601b3621],
26	gene	NN	O	gene	nn	27	SENT_431	[p25l632t3579r745b3622],
27	mutations	NNS	O	mutation	prep_with	20	SENT_431	[p25l778t3566r1040b3610],
28	.	.	O	.	_	0	SENT_431	[p25l778t3566r1040b3610],

1	J	NNP	O	J	nn	3	SENT_432	[p25l7t3640r28b3687],
2	Clin	NNP	O	Clin	nn	3	SENT_432	[p25l46t3636r147b3681],
3	Oncol	NNP	O	Oncol	_	0	SENT_432	[p25l166t3636r311b3681],
4	2006	CD	DATE	2006	num	3	SENT_432	[p25l330t3640r724b3690],
5	;	:	O	;	_	0	SENT_432	[p25l330t3640r724b3690],
6	24:3340	CD	NUMBER	24:3340	number	7	SENT_432	[p25l330t3640r724b3690],
7	-6	CD	NUMBER	-6	dep	3	SENT_432	[p25l330t3640r724b3690],
8	.	.	O	.	_	0	SENT_432	[p25l330t3640r724b3690],

1	13	CD	NUMBER	13	_	0	SENT_433	[p25l15t3714r77b3752],
2	.	.	O	.	_	0	SENT_433	[p25l15t3714r77b3752],

1	Asahina	NNP	PERSON	Asahina	nn	2	SENT_434	[p25l107t3708r310b3752],
2	H	NNP	PERSON	H	_	0	SENT_434	[p25l332t3712r386b3762],
3	,	,	O	,	_	0	SENT_434	[p25l332t3712r386b3762],
4	Yamazaki	NNP	PERSON	Yamazaki	nn	5	SENT_434	[p25l410t3708r651b3753],
5	K	NNP	PERSON	K	dep	2	SENT_434	[p25l673t3712r722b3762],
6	,	,	O	,	_	0	SENT_434	[p25l673t3712r722b3762],
7	Kinoshita	NNP	PERSON	Kinoshita	appos	5	SENT_434	[p25l748t3708r989b3753],
8	1	CD	NUMBER	1	num	7	SENT_434	[p25l1010t3712r1040b3762],
9	,	,	O	,	_	0	SENT_434	[p25l1010t3712r1040b3762],

1	East	NNP	LOCATION	East	nn	5	SENT_435	[p25l1118t2789r1220b2829],
2	Japan	NNP	LOCATION	Japan	nn	5	SENT_435	[p25l1239t2789r1376b2841],
3	Gefitinib	NNP	O	Gefitinib	nn	5	SENT_435	[p25l1405t2785r1624b2829],
4	Study	NNP	O	Study	nn	5	SENT_435	[p25l1655t2785r1787b2841],
5	Group	NNP	O	Group	_	0	SENT_435	[p25l1813t2789r1976b2841],
6	.	.	O	.	_	0	SENT_435	[p25l1813t2789r1976b2841],

1	J	NNP	O	J	nn	3	SENT_436	[p25l2002t2789r2023b2836],
2	Clin	NNP	O	Clin	nn	3	SENT_436	[p25l2050t2785r2149b2829],
3	Oncol	NNP	O	Oncol	_	0	SENT_436	[p25l1118t2855r1261b2900],
4	2009	CD	DATE	2009	num	6	SENT_436	[p25l1279t2855r1753b2911],
5	;	:	O	;	_	0	SENT_436	[p25l1279t2855r1753b2911],
6	27	CD	NUMBER	27	dep	3	SENT_436	[p25l1279t2855r1753b2911],
7	:	:	O	:	_	0	SENT_436	[p25l1279t2855r1753b2911],
8	Suppl	NNP	O	Suppl	dep	3	SENT_436	[p25l1279t2855r1753b2911],
9	:411	CD	NUMBER	:411	num	10	SENT_436	[p25l1279t2855r1753b2911],
10	s.	NN	O	s.	npadvmod	11	SENT_436	[p25l1279t2855r1753b2911],
11	abstract	JJ	O	abstract	amod	8	SENT_436	[p25l1774t2855r1978b2899],
12	.	.	O	.	_	0	SENT_436	[p25l1774t2855r1978b2899],

1	21	CD	NUMBER	21	_	0	SENT_437	[p25l1118t2932r1184b2970],
2	.	.	O	.	_	0	SENT_437	[p25l1118t2932r1184b2970],

1	Mitsudomi	JJ	ORGANIZATION	mitsudomi	amod	2	SENT_438	[p25l1213t2926r1482b2971],
2	T	NN	ORGANIZATION	t	_	0	SENT_438	[p25l1496t2930r1540b2980],
3	,	,	O	,	_	0	SENT_438	[p25l1496t2930r1540b2980],
4	Morita	NNP	PERSON	Morita	nn	5	SENT_438	[p25l1558t2927r1723b2970],
5	S	NNP	O	S	appos	2	SENT_438	[p25l1740t2930r1778b2980],
6	,	,	O	,	_	0	SENT_438	[p25l1740t2930r1778b2980],
7	Yatabe	NNP	PERSON	Yatabe	nn	8	SENT_438	[p25l1796t2926r1957b2971],
8	Y	NN	PERSON	y	appos	2	SENT_438	[p25l1972t2930r2013b2980],
9	,	,	O	,	_	0	SENT_438	[p25l1972t2930r2013b2980],
10	et	FW	O	et	nn	11	SENT_438	[p25l2033t2935r2076b2970],
11	al.	FW	O	al.	appos	2	SENT_438	[p25l2090t2926r2146b2970],
12	.	.	O	.	_	0	SENT_438	[p25l2090t2926r2146b2970],

1	Gefitinib	NNP	O	Gefitinib	nn	3	SENT_439	[p25l1118t2997r1343b3042],
2	Versus	NNP	O	Versus	nn	3	SENT_439	[p25l1369t3012r1522b3042],
3	cisplatin	NN	O	cisplatin	_	0	SENT_439	[p25l1551t2997r1761b3053],
4	plus	CC	O	plus	prep	3	SENT_439	[p25l1787t2997r1888b3053],
5	docetaxel	NN	O	docetaxel	dep	4	SENT_439	[p25l1917t2997r2149b3041],
6	in	IN	O	in	_	0	SENT_439	[p25l1118t3069r1165b3112],
7	patients	NNS	O	patient	prep_in	5	SENT_439	[p25l1187t3069r1383b3124],
8	with	IN	O	with	_	0	SENT_439	[p25l1404t3068r1515b3113],
9	non	JJ	O	non	amod	15	SENT_439	[p25l1537t3068r1892b3112],
10	—	JJ	O	—	amod	15	SENT_439	[p25l1537t3068r1892b3112],
11	small	JJ	O	small	amod	15	SENT_439	[p25l1537t3068r1892b3112],
12	—	NN	O	—	nn	15	SENT_439	[p25l1537t3068r1892b3112],
13	cell	NN	O	cell	nn	15	SENT_439	[p25l1537t3068r1892b3112],
14	lung	NN	O	lung	nn	15	SENT_439	[p25l1914t3068r2024b3125],
15	cancer	NN	O	cancer	prep_with	7	SENT_439	[p25l2045t3083r2148b3112, p25l1119t3154r1191b3183],
16	harbouring	VBG	O	harbour	partmod	3	SENT_439	[p25l1217t3139r1498b3196],
17	mutations	NNS	O	mutation	dobj	16	SENT_439	[p25l1524t3140r1772b3184],
18	of	IN	O	of	_	0	SENT_439	[p25l1802t3139r1858b3183],
19	the	DT	O	the	det	22	SENT_439	[p25l1876t3139r1952b3183],
20	epidermal	JJ	O	epidermal	amod	22	SENT_439	[p25l1980t3139r2148b3195, p25l1118t3210r1211b3254],
21	growth	NN	O	growth	nn	22	SENT_439	[p25l1223t3210r1402b3267],
22	factor	NN	O	factor	prep_of	17	SENT_439	[p25l1414t3210r1558b3255],
23	receptor	NN	O	receptor	nn	25	SENT_439	[p25l1568t3220r1772b3266],
24	(	NN	O	(	nn	25	SENT_439	[p25l1785t3214r2146b3261],
25	WJTOG3405	NN	O	wjtog3405	dep	3	SENT_439	[p25l1785t3214r2146b3261],
26	)	CD	NUMBER	)	dep	25	SENT_439	[p25l1785t3214r2146b3261],
27	:	:	O	:	_	0	SENT_439	[p25l1785t3214r2146b3261],
28	an	DT	O	a	det	30	SENT_439	[p25l1118t3296r1176b3326],
29	open	JJ	O	open	amod	30	SENT_439	[p25l1200t3296r1319b3338],
30	label	NN	O	label	dep	3	SENT_439	[p25l1342t3282r1472b3336],
31	,	,	O	,	_	0	SENT_439	[p25l1342t3282r1472b3336],
32	randomised	JJ	O	randomised	amod	33	SENT_439	[p25l1499t3282r1792b3326],
33	phase	NN	O	phase	appos	30	SENT_439	[p25l1814t3282r1956b3338],
34	3	CD	NUMBER	3	num	35	SENT_439	[p25l1980t3286r2005b3327],
35	trial	NN	O	trial	dep	33	SENT_439	[p25l2031t3282r2146b3326],
36	.	.	O	.	_	0	SENT_439	[p25l2031t3282r2146b3326],

1	Lancet	NNP	O	Lancet	nn	2	SENT_440	[p25l1118t3356r1281b3396],
2	Oncol	NNP	O	Oncol	_	0	SENT_440	[p25l1298t3352r1443b3396],
3	2010	CD	DATE	2010	num	2	SENT_440	[p25l1462t3356r1815b3406],
4	;	:	O	;	_	0	SENT_440	[p25l1462t3356r1815b3406],
5	11:121	CD	NUMBER	11:121	number	6	SENT_440	[p25l1462t3356r1815b3406],
6	—	CD	NUMBER	—	dep	2	SENT_440	[p25l1462t3356r1815b3406],
7	8	CD	NUMBER	8	dep	6	SENT_440	[p25l1462t3356r1815b3406],
8	.	.	O	.	_	0	SENT_440	[p25l1462t3356r1815b3406],

1	22	CD	NUMBER	22	_	0	SENT_441	[p25l1118t3430r1185b3468],
2	.	.	O	.	_	0	SENT_441	[p25l1118t3430r1185b3468],

1	Morita	NNP	PERSON	Morita	nn	2	SENT_442	[p25l1213t3425r1375b3468],
2	S	NNP	PERSON	S	_	0	SENT_442	[p25l1398t3428r1436b3478],
3	,	,	O	,	_	0	SENT_442	[p25l1398t3428r1436b3478],
4	Okamoto	NNP	PERSON	Okamoto	nn	8	SENT_442	[p25l1462t3424r1686b3469],
5	I	PRP	O	I	dep	8	SENT_442	[p25l1709t3428r1739b3478],
6	,	,	O	,	_	0	SENT_442	[p25l1709t3428r1739b3478],
7	Kobayashi	NNP	LOCATION	Kobayashi	dep	8	SENT_442	[p25l1764t3424r2011b3480],
8	K	NNP	LOCATION	K	appos	2	SENT_442	[p25l2033t3428r2082b3478],
9	,	,	O	,	_	0	SENT_442	[p25l2033t3428r2082b3478],
10	et	FW	O	et	nn	11	SENT_442	[p25l2108t3434r2151b3468],
11	al.	FW	O	al.	appos	8	SENT_442	[p25l1118t3494r1172b3538],
12	.	.	O	.	_	0	SENT_442	[p25l1118t3494r1172b3538],

1	Combined	VBN	O	combine	amod	3	SENT_443	[p25l1195t3494r1444b3539],
2	survival	NN	O	survival	nn	3	SENT_443	[p25l1463t3494r1649b3539],
3	analysis	NN	O	analysis	_	0	SENT_443	[p25l1667t3494r1857b3550],
4	of	IN	O	of	_	0	SENT_443	[p25l1878t3494r1934b3539],
5	prospective	JJ	O	prospective	amod	7	SENT_443	[p25l1941t3508r2148b3550, p25l1119t3566r1201b3610],
6	clinical	JJ	O	clinical	amod	7	SENT_443	[p25l1215t3565r1391b3609],
7	trials	NNS	O	trial	prep_of	3	SENT_443	[p25l1404t3565r1527b3609],
8	of	IN	O	of	_	0	SENT_443	[p25l1542t3565r1598b3610],
9	gefitinib	NN	O	gefitinib	prep_of	7	SENT_443	[p25l1602t3565r1809b3622],
10	for	IN	O	for	_	0	SENT_443	[p25l1824t3565r1893b3609],
11	non	JJ	O	non	amod	16	SENT_443	[p25l1905t3565r2149b3609],
12	—	JJ	O	—	amod	16	SENT_443	[p25l1905t3565r2149b3609],
13	small	JJ	O	small	amod	16	SENT_443	[p25l1905t3565r2149b3609],
14	cell	NN	O	cell	nn	16	SENT_443	[p25l1119t3636r1200b3680],
15	lung	NN	O	lung	nn	16	SENT_443	[p25l1236t3636r1345b3693],
16	cancer	NN	O	cancer	prep_for	9	SENT_443	[p25l1380t3650r1537b3680],
17	with	IN	O	with	_	0	SENT_443	[p25l1569t3636r1679b3681],
18	EGFR	NN	ORGANIZATION	egfr	nn	19	SENT_443	[p25l1715t3640r1858b3683],
19	mutations	NNS	O	mutation	prep_with	16	SENT_443	[p25l1888t3637r2146b3681],
20	.	.	O	.	_	0	SENT_443	[p25l1888t3637r2146b3681],

1	Clin	NNP	O	Clin	nn	3	SENT_444	[p25l1118t3708r1218b3752],
2	Cancer	NNP	O	Cancer	nn	3	SENT_444	[p25l1236t3712r1403b3752],
3	Res	NNP	O	Res	_	0	SENT_444	[p25l1418t3712r1503b3755],
4	2009	CD	DATE	2009	num	3	SENT_444	[p25l1522t3712r1904b3761],
5	;	:	O	;	_	0	SENT_444	[p25l1522t3712r1904b3761],
6	15:4493	CD	NUMBER	15:4493	number	7	SENT_444	[p25l1522t3712r1904b3761],
7	—	CD	NUMBER	—	dep	3	SENT_444	[p25l1522t3712r1904b3761],
8	8	CD	NUMBER	8	dep	7	SENT_444	[p25l1522t3712r1904b3761],
9	.	.	O	.	_	0	SENT_444	[p25l1522t3712r1904b3761],

1	et	FW	O	et	_	0	SENT_445	[p26l13t25r57b59],
2	al.	FW	O	al.	dep	1	SENT_445	[p26l75t15r130b59],
3	.	.	O	.	_	0	SENT_445	[p26l75t15r130b59],

1	A	DT	O	a	det	2	SENT_446	[p26l153t19r190b59],
2	phase	NN	O	phase	_	0	SENT_446	[p26l208t15r350b71],
3	II	CD	NUMBER	ii	num	4	SENT_446	[p26l370t19r407b59],
4	trial	NN	O	trial	dep	2	SENT_446	[p26l428t15r530b59],
5	of	IN	O	of	_	0	SENT_446	[p26l551t15r608b59],
6	gefitinib	NN	O	gefitinib	prep_of	4	SENT_446	[p26l618t15r831b72],
7	as	IN	O	as	_	0	SENT_446	[p26l852t30r901b59],
8	firstline	NN	O	firstline	nn	9	SENT_446	[p26l923t15r1043b59, p26l12t87r103b131],
9	therapy	NN	O	therapy	prep_as	6	SENT_446	[p26l130t87r314b143],
10	for	IN	O	for	_	0	SENT_446	[p26l338t87r408b131],
11	advanced	JJ	O	advanced	amod	13	SENT_446	[p26l432t87r658b132],
12	non	JJ	O	non	amod	13	SENT_446	[p26l685t87r934b131],
13	—	NN	O	—	prep_for	9	SENT_446	[p26l685t87r934b131],
14	small	JJ	O	small	amod	17	SENT_446	[p26l685t87r934b131],
15	cell	NN	O	cell	nn	17	SENT_446	[p26l960t87r1044b131],
16	lung	NN	O	lung	nn	17	SENT_446	[p26l12t157r122b214],
17	cancer	NN	O	cancer	dep	2	SENT_446	[p26l139t171r299b201],
18	with	IN	O	with	_	0	SENT_446	[p26l312t157r423b202],
19	epidermal	JJ	O	epidermal	amod	23	SENT_446	[p26l441t157r688b213],
20	growth	NN	O	growth	nn	23	SENT_446	[p26l705t157r884b214],
21	factor	NN	O	factor	nn	23	SENT_446	[p26l902t157r1045b202],
22	receptor	NN	O	receptor	nn	23	SENT_446	[p26l13t239r216b285],
23	mutations	NNS	O	mutation	prep_with	17	SENT_446	[p26l238t230r501b274],
24	.	.	O	.	_	0	SENT_446	[p26l238t230r501b274],

1	Br	NN	O	br	_	0	SENT_447	[p26l527t233r619b280],
2	]	CD	NUMBER	]	num	1	SENT_447	[p26l527t233r619b280],
3	Cancer	NN	O	cancer	dep	1	SENT_447	[p26l641t233r812b273],
4	2006	CD	DATE	2006	num	3	SENT_447	[p26l834t233r1041b283],
5	;	:	O	;	_	0	SENT_447	[p26l834t233r1041b283],
6	95	CD	NUMBER	95	num	8	SENT_447	[p26l834t233r1041b283],
7	:	:	O	:	_	0	SENT_447	[p26l834t233r1041b283],
8	998-1004	CD	NUMBER	998-1004	dep	1	SENT_447	[p26l13t303r249b344],
9	.	.	O	.	_	0	SENT_447	[p26l13t303r249b344],

1	14	CD	NUMBER	14	_	0	SENT_448	[p26l15t376r78b414],
2	.	.	O	.	_	0	SENT_448	[p26l15t376r78b414],

1	Sutani	NNP	MISC	Sutani	nn	2	SENT_449	[p26l110t371r266b415],
2	A	NNP	MISC	A	_	0	SENT_449	[p26l287t374r337b424],
3	,	,	O	,	_	0	SENT_449	[p26l287t374r337b424],
4	Nagai	NNP	PERSON	Nagai	nn	5	SENT_449	[p26l363t371r507b427],
5	Y	NN	PERSON	y	appos	2	SENT_449	[p26l528t374r569b424],
6	,	,	O	,	_	0	SENT_449	[p26l528t374r569b424],
7	Udagawa	NNP	PERSON	Udagawa	nn	8	SENT_449	[p26l596t370r821b427],
8	K	NNP	PERSON	K	appos	2	SENT_449	[p26l843t374r892b424],
9	,	,	O	,	_	0	SENT_449	[p26l843t374r892b424],
10	et	FW	O	et	nn	11	SENT_449	[p26l920t379r964b414],
11	al.	FW	O	al.	appos	2	SENT_449	[p26l985t370r1040b414],
12	.	.	O	.	_	0	SENT_449	[p26l985t370r1040b414],

1	Gefitinib	NNP	O	Gefitinib	nsubj	18	SENT_450	[p26l13t441r237b486],
2	for	IN	O	for	_	0	SENT_450	[p26l267t441r337b486],
3	non	JJ	O	non	amod	10	SENT_450	[p26l364t441r719b485],
4	—	JJ	O	—	amod	10	SENT_450	[p26l364t441r719b485],
5	small	JJ	O	small	amod	10	SENT_450	[p26l364t441r719b485],
6	—	NN	O	—	nn	10	SENT_450	[p26l364t441r719b485],
7	cell	NN	O	cell	nn	10	SENT_450	[p26l364t441r719b485],
8	lung	NN	O	lung	nn	10	SENT_450	[p26l747t441r857b498],
9	cancer	NN	O	cancer	nn	10	SENT_450	[p26l885t455r1045b485],
10	patients	NNS	O	patient	prep_for	1	SENT_450	[p26l12t513r207b568],
11	with	IN	O	with	_	0	SENT_450	[p26l225t512r336b557],
12	epidermal	JJ	O	epidermal	amod	17	SENT_450	[p26l355t512r601b568],
13	growth	NN	O	growth	nn	17	SENT_450	[p26l620t512r799b569],
14	factor	NN	O	factor	nn	17	SENT_450	[p26l817t512r961b556],
15	receptor	NN	O	receptor	nn	17	SENT_450	[p26l978t527r1042b556, p26l13t592r168b639],
16	gene	NN	O	gene	nn	17	SENT_450	[p26l194t597r307b640],
17	mutations	NNS	O	mutation	prep_with	10	SENT_450	[p26l335t584r583b628],
18	screened	VBN	O	screen	_	0	SENT_450	[p26l613t583r826b627],
19	by	IN	O	by	_	0	SENT_450	[p26l855t583r909b639],
20	peptide	NN	O	peptide	prep_by	18	SENT_450	[p26l934t598r1043b639, p26l13t655r103b699],
21	nucleic	JJ	O	nucleic	amod	24	SENT_450	[p26l128t655r299b700],
22	acid	NN	O	acid	nn	24	SENT_450	[p26l323t655r600b700],
23	—	NN	O	—	nn	24	SENT_450	[p26l323t655r600b700],
24	locl	NN	O	locl	dep	25	SENT_450	[p26l323t655r600b700],
25	<	JJR	O	<	nn	30	SENT_450	[p26l323t655r600b700],
26	ed	CD	NUMBER	ed	num	29	SENT_450	[p26l323t655r600b700],
27	nucleic	JJ	O	nucleic	amod	29	SENT_450	[p26l625t655r796b700],
28	acid	NN	O	acid	nn	29	SENT_450	[p26l819t655r917b699],
29	PCR	NN	O	pcr	dep	25	SENT_450	[p26l940t659r1049b702],
30	clamp	NN	O	clamp	dobj	18	SENT_450	[p26l13t725r174b781],
31	.	.	O	.	_	0	SENT_450	[p26l13t725r174b781],

1	Br	NN	O	br	_	0	SENT_451	[p26l196t729r284b776],
2	]	CD	NUMBER	]	num	1	SENT_451	[p26l196t729r284b776],
3	Cancer	NN	O	cancer	dep	1	SENT_451	[p26l302t729r472b769],
4	2006	CD	DATE	2006	num	3	SENT_451	[p26l490t729r875b778],
5	;	:	O	;	_	0	SENT_451	[p26l490t729r875b778],
6	95:1483	CD	NUMBER	95:1483	number	7	SENT_451	[p26l490t729r875b778],
7	—	CD	NUMBER	—	dep	1	SENT_451	[p26l490t729r875b778],
8	9	CD	NUMBER	9	dep	7	SENT_451	[p26l490t729r875b778],
9	.	.	O	.	_	0	SENT_451	[p26l490t729r875b778],

1	15	CD	NUMBER	15	_	0	SENT_452	[p26l15t802r77b840],
2	.	.	O	.	_	0	SENT_452	[p26l15t802r77b840],

1	Nagai	NNP	PERSON	Nagai	nn	2	SENT_453	[p26l108t797r252b853],
2	Y	NN	PERSON	y	_	0	SENT_453	[p26l277t800r318b850],
3	,	,	O	,	_	0	SENT_453	[p26l277t800r318b850],
4	Miyazawa	NNP	PERSON	Miyazawa	nn	5	SENT_453	[p26l348t797r591b852],
5	H	NNP	PERSON	H	appos	2	SENT_453	[p26l618t800r672b850],
6	,	,	O	,	_	0	SENT_453	[p26l618t800r672b850],
7	Huqun	NNP	PERSON	Huqun	appos	2	SENT_453	[p26l703t800r884b852],
8	,	,	O	,	_	0	SENT_453	[p26l703t800r884b852],
9	et	FW	O	et	nn	10	SENT_453	[p26l916t806r960b840],
10	al.	FW	O	al.	appos	2	SENT_453	[p26l985t796r1040b840],
11	.	.	O	.	_	0	SENT_453	[p26l985t796r1040b840],

1	Genetic	JJ	O	genetic	amod	2	SENT_454	[p26l13t868r201b912],
2	heterogeneity	NN	O	heterogeneity	nsubj	18	SENT_454	[p26l236t867r571b924],
3	of	IN	O	of	_	0	SENT_454	[p26l604t867r661b911],
4	the	DT	O	the	det	8	SENT_454	[p26l686t867r761b911],
5	epidermal	JJ	O	epidermal	amod	8	SENT_454	[p26l797t867r1044b923],
6	growth	NN	O	growth	nn	8	SENT_454	[p26l13t938r192b995],
7	factor	NN	O	factor	nn	8	SENT_454	[p26l217t938r361b982],
8	receptor	NN	O	receptor	prep_of	2	SENT_454	[p26l385t947r588b994],
9	in	IN	O	in	_	0	SENT_454	[p26l612t939r659b982],
10	non	JJ	O	non	amod	17	SENT_454	[p26l685t938r934b983],
11	—	JJ	O	—	amod	17	SENT_454	[p26l685t938r934b983],
12	small	JJ	O	small	amod	17	SENT_454	[p26l685t938r934b983],
13	cell	NN	O	cell	nn	17	SENT_454	[p26l960t938r1044b982],
14	lung	NN	O	lung	nn	17	SENT_454	[p26l12t1009r122b1066],
15	cancer	NN	O	cancer	nn	17	SENT_454	[p26l144t1023r304b1053],
16	cell	NN	O	cell	nn	17	SENT_454	[p26l326t1009r410b1053],
17	lines	NNS	O	line	prep_in	8	SENT_454	[p26l432t1009r547b1053],
18	revealed	VBN	O	reveal	_	0	SENT_454	[p26l572t1009r772b1054],
19	by	IN	O	by	_	0	SENT_454	[p26l796t1009r851b1065],
20	a	DT	O	a	det	25	SENT_454	[p26l871t1024r896b1053],
21	rapid	JJ	O	rapid	amod	25	SENT_454	[p26l919t1009r1044b1065],
22	and	CC	O	and	_	0	SENT_454	[p26l13t1081r102b1125],
23	sensitive	JJ	O	sensitive	amod	25	SENT_454	[p26l130t1082r339b1126],
24	detection	NN	O	detection	nn	25	SENT_454	[p26l366t1081r594b1125],
25	system	NN	O	system	prep_by	18	SENT_454	[p26l621t1090r801b1137],
26	,	,	O	,	_	0	SENT_454	[p26l621t1090r801b1137],
27	the	DT	O	the	det	28	SENT_454	[p26l832t1081r908b1125],
28	peptide	NN	O	peptide	appos	25	SENT_454	[p26l934t1096r1043b1137, p26l13t1152r103b1196],
29	nucleic	JJ	O	nucleic	amod	32	SENT_454	[p26l128t1152r299b1197],
30	acid	NN	O	acid	nn	32	SENT_454	[p26l323t1152r600b1197],
31	—	NN	O	—	nn	32	SENT_454	[p26l323t1152r600b1197],
32	locl	NN	O	locl	dep	28	SENT_454	[p26l323t1152r600b1197],
33	<	JJR	O	<	nn	38	SENT_454	[p26l323t1152r600b1197],
34	ed	CD	NUMBER	ed	num	37	SENT_454	[p26l323t1152r600b1197],
35	nucleic	JJ	O	nucleic	amod	37	SENT_454	[p26l625t1152r796b1197],
36	acid	NN	O	acid	nn	37	SENT_454	[p26l819t1152r917b1196],
37	PCR	NN	O	pcr	dep	33	SENT_454	[p26l940t1156r1049b1199],
38	clamp	NN	O	clamp	dobj	18	SENT_454	[p26l13t1222r174b1278],
39	.	.	O	.	_	0	SENT_454	[p26l13t1222r174b1278],

1	Cancer	NNP	O	Cancer	nn	2	SENT_455	[p26l197t1226r367b1267],
2	Res	NNP	O	Res	_	0	SENT_455	[p26l384t1226r470b1269],
3	2005	CD	DATE	2005	num	2	SENT_455	[p26l490t1226r904b1275],
4	;	:	O	;	_	0	SENT_455	[p26l490t1226r904b1275],
5	65:7276	CD	NUMBER	65:7276	number	6	SENT_455	[p26l490t1226r904b1275],
6	—	CD	NUMBER	—	dep	2	SENT_455	[p26l490t1226r904b1275],
7	82	CD	NUMBER	82	dep	6	SENT_455	[p26l490t1226r904b1275],
8	.	.	O	.	_	0	SENT_455	[p26l490t1226r904b1275],

1	16	CD	NUMBER	16	_	0	SENT_456	[p26l15t1299r78b1338],
2	.	.	O	.	_	0	SENT_456	[p26l15t1299r78b1338],

1	Tanaka	NNP	PERSON	Tanaka	nn	2	SENT_457	[p26l107t1293r288b1338],
2	T	NN	O	t	_	0	SENT_457	[p26l312t1297r355b1347],
3	,	,	O	,	_	0	SENT_457	[p26l312t1297r355b1347],
4	Matsuoka	NNP	PERSON	Matsuoka	nn	5	SENT_457	[p26l384t1293r624b1338],
5	M	NNP	PERSON	M	appos	2	SENT_457	[p26l649t1297r710b1347],
6	,	,	O	,	_	0	SENT_457	[p26l649t1297r710b1347],
7	Sutani	NNP	PERSON	Sutani	nn	8	SENT_457	[p26l742t1294r897b1338],
8	A	NNP	O	A	appos	2	SENT_457	[p26l922t1297r971b1347],
9	,	,	O	,	_	0	SENT_457	[p26l922t1297r971b1347],
10	et	FW	O	et	nn	11	SENT_457	[p26l1002t1302r1046b1337],
11	al.	FW	O	al.	appos	2	SENT_457	[p26l13t1364r68b1408],
12	.	.	O	.	_	0	SENT_457	[p26l13t1364r68b1408],

1	Frequency	NN	O	frequency	nsubj	5	SENT_458	[p26l94t1368r345b1420],
2	of	IN	O	of	prep	1	SENT_458	[p26l367t1364r424b1408],
3	and	CC	O	and	_	0	SENT_458	[p26l437t1364r526b1409],
4	variables	NNS	O	variable	conj_and	1	SENT_458	[p26l547t1364r764b1409],
5	associated	VBN	O	associate	_	0	SENT_458	[p26l789t1364r1043b1409],
6	with	IN	O	with	_	0	SENT_458	[p26l10t1436r122b1481],
7	the	DT	O	the	det	9	SENT_458	[p26l139t1436r215b1480],
8	EGFR	NN	ORGANIZATION	egfr	nn	9	SENT_458	[p26l231t1440r376b1483],
9	mutation	NN	O	mutation	prep_with	5	SENT_458	[p26l388t1437r612b1481],
10	and	CC	O	and	_	0	SENT_458	[p26l629t1436r719b1480],
11	its	PRP$	O	its	poss	12	SENT_458	[p26l736t1437r792b1480],
12	subtypes	NNS	O	subtype	prep_with	5	SENT_458	[p26l812t1436r1040b1492],
13	.	.	O	.	_	0	SENT_458	[p26l812t1436r1040b1492],

1	Int	NN	O	int	nn	3	SENT_459	[p26l12t1511r115b1558],
2	]	CD	NUMBER	]	num	3	SENT_459	[p26l12t1511r115b1558],
3	Cancer	NN	O	cancer	_	0	SENT_459	[p26l133t1511r303b1551],
4	2010	CD	DATE	2010	num	6	SENT_459	[p26l321t1511r700b1560],
5	;	:	O	;	_	0	SENT_459	[p26l321t1511r700b1560],
6	126:6515	CD	NUMBER	126:6515	dep	3	SENT_459	[p26l321t1511r700b1560],
7	.	.	O	.	_	0	SENT_459	[p26l321t1511r700b1560],

1	17	CD	NUMBER	17	_	0	SENT_460	[p26l15t1584r73b1622],
2	.	.	O	.	_	0	SENT_460	[p26l15t1584r73b1622],

1	Therasse	NN	O	therasse	nn	2	SENT_461	[p26l107t1578r325b1622],
2	P	NN	O	p	_	0	SENT_461	[p26l361t1582r399b1632],
3	,	,	O	,	_	0	SENT_461	[p26l361t1582r399b1632],
4	Arbuck	NNP	O	Arbuck	nn	5	SENT_461	[p26l437t1578r617b1623],
5	SG	NNP	O	SG	appos	2	SENT_461	[p26l652t1582r733b1632],
6	,	,	O	,	_	0	SENT_461	[p26l652t1582r733b1632],
7	Eisenhauer	NNP	PERSON	Eisenhauer	nn	8	SENT_461	[p26l772t1578r1045b1623],
8	EA	NN	PERSON	ea	appos	2	SENT_461	[p26l12t1652r94b1702],
9	,	,	O	,	_	0	SENT_461	[p26l12t1652r94b1702],
10	et	FW	O	et	nn	11	SENT_461	[p26l120t1657r164b1692],
11	al.	FW	O	al.	appos	2	SENT_461	[p26l184t1648r240b1693],
12	.	.	O	.	_	0	SENT_461	[p26l184t1648r240b1693],

1	New	NNP	O	New	nn	2	SENT_462	[p26l265t1652r376b1693],
2	guidelines	NNS	O	guideline	nsubj	4	SENT_462	[p26l397t1648r651b1705],
3	to	TO	O	to	aux	4	SENT_462	[p26l676t1658r722b1693],
4	evaluate	VB	O	evaluate	_	0	SENT_462	[p26l747t1648r944b1693],
5	the	DT	O	the	det	6	SENT_462	[p26l968t1648r1043b1692],
6	response	NN	O	response	dobj	4	SENT_462	[p26l13t1734r230b1776],
7	to	TO	O	to	_	0	SENT_462	[p26l264t1729r311b1764],
8	treatment	NN	O	treatment	prep_to	4	SENT_462	[p26l345t1729r587b1764],
9	in	IN	O	in	_	0	SENT_462	[p26l618t1721r665b1764],
10	solid	JJ	O	solid	amod	11	SENT_462	[p26l700t1720r817b1764],
11	tumors	NNS	O	tumor	prep_in	8	SENT_462	[p26l851t1729r1040b1765],
12	.	.	O	.	_	0	SENT_462	[p26l851t1729r1040b1765],

1	J	NNP	O	J	nn	4	SENT_463	[p26l7t1794r28b1841],
2	Natl	NNP	O	Natl	nn	4	SENT_463	[p26l45t1790r149b1835],
3	Cancer	NNP	O	Cancer	nn	4	SENT_463	[p26l168t1794r339b1835],
4	Inst	NNP	O	Inst	_	0	SENT_463	[p26l355t1794r451b1834],
5	2000	CD	DATE	2000	num	4	SENT_463	[p26l468t1794r854b1843],
6	;	:	O	;	_	0	SENT_463	[p26l468t1794r854b1843],
7	92:205	CD	NUMBER	92:205	number	8	SENT_463	[p26l468t1794r854b1843],
8	—	CD	NUMBER	—	dep	4	SENT_463	[p26l468t1794r854b1843],
9	16	CD	NUMBER	16	dep	8	SENT_463	[p26l468t1794r854b1843],
10	.	.	O	.	_	0	SENT_463	[p26l468t1794r854b1843],

1	18	CD	NUMBER	18	_	0	SENT_464	[p26l15t1867r79b1907],
2	.	.	O	.	_	0	SENT_464	[p26l15t1867r79b1907],

1	Bell	NNP	ORGANIZATION	Bell	nn	2	SENT_465	[p26l108t1862r201b1906],
2	DW	NNP	ORGANIZATION	DW	_	0	SENT_465	[p26l220t1866r319b1916],
3	,	,	O	,	_	0	SENT_465	[p26l220t1866r319b1916],
4	Lynch	NNP	PERSON	Lynch	nn	5	SENT_465	[p26l340t1862r485b1918],
5	TJ	NNP	PERSON	TJ	appos	2	SENT_465	[p26l502t1866r567b1916],
6	,	,	O	,	_	0	SENT_465	[p26l502t1866r567b1916],
7	Haserlat	NNP	O	Haserlat	nn	8	SENT_465	[p26l589t1862r796b1906],
8	SM	NNP	O	SM	appos	2	SENT_465	[p26l814t1866r901b1916],
9	,	,	O	,	_	0	SENT_465	[p26l814t1866r901b1916],
10	et	FW	O	et	nn	11	SENT_465	[p26l924t1871r968b1906],
11	al.	FW	O	al.	appos	2	SENT_465	[p26l984t1862r1040b1906],
12	.	.	O	.	_	0	SENT_465	[p26l984t1862r1040b1906],

1	Epidermal	JJ	O	epidermal	amod	5	SENT_466	[p26l12t1932r265b1988],
2	growth	NN	O	growth	nn	5	SENT_466	[p26l293t1932r472b1989],
3	factor	NN	O	factor	nn	5	SENT_466	[p26l500t1932r644b1977],
4	receptor	NN	O	receptor	nn	5	SENT_466	[p26l670t1941r873b1988],
5	mutations	NNS	O	mutation	_	0	SENT_466	[p26l900t1941r1042b1977, p26l13t2004r129b2047],
6	and	CC	O	and	_	0	SENT_466	[p26l145t2003r232b2047],
7	gene	NN	O	gene	nn	8	SENT_466	[p26l247t2018r357b2060],
8	amplification	NN	O	amplification	conj_and	5	SENT_466	[p26l372t2003r692b2059],
9	in	IN	O	in	_	0	SENT_466	[p26l707t2004r753b2047],
10	non	JJ	O	non	amod	14	SENT_466	[p26l768t2003r1043b2047, p26l13t2074r97b2118],
11	—	NN	O	—	nn	14	SENT_466	[p26l768t2003r1043b2047, p26l13t2074r97b2118],
12	smallcell	NN	O	smallcell	nn	14	SENT_466	[p26l768t2003r1043b2047, p26l13t2074r97b2118],
13	lung	NN	O	lung	nn	14	SENT_466	[p26l112t2074r223b2131],
14	cancer	NN	O	cancer	prep_in	8	SENT_466	[p26l238t2089r410b2118],
15	:	:	O	:	_	0	SENT_466	[p26l238t2089r410b2118],
16	molecular	JJ	O	molecular	amod	17	SENT_466	[p26l430t2074r677b2119],
17	analysis	NN	O	analysis	dep	5	SENT_466	[p26l691t2074r886b2130],
18	of	IN	O	of	_	0	SENT_466	[p26l904t2074r961b2118],
19	the	DT	O	the	det	22	SENT_466	[p26l968t2074r1043b2118],
20	IDEALIINTACT	NN	O	idealiintact	nn	22	SENT_466	[p26l12t2148r394b2195],
21	gefitinib	NN	O	gefitinib	nn	22	SENT_466	[p26l410t2145r623b2202],
22	trials	NNS	O	trial	prep_of	17	SENT_466	[p26l641t2145r781b2189],
23	.	.	O	.	_	0	SENT_466	[p26l641t2145r781b2189],

1	J	NNP	O	J	nn	3	SENT_467	[p26l797t2149r818b2196],
2	Clin	NNP	O	Clin	nn	3	SENT_467	[p26l834t2145r935b2190],
3	Oncol	NNP	O	Oncol	_	0	SENT_467	[p26l953t2149r1043b2189, p26l13t2216r83b2261],
4	2005	CD	DATE	2005	num	3	SENT_467	[p26l102t2220r518b2269],
5	;	:	O	;	_	0	SENT_467	[p26l102t2220r518b2269],
6	23:8081	CD	NUMBER	23:8081	number	7	SENT_467	[p26l102t2220r518b2269],
7	—	CD	NUMBER	—	dep	3	SENT_467	[p26l102t2220r518b2269],
8	92	CD	NUMBER	92	dep	7	SENT_467	[p26l102t2220r518b2269],
9	.	.	O	.	_	0	SENT_467	[p26l102t2220r518b2269],

1	19	CD	NUMBER	19	_	0	SENT_468	[p26l15t2293r76b2332],
2	.	.	O	.	_	0	SENT_468	[p26l15t2293r76b2332],

1	Oken	NNP	O	Oken	nn	2	SENT_469	[p26l109t2288r237b2333],
2	MM	NN	O	mm	_	0	SENT_469	[p26l255t2292r366b2342],
3	,	,	O	,	_	0	SENT_469	[p26l255t2292r366b2342],
4	Creech	NNP	PERSON	Creech	nn	5	SENT_469	[p26l388t2288r556b2332],
5	RH	NNP	O	RH	appos	2	SENT_469	[p26l574t2292r667b2342],
6	,	,	O	,	_	0	SENT_469	[p26l574t2292r667b2342],
7	Tormey	NNP	ORGANIZATION	Tormey	nn	8	SENT_469	[p26l687t2292r874b2344],
8	DC	NNP	ORGANIZATION	DC	appos	2	SENT_469	[p26l890t2292r979b2342],
9	,	,	O	,	_	0	SENT_469	[p26l890t2292r979b2342],
10	et	FW	O	et	nn	11	SENT_469	[p26l1002t2297r1046b2332],
11	al.	FW	O	al.	appos	2	SENT_469	[p26l13t2358r68b2402],
12	.	.	O	.	_	0	SENT_469	[p26l13t2358r68b2402],

1	Toxicity	NN	O	toxicity	nn	4	SENT_470	[p26l99t2359r294b2414],
2	and	CC	O	and	_	0	SENT_470	[p26l321t2358r410b2403],
3	response	NN	O	response	nn	4	SENT_470	[p26l440t2372r657b2414],
4	criteria	NNS	O	criterion	_	0	SENT_470	[p26l688t2359r862b2402],
5	of	IN	O	of	_	0	SENT_470	[p26l891t2358r948b2403],
6	the	DT	O	the	det	10	SENT_470	[p26l968t2358r1043b2402],
7	Eastern	NNP	ORGANIZATION	Eastern	nn	10	SENT_470	[p26l12t2433r196b2473],
8	Cooperative	NNP	ORGANIZATION	Cooperative	nn	10	SENT_470	[p26l213t2430r505b2485],
9	Oncology	NNP	ORGANIZATION	Oncology	nn	10	SENT_470	[p26l522t2429r758b2486],
10	Group	NNP	ORGANIZATION	Group	prep_of	4	SENT_470	[p26l772t2433r939b2485],
11	.	.	O	.	_	0	SENT_470	[p26l772t2433r939b2485],

1	Am	NNP	O	Am	nn	4	SENT_471	[p26l957t2433r1043b2473],
2	J	NNP	O	J	nn	4	SENT_471	[p26l7t2505r28b2552],
3	Clin	NNP	O	Clin	nn	4	SENT_471	[p26l46t2501r147b2545],
4	Oncol	NNP	O	Oncol	_	0	SENT_471	[p26l166t2501r311b2545],
5	1982	CD	DATE	1982	num	4	SENT_471	[p26l332t2505r686b2554],
6	;	:	O	;	_	0	SENT_471	[p26l332t2505r686b2554],
7	5:649	CD	NUMBER	5:649	number	8	SENT_471	[p26l332t2505r686b2554],
8	—	CD	NUMBER	—	dep	4	SENT_471	[p26l332t2505r686b2554],
9	55	CD	NUMBER	55	dep	8	SENT_471	[p26l332t2505r686b2554],
10	.	.	O	.	_	0	SENT_471	[p26l332t2505r686b2554],

1	20	CD	NUMBER	20	_	0	SENT_472	[p26l12t2577r78b2616],
2	.	.	O	.	_	0	SENT_472	[p26l12t2577r78b2616],

1	Kobayashi	NNP	LOCATION	Kobayashi	nn	2	SENT_473	[p26l109t2572r356b2628],
2	K	NNP	LOCATION	K	_	0	SENT_473	[p26l379t2576r427b2626],
3	,	,	O	,	_	0	SENT_473	[p26l379t2576r427b2626],
4	Inoue	NNP	PERSON	Inoue	nn	5	SENT_473	[p26l453t2576r589b2617],
5	A	NNP	O	A	appos	2	SENT_473	[p26l611t2576r660b2626],
6	,	,	O	,	_	0	SENT_473	[p26l611t2576r660b2626],
7	Maemondo	NNP	O	Maemondo	nn	8	SENT_473	[p26l685t2572r957b2616],
8	M	NNP	O	M	appos	2	SENT_473	[p26l979t2576r1040b2626],
9	,	,	O	,	_	0	SENT_473	[p26l979t2576r1040b2626],
10	et	FW	O	et	nn	11	SENT_473	[p26l13t2652r56b2686],
11	al.	FW	O	al.	appos	2	SENT_473	[p26l88t2642r141b2686],
12	.	.	O	.	_	0	SENT_473	[p26l88t2642r141b2686],

1	First	NNP	ORDINAL	First	nn	4	SENT_474	[p26l179t2642r387b2686],
2	—	NNP	O	—	nn	4	SENT_474	[p26l179t2642r387b2686],
3	line	NN	O	line	nn	4	SENT_474	[p26l179t2642r387b2686],
4	gefitinib	NN	O	gefitinib	dep	28	SENT_474	[p26l422t2642r625b2699],
5	versus	CC	O	versus	prep	4	SENT_474	[p26l659t2657r805b2687],
6	ﬁrst	NN	O	ﬁrst	nn	9	SENT_474	[p26l841t2642r1043b2686],
7	—	CD	NUMBER	—	num	9	SENT_474	[p26l841t2642r1043b2686],
8	line	NN	O	line	nn	9	SENT_474	[p26l841t2642r1043b2686],
9	chemotherapy	NN	O	chemotherapy	dep	5	SENT_474	[p26l13t2713r349b2769],
10	by	IN	O	by	_	0	SENT_474	[p26l363t2713r417b2769],
11	carboplatin	NN	O	carboplatin	nn	14	SENT_474	[p26l431t2713r701b2769],
12	(	CD	NUMBER	(	num	14	SENT_474	[p26l720t2717r925b2764],
13	CBDCA	NN	O	cbdca	nn	14	SENT_474	[p26l720t2717r925b2764],
14	)	NN	O	)	prep_by	9	SENT_474	[p26l720t2717r925b2764],
15	plus	CC	O	plus	prep	14	SENT_474	[p26l943t2713r1042b2769],
16	paclitaxel	NN	O	paclitaxel	nn	19	SENT_474	[p26l12t2784r242b2840],
17	(	CD	NUMBER	(	num	19	SENT_474	[p26l259t2788r387b2835],
18	TXL	NN	O	txl	nn	19	SENT_474	[p26l259t2788r387b2835],
19	)	NN	O	)	dep	15	SENT_474	[p26l259t2788r387b2835],
20	in	IN	O	in	_	0	SENT_474	[p26l404t2785r451b2828],
21	non	JJ	O	non	amod	25	SENT_474	[p26l465t2784r710b2829],
22	—	JJ	O	—	amod	25	SENT_474	[p26l465t2784r710b2829],
23	small	JJ	O	small	amod	25	SENT_474	[p26l465t2784r710b2829],
24	cell	NN	O	cell	nn	25	SENT_474	[p26l724t2784r806b2828],
25	lung	NN	O	lung	prep_in	19	SENT_474	[p26l820t2784r928b2841],
26	cancer	NN	O	cancer	dep	28	SENT_474	[p26l941t2798r1042b2828, p26l13t2871r84b2900],
27	(	CD	NUMBER	(	num	26	SENT_474	[p26l105t2860r307b2907],
28	NSCLC	NN	O	nsclc	dep	33	SENT_474	[p26l105t2860r307b2907],
29	)	CD	NUMBER	)	num	30	SENT_474	[p26l105t2860r307b2907],
30	patients	NNS	O	patient	dep	28	SENT_474	[p26l329t2857r520b2912],
31	(	IN	O	(	_	0	SENT_474	[p26l543t2860r645b2912],
32	pts	NNS	O	pt	prep_(	33	SENT_474	[p26l543t2860r645b2912],
33	)	VBP	O	)	_	0	SENT_474	[p26l543t2860r645b2912],
34	with	IN	O	with	_	0	SENT_474	[p26l664t2856r773b2901],
35	EGFR	NN	ORGANIZATION	egfr	nn	36	SENT_474	[p26l792t2860r935b2903],
36	mutations	NNS	O	mutation	prep_with	33	SENT_474	[p26l949t2871r1042b2901, p26l13t2928r192b2971],
37	:	:	O	:	_	0	SENT_474	[p26l949t2871r1042b2901, p26l13t2928r192b2971],
38	a	DT	O	a	det	42	SENT_474	[p26l220t2942r245b2971],
39	phase	NN	O	phase	nn	42	SENT_474	[p26l270t2927r410b2983],
40	III	CD	NUMBER	iii	num	42	SENT_474	[p26l436t2931r493b2971],
41	study	NN	O	study	nn	42	SENT_474	[p26l519t2927r648b2983],
42	(	NN	O	(	dep	36	SENT_474	[p26l675t2931r791b2978],
43	002	CD	NUMBER	002	num	44	SENT_474	[p26l675t2931r791b2978],
44	)	NN	O	)	dep	42	SENT_474	[p26l675t2931r791b2978],
45	by	IN	O	by	_	0	SENT_474	[p26l821t2927r875b2983],
46	North	NNP	O	North	prep_by	33	SENT_474	[p26l898t2927r1043b2972],

1	23	CD	NUMBER	23	_	0	SENT_475	[p26l1118t21r1184b59],
2	.	.	O	.	_	0	SENT_475	[p26l1118t21r1184b59],

1	Shepherd	NNP	ORGANIZATION	Shepherd	nn	2	SENT_476	[p26l1216t15r1443b71],
2	FA	NNP	ORGANIZATION	FA	_	0	SENT_476	[p26l1468t19r1544b69],
3	,	,	O	,	_	0	SENT_476	[p26l1468t19r1544b69],
4	Pereira	NNP	PERSON	Pereira	nn	5	SENT_476	[p26l1571t16r1742b59],
5	JR	NNP	O	JR	appos	2	SENT_476	[p26l1761t19r1834b69],
6	,	,	O	,	_	0	SENT_476	[p26l1761t19r1834b69],
7	Ciuleanu	NNP	ORGANIZATION	Ciuleanu	nn	8	SENT_476	[p26l1862t15r2079b60],
8	T	NN	ORGANIZATION	t	appos	2	SENT_476	[p26l2103t19r2146b69],
9	,	,	O	,	_	0	SENT_476	[p26l2103t19r2146b69],
10	et	FW	O	et	nn	11	SENT_476	[p26l1119t96r1163b131],
11	al.	FW	O	al.	appos	2	SENT_476	[p26l1181t87r1236b131],
12	.	.	O	.	_	0	SENT_476	[p26l1181t87r1236b131],

1	Erlotinib	NNP	O	Erlotinib	nsubj	4	SENT_477	[p26l1259t87r1476b131],
2	in	IN	O	in	prep	1	SENT_477	[p26l1497t88r1545b131],
3	previously	RB	DATE	previously	pcomp	2	SENT_477	[p26l1564t87r1816b143],
4	treated	VBN	O	treat	_	0	SENT_477	[p26l1835t87r2005b131],
5	nonsmall	JJ	O	nonsmall	amod	9	SENT_477	[p26l2026t101r2151b131, p26l1119t157r1359b201],
6	—	NN	O	—	nn	9	SENT_477	[p26l2026t101r2151b131, p26l1119t157r1359b201],
7	cell	NN	O	cell	nn	9	SENT_477	[p26l2026t101r2151b131, p26l1119t157r1359b201],
8	lung	NN	O	lung	nn	9	SENT_477	[p26l1398t157r1508b214],
9	cancer	NN	O	cancer	dobj	4	SENT_477	[p26l1547t172r1718b201],
10	.	.	O	.	_	0	SENT_477	[p26l1547t172r1718b201],

1	N	NN	O	n	nn	3	SENT_478	[p26l1760t161r1802b202],
2	Engl	NNP	O	Engl	nn	3	SENT_478	[p26l1840t157r1950b214],
3	J	NNP	O	J	nsubj	4	SENT_478	[p26l1985t161r2006b208],
4	Med	VBD	O	med	_	0	SENT_478	[p26l2043t157r2149b201],
5	2005	CD	DATE	2005	dobj	4	SENT_478	[p26l1118t233r1532b282],
6	;	:	O	;	_	0	SENT_478	[p26l1118t233r1532b282],
7	353:123	CD	NUMBER	353:123	num	8	SENT_478	[p26l1118t233r1532b282],
8	-32	CD	NUMBER	-32	dep	5	SENT_478	[p26l1118t233r1532b282],
9	.	.	O	.	_	0	SENT_478	[p26l1118t233r1532b282],

1	24	CD	NUMBER	24	_	0	SENT_479	[p26l1118t305r1185b343],
2	.	.	O	.	_	0	SENT_479	[p26l1118t305r1185b343],

1	Thatcher	NNP	PERSON	Thatcher	nn	2	SENT_480	[p26l1213t299r1433b343],
2	N	NNP	O	N	_	0	SENT_480	[p26l1452t303r1505b353],
3	,	,	O	,	_	0	SENT_480	[p26l1452t303r1505b353],
4	Chang	NNP	PERSON	Chang	nn	5	SENT_480	[p26l1530t299r1690b356],
5	A	NNP	O	A	appos	2	SENT_480	[p26l1708t303r1758b353],
6	,	,	O	,	_	0	SENT_480	[p26l1708t303r1758b353],
7	Parikh	NNP	ORGANIZATION	Parikh	nn	8	SENT_480	[p26l1782t299r1944b344],
8	P	NN	ORGANIZATION	p	appos	2	SENT_480	[p26l1965t303r2002b353],
9	,	,	O	,	_	0	SENT_480	[p26l1965t303r2002b353],
10	et	FW	O	et	nn	11	SENT_480	[p26l2028t309r2071b343],
11	al.	FW	O	al.	appos	2	SENT_480	[p26l2090t299r2146b343],
12	.	.	O	.	_	0	SENT_480	[p26l2090t299r2146b343],

1	Gefitinib	NN	O	gefitinib	nsubj	26	SENT_481	[p26l1118t370r1343b415],
2	plus	CC	O	plus	prep	1	SENT_481	[p26l1360t370r1461b426],
3	best	JJS	O	best	dep	4	SENT_481	[p26l1480t370r1580b414],
4	supportive	JJ	O	supportive	amod	5	SENT_481	[p26l1596t371r1852b426],
5	care	NN	O	care	dep	2	SENT_481	[p26l1870t385r1970b414],
6	in	IN	O	in	_	0	SENT_481	[p26l1987t371r2035b414],
7	previously	RB	DATE	previously	advmod	8	SENT_481	[p26l2051t385r2148b426, p26l1116t441r1288b497],
8	treated	VBN	O	treat	amod	9	SENT_481	[p26l1323t441r1493b485],
9	patients	NNS	O	patient	prep_in	5	SENT_481	[p26l1529t442r1725b497],
10	with	IN	O	with	_	0	SENT_481	[p26l1760t441r1871b486],
11	refractory	JJ	O	refractory	amod	15	SENT_481	[p26l1908t441r2151b497],
12	advanced	JJ	O	advanced	amod	15	SENT_481	[p26l1118t512r1344b557],
13	non-small-cell	JJ	O	non-small-cell	amod	15	SENT_481	[p26l1369t512r1724b556],
14	lung	NN	O	lung	nn	15	SENT_481	[p26l1749t512r1859b569],
15	cancer	NN	O	cancer	prep_with	9	SENT_481	[p26l1883t526r2056b557],
16	:	:	O	:	_	0	SENT_481	[p26l1883t526r2056b557],
17	results	NNS	O	result	dep	5	SENT_481	[p26l2084t527r2148b556, p26l1119t583r1232b628],
18	from	IN	O	from	advmod	20	SENT_481	[p26l1269t583r1389b627],
19	a	DT	O	a	dep	18	SENT_481	[p26l1425t598r1450b627],
20	randomised	VBN	O	randomise	partmod	17	SENT_481	[p26l1485t583r1792b637],
21	,	,	O	,	_	0	SENT_481	[p26l1485t583r1792b637],
22	placebo	NN	O	placebo	appos	5	SENT_481	[p26l1831t583r2148b639],
23	—	CD	NUMBER	—	num	22	SENT_481	[p26l1831t583r2148b639],
24	con	NN	O	con	dep	22	SENT_481	[p26l1831t583r2148b639],
25	—	CD	NUMBER	—	num	24	SENT_481	[p26l1831t583r2148b639],
26	trolled	VBD	O	troll	_	0	SENT_481	[p26l1119t655r1293b709],
27	,	,	O	,	_	0	SENT_481	[p26l1119t655r1293b709],
28	multicentre	JJ	O	multicentre	amod	33	SENT_481	[p26l1316t655r1600b700],
29	study	NN	O	study	nn	33	SENT_481	[p26l1621t655r1752b711],
30	(	CD	NUMBER	(	num	33	SENT_481	[p26l1772t659r1935b706],
31	Iressa	NNP	O	Iressa	nn	33	SENT_481	[p26l1772t659r1935b706],
32	Survival	NNP	O	Survival	nn	33	SENT_481	[p26l1955t655r2149b700],
33	Evaluation	NN	O	evaluation	ccomp	26	SENT_481	[p26l1118t725r1376b770],
34	in	IN	O	in	dep	33	SENT_481	[p26l1436t726r1483b769],
35	Lung	NN	O	lung	nn	37	SENT_481	[p26l1543t729r1668b782],
36	Cancer	NN	O	cancer	nn	37	SENT_481	[p26l1727t729r1925b776],
37	)	NN	O	)	pobj	34	SENT_481	[p26l1727t729r1925b776],
38	.	.	O	.	_	0	SENT_481	[p26l1727t729r1925b776],

1	Lancet	NNP	O	Lancet	_	0	SENT_482	[p26l1988t729r2151b769],
2	2005	CD	DATE	2005	num	1	SENT_482	[p26l1118t800r1553b849],
3	;	:	O	;	_	0	SENT_482	[p26l1118t800r1553b849],
4	366:1527	CD	NUMBER	366:1527	number	5	SENT_482	[p26l1118t800r1553b849],
5	—	CD	NUMBER	—	dep	1	SENT_482	[p26l1118t800r1553b849],
6	37	CD	NUMBER	37	dep	5	SENT_482	[p26l1118t800r1553b849],
7	.	.	O	.	_	0	SENT_482	[p26l1118t800r1553b849],

1	25	CD	NUMBER	25	_	0	SENT_483	[p26l1118t873r1184b911],
2	.	.	O	.	_	0	SENT_483	[p26l1118t873r1184b911],

1	Rosell	NNP	PERSON	Rosell	nn	2	SENT_484	[p26l1214t867r1366b914],
2	R	NNP	PERSON	R	_	0	SENT_484	[p26l1393t871r1442b921],
3	,	,	O	,	_	0	SENT_484	[p26l1393t871r1442b921],
4	Moran	NNP	PERSON	Moran	nn	5	SENT_484	[p26l1472t871r1633b912],
5	T	NN	O	t	appos	2	SENT_484	[p26l1659t871r1702b921],
6	,	,	O	,	_	0	SENT_484	[p26l1659t871r1702b921],
7	Queralt	NN	O	queralt	nn	8	SENT_484	[p26l1734t867r1918b922],
8	C	NN	O	c	appos	2	SENT_484	[p26l1943t871r1990b921],
9	,	,	O	,	_	0	SENT_484	[p26l1943t871r1990b921],
10	et	FW	O	et	nn	11	SENT_484	[p26l2021t876r2066b911],
11	al.	FW	O	al.	appos	2	SENT_484	[p26l2090t867r2146b911],
12	.	.	O	.	_	0	SENT_484	[p26l2090t867r2146b911],

1	Screening	VBG	O	screen	_	0	SENT_485	[p26l1120t939r1362b995],
2	for	IN	O	for	_	0	SENT_485	[p26l1378t938r1448b983],
3	epidermal	JJ	O	epidermal	amod	7	SENT_485	[p26l1464t938r1711b994],
4	growth	NN	O	growth	nn	7	SENT_485	[p26l1728t938r1907b995],
5	factor	NN	O	factor	nn	7	SENT_485	[p26l1925t938r2068b983],
6	receptor	NN	O	receptor	nn	7	SENT_485	[p26l2084t953r2148b982, p26l1119t1018r1273b1065],
7	mutations	NNS	O	mutation	prep_for	1	SENT_485	[p26l1291t1010r1539b1054],
8	in	IN	O	in	_	0	SENT_485	[p26l1559t1010r1606b1053],
9	lung	NN	O	lung	nn	10	SENT_485	[p26l1625t1009r1735b1066],
10	cancer	NN	O	cancer	prep_in	7	SENT_485	[p26l1753t1024r1924b1053],
11	.	.	O	.	_	0	SENT_485	[p26l1753t1024r1924b1053],

1	N	NN	O	n	nn	3	SENT_486	[p26l1945t1013r1987b1054],
2	Engl	NNP	O	Engl	nn	3	SENT_486	[p26l2005t1009r2150b1066],
3	]	NNP	O	]	nsubj	4	SENT_486	[p26l2005t1009r2150b1066],
4	Med	VBD	O	med	_	0	SENT_486	[p26l1117t1081r1223b1125],
5	2009	CD	DATE	2009	dobj	4	SENT_486	[p26l1242t1085r1654b1134],
6	;	:	O	;	_	0	SENT_486	[p26l1242t1085r1654b1134],
7	361:958	CD	NUMBER	361:958	number	8	SENT_486	[p26l1242t1085r1654b1134],
8	—	CD	NUMBER	—	dep	5	SENT_486	[p26l1242t1085r1654b1134],
9	67	CD	NUMBER	67	dep	8	SENT_486	[p26l1242t1085r1654b1134],
10	.	.	O	.	_	0	SENT_486	[p26l1242t1085r1654b1134],

1	26	CD	NUMBER	26	_	0	SENT_487	[p26l1118t1158r1186b1196],
2	.	.	O	.	_	0	SENT_487	[p26l1118t1158r1186b1196],

1	Inoue	NNP	O	Inoue	nn	2	SENT_488	[p26l1214t1156r1352b1197],
2	A	NNP	O	A	_	0	SENT_488	[p26l1376t1156r1426b1206],
3	,	,	O	,	_	0	SENT_488	[p26l1376t1156r1426b1206],
4	Kobayashi	NNP	PERSON	Kobayashi	nn	5	SENT_488	[p26l1455t1152r1706b1208],
5	K	NNP	PERSON	K	appos	2	SENT_488	[p26l1732t1156r1781b1206],
6	,	,	O	,	_	0	SENT_488	[p26l1732t1156r1781b1206],
7	Usui	NNP	PERSON	Usui	nn	8	SENT_488	[p26l1809t1153r1920b1197],
8	K	NNP	PERSON	K	appos	2	SENT_488	[p26l1945t1156r1994b1206],
9	,	,	O	,	_	0	SENT_488	[p26l1945t1156r1994b1206],
10	et	FW	O	et	nn	11	SENT_488	[p26l2023t1162r2067b1196],
11	al.	FW	O	al.	appos	2	SENT_488	[p26l2090t1152r2145b1196],
12	.	.	O	.	_	0	SENT_488	[p26l2090t1152r2145b1196],

1	First	NNP	ORDINAL	First	nn	4	SENT_489	[p26l1118t1222r1337b1266],
2	—	NNP	O	—	nn	4	SENT_489	[p26l1118t1222r1337b1266],
3	line	NN	O	line	nn	4	SENT_489	[p26l1118t1222r1337b1266],
4	gefitinib	NN	O	gefitinib	_	0	SENT_489	[p26l1367t1222r1580b1279],
5	for	IN	O	for	_	0	SENT_489	[p26l1611t1222r1681b1266],
6	patients	NNS	O	patient	prep_for	4	SENT_489	[p26l1709t1223r1904b1278],
7	with	IN	O	with	_	0	SENT_489	[p26l1934t1222r2044b1267],
8	advanced	JJ	O	advanced	amod	10	SENT_489	[p26l2075t1222r2148b1266, p26l1116t1293r1285b1338],
9	non	JJ	O	non	amod	10	SENT_489	[p26l1321t1293r1676b1337],
10	—	NN	O	—	prep_with	6	SENT_489	[p26l1321t1293r1676b1337],
11	small	JJ	O	small	amod	15	SENT_489	[p26l1321t1293r1676b1337],
12	—	NN	O	—	nn	15	SENT_489	[p26l1321t1293r1676b1337],
13	cell	NN	O	cell	nn	15	SENT_489	[p26l1321t1293r1676b1337],
14	lung	NN	O	lung	nn	15	SENT_489	[p26l1711t1293r1821b1350],
15	cancer	NN	O	cancer	dep	4	SENT_489	[p26l1855t1307r2016b1337],
16	harboring	VBG	O	harbor	partmod	4	SENT_489	[p26l2050t1293r2148b1337, p26l1119t1364r1283b1421],
17	epidermal	JJ	O	epidermal	amod	21	SENT_489	[p26l1306t1364r1553b1420],
18	growth	NN	O	growth	nn	21	SENT_489	[p26l1577t1364r1756b1421],
19	factor	NN	O	factor	nn	21	SENT_489	[p26l1781t1364r1924b1409],
20	receptor	NN	O	receptor	nn	21	SENT_489	[p26l1947t1374r2150b1420],
21	mutations	NNS	O	mutation	dobj	16	SENT_489	[p26l1118t1437r1367b1481],
22	without	IN	O	without	_	0	SENT_489	[p26l1388t1436r1582b1481],
23	indication	NN	O	indication	prep_without	16	SENT_489	[p26l1602t1436r1852b1480],
24	for	IN	O	for	_	0	SENT_489	[p26l1875t1436r1945b1480],
25	chemotherapy	NN	O	chemotherapy	prep_for	23	SENT_489	[p26l1967t1436r2148b1480, p26l1119t1507r1311b1563],
26	.	.	O	.	_	0	SENT_489	[p26l1967t1436r2148b1480, p26l1119t1507r1311b1563],

1	J	NNP	O	J	nn	3	SENT_490	[p26l1338t1511r1360b1558],
2	Clin	NNP	O	Clin	nn	3	SENT_490	[p26l1389t1507r1489b1551],
3	Oncol	NNP	O	Oncol	_	0	SENT_490	[p26l1520t1507r1665b1551],
4	2009	CD	DATE	2009	num	3	SENT_490	[p26l1695t1511r2146b1560],
5	;	:	O	;	_	0	SENT_490	[p26l1695t1511r2146b1560],
6	27:1394	CD	NUMBER	27:1394	number	7	SENT_490	[p26l1695t1511r2146b1560],
7	-400	CD	NUMBER	-400	dep	3	SENT_490	[p26l1695t1511r2146b1560],
8	.	.	O	.	_	0	SENT_490	[p26l1695t1511r2146b1560],

1	[	NNP	O	[	_	0	SENT_491	[p26l1123t1582r1357b1632],
2	Erratum	NNP	O	Erratum	nn	6	SENT_491	[p26l1123t1582r1357b1632],
3	,	,	O	,	_	0	SENT_491	[p26l1123t1582r1357b1632],
4	J	NNP	O	J	appos	6	SENT_491	[p26l1374t1582r1395b1629],
5	Clin	NNP	O	Clin	nn	6	SENT_491	[p26l1413t1578r1514b1622],
6	Oncol	NNP	O	Oncol	dep	1	SENT_491	[p26l1533t1578r1678b1622],
7	2009	CD	DATE	2009	rcmod	6	SENT_491	[p26l1697t1582r2048b1631],
8	;	:	O	;	_	0	SENT_491	[p26l1697t1582r2048b1631],
9	27:3071	CD	NUMBER	27:3071	dep	7	SENT_491	[p26l1697t1582r2048b1631],
10	.	.	O	.	_	0	SENT_491	[p26l1697t1582r2048b1631],
11	]	SYM	O	]	dep	7	SENT_491	[p26l1697t1582r2048b1631],

1	27	CD	NUMBER	27	_	0	SENT_492	[p26l1118t1654r1180b1692],
2	.	.	O	.	_	0	SENT_492	[p26l1118t1654r1180b1692],

1	Inoue	NNP	O	Inoue	nn	2	SENT_493	[p26l1214t1652r1352b1693],
2	A	NNP	O	A	_	0	SENT_493	[p26l1372t1652r1421b1702],
3	,	,	O	,	_	0	SENT_493	[p26l1372t1652r1421b1702],
4	Saijo	NNP	LOCATION	Saijo	nn	5	SENT_493	[p26l1447t1649r1562b1704],
5	Y	NN	LOCATION	y	appos	2	SENT_493	[p26l1582t1652r1623b1702],
6	,	,	O	,	_	0	SENT_493	[p26l1582t1652r1623b1702],
7	Maemondo	NNP	O	Maemondo	nn	8	SENT_493	[p26l1646t1648r1921b1693],
8	M	NNP	O	M	appos	2	SENT_493	[p26l1942t1652r2003b1702],
9	,	,	O	,	_	0	SENT_493	[p26l1942t1652r2003b1702],
10	et	FW	O	et	nn	11	SENT_493	[p26l2028t1657r2072b1692],
11	al.	FW	O	al.	appos	2	SENT_493	[p26l2090t1648r2146b1692],
12	.	.	O	.	_	0	SENT_493	[p26l2090t1648r2146b1692],

1	Severe	JJ	O	severe	_	0	SENT_494	[p26l1120t1724r1271b1765],
2	acute	JJ	O	acute	amod	4	SENT_494	[p26l1303t1729r1429b1765],
3	interstitial	JJ	O	interstitial	amod	4	SENT_494	[p26l1460t1720r1719b1764],
4	pneumonia	NN	O	pneumonia	dep	1	SENT_494	[p26l1749t1721r2029b1776],
5	and	CC	O	and	_	0	SENT_494	[p26l2059t1720r2149b1764],
6	gefitinib	NN	O	gefitinib	dep	1	SENT_494	[p26l1118t1790r1344b1847],
7	.	.	O	.	_	0	SENT_494	[p26l1118t1790r1344b1847],

1	Lancet	NNP	O	Lancet	_	0	SENT_495	[p26l1366t1794r1530b1834],
2	2003	CD	DATE	2003	num	1	SENT_495	[p26l1546t1794r1925b1843],
3	;	:	O	;	_	0	SENT_495	[p26l1546t1794r1925b1843],
4	361:137	CD	NUMBER	361:137	number	5	SENT_495	[p26l1546t1794r1925b1843],
5	—	CD	NUMBER	—	dep	1	SENT_495	[p26l1546t1794r1925b1843],
6	9	CD	NUMBER	9	dep	5	SENT_495	[p26l1546t1794r1925b1843],
7	.	.	O	.	_	0	SENT_495	[p26l1546t1794r1925b1843],

1	28	CD	NUMBER	28	_	0	SENT_496	[p26l1118t1867r1186b1907],
2	.	.	O	.	_	0	SENT_496	[p26l1118t1867r1186b1907],

1	Cohen	NNP	PERSON	Cohen	nn	2	SENT_497	[p26l1215t1862r1371b1906],
2	MH	NNP	O	MH	_	0	SENT_497	[p26l1388t1866r1494b1916],
3	,	,	O	,	_	0	SENT_497	[p26l1388t1866r1494b1916],
4	Williams	NNP	ORGANIZATION	Williams	nn	5	SENT_497	[p26l1514t1862r1738b1906],
5	GA	NNP	ORGANIZATION	GA	appos	2	SENT_497	[p26l1758t1866r1848b1916],
6	,	,	O	,	_	0	SENT_497	[p26l1758t1866r1848b1916],
7	Sridhara	NNP	O	Sridhara	nn	8	SENT_497	[p26l1872t1862r2079b1906],
8	R	NNP	O	R	appos	2	SENT_497	[p26l2097t1866r2146b1916],
9	,	,	O	,	_	0	SENT_497	[p26l2097t1866r2146b1916],
10	Chen	NNP	PERSON	Chen	nn	11	SENT_497	[p26l1118t1932r1243b1977],
11	G	NNP	PERSON	G	appos	2	SENT_497	[p26l1277t1936r1329b1986],
12	,	,	O	,	_	0	SENT_497	[p26l1277t1936r1329b1986],
13	Pazdur	NNP	ORGANIZATION	Pazdur	nn	18	SENT_497	[p26l1366t1932r1538b1977],
14	R.	NNP	ORGANIZATION	R.	nn	18	SENT_497	[p26l1569t1936r1619b1979],
15	FDA	NNP	ORGANIZATION	FDA	nn	18	SENT_497	[p26l1655t1936r1759b1976],
16	drug	NN	O	drug	nn	18	SENT_497	[p26l1792t1932r1908b1989],
17	approval	NN	O	approval	nn	18	SENT_497	[p26l1939t1932r2149b1988],
18	summary	NN	O	summary	appos	2	SENT_497	[p26l1119t2018r1364b2059],
19	:	:	O	:	_	0	SENT_497	[p26l1119t2018r1364b2059],
20	gefitinib	NN	O	gefitinib	nn	22	SENT_497	[p26l1383t2003r1595b2060],
21	(	CD	NUMBER	(	num	22	SENT_497	[p26l1615t2007r1833b2054],
22	ZD1839	NN	O	zd1839	dep	2	SENT_497	[p26l1615t2007r1833b2054],
23	)	CD	NUMBER	)	number	24	SENT_497	[p26l1615t2007r1833b2054],
24	(	CD	NUMBER	(	num	27	SENT_497	[p26l1856t2007r2032b2054],
25	Iressa	NNP	O	Iressa	nn	27	SENT_497	[p26l1856t2007r2032b2054],
26	)	CD	NUMBER	)	num	27	SENT_497	[p26l1856t2007r2032b2054],
27	tablets	NNS	O	tablet	dep	22	SENT_497	[p26l2053t2003r2148b2047, p26l1118t2074r1216b2118],
28	.	.	O	.	_	0	SENT_497	[p26l2053t2003r2148b2047, p26l1118t2074r1216b2118],

1	Oncologist	NN	O	oncologist	_	0	SENT_498	[p26l1238t2074r1508b2131],
2	2003	CD	DATE	2003	num	1	SENT_498	[p26l1524t2078r1854b2127],
3	;	:	O	;	_	0	SENT_498	[p26l1524t2078r1854b2127],
4	8:303	CD	NUMBER	8:303	number	5	SENT_498	[p26l1524t2078r1854b2127],
5	-6	CD	NUMBER	-6	dep	1	SENT_498	[p26l1524t2078r1854b2127],
6	.	.	O	.	_	0	SENT_498	[p26l1524t2078r1854b2127],

1	29	CD	NUMBER	29	_	0	SENT_499	[p26l1118t2150r1184b2189],
2	.	.	O	.	_	0	SENT_499	[p26l1118t2150r1184b2189],

1	Ando	NNP	PERSON	Ando	nn	2	SENT_500	[p26l1213t2145r1344b2189],
2	M	NNP	O	M	_	0	SENT_500	[p26l1363t2149r1424b2199],
3	,	,	O	,	_	0	SENT_500	[p26l1363t2149r1424b2199],
4	Okamoto	NNP	PERSON	Okamoto	nn	5	SENT_500	[p26l1447t2145r1675b2190],
5	I	NNP	O	I	appos	2	SENT_500	[p26l1695t2149r1725b2199],
6	,	,	O	,	_	0	SENT_500	[p26l1695t2149r1725b2199],
7	Yamamoto	NNP	PERSON	Yamamoto	nn	8	SENT_500	[p26l1746t2149r2012b2190],
8	N	NNP	O	N	appos	2	SENT_500	[p26l2031t2149r2084b2199],
9	,	,	O	,	_	0	SENT_500	[p26l2031t2149r2084b2199],
10	et	FW	O	et	nn	11	SENT_500	[p26l2108t2154r2151b2189],
11	al.	FW	O	al.	appos	2	SENT_500	[p26l1118t2216r1174b2260],
12	.	.	O	.	_	0	SENT_500	[p26l1118t2216r1174b2260],

1	Predictive	JJ	O	predictive	amod	2	SENT_501	[p26l1202t2216r1443b2261],
2	factors	NNS	O	factor	nsubj	22	SENT_501	[p26l1469t2216r1635b2261],
3	for	IN	O	for	_	0	SENT_501	[p26l1662t2216r1732b2260],
4	interstitial	JJ	O	interstitial	amod	6	SENT_501	[p26l1757t2216r2015b2260],
5	lung	NN	O	lung	nn	6	SENT_501	[p26l2040t2216r2151b2273],
6	disease	NN	O	disease	prep_for	2	SENT_501	[p26l1119t2288r1310b2342],
7	,	,	O	,	_	0	SENT_501	[p26l1119t2288r1310b2342],
8	antitumor	NN	O	antitumor	nn	9	SENT_501	[p26l1331t2289r1581b2333],
9	response	NN	O	response	prep_for	2	SENT_501	[p26l1598t2302r1829b2344],
10	,	,	O	,	_	0	SENT_501	[p26l1598t2302r1829b2344],
11	and	CC	O	and	_	0	SENT_501	[p26l1850t2288r1940b2332],
12	survival	NN	O	survival	prep_for	2	SENT_501	[p26l1959t2288r2149b2333],
13	in	IN	O	in	_	0	SENT_501	[p26l1118t2359r1165b2402],
14	non	JJ	O	non	amod	21	SENT_501	[p26l1207t2358r1562b2403],
15	—	JJ	O	—	amod	21	SENT_501	[p26l1207t2358r1562b2403],
16	small	JJ	O	small	amod	21	SENT_501	[p26l1207t2358r1562b2403],
17	—	NN	O	—	nn	21	SENT_501	[p26l1207t2358r1562b2403],
18	cell	NN	O	cell	nn	21	SENT_501	[p26l1207t2358r1562b2403],
19	lung	NN	O	lung	nn	21	SENT_501	[p26l1603t2358r1713b2415],
20	cancer	NN	O	cancer	nn	21	SENT_501	[p26l1753t2373r1913b2402],
21	patients	NNS	O	patient	prep_in	12	SENT_501	[p26l1952t2359r2148b2414],
22	treated	VBN	O	treat	_	0	SENT_501	[p26l1119t2429r1289b2473],
23	with	IN	O	with	_	0	SENT_501	[p26l1308t2429r1419b2474],
24	gefitinib	NN	O	gefitinib	prep_with	22	SENT_501	[p26l1440t2429r1666b2486],
25	.	.	O	.	_	0	SENT_501	[p26l1440t2429r1666b2486],

1	J	NNP	O	J	nn	3	SENT_502	[p26l1685t2433r1706b2480],
2	Clin	NNP	O	Clin	nn	3	SENT_502	[p26l1726t2429r1827b2473],
3	Oncol	NNP	O	Oncol	_	0	SENT_502	[p26l1848t2429r1993b2473],
4	2006	CD	DATE	2006	num	3	SENT_502	[p26l2014t2433r2147b2482],
5	;	:	O	;	_	0	SENT_502	[p26l2014t2433r2147b2482],
6	24:2549	CD	NUMBER	24:2549	number	7	SENT_502	[p26l1118t2505r1401b2545],
7	—	CD	NUMBER	—	dep	3	SENT_502	[p26l1118t2505r1401b2545],
8	56	CD	NUMBER	56	dep	7	SENT_502	[p26l1118t2505r1401b2545],
9	.	.	O	.	_	0	SENT_502	[p26l1118t2505r1401b2545],

1	30	CD	NUMBER	30	_	0	SENT_503	[p26l1119t2577r1183b2616],
2	.	.	O	.	_	0	SENT_503	[p26l1119t2577r1183b2616],

1	Kudoh	NNP	PERSON	Kudoh	nn	2	SENT_504	[p26l1214t2572r1372b2618],
2	S	NNP	PERSON	S	_	0	SENT_504	[p26l1400t2576r1437b2626],
3	,	,	O	,	_	0	SENT_504	[p26l1400t2576r1437b2626],
4	Kato	NNP	PERSON	Kato	nn	5	SENT_504	[p26l1466t2576r1577b2618],
5	H	NNP	PERSON	H	appos	2	SENT_504	[p26l1604t2576r1657b2626],
6	,	,	O	,	_	0	SENT_504	[p26l1604t2576r1657b2626],
7	Nishiwaki	NNP	LOCATION	Nishiwaki	nn	8	SENT_504	[p26l1685t2572r1932b2617],
8	Y	NN	O	y	appos	2	SENT_504	[p26l1955t2576r1996b2626],
9	,	,	O	,	_	0	SENT_504	[p26l1955t2576r1996b2626],
10	et	FW	O	et	nn	11	SENT_504	[p26l2025t2581r2068b2616],
11	al.	FW	O	al.	appos	2	SENT_504	[p26l2091t2572r2145b2616],
12	.	.	O	.	_	0	SENT_504	[p26l2091t2572r2145b2616],

1	Interstitial	JJ	O	interstitial	amod	3	SENT_505	[p26l1118t2642r1373b2686],
2	lung	NN	O	lung	nn	3	SENT_505	[p26l1406t2642r1514b2699],
3	disease	NN	O	disease	_	0	SENT_505	[p26l1546t2642r1720b2687],
4	in	IN	O	in	_	0	SENT_505	[p26l1754t2643r1800b2686],
5	Japanese	JJ	MISC	japanese	amod	6	SENT_505	[p26l1829t2646r2041b2698],
6	patients	NNS	O	patient	prep_in	3	SENT_505	[p26l2074t2657r2148b2698, p26l1119t2714r1251b2757],
7	with	IN	O	with	_	0	SENT_505	[p26l1268t2713r1378b2758],
8	lung	NN	O	lung	nn	9	SENT_505	[p26l1396t2713r1504b2770],
9	cancer	NN	O	cancer	prep_with	6	SENT_505	[p26l1521t2727r1690b2757],
10	:	:	O	:	_	0	SENT_505	[p26l1521t2727r1690b2757],
11	a	DT	O	a	det	15	SENT_505	[p26l1711t2728r1736b2757],
12	cohort	NN	O	cohort	nn	15	SENT_505	[p26l1754t2713r1912b2757],
13	and	CC	O	and	_	0	SENT_505	[p26l1928t2713r2016b2757],
14	nested	JJ	O	nested	nn	15	SENT_505	[p26l2035t2722r2148b2757, p26l1119t2784r1173b2829],
15	case	NN	O	case	dep	3	SENT_505	[p26l1207t2784r1502b2829],
16	—	CD	NUMBER	—	num	18	SENT_505	[p26l1207t2784r1502b2829],
17	control	NN	O	control	nn	18	SENT_505	[p26l1207t2784r1502b2829],
18	study	NN	O	study	dep	15	SENT_505	[p26l1537t2784r1672b2840],
19	.	.	O	.	_	0	SENT_505	[p26l1537t2784r1672b2840],

1	Am	NNP	O	Am	nn	5	SENT_506	[p26l1708t2788r1793b2828],
2	J	NNP	O	J	nn	5	SENT_506	[p26l1821t2788r1843b2835],
3	Respir	NNP	O	Respir	nn	5	SENT_506	[p26l1874t2785r2029b2840],
4	Crit	NNP	O	Crit	nn	5	SENT_506	[p26l2061t2785r2152b2828],
5	Care	NNP	O	Care	nsubj	6	SENT_506	[p26l1118t2860r1226b2900],
6	Med	VBD	O	med	_	0	SENT_506	[p26l1243t2856r1348b2900],
7	2008	CD	DATE	2008	dobj	6	SENT_506	[p26l1366t2860r1795b2909],
8	;	:	O	;	_	0	SENT_506	[p26l1366t2860r1795b2909],
9	177:1348	CD	NUMBER	177:1348	number	10	SENT_506	[p26l1366t2860r1795b2909],
10	—	CD	NUMBER	—	dep	7	SENT_506	[p26l1366t2860r1795b2909],
11	57	CD	NUMBER	57	dep	10	SENT_506	[p26l1366t2860r1795b2909],
12	.	.	O	.	_	0	SENT_506	[p26l1366t2860r1795b2909],

1	Copyright	NN	O	copyright	_	0	SENT_507	[p26l1120t2935r1299b2983],
2	©	CD	NUMBER	©	num	6	SENT_507	[p26l1317t2938r1357b2979],
3	2010	CD	DATE	2010	num	6	SENT_507	[p26l1377t2937r1473b2971],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_507	[p26l1488t2935r1757b2971],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_507	[p26l1775t2935r1923b2971],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_507	[p26l1938t2936r2076b2982],
7	.	.	O	.	_	0	SENT_507	[p26l1938t2936r2076b2982],

1	NENGLjMED352	NN	O	nengljmed352	_	0	SENT_508	[p26l963t3062r1225b3090],
2	;	:	O	;	_	0	SENT_508	[p26l963t3062r1225b3090],
3	25	CD	NUMBER	25	num	4	SENT_508	[p26l963t3062r1225b3090],
4	NEJM.ORG	NN	O	nejm.org	nsubj	5	SENT_508	[p26l1260t3068r1384b3090],
5	jUNE24	NN	O	june24	dep	1	SENT_508	[p26l1415t3068r1597b3090],
6	,20	CD	NUMBER	,20	num	5	SENT_508	[p26l1415t3068r1597b3090],
7	'	''	O	'	_	0	SENT_508	[p26l1415t3068r1597b3090],
8	|	JJ	O	|	amod	9	SENT_508	[p26l1415t3068r1597b3090],
9	O	NN	O	o	dobj	5	SENT_508	[p26l1415t3068r1597b3090],
10	The	DT	O	the	det	13	SENT_508	[p26l936t3101r987b3125],
11	New	NNP	O	New	nn	13	SENT_508	[p26l996t3102r1058b3125],
12	England	NNP	O	England	nn	13	SENT_508	[p26l1067t3101r1178b3132],
13	Journal	NNP	O	Journal	dep	9	SENT_508	[p26l1187t3101r1284b3125],
14	of	IN	O	of	_	0	SENT_508	[p26l1294t3101r1323b3125],
15	Medicine	NNP	O	Medicine	prep_of	5	SENT_508	[p26l1330t3101r1455b3125],

1	Copyright	NN	O	copyright	_	0	SENT_509	[p26l729t3183r863b3214],
2	©	CD	NUMBER	©	num	6	SENT_509	[p26l872t3183r896b3207],
3	2010	CD	DATE	2010	num	6	SENT_509	[p26l906t3183r971b3207],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_509	[p26l980t3183r1171b3207],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_509	[p26l1181t3183r1289b3207],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_509	[p26l1300t3183r1405b3214],
7	.	.	O	.	_	0	SENT_509	[p26l1300t3183r1405b3214],

1	All	DT	O	all	det	2	SENT_510	[p26l1416t3183r1457b3207],
2	rights	NNS	O	rights	nsubj	3	SENT_510	[p26l1466t3183r1541b3214],
3	reserved	VBN	O	reserve	_	0	SENT_510	[p26l1551t3183r1669b3207],
4	.	.	O	.	_	0	SENT_510	[p26l1551t3183r1669b3207],

